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Abstract 
 
There is significant inter-individual variation in response to morphine in terms of analgesia 
and side-effects. In recent years there has been growing interest in the possibility that genetic 
factors may play a role in variability in morphine response.  
 
The aims of this thesis were to develop a clinically relevant method of defining response to 
morphine, to investigate how multiple clinical and genetic factors may interact together to 
influence response to morphine and to explore constipation as a common side-effect of 
morphine. 
 
Clinical and biological data were collected as part of two clinical trials: 1) A prospective 
observational study which included patients taking oral morphine for cancer pain (N=298) 
and 2) A prospective follow-up randomised controlled trial of oral morphine versus oral 
oxycodone for cancer pain (recruitment ongoing). Symptom complexes were examined using 
Principal Components Analysis. Genetic association testing was carried out using both the 
candidate gene approach (sequence-specific primers with polymerase chain reaction) and 
genome-wide assays. Multivariate regression analyses were used to explore gene-gene and 
gene-environment interactions. Preliminary testing of a constipation assessment tool was 
performed. 
 
Analgesic response and central side-effects appear to be distinct components of morphine 
response. The genetic and clinical factors associated with these clinical outcomes and with 
daily morphine dose requirements are markedly different.  
There is inter-individual variation in bowel function in cancer patients on oral morphine. 
Constipation is a common symptom and is generally poorly managed.  
 
It is too early to be able to apply the results of genetic association studies of morphine 
response in cancer pain to clinical practice. Response to morphine is complex, both in terms 
of clinical confounders and pharmacogenetics. Challenges for future research include 
carrying out carefully designed studies of adequate power, standardising outcome measures 
of response to morphine and expansion of the genetic association testing.  
 4
Table of Contents  
 
Declaration of Originality ........................................................................................... 2 
Abstract ......................................................................................................................... 3 
Table of Contents ......................................................................................................... 4 
List of Figures ............................................................................................................. 13 
List of Tables .............................................................................................................. 15 
1 Chapter 1: Background and General Introduction ................................ 21 
1.1 CANCER PAIN AND OPIOIDS: WORLDWIDE PERSPECTIVE .................. 22 
1.2 INTER-INDIVIDUAL VARIATION IN RESPONSE TO MORPHINE FOR 
CANCER PAIN ................................................................................................................... 24 
1.2.1 Opioid analgesia and side-effects: Mechanism of action: ................................... 25 
1.2.2 Opioid switching .................................................................................................. 29 
1.2.2.1 Opioid switching: what dose? ...................................................................... 33 
1.3 CLINICAL FACTORS INFLUENCING MORPHINE RESPONSE ................. 34 
1.4 PHARMACOGENETICS OF MORPHINE ....................................................... 37 
1.4.1 Evidence to support genetic variation in response to opioids .............................. 38 
1.4.2 Genetic association studies: The genetic code ..................................................... 40 
1.4.3 DNA variation: Single Nucleotide Polymorphisms ............................................. 41 
1.4.4 Genetic association studies: Candidate genes and Genome-Wide Association 
Studies 43 
1.4.5 Pharmacogenetics of response to morphine: published data ............................... 44 
1.4.5.1 OPRM .......................................................................................................... 45 
1.4.5.2 COMT .......................................................................................................... 47 
1.4.5.3 MDR-1 ......................................................................................................... 49 
1.4.5.4 Other Genes ................................................................................................. 50 
1.4.6 RNA variation: Splice Variants ........................................................................... 53 
1.4.7 Protein variation: receptor dimerisation............................................................... 56 
1.5 CLINICAL PHENOTYPE IN OPIOID GENETIC STUDIES ........................... 56 
1.6 OPIOIDS FOR NEUROPATHIC PAIN ............................................................. 59 
1.7 CONSTIPATION ON MORPHINE .................................................................... 61 
1.7.1 Constipation in cancer patients taking opioids .................................................... 61 
1.7.2 Action of opioids on the gastrointestinal tract ..................................................... 61 
 5
1.7.3 Current management of constipation in patients taking opioids .......................... 63 
1.7.4 Opioid antagonists for opioid-induced constipation ............................................ 63 
1.7.5 Assessment of constipation in cancer and palliative care patients ...................... 67 
1.7.5.1 Constipation: subjective assessment ............................................................ 67 
1.7.5.2 Constipation: objective assessment .............................................................. 67 
1.7.5.3 Constipation assessment tools ...................................................................... 68 
1.8 AIMS OF THE THESIS: ..................................................................................... 73 
1.8.1 Clinical data presented in this thesis: ................................................................... 74 
1.8.2 Genetic data presented in this thesis .................................................................... 75 
1.8.2.1 Candidate genes ........................................................................................... 75 
1.9 THESIS OUTLINE .............................................................................................. 76 
2 Chapter 2 Methods ..................................................................................... 79 
2.1 CLINICAL STUDIES ......................................................................................... 80 
2.1.1 Prospective Morphine Study ................................................................................ 81 
2.1.1.1 Study design ................................................................................................. 81 
2.1.1.2 Data collection ............................................................................................. 82 
2.1.1.3 Biological samples ....................................................................................... 82 
2.1.1.4 Limitations of the Prospective Morphine Study .......................................... 83 
2.1.2 A Prospective Randomized Controlled Trial of Morphine versus Oxycodone for 
Cancer Pain ...................................................................................................................... 85 
2.1.2.1 Study design ................................................................................................. 85 
2.1.2.2 Data collection ............................................................................................. 87 
2.2 DATABASE CONSTRUCTION AND MAINTENANCE ................................ 89 
2.3 LABORATORY METHODS .............................................................................. 90 
2.3.1 DNA extraction from fresh blood ........................................................................ 90 
2.3.2 DNA amplification of genomic DNA .................................................................. 91 
2.3.2.1 Preparation of Genomic DNA for amplification ......................................... 91 
2.3.2.2 DNA extraction from dried blood spots ....................................................... 91 
2.3.2.3 Amplification of Human Genomic DNA by MDA ..................................... 92 
2.3.3 DNA quantification .............................................................................................. 93 
2.3.4 DNA quality control checks................................................................................. 96 
2.3.5 Sequence-Specific Primers and Polymerase Chain Reaction .............................. 97 
2.3.5.1 SSP-PCR Primer Design .............................................................................. 98 
 6
2.3.5.2 SNP selection ............................................................................................. 101 
2.3.5.3 SSP-PCR protocol ...................................................................................... 101 
2.3.5.4 Gel electophoresis ...................................................................................... 102 
2.3.5.5 SSP-PCR primer setup, titration and optimisation .................................... 103 
2.3.5.6 Primer titration for primer concentration optimisation .............................. 104 
2.3.5.7 SSP-PCR for deletion-insertion polymorphism ......................................... 106 
2.3.6 Affymetrix genome wide SNP array ................................................................. 107 
2.4 PRELIMINARY GENETIC ANALYSES AND GENETIC DATA 
MANAGEMENT ............................................................................................................... 108 
2.4.1 Genetic modelling .............................................................................................. 109 
2.4.2 Hardy-Weinberg Equilibrium ............................................................................ 111 
2.4.3 Linkage Disequilibrium and Haplotypes ........................................................... 112 
2.5 STATISTICAL ANALYSES ............................................................................ 117 
2.5.1 Regression .......................................................................................................... 117 
2.5.2 Principal Components Analysis (PCA) ............................................................. 120 
3 Chapter 3: Results from Prospective Morphine Study and Definition of 
the clinical phenotype ..................................................................................... 121 
3.1 SUMMARY OF THE RATIONALE BEHIND THIS STUDY ........................ 122 
3.1.1 Aim .................................................................................................................... 122 
3.2 SUBJECTS AND METHODS .......................................................................... 123 
3.2.1 Maintaining a tight clinical phenotype .............................................................. 124 
3.3 RESULTS .......................................................................................................... 126 
3.3.1 Morphine responders versus morphine non-responders .................................... 126 
3.3.2 Prospective Morphine Study: Pain scores ......................................................... 129 
3.3.3 Prospective Morphine study: Side-effect scores ................................................ 130 
3.3.4 Phenotype 1: Composite scores of analgesic response and central side-effects on 
morphine, as defined by PCA ........................................................................................ 134 
3.3.5 Phenotype 2: Daily morphine dose requirements .............................................. 141 
3.4 DISCUSSION .................................................................................................... 143 
3.4.1 Main Findings .................................................................................................... 143 
3.4.2 Study design ....................................................................................................... 143 
3.4.3 Phenotype definition .......................................................................................... 144 
3.4.4 Clinical factors influencing morphine response ................................................ 147 
 7
3.4.5 Limitations ......................................................................................................... 150 
3.5 CONCLUSION .................................................................................................. 151 
4 Chapter 4: Results from candidate gene association study: Opioid 
receptors ........................................................................................................... 153 
4.1 INTRODUCTION AND SUMMARY OF THE RATIONALE BEHIND THIS 
STUDY 154 
4.1.1 Aim .................................................................................................................... 156 
4.2 SUBJECTS AND METHODS .......................................................................... 156 
4.2.1 Genetic Marker inclusion ................................................................................... 156 
4.2.2 Statistical analysis .............................................................................................. 157 
4.3 RESULTS .......................................................................................................... 158 
4.3.1 Genetic marker data ........................................................................................... 158 
4.3.2 Analgesic response ............................................................................................ 163 
4.3.3 Central side-effects ............................................................................................ 170 
4.3.4 Variation in daily morphine dose to achieve adequate analgesia ...................... 177 
4.4 DISCUSSION .................................................................................................... 185 
4.4.1 Main findings ..................................................................................................... 185 
4.4.2 Analgesic response to morphine ........................................................................ 185 
4.4.3 Central side-effects on morphine ....................................................................... 186 
4.4.4 Morphine dose required to achieve adequate pain control ................................ 186 
4.4.5 OPRM, OPRK and OPRD ................................................................................. 187 
4.5 CONCLUSION .................................................................................................. 188 
5 Chapter 5: Results from candidate gene association study:                  
Other genes ...................................................................................................... 189 
5.1 INTRODUCTION AND SUMMARY OF THE RATIONALE BEHIND THIS 
STUDY 190 
5.1.1 Aim .................................................................................................................... 191 
5.2 SUBJECTS AND METHODS .......................................................................... 192 
5.3 ADORA1 ........................................................................................................... 193 
5.3.1 ADORA1 Results .............................................................................................. 194 
5.4 ADRA2A ........................................................................................................... 199 
5.4.1 ADRA2A Results .............................................................................................. 200 
5.5 TRPV1 ............................................................................................................... 202 
 8
5.5.1 TRPV1 Results .................................................................................................. 203 
5.6 ALOX12 ............................................................................................................ 207 
5.6.1 ALOX12 Results ................................................................................................ 208 
5.7 SLC6A4 ............................................................................................................. 210 
5.7.1 SLC6A4 Results ................................................................................................ 211 
5.8 ARRB2 ............................................................................................................... 216 
5.8.1 ARRB2: Results ................................................................................................. 216 
5.9 GENE-GENE INTERACTION / GENE-ENVIRONMENT INTERACTION . 221 
5.9.1 Analgesic response to morphine ........................................................................ 222 
5.9.1.1 SLC6A4 and opioid receptor genes ........................................................... 222 
5.9.1.2 ADORA1 and opioid receptor genes ......................................................... 224 
5.9.2 Variation in central side-effects on morphine .................................................... 225 
5.9.3 Variation in daily morphine dose to achieve adequate analgesia ...................... 225 
5.9.3.1 ADORA1 and opioid receptor genes ......................................................... 225 
5.9.3.2 ADRA2A and opioid receptor genes ......................................................... 226 
5.9.3.3 Other gene combinations ........................................................................... 226 
5.10 GENERAL DISCUSSION ................................................................................ 228 
5.10.1 Main findings ................................................................................................. 228 
5.10.2 Models predicting analgesic response to morphine ....................................... 229 
5.10.3 Models predicting central side-effects on morphine ...................................... 230 
5.10.4 Models predicting morphine dose requirements ............................................ 230 
5.11 CONCLUSION .................................................................................................. 233 
6 Chapter 6: Results from a Genome-Wide Association Study .............. 235 
6.1 INTRODUCTION AND SUMMARY OF THE RATIONALE BEHIND 
STUDY 236 
6.1.1 Aim .................................................................................................................... 236 
6.2 SUBJECTS AND METHODS .......................................................................... 237 
6.2.1 Clinical Phenotype / outcome ............................................................................ 237 
6.2.2 Experimental design .......................................................................................... 238 
6.2.2.1 Stage 1: Genotyping using Affymetrix 5 gene chip and analysis of the 
resulting “Affy dataset” ............................................................................................. 240 
6.2.2.2 Stage 2: Chosing Affy SNPs to genotype on the second population using 
SSP-PCR 242 
 9
6.2.2.3 Stage 3: Comparison of the “Affy” and SSP-PCR methods and datasets . 243 
6.3 RESULTS .......................................................................................................... 245 
6.3.1 Stage 1: Genome-wide-association study results (N=115) ................................ 245 
6.3.1.1 Average pain ≤ 4 ........................................................................................ 246 
6.3.1.2 Pain Relief ≥ 70% ...................................................................................... 247 
6.3.2 Stage 2: Replication study using SSP-PCR ....................................................... 248 
6.3.2.1 Chosing SNPS and designing primers for SSP-PCR set (N=125) ............. 248 
PRKD3 primers for SSP-PCR ................................................................................... 248 
ZDHHC14 primers for SSP-PCR .............................................................................. 249 
NTRK3 primers for SSP-PCR ................................................................................... 251 
6.3.2.2 Stage 2: Analysis of “SSP-PCR” dataset ................................................... 254 
6.3.3 Stage 3: Comparing “Affy” and “SSP-PCR” datasets ....................................... 259 
6.3.3.1 Assessing validity of genotyping methods ................................................ 259 
6.3.3.2 Comparing “Affy” and “SSP-PCR” datasets ............................................. 261 
6.4 DISCUSSION .................................................................................................... 267 
6.4.1 Main Findings .................................................................................................... 267 
6.4.2 Identification of novel candidate genes ............................................................. 267 
6.4.3 Sample size influences power to detect associations ......................................... 269 
6.4.4 The genetic association results fail to replicate in the “Affy” and the “SSP-PCR” 
datasets ........................................................................................................................... 271 
6.4.4.1 NTRK3 appears to be associated with a flip-flop ...................................... 273 
6.5 CONCLUSIONS ............................................................................................... 275 
7 Chapter 7: Constipation in cancer patients taking morphine ............. 276 
7.1 SUMMARY OF THE RATIONALE BEHIND THIS STUDY ........................ 277 
7.1.1 Aims ................................................................................................................... 277 
7.2 STUDY 1: EXAMINATION OF THE PREVALENCE AND MANAGEMENT 
OF CONSTIPATION IN CANCER PATIENTS TAKING MORPHINE ........................ 278 
7.2.1 Subjects and Methods ........................................................................................ 278 
7.2.2 Results ................................................................................................................ 281 
7.3 STUDY 2: CONSTIPATION ON MORPHINE IN CANCER PATIENTS: 
CLINICAL PHENOTYPE DEFINITION ......................................................................... 285 
7.3.1 Subjects and Methods ........................................................................................ 285 
7.3.2 Results ................................................................................................................ 287 
 10
7.4 STUDY 3: CONSTIPATION ON MORPHINE: GENETIC ASSOCIATION 
STUDY 289 
7.4.1 Subjects and methods ......................................................................................... 290 
7.4.2 Results ................................................................................................................ 291 
7.5 STUDY 4: CONSTIPATION ASSESSMENT AUDIT .................................... 295 
7.5.1 Subjects and methods ......................................................................................... 295 
7.5.2 Results ................................................................................................................ 296 
7.6 STUDY 5: CONSTIPATION ASSESSMENT TOOL ...................................... 301 
7.6.1 Subjects and Methods ........................................................................................ 302 
7.6.2 Constipation Assessment Tool Items ................................................................. 302 
7.6.3 Data analysis ...................................................................................................... 305 
7.6.3.1 Assessment of the rates of incorrect response ........................................... 305 
7.6.3.2 Psychometric analyses ............................................................................... 306 
7.6.3.3 Comparison of constipation scores across time ......................................... 306 
7.6.4 Results ................................................................................................................ 307 
7.6.4.1 Assessment of the rates of incorrect response ........................................... 308 
7.6.4.2 Psychometric analyses ............................................................................... 310 
7.6.4.3 Developing a composite Constipation Assessment Score ......................... 317 
7.7 OVERALL DISCUSSION ................................................................................ 319 
7.7.1 Constipation management .................................................................................. 320 
7.7.2 Inter-individual variation in constipation on morphine ..................................... 322 
7.7.2.1 Clinical factors associated with inter-individual variation in constipation on 
morphine 322 
7.7.2.2 Inter-individual variation in constipation on morphine and variation in 
candidate genes .......................................................................................................... 324 
7.7.3 Constipation Assessment ................................................................................... 325 
7.7.4 Constipation Assessment Tool ........................................................................... 327 
7.7.5 Limitations of these studies: .............................................................................. 331 
7.7.5.1 Limitations of the Prospective Morphine Study ........................................ 331 
7.7.5.2 Limitations of the Constipation Audit ....................................................... 331 
7.7.5.3 Limitations of the Randomised Controlled Trial ....................................... 332 
8 Chapter 8: General Discussion and Future work ................................. 333 
8.1 SUMMARY OF THESIS .................................................................................. 334 
 11
8.2 CHALLENGES HIGHLIGHTED BY THIS THESIS ...................................... 335 
8.2.1 Pain perception and response to morphine are complex traits, both clinically and 
genetically ...................................................................................................................... 335 
8.2.1.1 Gene-gene and gene-environment interactions .......................................... 336 
8.2.1.2 Population stratification ............................................................................. 340 
8.2.1.3 More complex genetic variation ................................................................ 340 
8.2.2 Study size ........................................................................................................... 341 
8.2.2.1 Multiple testing .......................................................................................... 342 
8.2.3 Accurate Phenotype to reduce required study size ............................................ 343 
8.2.4 Recruitment to palliative care studies ................................................................ 344 
8.3 CHALLENGES FOR CURRENT AND FUTURE RESEARCH ..................... 345 
8.4 CLOSING REMARKS ...................................................................................... 348 
 
References .................................................................................................................. 350 
 
Appendix A Publications arising from the work of this thesis .............................................. 392 
 
Appendix B Case Report forms for the clinical trials presented in this thesis ...................... 393 
Prospective Morphine Study Case Report Form ................................................................... 394 
Randomised Controlled Trial Case Report Form .................................................................. 403 
Constipation on Opioids Assessment..................................................................................... 419 
Adverse / Serious Adverse Event Log ................................................................................... 423 
 
Appendix C OPRM, OPRD and OPRK ................................................................................. 424 
Primer sequences ................................................................................................................... 424 
Analgesic response................................................................................................................. 427 
Central Side-effects ................................................................................................................ 430 
Daily morphine dose .............................................................................................................. 432 
 
Appendix D ADORA1 / ADRA2A / TRPV1 / ALOX12 / ARRB2 / SLC6A4 .................... 434 
Primer sequences ................................................................................................................... 434 
ADORA1 ............................................................................................................................... 440 
ADRA2A ............................................................................................................................... 444 
TRPV1 ................................................................................................................................... 450 
 12
ALOX12 ................................................................................................................................ 454 
SLC6A4 ................................................................................................................................. 457 
ARRB2 ................................................................................................................................... 461 
 
Appendix E GWA primers..................................................................................................... 465 
 
Appendix F Constipation on morphine: Genetic association study ....................................... 468 
 
Appendix G Proforma for Constipation Audit....................................................................... 471 
 13
List of Figures 
 
Figure 1.1 Inter-individual variation in response to morphine .................................... 28 
Figure 1.2 Genetic variation at DNA, RNA or protein level may influence response to 
morphine ...................................................................................................................... 41 
Figure 1.3 Structure of opioid receptor ........................................................................ 54 
Figure 1.4 Trait heterogeneity in morphine response. ................................................. 58 
Figure 2.2 A DNA standard concentration curve ........................................................ 94 
Figure 2.3 96 well plate set up for DNA quantification .............................................. 95 
Figure 2.4 DNA quality control ................................................................................... 96 
Figure 2.5 SSP-PCR products on an agarose gel using 63/64 and 210 / 211 control primers.
.................................................................................................................................... 103 
Figure 2.6 SSP-PCR primer titration ......................................................................... 105 
Figure 2.7 SERTP deletion-insertion polymorphism................................................. 106 
Figure 3.1 Ethnicity data ............................................................................................ 125 
Figure 3.2 Study population used in thesis (Prospective Morphine Study) ............... 125 
Figure 3.3 Morphine dose and Length of time on morphine ..................................... 126 
Figure 3.4 Principal Components of morphine response ........................................... 135 
Figure 3.5 Correlations between pain scores and component analgesic response score136 
Figure 4.1 LD Plots for OPRM .................................................................................. 160 
Figure 4.2 LD Plots for OPRD  (Haploview version 4.0, Broad Institute, Cambridge, USA).
.................................................................................................................................... 161 
Figure 4.3 LD Plots for OPRK .................................................................................. 162 
Figure 4.4 OPRK rs7824175 and analgesic response ................................................ 167 
Figure 4.5 OPRM rs1799971 and morphine dose requirements................................ 182 
Figure 5.1 ADORA1 rs10920568 and daily morphine dose ...................................... 195 
Figure 5.2 LD Plots for ADORA1 ............................................................................. 196 
Figure 5.3 LD plot for ADRA2A ............................................................................... 201 
Figure 5.4 LD Plots for TRPV1 ................................................................................. 204 
Figure 5.5 LD plots for ALOX12 .............................................................................. 209 
Figure 5.6 LD Plots for SLC6A4 ............................................................................... 212 
Figure 5.7 SLC6A4 and analgesic response .............................................................. 213 
Figure 5.8 LD plots for ARRB2 ................................................................................ 218 
 14
Figure 6.1 Experimental design for genetic association study .................................. 239 
Figure 6.2 Comparing methods and results from different datasets .......................... 244 
Figure 6.3 PCA demonstrating separation of genotypes according to ethnicity in two 
chromosomes ............................................................................................................. 245 
Figure 6.4 Results for genome-wide association testing with the clinical outcome, average 
pain ≤4 ....................................................................................................................... 246 
Figure 6.5 Results for genome-wide association testing with the clinical outcome, pain relief 
≥70%. ......................................................................................................................... 247 
Figure 6.6 LD plots for PRKD3 in the “Affy” dataset .............................................. 249 
Figure 6.7 LD plots for ZDHHC14 in the “Affy” dataset ......................................... 250 
Figure 6.8 L D plots for NTRK3 in the “Affy” dataset ............................................. 253 
Figure 6.9 NTRK3 Flip-Flop ..................................................................................... 255 
Figure 6.10 Comparing Affymetrix and SSP-PCR genotype results ......................... 260 
Figure 6.11 Comparing pairwise LD and haploblock structure in NTRK3 ............... 264 
Figure 6.12 LD values may be determined by marker frequency values .................. 273 
Figure 7.1 Type of laxatives taken by patients reporting constipation (N = 197) ..... 284 
Figure 7.2 Defining the “Constipation on opioids” clinical phenotype ..................... 286 
Figure 7.3 Identification of constipation in medical records ..................................... 297 
Figure 7.4 Documentation of identification and assessment of constipation. ........... 298 
Figure 7.5 Documentation of constipation management ........................................... 300 
Figure 7.6“What does being constipated mean to you”. ............................................ 307 
Figure 7.7 Usual bowel frequency ............................................................................. 308 
Figure 7.8 Principal component analysis for constipation assessment tool items ..... 313 
Figure 7.9 Discriminant validity ................................................................................ 315 
Figure 7.10 Constipation assessment items week 0-1 ............................................... 317 
Figure 7.11 The Composite Constipation Assessment Score .................................... 318 
 
 15
List of Tables 
Table 1.1Morphine side-effects ................................................................................... 28 
Table 1.2 Studies assessing efficacy of opioid switching ............................................ 32 
Table 1.3 Summary of available Constipation Assessment Tools ............................... 71 
Table 2.1 DNA dilution protocol to prepare the standard curve .................................. 93 
Table 2.2 SSP-PCR primer titration grid ................................................................... 104 
Table 2.3 Allele carriage in genetic association tests assumes a dominant / recessive mode of 
SNP-phenotype inheritance ....................................................................................... 110 
Table 3.1 Patient characteristics for total study population (N=207) ........................ 127 
Table 3.2 Reason for morphine "non-response" (N=62) ........................................... 128 
Table 3.3 Pain scores, shown as median (range) ....................................................... 129 
Table 3.4 Correlation between pain scores ................................................................ 129 
Table 3.5 Pain scores predictive of morphine response ............................................. 130 
Table 3.6 Side-effects on morphine. .......................................................................... 131 
Table 3.7 Correlation between side-effects on morphine .......................................... 132 
Table 3.8 Side-effects predictive of morphine response ............................................ 133 
Table 3.9 Pattern matrix showing the loading of each variable onto each component after 
rotation ....................................................................................................................... 136 
Table 3.10 Comparing component central side-effect scores with symptom severity scores
.................................................................................................................................... 137 
Table 3.11 Clinical factors predictive of variability in analgesic response ............... 139 
Table 3.12 Clinical factors predictive of central side-effects on morphine ............... 140 
Table 3.13 Clinical factors predictive of variability in daily morphine dose requirements 142 
Table 4.1 OPRM marker data .................................................................................... 159 
Table 4.2 OPRK marker data ..................................................................................... 159 
Table 4.3 OPRD marker data ..................................................................................... 159 
Table 4.4 OPRM haplotypes ...................................................................................... 160 
Table 4.5 OPRD haplotypes ...................................................................................... 161 
Table 4.6 OPRK haplotypes ...................................................................................... 162 
Table 4.7 Effects of OPRM on analgesic response to morphine (dominant model) . 164 
Table 4.8 Effects of OPRK on analgesic response to morphine (dominant model) .. 165 
Table 4.9 Effects of OPRK on analgesic response to morphine (additive model) .... 166 
 16
Table 4.10 Clinical and genetic factors predictive of analgesic response to morphine (additive 
model) ........................................................................................................................ 169 
Table 4.11 Clinical and genetic factors predictive of response to morphine, dominant model 
(allele carriage) .......................................................................................................... 169 
Table 4.12 Effects of OPRM on central side-effects of morphine (dominant model)171 
Table 4.13 Effects of OPRM on central side-effects of morphine (additive model) . 172 
Table 4.14 Effects of OPRK on central side-effects of morphine (dominant model) 173 
Table 4.15 Effects of OPRK on central side-effects of morphine (additive model) .. 174 
Table 4.16 Clinical and genetic factors predictive of central side-effects on morphine 
(dominant model) ....................................................................................................... 176 
Table 4.17 Clinical and genetic factors predictive of central side-effects on morphine 
(additive model) ......................................................................................................... 176 
Table 4.18 Effects of OPRM on daily morphine dose (dominant model) ................. 178 
Table 4.19 Effects of OPRM on daily morphine dose (additive model) ................... 179 
Table 4.20 Effects of OPRD on daily morphine dose (dominant model) .................. 180 
Table 4.21 Effects of OPRK on daily morphine dose (dominant model) .................. 181 
Table 4.22 Clinical and genetic factors associated with variability in daily morphine dose 
requirements (dominant model) ................................................................................. 184 
Table 4.23 Clinical and genetic factors associated with variability in daily morphine dose 
requirements (additive model) ................................................................................... 184 
Table 5.1 ADORA1 marker data ............................................................................... 194 
Table 5.2 ADORA1 Haplotypes ................................................................................ 196 
Table 5.3 Effects of ADORA1 on morphine dose (dominant model) ....................... 197 
Table 5.4 Effects of ADORA1 on morphine dose (additive model) ......................... 198 
Table 5.5 ADRA2A marker data ............................................................................... 200 
Table 5.6 ADRA2A haplotypes ................................................................................. 201 
Table 5.7 TRPV1 marker data ................................................................................... 203 
Table 5.8 TRPV1 haploblocks and haplotypes .......................................................... 204 
Table 5.9 Effects of TPRV1 on morphine dose (dominant model) ........................... 205 
Table 5.10 Effects of TPRV1 on morphine dose (additive model) ........................... 206 
Table 5.11 ALOX12 marker data .............................................................................. 208 
Table 5.12 ALOX12 haplotypes ................................................................................ 209 
Table 5.13 SLC6A4 marker data ............................................................................... 211 
Table 5.14 SLC6A4 haploblock and haplotypes ....................................................... 212 
 17
Table 5.15 SLC6A4 and analgesic response to morphine (dominant model) ........... 214 
Table 5.16 SLC6A4 and analgesic response to morphine (additive model).............. 215 
Table 5.17 ARRB2 marker data ................................................................................. 216 
Table 5.18 ARRB2 haplotypes .................................................................................. 218 
Table 5.19 ARRB2 and central side-effects on morphine (dominant model) ........... 219 
Table 5.20 ARRB2 and central side-effects on morphine (additive model) .............. 220 
Table 5.21 Summary of positive associations of genes with clinical outcomes ........ 221 
Table 5.22 OPRM, OPRD, OPRK and SLC6A4 and analgesic response (additive model) 223 
Table 5.23 OPRM, OPRD, OPRK and SLC6A4 and analgesic response (dominant model)
.................................................................................................................................... 223 
Table 5.24 OPRM, OPRD, OPRK and ADORA1 and daily morphine dose (additive model)
.................................................................................................................................... 226 
Table 5.25 OPRM, OPRD, OPRK and ADRA2A and daily morphine dose (dominant model)
.................................................................................................................................... 227 
Table 5.26 OPRM, OPRD, OPRK and ADRA2A and daily morphine dose (additive model)
.................................................................................................................................... 227 
Table 6.1 PRKD3 SNPS (p<0.01) chosen from the “Affy dataset” as candidates for SSP-PCR
.................................................................................................................................... 248 
Table 6.2 ZDHHC14 SNPS (p<0.01) chosen from the “Affy dataset” as candidates for SSP-
PCR ............................................................................................................................ 250 
Table 6.3 NTRK3 SNPS (p<0.01) chosen from the “Affy dataset” as candidates for SSP-PCR
.................................................................................................................................... 251 
Table 6.4 ZDHHC14 and Pain relief ......................................................................... 256 
Table 6.5 PRKD3 and average pain ≤ 4 .................................................................... 256 
Table 6.6 NTRK3 and Average Pain ......................................................................... 257 
Table 6.7 NTRK3 and Pain Relief ............................................................................. 258 
Table 6.8 Comparing “Affy” results against SSP-PCR data for 16 samples ............. 259 
Table 6.9 Comparing genotype frequency data ......................................................... 262 
Table 6.10 Pairwise LD between SNPs in NTRK3 ................................................... 263 
Table 6.11 Comparing the Affymetrix and SSP-PCR data sets in terms of clinical factors 266 
Table 7.1 Laxative Dose Groups (LDG) for each laxative ........................................ 280 
Table 7.2 Proportion of patients on laxatives and not on laxatives according to the reported 
severity of constipation .............................................................................................. 283 
Table 7.3 Laxatives used by study population ........................................................... 283 
 18
Table 7.4 Severity of constipation and laxative use in study population................... 287 
Table 7.5 Other clinical factors associated with constipation .................................... 288 
Table 7.6 OPRM and Bowel problems on morphine ................................................. 292 
Table 7.7 OPRK and Bowel problems on morphine ................................................. 293 
Table 7.8 OPRD and Bowel problems on morphine ................................................. 294 
Table 7.9 Stool frequency score................................................................................. 304 
Table 7.10 Scoring using the Bristol Stool Chart ...................................................... 304 
Table 7.11 Proportion of patients who gave correct / incorrect responses to the constipation 
assessment scales ....................................................................................................... 309 
Table 7.12 Correlations between subjective and objective constipation assessment scores 311 
Table 7.13 Pattern matrix showing the loading of each variable onto each component after 
rotation ....................................................................................................................... 313 
Table 7.14 Discriminant validity: Grade of constipation........................................... 314 
Table 7.15 Reliability statistics for subjective constipation assessment items .......... 316 
Table 7.16 Reliability statistics for objective constipation assessment items ........... 316 
 19
List of Abbreviations 
 
AA Amino acid 
ADORA1 A1-adenosine receptor 
ADRA2A α2A adrenergic receptor 
ALOX12 arachidonate 12-lipoxygenase 
ARRB2 Β-arrestin 2 gene 
Asn Asparagine 
Asp Aspartic acid 
bp Base pair 
CEU HapMap population of Utah residents of northern and 
western European ancestry 
CI Confidence Interval 
COMT catechol-O-methyltransferase 
CRF Clinical research file 
dH2O Distilled water 
DIP deletion-insertion polymorphism 
DNA Deoxyribonucleic acid 
dsDNA Double stranded DNA 
DOR Delta opioid receptor 
dATP deoxyadenosine triphosphate 
dCTP deoxyguanosine triphosphate 
dGTP deoxycytidine triphosphate 
dNTP Deoxyribonucleotide triphosphate 
dTTP deoxythymidine triphosphate 
DRG Dorsal Root Ganglion 
ds Double stranded 
EDTA Ethylenediaminetetraacetic acid 
GABA gamma-Aminobutyric acid 
GCH1 Guanosine Triphosphate Cyclohydrolase 1 
GCP Good Clinical Practice 
GWAS Genome Wide Association study 
HWE Hardy Weinberg Equilibrium 
KOR Kappa opioid receptor 
LD Linkage Disequilibrium 
LDG Laxative Dose Group 
LOD score logarithm (base 10) of odds score. An estimate of whether 
two loci are likely to lie near each other on a chromosome 
and thus likely to be inherited together. A LOD score of 
≥3 suggests that the odds are 1000 to 1 in favour of 
genetic linkage i.e. a LOD score of ≥3 suggests that the 
two loci are close in terms of genetic distance. 
mAF Marker Allele Frequency 
MAF Minor Allele Frequency 
MDA Multiple Displacement Amplification 
MDR1 Multidrug resistance 1 gene 
Met Methionine 
M-3-G morphine-3-glucuronide 
M-6-G morphine-6-glucuronide 
 20
MHRA Medicines and Healthcare Products Regulatory Agency 
MOR Mu-opioid receptor 
mRNA Messenger RNA 
NRS Numerical rating scale 
OPRM Mu opioid receptor gene 
OPRD Delta opioid receptor gene 
OPRK Kappa opioid receptor gene 
OR Odds Ratio 
PCA Principal Components Analysis 
PCR Polymerase Chain Reaction 
PR Prolonged release 
R&D Research and Development Committee 
REC Research Ethics Committees 
rpm Revolutions per minute 
sAF Susceptibility allele frequency 
SC subcutaneous 
SD Standard Deviation 
SEM Standard error of the mean 
SERT Serotonin reuptake transporter  
SLC6A4 Gene coding for the serotonin reuptake transporter  
SNP Single Nucleotide Polymorphism 
SSP Sequence specific primer 
Ta Annealing Temperature (During PCR) 
Tm Melting Temperature (During PCR) 
TRPV1 Transient receptor potential cation channel, subfamily V / 
capsaicin receptor 
UGT2B7 uridine diphosphate-glucuronosyltransferase 2B7 
Val Valine 
VNTR Variable Number Tandem Repeat 
WHO World Health Organisation 
12(S)-HPETE 12(S)-hydroperoxy-5,8,10,14-eicosatetraenoic acid 
 
Colour scheme for LD plots (Haploview version 4.0, Broad Institute, Cambridge, USA): 
Each box represents pairwise LD between markers. Numbers represent D’ or R2 x 100. No 
number represents D’ value of 1. Pink-Red boxes represent D’≤1 and LOD≥2. White boxes 
represent D’ <1 and LOD <2. Blue boxes represent areas where D’ = 1 and LOD < 2. 
 
 21
1 Chapter 1: Background and General Introduction 
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1.1 Cancer pain and opioids: worldwide perspective 
 
Most patients with cancer experience pain at some stage in their illness and many require 
opioid analgesia. For the past 20 years cancer pain has been managed according to The World 
Health Organisation (WHO) analgesic ladder. This three-step ladder recommends sequential 
increases in the strength of analgesia, starting with paracetamol (step 1), adding in a weak 
opioid (step 2) if the pain persists and finally progressing to a strong opioid (step 3) if pain is 
still not controlled . Adjuncts (e.g. non steroidal anti-inflammatories) are permissible at any 
stage along the ladder. This three-step analgesic ladder is under scrutiny currently with a 
proposal to exclude step 2, however the results of these trials are outstanding. 
 
Morphine is the WHO first line strong opioid of choice for cancer pain 1;2. This 
recommendation is based on availability, familiarity and cost rather then evidence of superior 
efficacy or tolerability. Despite this recommendation however, until relatively recently 
morphine was unavailable or not commonly used in many countries. In 1991 twenty countries 
accounted for 86% of morphine consumption 3. In 2006 Europe and North America 
accounted for 89% of global morphine consumption with developing countries, which 
account for 80% of the world’s population, only consuming 6% of worldwide morphine 4. 
Reasons for this inequality in morphine use / availability include: 
• Inadequate health care infrastructures or pain control as a low priority item in a 
country’s national health agenda 
• Lack of knowledge / skills in pain treatment. Even in the USA, a survey of 897 
physicians, reluctance to prescribe opioids for cancer pain was cited by 61% of 
respondents 5. 
• Legal and regulatory issues surrounding the use and availability of opioids6. 
• Fear of addiction and misuse or re-direction of opioids into the illegal drug trade 7. 
 
 
In 1984 the WHO Cancer Pain Relief Programme was established in which a country’s 
morphine consumption was considered to be an indicator of progress to improve cancer pain 
relief 1;3. Between 1984 and 1992, global consumption of morphine increased by nearly 
300%3;8.  Since then morphine availability has increased worldwide and it has been 
introduced to many more countries.  
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Other alternative opioids have also become more widely available, although as with 
morphine, availability and consumption is not uniform worldwide e.g. 94% of oxycodone is 
consumed by USA, UK, Canada, Germany and Australia 4. In a recent survey of 3030 cancer 
patients across Europe, morphine (oral or systemic) was the most commonly used strong 
opioid (50%), followed by fentanyl (14%) , oxycodone (4%), methadone (2%) and 
hydromorphine (1%) 9. There are marked differences in the choice of first line strong opioid 
in different countries, eg in Belgium it is fentanyl while in Finland it is oxycodone 9. 
International differences in choice of opioid and opioid consumption was also shown in a 
study comparing opioid consumption in Denmark, Finland, Germany, Iceland, The 
Netherlands, Norway and Sweden 10. 
 
Some opioids differ in their mode of metabolism and therefore some are recommended as 
being safer in certain circumstances than others e.g. alfentanil in renal failure. There is little 
evidence however to suggest superiority of one opioid over another in terms of efficacy 2. 
There have been very few randomized controlled trials comparing different opioids and those 
that have been carried out have tended to be small.  
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1.2 Inter-individual variation in response to morphine for cancer pain 
 
Although there appears to be little difference between opioids on a population level, on an 
individual level, variation in response to opioids is a well recognised phenomenon. Patients 
taking morphine for cancer pain may be categorised clinically into “morphine responders” 
and “morphine non-responders” depending on their sensitivity to the analgesic effects of 
morphine, and their tolerance or intolerance of morphine-related side-effects: 
 
• “Morphine responders”: 
o Most patients who are prescribed morphine for cancer pain are “Morphine 
responders”. These patients achieve good pain control without problematic 
side-effects. These patients are thus sensitive to the analgesic effects of 
morphine and are tolerant of (or resistant to) morphine-related side-effects. 
 
• “Morphine non-responders”: 
A significant proportion of patients, (up to 30%), do not have a satisfactory clinical 
outcome on morphine 11. These “morphine non-responders” present in a number of 
different ways 12: 
 
o Patients who achieve good analgesia but with intolerable side-effects. These 
patients appear to be sensitive to the analgesic actions of morphine but are 
intolerant of the side-effects.  
 
o Patients who do not achieve good analgesia because of dose-limiting side-
effects. It is unclear whether these patients are in fact sensitive to the analgesic 
effects of morphine because their intolerance of the side-effects precludes 
upwards dose titration.  
 
It is not uncommon for morphine side-effects such as nausea, vomiting, dry 
mouth, nightmares, sedation, confusion, hallucinations and myoclonus to 
become apparent as the dose is increased. These toxicities may often be 
managed with other medications e.g. antiemetics / antipsychotics, but 
sometimes they persist or become intolerable and thus dose-limiting.  In this 
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case current practice in our palliative care department is to switch these 
patients (morphine non-responders) from morphine to an alternative opioid. 
 
o Patients who do not achieve good analgesia but do not experience side-effects 
either, despite escalating morphine doses. These patients are insensitive to the 
analgesic effects of morphine but are also tolerant of any potential side-effects.  
 
There also appears to be considerable variation in the doses of morphine required to achieve 
pain control.  
 
At present the clinical use of morphine and other opioids in cancer pain management involves 
careful titration of the dose of an initial opioid (usually morphine) according to response 
(analgesia and side-effects). As there is currently no way of prospectively predicting such 
response, in many instances patients experience significant pain and/or side-effects or delay 
in adequate symptom management. 
 
1.2.1 Opioid analgesia and side-effects: Mechanism of action: 
 
The pharmacokinetic and pharmacodynamic factors which may underpin inter-individual 
variation in response to morphine have yet to be elucidated. Based on current knowledge of 
opioid action however, it may be hypothesised that such variation in analgesic sensitivity and 
side-effect tolerance may be, in part, associated with: 
• Morphine metabolism 
• Site of u-opioid receptor activation 
• The influence of second messengers 
Morphine is metabolised in the liver to the metabolites, morphine-3-glucuronide (M3G) 
(55%) and morphine-6-glucuronide (M6G) (15%). M6G is a potent analgesic agent 13 but 
M3G, whilst being considered to be analgesically inactive, is thought to have neuroexcitatory 
properties 14. M6G has been associated with drowsiness, nausea and vomiting, 
unconsciousness and respiratory depression. M3G has been proposed to play a role in 
morphine-related agitation, myoclonus, hyperalgesia and delirium 15. 
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To date, serum measurements of morphine and its metabolites have not demonstrated any 
reproducible association with analgesic sensitivity or development of opioid side-effects 16;17. 
There is however, continued interest in this field. Variation in a number of factors might 
influence the formation and action of morphine and its metabolites in the central nervous 
system. These include:  
 
• Expression and activity of UDP-glucuronosyltransferase (UGT) 2B7, the major 
enzyme involved in morphine metabolism. 
• Morphine oral bioavailability. This varies from 35-75% 18. Morphine uptake into the 
systemic circulation from the gastrointestinal tract and circulating levels of morphine 
and its metabolites in the central nervous system are influenced by P-glycoprotein 
levels and expression 19;20.  
• Renal function. Morphine and its metabolites (including morphine-6-glucuronide) are 
eliminated via the kidneys 21;22. Therefore in renal impairment, the effect of morphine 
is prolonged and more pronounced.  
 
The location of opioid receptors throughout the central nervous system has been 
demonstrated by immunohistochemical and in-situ hybridization techniques. Neuroimaging 
advances such as fMRI has increased our knowledge of which areas of the central nervous 
system are involved in pain and its modulation 23. Opioids produce analgesia and/or opioid-
related side-effects through action at different areas in the central nervous system.   
 
Opioids produce analgesia by acting at opioid receptors along the ascending pain pathways, 
which involves the dorsal horn, the brain stem, thalamus and cerebral cortex. Opioids also 
have an action on descending inhibitory pain pathways, which include the midbrain 
periaqueductal grey, the nucleus raphe magnus and the rostral ventral medulla18.  
 
Opioids produce analgesia though a reduction in presynaptic neurotransmitter release, 
neurone hyperpolarisation and a reduction in cellular excitability and thus a decrease in 
synaptic transmission. Opioids also inhibit GABAergic transmission 18;24.  
 
Opioids cause nausea and vomiting through action on the chemoceptor trigger zone which is 
close to the area postrema in the floor of the fourth ventricle. This is outside the blood brain 
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barrier. They also have a direct action on the vomiting centre, which is located in the 
brainstem. 
 
Persistent sedation and drowsiness due to opioids is problematic because it impairs quality of 
life and impinges on the patient’s ability to function at home and in the workplace. Other 
common central side-effects include nausea, confusion and hallucinations. The central side-
effects of drowsiness, confusion, hallucinations, nausea and myoclonus can occur 
independently of each other. There is a phenomenon known as opioid-induced neurotoxicity 
which may manifest as any or all of the following symptoms: hallucinations, cognitive 
dysfunction, severe sedation, myoclonus and opioid hyperalgesia.  
 
Despite the fact that these effects of opioids are quite common, little is known about their 
precise pathogenesis 25. Possible contributing factors include: 
 
• The accumulation of opioid metabolites, especially M-3-G (although the evidence for 
this is conflicting) 
• The anticholinergic effects of opioids 
• An interaction between opioids and catecholamines in the central nervous systems 
• Activation of NMDA receptors and the stimulation of excitatory second messengers 
e.g. glutamate 26;27. 
The mechanism of opioid-induced constipation is discussed in section 1.6.2.  
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Figure 1.1 Inter-individual variation in response to morphine 
 
Table 1.1Morphine side-effects 
Common Less common Rare* Possible 
Confusion Prutitus Respiratory 
depression 
Suppression of 
immune system 
Drowsiness Sweating  Suppression of 
hypothalamic-
pituitary axis 
Hallucinations Myoclonus   
Myoclonus Allodynia   
Bad dreams Hyperalsgesia   
Constipation Delerium   
Nausea    
Dry mouth    
* These side-effects are rare in cancer patients if opioids are titrated carefully 
according to response 
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Recognition of this substantial inter-individual variation in response to morphine for cancer 
pain has resulted in the emergence of two clinical phenomena. Firstly "opioid switching" as a 
clinical manoeuvre to redress the balance between analgesia and side-effects has become 
widely accepted. Secondly there has been a surge of interest in the mechanisms (clinical and 
molecular) underlying inter-individual variation in morphine response with a number of 
clinical studies being carried out in this area. 
 
1.2.2 Opioid switching 
 
Morphine “non-responders” often benefit from changing to an alternative opioid in a practice 
known as “opioid switching”. The same principle applies for patients who do not respond 
well to any other opioid also. When used carefully the practice of opioid switching is a 
powerful therapeutic tool in the individualisation of cancer pain management.  
 
The terms “opioid switching” and “opioid rotation” are often used interchangeably in the 
literature. For the purpose of this thesis opioid switching refers to the use of an alternative 
opioid for the purpose of improving analgesia and/or reducing intolerable side-effects. Opioid 
rotation is taken to refer to the use of an alternative opioid because of availability, patient or 
physician choice or a change in the route of administration of the opioid. In some studies 
patients undergoing opioid switching and opioid rotation are included together 28;29.  
 
A Cochrane review in 2004 examined the evidence base for the effectiveness of opioid 
switching to improve drug tolerability. 52 studies were included in this review, including 23 
case reports, 15 retrospective studies or audits and 14 prospective uncontrolled studies. All 
studies except one reported opioid switching as a beneficial clinical practice. The numbers of 
patients included in these studies tended to be small. At that time no randomized controlled 
trials or prospective controlled studies had been carried out in this area. Therefore the 
conclusion of the systematic review was that there was no substantial evidence to support the 
practice of opioid switching. The author called for further research in a number of areas: 1) to 
establish the true efficacy of opioid switching and 2) to determine which opioid should be 
used first line and second line 30. 
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A further systematic review in 2006 suggested that opioid switching is associated with 
improvement in response to opioids in at least 50% of patients 12. A more detailed look at 
some of the larger studies suggests that careful opioid switching may in fact be associated 
with much higher response rates. Table 1.2 details the results of some of the largest studies in 
this area. 
 
To date there has been only one prospective case-controlled study of opioid switching. This 
study was initially carried out at the Royal Marsden Hospital by Drs Joy Ross and Dag Rutter 
and upon this study much of this present thesis is based. In the original papers from this study 
186 patients were included which comprised two cohorts. 74% (138/186) were morphine 
“responders”, who had been on morphine for at least 4 weeks and who had good pain control 
with minimal side-effects. 26% (48/186) were morphine “non-responders” who had either 
poor pain control and / or intolerable side-effects despite adequate morphine dose-titration. 
Morphine non-responders were switched to oxycodone as the second-line strong opioid, 
resulting in an overall 87% good clinical outcome in terms of pain and side-effect profile 31. 
 
After an opioid switch is undertaken, it usually takes a few days of dose titration for the 
maximum effect to become apparent. Time to stabilization on the second opioid may be 
slightly longer if the patient was switched because of both pain and side-effects 29. 
 
The dose of the original opioid at which an opioid switch is required varies widely. In one 
study in which 54 patients were switched from morphine to methadone, the median daily 
morphine dose was 200mg (range 30-1000mg) 32. In another study the morphine equivalent 
daily dose was 577 +/- 1535mg 33. In the Royal Marsden study in which morphine non-
responders were switched to oxycodone, the median dose of morphine at time of switching 
was 70mg (range 15-580mg) 31. 
 Similarly the duration of the initial opioid therapy is variable. In one study patients were on 
the initial opioid for a median of 44 days (range 20-240 days) before switching to an 
alternative opioid 32. In another study the mean duration of the previous opioid therapy is 
reported as 25.8 weeks (180.6 days) (range 1-104 weeks) 34.   There appears to be two broad 
groups of patients which require opioid switching. The first group require switching shortly 
after initiation of the initial opioid, when the opioid dose is relatively low. The second group 
appear to become non-responsive to the initial opioid at either higher doses or after chronic 
opioid therapy. It has recently been proposed that these two groups of patients represent 
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different clinical phenomona 35. The first group, i.e. those failing on the initial opioid shortly 
after opioid initiation, may represent the fact that not all drugs are efficacious in all patients. 
“Heterogeneity of treatment effects” is seen with most pharmaceutical medications and may 
be explained in part by individual pharmacokinetic or pharmacodynamic factors. The second 
group of patients however, i.e. those patients who experience pain or intolerable side-effects 
after chronic opioid therapy, may be the result of physical tolerance to the initial opioid.  
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Table 1.2 Studies assessing efficacy of opioid switching 
Author Type of study Number of 
patients 
undergoing 
opioid 
switch 
Successful 
outcome 
after 
opioid 
switching 
Reason for switching Comment 
Mercadante 
2009 *29 
Prospective 
uncontrolled 
study 
118 87% Uncontrolled pain 15.2% 
Adverse effects 28.8% 
Uncontrolled pain and adverse effects 50.8% 
More than 1 opioid 
switch required in 
7 patients (6%) 
Riley 2006 31 
 
Prospective case-
controlled 
study 
47 87% Morphine responders compared to morphine non responders: 
Confusion and drowsiness p=5 x 10-12  
Pain relief p=2.4 x 10-6 
Nightmares p=5 x 10-5 
Nausea p=7.3 x 10-3 
More than 1 opioid 
switch required in 
4 patients (8.5%) 
Wirz 200634 Prospective 
uncontrolled 
study 
50 64% Uncontrolled pain 60% 
Sedation 4% 
Itch 2% 
Gastroimtestinal effects (nausea, constipation) 40% 
 
Mercadante 
200136 
Prospective 
uncontrolled 
study 
52 80% Uncontrolled pain 20% 
Adverse effects 16% 
Uncontrolled pain and adverse effects 64% 
 
Kloke 
2000*28 
Retrospective 
uncontrolled 
study 
103 65% Uncontrolled pain 43% 
Adverse effects 20% 
Uncontrolled pain and adverse effects 15% 
 
De Stoutz 
199533 
Retrospective 
uncontrolled 
study 
80 73% Uncontrolled pain 16% 
Cognitive failure 39% 
Hallucinations 24% 
Myoclonus 11% 
Nausea 9% 
Local irritation 1% 
More than 1 opioid 
switch required in 
some patients 
* studies included changing from one opioid to another in order to improve pain and side-effect profile (i.e. opioid switching) and also for other reasons (opioid 
rotation) 
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1.2.2.1 Opioid switching: what dose? 
 
One of the most challenging aspects of switching from one opioid to another is 
deciding on the starting dose of the second opioid. Although equianalgesic dose ratios 
are available, these are merely guidelines to the relative potencies of different opioids. 
These ratios were derived largely from single dose studies and do not take into 
account individual patient factors which may contribute to effect, such as previous 
opioid therapy, opioid tolerance or underlying disease 37;38. The reported 
equianalgesic dose ratios between opioids also may be quite variable depending on 
the study. The generally accepted equianalgesic dose ratio for oral morphine: 
oxycodone lies between 1:1 and 1:2 37. In one study the median dose ratio of 
morphine: oxycodone was 1.7 with a broad range from 0.25 – 12 39. To make matters 
even more complicated the equianalgesic dose ratios may change according to the 
initial opioid dose, as has been proposed when switching morphine to methadone 32.  
 
One of the major factors contributing to the difficulties in determining the dose of the 
alternative opioid is the phenomenon of opioid tolerance. This is defined as a 
reduction in response to a drug after repeated administration. Tolerance to both opioid 
induced analgesia and side-effects may occur, although not necessarily in tandem 
together 40. Incomplete cross tolerance to different opioids exists, which may be 
explained in part by differing pharmacodynamic and pharmacokinetic factors. There 
appears to be no defined relationship between the dose of the initial opioid at time of 
switching and the final stable alternative opioid dose after switching 12;29. In some 
cases opioid switching facilitates upward dose titration to achieve good analgesia 41. 
In others the final equivalent dose of opioid required was reduced 33. These data 
demonstrate the importance of individualised dose titration when switching opioids 12. 
Most authors recommend deciding on the dose of the alternative opioid in the context 
of a) the individual patient experience (ie whether switching because of uncontrolled 
pain or side-effects) and b) the type of opioid used. Conservative dose ratios 37 and an 
initial dose reduction of the equianalgesic dose by 25-50% 37;38 are recommended with 
subsequent careful individualised dose titration.  
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1.3 Clinical Factors influencing morphine response 
 
Response to morphine is potentially influenced by a number of different clinical and 
environmental factors.  
 
Many studies have demonstrated gender-related differences in pain sensitivity and 
analgesic response to opioids. A recent review suggests that women experience more 
pain post-operatively and that women are more sensitive to experimental pain 42. The 
data pertaining to analgesic response however are quite mixed and often inconsistent. 
Animal studies have demonstrated that males are more sensitive to both morphine and 
alfentanil mediated analgesia 43.A prospective cohort study of a heterogeneous group 
of 423 women and 277 men in the post-operative period concluded that women had 
more severe pain and required larger doses of morphine than men 44. A human healthy 
volunteer study however demonstrated that morphine has a greater potency and a 
slower speed of analgesic onset and offset in women rather than in men 45. A further 
study found that post-operative kappa-opioid agonists were associated with greater 
analgesia in females than males 46. Any potential gender-related differences may be 
species-related or may be due to differences in the study population or pain outcomes. 
It is not clear why gender-related differences occur. It is not thought to be related to 
differences in the pharmacokinetics of opioids 43;45. Hormonal differences or 
neurobiological factors may play a role 42;47.  
 
Age has been shown to be associated with variation in pain perception and analgesia 
in other studies. In most studies there was a negative correlation between age and pain 
sensitivity / analgesic response. Younger patients appear to have higher pain scores 
and greater morphine requirements post-operatively 48-50. One retrospective study 
went so far as to suggest a formula for estimating post-operative morphine dose 
requirements based on the patient’s age 51. A recent systematic review however 
suggests that the association between age and pain / analgesia is somewhat conflicting 
and inconsistent 47. Again, it is not entirely clear why such differences may occur. 
Animal studies have demonstrated differences in receptor levels of dopamine, 
serotonin and enkephaline with age 52. Other suggested explanations are differences in 
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drug handling in terms of pharmacokinetics or age –related differences in the number 
or binding of opioid receptors 51.  
 
In a retrospective study of cancer patients taking morphine, differences in patient age, 
white cell and platelet count were found when 100 “morphine responders” were 
compared to 70 “morphine non-responders”. These factors only accounted for 6.9% of 
variability in the study population and there were a number of limitations to the study 
due to its retrospective nature 53. In another retrospective analysis, 103 cancer patients 
who underwent an opioid change (due to inadequate pain control, adverse effects from 
the opioid or other reasons) were compared to 170 patients who responded well to 
their initial opioid. In this study there was no difference in terms of age, gender, 
tumour diagnosis, pain syndrome or co-analgesics, with the exception of 
corticosteroids 28.  
 
In the original cohort of patients included in the Royal Marsden study of cancer 
patients on morphine carried out in our department, regression analysis was used to 
develop a model to predict “morphine responders” (n=138) versus “morphine non-
responders” (n=47). Morphine non-response was found to be associated with white 
cell count, weight, tumours of the lower gastrointestinal tract, recent chemotherapy 
and concomitant use of beta blockers, proton pump inhibitors or 5HT3 antiemetics 31. 
These findings have not been replicated in other studies. A further prospective study 
by a different group found no relationship between the need for an opioid switch (due 
to uncontrolled pain, adverse opioid effects or convenience) and age, gender, pain 
type, the use of adjuvant medications (including corticosteroids) or biochemical 
factors 29. 
 
There are few data explaining why not all patients benefit from opioid switching. In a 
study by Mercadante et al, patients who had both poor pain control and adverse opioid 
effects were more likely to be unsuccessful in switching (p=0.004). No association 
was found with clinical factors (including age of patient, gender), type or dose of 
opioid, pain type, the use of adjuvant medications or renal impairment. The number of 
patients who did not respond to opioid switching in this study however was small 
(N=15/118), therefore it is difficult to extrapolate these data into meaningful clinical 
practice 29. 
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If a switch from one opioid to another is unsuccessful a number of factors should be 
taken into consideration: 
• A further opioid switch may be indicated. More than 1 opioid switch is 
sometimes required to achieve an optimum balance between analgesia and 
side-effects 29;31;33.  
• The pain may not be opioid responsive. 
• Central delivery of opioids may be required (via the epidural or intrathecal 
route). Eight patients in Mercadante’s study required intrathecal pain 
management 29. In the Royal Marsden study, 5/48 patients did not have a 
successful outcome after opioid switching. One of these required an epidural 
and the authors suggest that for 3 others anaesthetic intervention would have 
been appropriate 31.  
• Other factors may be contributing to the side-effects experienced e.g. renal 
impairment, concurrent medications or factors related to the underlying 
disease.  
 
To date the only clinical factor which is consistently and reliably associated with 
altered morphine response is renal dysfunction (see section 1.2.1). However marked 
inter-individual variability in morphine response occurs even in patients with normal 
renal function.  
 
At present, for the large majority of patients, no clinical factor has been identified 
which allows prospective prediction of which patient will respond best to which 
opioid. Therefore in recent years much attention has been focused on 
pharmacogenetics: the notion that an individual’s genetic makeup may underpin 
variability in morphine response. 
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1.4 Pharmacogenetics of morphine  
 
In many areas of medicine, pharmacogenetics has yielded some very exciting results. 
An individual’s response to drugs such as irinotecan, abacavir and warfarin can now 
be accurately predicted through integration of genetic and clinical data. This 
facilitates prospective decision making regarding choice of the correct dose of the 
correct drug for a given patient and reduces subsequent side-effects. Thus in a number 
of different areas of medicine including oncology and haematology, 
pharmacogenetics has revolutionised drug prescribing.  
 
Irinotecan in a chemotherapeutic agent used in the treatment of colorectal cancer. The 
active metabolite of irinotecan, SN-38, is associated with potentially serious side-
effects such as diarrhoea and neutropenia. SN-38 is inactivated through 
glucuronidation by the enzyme uridine diphosphate glucuronosyl transferase 
(UGT1A1). Reduced activity of UGT1A1, which is seen in patients with specific 
variations in the gene coding for this enzyme, is associated with increased risk of 
serious side-effects. Prospective genotyping of patients who are prescribed irinotecan 
allows dose reduction (with a subsequent reduction in side-effects) in patients 
carrying these genetic variants 54;55.   
 
Polymorphisms in two genes, VKORC1 and CYP2C9 account for up to 30% and 10% 
of variability in warfarin therapeutic dose requirements 56;57. 
 
Similarly, side-effects with Abacavir, a nucleoside analogue reverse transcriptase 
inhibitor used in the treatment of HIV and AIDS, are predicted through genotyping 
for HLA-B*5701 58. 
 
Recently there has been a growing interest in the possibility that genetic factors might 
play a role in variability of opioid response. The hypothesis held by many researchers 
is that changes at a molecular level in an opioid’s pharmacokinetic and 
pharmacodynamic pathways may be responsible for altered opioid response 59.  
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In terms of cancer pain, pharmacogentics may potentially allow prospective prediction 
of response to different opioids. Personalised prescribing involving choosing the 
correct dose of the correct opioid for the each individual patient would result in more 
rapid pain management, reduced side-effects and potentially a better quality of life.  
 
1.4.1 Evidence to support genetic variation in response to opioids 
 
There are a few well defined pain-related conditions in which a definitive causal gene 
has been identified. Mutations in SCN9A, which codes for a peripheral sodium 
channel, have been associated with either a complete inability to sense pain or, quite 
the opposite, an extreme pain disorder 60;61.  
 
There are substantial animal data to support the hypothesis that opioid response may 
be under genetic control. Morphine acts primarily through the mu-opioid receptor 
(MOR). MOR-knockout mice (in which the MOR gene has been “turned off”) are 
entirely refractory to the analgesic effects of morphine 62-64  and do not experience any 
side-effects from morphine 63;65. Other genetically bred strains of mice exhibit 
differential response to pain perception and opioid analgesia. For example, the CXBK 
mouse  is a genetically inbred strain which has decreased MOR expression 66. These 
animals experience markedly reduced analgesia from morphine compared to other 
mice 67. Current research summarised in the “Pain Genes database” suggests that there 
are over 300 genes, variation in which may play a role in differential pain perception 
and analgesia in animals 68.  
 
A number of genetic association studies involving pain and response to opioids have 
been carried out in healthy volunteers and non-cancer patients. As detailed later in this 
chapter, these studies have often been influential in the design of research in cancer 
patients taking opioids for pain. 
 
One of the best characterised pharmacogenetic phenomena involves codeine. Codeine, 
a weak opioid, is metabolised to morphine via the genetically heterogenous enzyme 
CYP2D6 (debrisoquine/spartenine hydroxylase) 69. Up to 10% of Caucasians (and 
varying proportions of other populations) lack CYP2D6 activity. These are known as 
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“poor metabolisers” and thus experience little analgesia from codeine, as compared to 
“extensive metabolisers 70. On the other hand, CYP2D6 gene duplication (where the 
individual has an extra copy of the region of DNA containing the gene) is associated 
with ultra-rapid metabolism of codeine to morphine, found in 3% of Caucasians 71.  
There are case reports of fatal neonatal opioid toxicity in children who are breastfed 
by a codeine-ingesting CYP2D6 ultra-rapid metabolising mother 72;73. Variation in at 
least 16 alleles has been shown to influence CYP2D6 activity 74. Recent data suggest 
that CYP2D6 phenotype also plays a role in response to tramadol 75, with CYP2D6 
gene duplication playing a role in development of respiratory depression 76. 
Surprisingly, the impact of genetic variation in CYP2D6 on codeine response has not 
been extensively studied in cancer patients. 
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1.4.2 Genetic association studies: The genetic code 
 
A number of genetic association studies have been carried out in cancer patients 
taking opioids. The aim of genetic association studies is to identify areas of genetic 
variation which are associated with an altered clinical outcome or phenotype. Genetic 
association studies are based on the central dogma of molecular biology i.e. the 
expression of genetic information stored in DNA involves transcription of this 
information into mRNA which subsequently specifies the synthesis of protein via the 
process of translation.  
 
Most of the genetic information which is interpreted to give the final protein product 
is packaged in segments known as exons. The intervening intronic sequences do not 
contain information which is used in production of the protein product.  Only a 
proportion of DNA encodes the amino acid sequence for a protein. The untranslated 
region (UTR) (which may be exonic and may be upstream to the gene (5’UTR) or 
downstream (3’UTR)) undergoes transcription but not translation. These UTRs are 
important for efficiency of translation. The promoter region is the DNA sequence 
which is located just upstream to the gene and is involved in initiation of transcription.  
 
Differences in response to drugs may be brought about by genetic variation at a DNA, 
RNA or protein level. (Figure 1.2)  
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Figure 1.2 Genetic variation at DNA, RNA or protein level may influence 
response to morphine 
 
1.4.3 DNA variation: Single Nucleotide Polymorphisms 
 
To date all genetic association studies in cancer patients taking opioids have examined 
DNA variation.  
 
DNA is made up of two opposing strands of nucleotides, with each nucleotide 
consisting of one of four bases (adenine (A), guanine (G), thymine (T) and cytosine 
(C)), a sugar and a phosphate bond. Each stretch of DNA constitutes a chromosome, 
which in turn consists of a number of genes. A gene is a stretch of DNA which carries 
the genetic information encoding a specific protein. The Human Genome project, 
which was completed in 2003, set out to map all of the genes in human DNA 
(approximately 30,000) and to sequence the 3 billion chemical base pairs that make 
up human DNA 77.  
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Polymorphisms are differences in the genetic structure which occur in greater than 1% 
of the population. Genetic variants which occur with a frequency of less than 1% are 
known as mutations. Single nucleotide polymorphisms (SNPs) are the most common 
type of genetic variant at a DNA level. A SNP represents a change in a single 
nucleotide at a particular position along the DNA strand. The different variants that a 
polymorphism may take are called alleles. In most cases there are two (but sometimes 
more) possible alternative alleles; the common (major) allele, which is carried by 
most people in the population, and the variant (minor) allele. Each SNP has a unique 
identifier, often known as an “rs number” (reference SNP number). SNPs are also 
often given names which are derived from their location in the gene and the amino 
acid change they are associated with. There are approximately 12 million known 
SNPs 78. Genetic association studies search for a link between the clinical outcome 
measured (phenotype) and these genetic variants. 
 
SNPs may influence clinical outcome through a change in the amino acid sequence 
produced by the gene, thus altering the structure or function of the enzyme / receptor / 
protein coded for by that gene. This is thought to occur in a number of ways: 
 
1) The SNP may occur in a region of the gene (known as an exon) which is translated 
into protein.   
 
 2) SNPs may also have an indirect association with changes in the final protein 
product of the gene if, through a process known as linkage disequilibrium (non-
random association), the SNP represents a marker for the true disease-susceptibility 
SNP. In this way SNPs occurring in non-coding (intronic) regions of the gene may 
appear to be associated with changes in clinical outcomes in genetic association 
studies. 
 
3) The SNP may occur in an area of the gene which subsequently alters the process 
and products of transcription and translation. 
 
As each individual has two versions of each chromosome, the genotype of an 
individual at a particular position is denoted by the combination of alleles at that 
position. In a situation where there are two possible allelic variants at a given position, 
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an individual’s genotype is determined by whether he is homozygous for either the 
major or the minor allele (i.e. carry two copies of the same allele) or heterozygous 
(carrying one copy of the major allele and one of the minor). 
Apart from SNPs there are a number of other genetic variants which may be 
associated with disease or clinical outcome, including deletion-insertion 
polymorphisms (DIPs), copy number variation (CNV) and VNTRs (variable 
nucleotide tandem repeat sequences) which alter chromosomal structure.  
 
1.4.4 Genetic association studies: Candidate genes and Genome-Wide Association 
Studies 
 
Until the recent emergence of genome-wide assays, candidate gene studies have 
traditionally been the standard for population-based (rather than family-based) genetic 
association studies. Genes are chosen for candidate gene association analysis because 
their end product (the protein they code for) is known to play a role in the outcome of 
interest, e.g. in opioid response. Candidate gene studies are therefore hypothesis 
driven, based on biologically plausible pathways. Candidate gene association studies 
have a number of advantages: 
• In general, the population frequency of most SNPs tested is known; therefore 
it is relatively easy to carry out power calculations.  
• The required sample size is often smaller than in genome-wide association 
studies (GWAS) because fewer tests are being carried out. 
• As the number of SNPs / genes tested is limited, the resulting genetic data are 
generally of a manageable volume and may be analysed using standard 
statistics and commonly used desktop statistical programmes.  
• Replication of candidate gene studies is not prohibitively expensive. 
However, candidate gene association studies are not without their limitations. As 
these studies are hypothesis driven, the amount of data and especially the amount of 
new information generated is limited by the breath of current biological and genetic 
knowledge.  
 
In recent years much attention has been focused on the concept of linkage 
disequilibrium (LD), the non-random association of genetic variants within a 
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population. It is now known that stretches of the genome are inherited together. 
Although the number of SNPs in any gene may be enormous, it is not necessary to 
analyse SNPs which are in tight LD with each other. Recent advances such as the 
International HapMap Project have involved extensive genotyping of common SNPs 
and have increased our understanding of the architecture of LD in different 
populations 79. Such data have facilitated methods of choosing subsets of SNPs (tag 
SNPs) which provide information on most of the allelic variation in a particular 
region. These data underpin the practical application of GWAS. These data also 
support the notion that all genetic association studies are indirect studies in that the 
genetic variant shown to be associated with the clinical outcome in the study may 
actually be merely a marker for the true association variant 80.  
 
GWAS allow the hypothesis-free simultaneous testing of multiple genetic variants 
across the whole genome. GWAS have recently become more feasible in terms of cost 
and statistical support. The most recent GWA platforms provide information on up to 
1 million SNPs.  
 
The first GWAS in pain was published in 2009 in a cohort of 221 patients undergoing 
oral surgery. 255,785 SNPs spanning the entire genome were simultaneously analysed 
in this study. The study outcomes included maximum post-operative pain, post-
operative pain onset and time to analgesia post ketorolac administration 81. To date all 
published genetic association studies involving cancer patients taking opioids for pain 
have been candidate gene studies. No GWAS has been yet published in this field. 
 
1.4.5 Pharmacogenetics of response to morphine: published data  
 
 
All published genetic association studies of variation in response to opioids for cancer 
pain involve analysis of SNPs. The genes involved have been chosen because their 
end product (the protein they code for) is known to play a role in opioid response.  
The opioid pharmacogenetic studies in cancer patients which have shown some 
positive results have primarily focused attention on three genes; OPRM (Mu opioid 
 45
receptor gene), COMT (catechol-O-methyltransferase gene) and MDR1 (Multidrug 
resistance 1 gene).  
 
1.4.5.1 OPRM 
 
OPRM is the gene which codes for the mu opioid receptor (MOR). This is a natural 
candidate gene as morphine and other opioids exert their effects primarily through this 
receptor. OPRM has been associated with variation in opioid response in non-cancer 
studies, including post-operative pain 82-84, labour pain 85 and in human volunteer 
studies 86-88.  
 
Over 800 polymorphisms in OPRM have been described 89. The most commonly 
studied SNP is rs1799971. This SNP is also known as A118G, the two alleles at this 
location being A and G. The frequency of the polymorphism (the G allele) varies 
depending on the population being studied, from 16% in Northern and Western 
Europeans to 46% in Japanese 90. A118G results in an amino acid change from 
asparagine to aspartic acid. This polymorphism occurs in the region of the gene which 
codes for the extracellular amino-terminus of MOR, the part of the receptor involved 
in ligand binding.  
 
Lotsch studied the association of A118G on the central effects of morphine and M6G 
in a single blind two-way crossover study healthy volunteers (N=12). Pupil 
constriction in response to IV administration of morphine or M6G was used as a 
measure of the central effects of the drug. Individuals carrying the G allele (GG or 
AG genotype) required larger doses of M6G to achieve 50% pupil constriction than 
subjects with AA genotype. In this study there was no association between morphine 
response and A118G 91. Another study of 20 healthy volunteers demonstrated that 
higher doses of alfentanil were needed to achieve analgesia in subjects with GG 
compared to AA genotype, whereas the former appeared to be protected against 
respiratory depression 86. 
 
In terms of cancer pain and response to morphine, A118G has been associated with 
variation in daily morphine dose requirements and also in overall analgesic response 
to morphine. In a single point observational study, Klepstad et al examined this SNP 
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in 99 cancer patients who were deemed to be well pain-controlled on morphine (i.e. 
their average pain score on a numerical rating scale (NRS) of 0-10 was 4 or less). 
Patients with the AA genotype (N=78) at this position required a lower dose of 
morphine (mean +/- standard deviation: 97 +/- 89 mg/day) compared to patients with 
GG genotype (N=4) (225 +/- 143mg/day), p=0.006 92. In a larger cohort of the same 
study, carriage of the G allele (genotype AG or GG) at this position was also 
associated with increased morphine dose requirements, p=0.012 93.  
 
In a study by Campa et al, 145 cancer patients who were being started on morphine 
for pain were titrated according to their individual needs and the patients were 
followed up prospectively for eight weeks. Pain scores were assessed using an 11 
point NRS and a verbal rating scale. At the end of week 1, patients with the AA 
genotype (N=106) had a mean drop in pain scores from baseline of 3.73 +/- 1.72 
(mean +/- SD) compared to 0.3 +/- 1.77 in those with GG genotype (N=10), p<0.001 
94
. 
 
The clinical relevance of OPRM A118G is difficult to interpret at this point. There are 
a number of inconsistencies in the results of studies in this area. A single time point 
observational study by Ross et al demonstrated no association between A118G and 
“morphine responders” versus “non-responders”. In this study morphine responders 
had been on morphine for at least a month and had good pain control without 
intolerable side-effects. Morphine non-responders had inadequate analgesia despite 
morphine dose-escalation and / or intolerable side-effects. 95 A study of fentanyl 
requirements in patients in labour suggested that the A allele (and not the G allele as 
in other studies) is associated with higher fentanyl dose requirements (p=0.0091) 85. A 
recent meta-analysis of eight clinical studies (cancer and non-cancer) concluded that 
at best there is only a weak association between this SNP and opioid dose 
requirements and that currently available data do not support personalised prescribing 
of opioids based on genotyping of this polymorphism 96. In this meta-analysis, the 
study by Klepstad et al 92 was excluded in favour of the larger study by Reyes-Gibby 
et al 93because of the overlap in the study population. The study by Campa et al was 
also excluded as the genotype frequencies were not in Hardy-Weinberg equilibrium 
(HWE) i.e. they deviated from expected frequencies (see chapter 2, section 2.4.2 for 
discussion about HWE). 
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A limited number of other SNPs across OPRM have also been studied in cancer 
patients on morphine. Klepstad et al examined three other OPRM SNPs (-172 G>T, 
IVS2+31 G>A and IVS2+691 G>C) but these were not found to associated with 
variation in the study endpoint, daily morphine dose requirements 92. Ross et al 
examined six other OPRM SNPs in addition to A118G (-172 G>T, 5433 C>T, 32459 
C>T, 50665 A>G, 51325 G>C and 80547 T>C). There was no difference in the 
frequencies of these SNPs between “morphine responders” versus “non-responders” 
95
.  
 
There is also controversy about the functional relevance of the A118G polymorphism. 
One study demonstrated altered receptor binding affinity for β-endorphin, but not for 
commonly used MOR agonists such as morphine or fentanyl 97. Another study 
however reported no difference in binding affinities for beta-endorphin between wild 
type receptor and the mu opioid receptor coded for by this variant but did find binding 
differences for other MOR agonists 98. A further study found no differences in binding 
of either morphine or beta-endorphin 99. One study reported reduced mRNA and 
receptor expression associated with the G allele 100. Overall, it is unclear whether 
A118G truly plays a significant role in inter-individual variation morphine response. 
 
1.4.5.2 COMT 
 
The COMT gene codes for catechol-O-methyltransferase, an enzyme involved in the 
metabolism of catecholamines including adrenaline, noradrenaline and dopamine. 
These substances act as neurotransmitters in the brain. There is considerable evidence 
of interaction between the opioidergic and catecholamine systems 101-103. Reduced 
COMT activity leads to elevated catecholamine levels which have been associated 
with increased experimental pain sensitivity 102;104.   
 
The most commonly studied polymorphism in this gene is rs4680, also known as 
Val158Met.  This SNP is associated with an amino acid change from valine (val) to 
methionine (met), which is associated with reduced enzyme activity 105. One of the 
earliest genetic studies of this polymorphism genotyped 29 healthy volunteers and 
measured pain response to saline infused into the masseter muscle. The volume of 
saline necessary to reach and maintain a certain level of pain intensity was used as a 
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measurement of pain sensitivity. Patients with the met-met genotype had increased 
pain sensitivity, i.e. they experienced pain at lower volumes compared to those with 
the val-val genotype. Subjects homozygous for met also exhibited decreased regional 
brain opioid system activation 102.  
 
Diatchenkos group subsequently identified haplotypes (combinations of SNPs, see 
section 2.4.3) which were associated with variability in pain sensitivity 106. It has been 
proposed that the COMT haplotypes alter mRNA structure 107. Interestingly the 
haplotype study did not find a significant association between pain sensitivity and 
Val158Met. Indeed, the haplotypes associated with “low pain sensitivity” and “high 
pain sensitivity” both contained the allele at this position which coded for the val 
variant and it was the haplotype representing the intermediate pain sensitivity which 
had the allele coding for the met variant 106. In a later paper the same group examined 
the influence of COMT haplotypes and the Val158Met SNP on different types of 
painful stimuli and concluded that while the haplotypes were associated with 
differential resting pain sensitivity, the Val158Met SNP was associated with the rate 
of temporal summation of heat pain 103. Like OPRM however, there are 
inconsistencies in the reported data. Kim et al did not find any strong association 
between Val158Met and experimental pain sensitivity (n=500) or post-operative oral 
pain 108;109. In the latter study results of COMT haplotype analysis also gave 
conflicting results to previous data.  
 
Intriguingly in two Norweigan studies (N=207, taken from the same study population) 
of response to morphine for cancer pain, patients with the met-met genotype required 
lower doses of morphine than those with val-val, (mean 24 hour dose 95mg met-met 
versus 155mg val-val)93;110. As the met allele is associated with reduced COMT 
activity, it is associated with increased dopamine concentrations with subsequent 
suppression of enkephalins 101. This in turn is associated with compensatory 
upregulation of mu-opioid receptor expression 102;111. The authors therefore propose 
that the opioid receptor upregulation might be associated with an increased effect 
from morphine in met-met individuals with subsequent lower morphine dose 
requirements 110. The same group also analysed haplotypes across the entire COMT 
gene and found an association between a haplotype containing the A allele coding for 
met and morphine dose requirements, p=0.006. Other haplotypes however which also 
 49
contained the A allele at this position were not associated with variability in morphine 
dose 112.  
 
The same Norweigan study population was used to examine the joint effects of 
COMT Val158Met and OPRM A118G on variability in morphine dose requirements 
for cancer pain. Consistent with the group’s previous findings, they concluded that 
subjects with genotype OPRM A118G AA and COMT met-met required the lowest 
morphine dose, p=0.012 93. 
 
One study in cancer pain compared inter-individual variation in response to oral 
morphine in terms of development of central side-effects, showing an association 
between two intronic SNPS in COMT (rs7290221 and rs5746849) but not Val158Met 
and an increase in confusion, drowsiness and hallucinations 113.  
Overall, as for OPRM, the number of studies examining genetic variation in COMT in 
cancer pain is small and the data regarding genetic variation in COMT and opioid 
response are as yet incomplete.  
 
1.4.5.3 MDR-1 
 
MDR-1 (Multidrug resistance 1 gene), also known as ABCB1 (ATP-binding cassette 
B1), codes for p-glycoprotein which regulates the transport (efflux) of morphine from 
the brain into the blood across the blood-brain barrier 114. Reduced p-glycoprotein 
levels / activity results in enhanced analgesia from systemically (but not centrally) 
administered morphine 115. MDR1 knockout mice exhibit an increased ratio of brain: 
plasma morphine concentrations compared to normal mice 116. In animal studies, 
pharmacological inhibition of p-glycoprotein increased the concentration of morphine 
in the brain, with improved analgesic effect 117;118.  
 
Most genetic studies have involved three MDR-1 SNPs; C3435T (rs1045642), 
GT2677A (rs2032582) and C1236T (rs1128503). A study of 126 Korean patients 
having intravenous fentanyl found an association between MDR-1 SNPs C3435T and 
GT2677A and respiratory suppression (p=0.0056) 119. Subjects homozygous for the 
variant of SNP C3435T (genotype TT) have a reduced level of p-glycoprotein 
expression 120.   
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SNPs in MDR-1 have been examined in two studies of cancer patients taking 
morphine. C3435T was found to be associated with variability in pain relief in 
Campa’s study of patients starting morphine for cancer pain. Patients with genotype 
TT (N=38) at this position had greater pain relief than those with CC (N=49), 
p<0.001.  In this study the joint effects of OPRM A118G and MDR-1 C3435T were 
also examined. Patients with genotype OPRM A118G AA and MDR-1 C3435T TT 
appeared to have better pain relief compared to other combinations. The interaction 
analysis however was not statistically significant 94.  GT2677A and C1236T, but not 
C3435T, were associated with a decreased level of central side-effects (drowsiness, 
confusion, hallucinations) in a study of 228 patients on morphine for cancer pain. In 
this study the protective alleles MDR-1 2677G and COMT -4873G were 
independently associated with fewer central side-effects on multivariate analysis 113.  
 
There remains some controversy about the functional relevance of MDR-1 
polymorphisms in opioid response 121-123. 
 
1.4.5.4 Other Genes 
 
The association between the response to morphine for cancer pain and a number of 
other genes has also been studied with mixed results.  
 
One study has examined the influence of cytokine gene polymorphisms on analgesic 
response based on the idea that tumour-induced mediators such as cytokines may 
cause inflammation and modulate cancer pain. This study included 140 patients with 
lung cancer who were referred for pain management to the supportive care specialists. 
Subjects scored their pain on an 11-point NRS at baseline and 30 days after their first 
assessment. TNFα -308G>A was associated with variation in pain severity at 30 days, 
p=0.04. IL-6 -174G>C was associated with differences in morphine equivalent daily 
dose, p=0.004 124.  
A SNP in the gene coding for β-arrestin (ARRB2) was found to be associated with 
differences between morphine responders and morphine non-responders (p=0.013) 95. 
β-arrestin is an intracellular protein which acts as inhibitor of receptor coupling and is 
a negative regulator of opioid receptor signalling. 125 B-arrestin2 knockout mice have 
enhanced morphine analgesia.126 Two SNPs in stat6, a gene involved in MOR 
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transcription, were found in the same study to be weakly associated with morphine 
responders versus non-responders 127.  
 
An obvious candidate gene in pharmacogenetic studies of opioids is UGT2B7 (uridine 
diphosphate-glucuronosyltransferase 2B7). The enzyme coded for by this gene 
metabolizes morphine to morphine-3- and morphine-6-glucuronide (M-3-G and M-6-
G). A small study (N=12) of patients using morphine via a patient-controlled 
analgesic pump found an association between a SNP in the promoter of UGT2B7 and 
morphine, M-3-G and M-6-G concentrations 128. Polymorphisms in this gene were not 
found to be associated with concentrations of morphine or its metabolites in two 
larger studies in cancer patients (N=70 and 239) 129;130. Similarly UGT2B7 SNPs were 
not found to be associated with any difference between morphine responders and non-
responders 95. 
 
GCH1 (Guanosine Triphosphate Cyclohydrolase 1) is an enzyme involved in the 
production of BH4 (tetrahydrobiopterin), which in turn is associated with pain 
sensitivity. SNPs in GCH1 have been associated with reduced BH4 expression and 
subsequently reduced non-cancer pain 131. A recent study of 251 cancer patients found 
an association between SNPs in GCHC1 and time between cancer diagnosis and 
opioid therapy initiation. The authors proposed that a longer time interval suggested 
protection from pain 132. The clinical application of such data are uncertain. 
 
There have been a number of other genes which have been analyzed in animal, human 
volunteer or non-cancer pain studies which may play a role in opioid responsiveness 
but which not to date been studied extensively in cancer pain. These include MC1R 
(melanocortin-1 receptor gene)133 and CYP2D6 134. 
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EPOS: multicentre European pharmacogenetics of opioids study 
 
The largest pharmacogenetics of opioids study in cancer patients has just recently 
been published. Two thousand two hundred and ninety four cancer patients on a 
variety of opioids, from 17 centres in 11 European countries were included. This was 
a single time point observational study. One hundred and twelve SNPs in 25 genes 
were analysed and the study population was divided into a test set and a validation set. 
None of the SNPs tested were significant in the validation set and none were 
significant on subgroup analyses which included stratification according to opioid 135. 
The genes tested were OPRM (Mu opioid receptor), OPRD (Delta opioid receptor), 
OPRK (Kappa opioid receptor), ARRB2 (Β-arrestin 2), GNAZ (guanine nucleotide 
binding protein), HINT1 (histidine triad nucleotide binding protein 1) , Stat6 (signal 
transducer and activator of transcription 6), ABCB1 (p-glycoprotein transporter/ 
Multidrug resistance 1), COMT (Catachol-O-methyl transferase), HRH1 (Histamine 
Receptor 1), ADRA2A (α2A adrenergic receptor), MC1R (melanocortin 1 receptor), 
TACR1 (neurokinin 1 receptor), GCH1 (GTP cyclohydrolase 1), DRD2 (Dopamine 
receptor D2), DRD3 (Dopamine receptor D3), HTR3A (serotonin 5HT-3A receptor), 
HTR3B(serotonin 5HT-3B receptor), HTR2A(serotonin 5HT-2A receptor), 
HTR3C(serotonin 5HT-3C receptor), HTR3D(serotonin 5HT-3D receptor), 
HTR3E(serotonin 5HT-3E receptor), HTR1 (Histamine receptor 1) and 
CNR1(cannabinoid receptor 1). 
 
The current data supporting a practical role for genetic variation on response to 
opioids for cancer pain is limited. A recent study analyzing the prospective impact of 
the most commonly studied genetic variants in OPRM, COMT, MDR1 and CYP2D6 
on opioid dose requirements, pain scores and side-effects in 352 patients attending an 
outpatient pain clinic concluded that, based on current knowledge, genotyping for 
current known genetic variants “barely merits the laboratory effort” 136. Current data 
do not support incorporation of genetic assays into the clinical management of cancer 
pain 137. None of the studies to date have identified any genetic variant which could be 
used to prospectively predict opioid response. 
 53
1.4.6 RNA variation: Splice Variants 
 
A single stretch of DNA can result in a number of different protein products, mainly 
through RNA modification. The existence of multiple mu opioid receptor subtypes as 
a result of a process known as alternative splicing has been recently proposed. 
Splicing refers to a process of post-transcription modification in which intronic 
material is removed and exons are joined together to form messenger RNA (mRNA). 
mRNA is subsequently translated into the protein product, which in the case of 
OPRM is the mu-opioid receptor. Different splicing products with potentially 
different functions can be formed through different arrangements of the exons in the 
mRNA.  
 
The concept of multiple receptor subtypes is not new, suggested by a) incomplete 
cross tolerance between various mu-opioid receptor agonists 138 and b) differential 
actions of mu-opioid receptor agonists and antagonists 139. Sophisticated rodent 
studies using inbred strains and knockout strains have further strengthened this 
concept. Mu-opioid receptor knockout mice demonstrate a complete loss of all mu-
opioid receptors from the brain, suggesting that if mu-opioid receptor subtypes exists, 
they must be derived from the same gene 64. The CXBK mouse, as mentioned above 
(section 1.4.1), is poorly responsive to morphine. CXBK mice have reduced levels of 
OPRM1 mRNA, with subsequent reduced expression of mu-opioid receptors and less 
signal transduction 66. CXBK mice however retain analgesic sensitivity to morphine-
6-glucuronide (M-6-G), heroin and fentanyl, all mu-opioid receptor agonists, 
suggesting that M-6-G, heroin and fentanyl act via a different mu-opioid receptor than 
morphine 140.  
 
Opioid receptors are G-protein coupled receptors. These receptors have an 
extracellular amino terminus and an intracellular carboxyl tail. (Figure 1.3) They span 
the cell membrane seven times resulting in three intracellular and three extracellular 
domains. The three opioid receptors (mu, delta and kappa) share approximately 60% 
structural homology 141, with the main differences being in the transmembrane regions 
and extracellular loops 142.  These extracellular loops are important for ligand binding. 
The first extracelluler loop has been shown to be critical for binding of the MOR-
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specific peptide, DAMGO.143 The extracellular amino chain is also important in 
ligand binding in MOR (mu-opioid receptor). The sixth transmembrane domain and 
the third extracellular loop of DOR (delta opioid receptor) is critical for DOR 
selectivity. 144 The 2nd and 3rd intracellular loops as well as the carboxyl tail are 
important in the interaction between the receptors and G-proteins 145. Receptor 
signaling is markedly impaired in DOR lacking the 3rd intracellular domain 146.  
 
 
Figure 1.3 Structure of opioid receptor 
 
The structure of the human mu-opioid receptor gene has been cloned 147. OPRM was 
initially thought to be made up of 4 exons, although more recent work suggests that it 
is in fact much more complex 148. Each exon is thought to be important for expression 
of different parts of the mu-opioid receptor. Exon 1 codes for the amino-terminal of 
the receptor and exons 1, 2 and 3 code for the transmembrane domains and 
intra/extracelluler loops 149. Exon 4 codes for the distal portion of the carboxyl chain 
of the receptor which is important in coupling the receptor to intracellular signalling 
systems and events. Knockout animals and antisense probes have been used to 
examine the impact of blocking expression of parts of a gene of interest. Rodents 
without expression of exon 1 have significantly reduced morphine analgesia but retain 
sensitivity to M-6-G 150;151. Conversely, rodents with loss of exon 2 expression exhibit 
decreased M-6-G and not morphine analgesia 150. These data suggest that morphine 
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and M-6-G may act on different mu-opioid receptor subtypes, which may be brought 
about through variation at an RNA level.  Even more intriguing is that although 
antisense blockade of exon 1 expression inhibited supraspinal morphine analgesia, it 
did not have any effect on spinal morphine analgesia, suggesting that perhaps 
different mu-opioid receptors are involved in both processes 152. Antisense blockade 
of exon 4 inhibited all morphine effects 150;152. Immunohistochemical labelling of mu-
opioid receptor splice variants demonstrated differential distribution in the brain and 
spinal cord suggesting region specific processing of OPRM into different mu-opioid 
receptor subtypes 153. 
 
Practical challenges of examining human brain RNA means that most research in this 
area has been carried out in vitro using cell lines expressing mu opioid receptors 154. 
Ten human splice variants have been identified resulting from alternative splicing at 
exon 4 154;155. Since exons 1-3 remain conserved, all of these splice variants bind mu-
opioid agonists, but there are differences in terms of function eg receptor 
internalisation and regional distribution 152. One study examining human brain tissue 
resected at time of temporal lobectomy for epilepsy demonstrated the presence of mu-
opioid receptor splice variants through reverse transcriptase polymerase chain reaction 
156
. Alternative splicing of delta and kappa opioid receptors has also been 
demonstrated 157.  
 
There are some human data supporting the role of splice variants in pain perception. A 
recent study by Diatchenko et al analysed patterns of genetic material between mice 
and humans. Although there are differences in the structure of mouse and human 
OPRM, this study demonstrated that a) most mouse OPRM exons (of which there are 
20) also exist in humans and b) the architecture of the human OPRM is probably more 
complex than previously thought. A SNP in OPRM, rs563649, was associated with 
both altered pain response and differential translation of splice variants of mu opioid 
receptor 148. To date no studies have been carried out examining the association 
between opioid receptor expression / splice variants and response to morphine in 
cancer patients in the clinical setting.  
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1.4.7 Protein variation: receptor dimerisation  
 
Finally, even after the genetic code is translated into a protein product, modifications 
and variation in function may occur through the process of receptor dimerisation.  
Morphine acts primarily through the mu-opioid receptor. Animal studies have 
demonstrated that disruption of the mu-opioid receptor gene abolishes the analgesic 
effect of morphine despite the presence of functional delta and kappa opioid receptors 
63
. However binding studies suggest that morphine does bind to delta and kappa 
receptors, albeit with less affinity than to mu-opioid receptors 24;158. Although the role 
of delta and kappa opioid receptors in morphine response is not entirely clear, there is 
a suggestion that opioid receptors interact with each other and influence function 159-
162
. For example delta-receptor knockout mice do not develop analgesic tolerance to 
morphine 163. Opioid receptors can form homo and hetero-dimers, thus producing 
novel functional properties through altered ligand binding and differential intracellular 
receptor trafficking 164-166. Opioid receptor dimerisation adds further to the complexity 
of inter-individual variation in opioid response. There have been no clinical studies 
examining the role of opioid receptor dimers on analgesic response to morphine for 
cancer pain.  
 
1.5 Clinical phenotype in opioid genetic studies 
 
One of the main challenges in interpreting genetic association studies in cancer and 
palliative care is that there is little consensus with respect to definition of outcome 
measures in pain and analgesia studies 167. Most opioid genetic association studies 
have chosen one aspect of pain or side-effects to determine the primary outcome. This 
approach risks overlooking the complexity that defines morphine response. Some 
studies have examined the level of pain sensation before and after administering the 
drug 94;168. Other studies have studied the dose of opioid required by individual 
patients 82;83;85;92;93;110;135. In cancer studies the dose of morphine for pain control 
92;93;110
 and the change in numerical rating scores (NRS) for pain 94 have been used as 
measures of response to opioids. One study explored differences in central side-
effects in cancer patients on morphine as an outcome measure 113 however most 
studies included side-effects as a secondary outcome. Another study has examined the 
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length of time between cancer diagnosis and initiation of opioid therapy as an 
outcome measure. 132  
 
The situation is made more complex by the fact that there is no standardised system 
for cancer pain assessment or indeed choice of pain intensity scale. 169;170 This lack of 
consensus and standardisation makes it difficult to compare results from different 
studies and may be one of the reasons underlying non-replication of genetic data in 
this field 171. 
 
For genetic association studies to be useful and translational to clinical practice, the 
phenotype of response to a drug must be clinically meaningful. 
 
Previous work in our department focused on the genetic and clinical associations with 
morphine responders and non-responders. 39;53;95  In the Royal Marsden study, patients 
were recruited into one of two cohorts according to patients’ subjective experience 
and the observations of the experienced clinical team. “Morphine responders” were 
patients who had been on morphine for at least one month and who were experiencing 
adequate analgesia without problematic side-effects. “Morphine non-responders” 
were defined as those patients who failed to achieve adequate analgesia despite 
escalating morphine doses or who experienced subjectively intolerable side-effects. 
Morphine response / non-response was reported by the patient and assessed and 
determined by the clinical palliative care team. The phenotype of morphine responder 
versus non-responder was used in subsequent genetic association studies 95.  To date 
no clinical or genetic factors have been identified which are significant or robust 
enough to be used in clinical practice to prospectively predict morphine responders / 
non-responders.   
 
Perhaps one of the reasons for this is that response to morphine must be considered a 
complex trait. Most complex human diseases are multi-factorial in nature. Pain is one 
of the most complex measurable traits, contributed to by a number of physical, 
genetic, environmental and psychological components 172. Therefore response to 
morphine for cancer pain must be equally as complex.  
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Morphine non-response is broadly defined as inadequate pain control or intolerable 
side-effects. What constitutes morphine response / non-response in one individual 
may be very different in another individual. Morphine response is not a 
homogenously defined outcome; rather it is determined by a balance between a 
number of interacting predictor variables contributing to pain control and different 
side-effects (see fig 1.4). There are no data to suggest that pain and side-effects may 
not be modified by different clinical and genetic factors. 
 
Two of the challenges in examining such a complex phenotype are 1) trait 
heterogeneity and 2) phenotypic variability 173. In terms of response to morphine, trait 
heterogeneity occurs when the definition of response / non-response does not take into 
account the fact that it is actually made up of a number of distinct underlying traits, 
e.g. pain and different side-effects. A patient who is considered a morphine non-
responder due to lack of analgesic efficacy does not have the same clinical phenotype 
as one which is a morphine responder because of intolerable drowsiness. Phenotypic 
variability occurs when there are differences in the time of onset of analgesia / side-
effects and / or the severity of side-effects or degree of analgesia in morphine 
responders / non-responders. Trait heterogeneity and phenotype variability result in a 
heterogeneous model of response to morphine.  
 
 
Figure 1.4 Trait heterogeneity in morphine response.  
Morphine response is not a homogenously defined outcome 
Adapted from 173 
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1.6 Opioids for neuropathic pain 
 
The role of opioids in the treatment of neuropathic pain in both cancer and non-cancer 
settings has been controversial. Evidence exists however supporting the analgesic 
efficacy of these agents for neuropathic pain. 
 
A Cochrane review in 2009 examined the efficacy and tolerability of opioids for 
neuropathic pain of mixed aetiologies. The authors divided the studies according to 
study duration. Short term studies were defined as those in which subjects received a 
single opioid dose or an intravenous infusion and in which outcomes were measured 
for less than 24 hours. All other studies included in the review were considered to be 
“intermediate-term” studies. The median duration of these latter studies was 28 days 
(range 8-70 days). Only studies of pure opioid agonists were included, therefore 
studies of tramadol or buprenorphine were excluded. The short terms studies did not 
provide convincing evidence for the use of opioids in the management of neuropathic 
pain. The intermediate studies however did demonstrate a significant reduction in 
neuropathic pain intensity of 13 points (CI -16 to -9) on a 100 point VAS. The 
subjects in these studies had a variety of neuropathic pains including post herpetic 
neuralgia, diabetic neuropathy and phantom limb pain 174. 
 
A review of RCTs between 2005 and 2010 calculated the NNT (number needed to 
treat) to achieve 50% pain relief for different neuropathic pain treatments. This review 
included RCTs which used chronic dosing and placebo but excluded studies of cancer 
neuropathic pain except for a number of defined post-surgical cases. The NNT for 
opioids in painful polyneuropathies (2.6 (CI 1.7-6) was less than that of gabapentin 
(6.4 (CI 4.3-12) but more than that for tricyclic antidepressants (2.1 (CI 1.9-2.6). The 
combined overall NNH (number needed to harm) were comparable between opioids 
(17.1 (CI 9.9-66)) and TCAs (15.9 (CI 11-26) but the NNH for gabapentin was much 
higher (32.5 (CI 18-222)) 175.  
 
Most published guidelines on the management of neuropathic pain recommend the 
use of opioids as second or third line treatment, after other agents such as tricyclic 
antidepressants, pregabalin and duloxetine. This recommendation is based on the lack 
of reliable quality evidence for strong opioids in neuropathic pain and the concerns of 
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long term dependence and the risk of serious adverse effects or overdose 176;177. The 
recent NICE guidelines suggest that strong opioids should only be started after review 
in a specialist clinic 176. However in some select clinical circumstances, such as cancer 
related neuropathic pain, opioids may be recommended as first line therapy 178.  
 
A review of 22 studies including 13,683 cancer patients demonstrated that 
neuropathic pain is a significant problem, with a prevalence among this population of 
19-39% 179. Despite the lack of reliable randomised controlled trials of opioids in 
neuropathic cancer pain, there are studies which promote the efficacy of these drugs 
in this setting. A study of 593 cancer patients demonstrated the efficacy of pain 
management according to the WHO analgesic ladder, the outcomes of which were not 
dependent on whether the pain was nociceptive (N=380), neuropathic (N=32) or 
mixed (N=181) 180. It appears however that neuropathic cancer pain may need a 
slightly different approach with opioids, as compared to non-neuropathic cancer pain. 
A prospective study of 167 cancer patients who were commenced on opioid therapy 
demonstrated the analgesic efficacy of opioids for patients with “definite neuropathic 
pain”, as classified by defined criteria. As compared to patients with “unlikely 
neuropathic cancer pain”, patients with “definite neuropathic pain” required more 
aggressive opioid titration and management, including opioid switching and the 
management of opioid side-effects 181. There is a lack of direct comparisons between 
opioids for cancer-related neuropathic pain.  
 
Cancer related neuropathic pain is often treated with additional adjunct analgesic 
agents which are used alongside opioids because they target specific neuropathic pain 
mechanisms. Compared to non-cancer neuropathic pain however, the analgesic effect 
sizes of these adjuncts are generally smaller and there is a high incidence of side-
effects 182.   
 
 61
1.7 Constipation on morphine  
 
1.7.1 Constipation in cancer patients taking opioids 
 
Constipation is a significant problem in cancer patients, occurring in 30 - 50% of this 
population 183-185.  Constipation in hospice patients is almost as prevalent as pain, 
(52% versus 62% respectively) 186. Constipation has also been shown to be a cause of 
considerable distress in patients approaching end of life.187 Although the pathogenesis 
of constipation is multi-factorial 188, opioid medication plays a key role 189.  The 
reported prevalence of constipation amongst all patients taking opioids ranges from 50 
– 100% 189;190. Constipation in palliative care patients on opioids also has financial 
implications 191. 
 
Although there have been a number of papers examining the effects of morphine in 
cancer patients in terms of analgesia and side-effects 192;193, there have been few 
studies specifically focusing on the constipating effects of opioids in cancer patients. 
The numbers of patients included in these studies have tended to be small 194-196. The 
current literature is conflicting in terms of the clinical relationship between opioids 
and constipation. The questions of whether there is a dose-response relationship and 
whether tolerance to constipation develops remain to be answered.    
 
Constipation in cancer patients taking morphine was chosen for in-depth evaluation as 
part of this thesis because 1) there has been relatively little comprehensive study in 
this area to date and 2) there is recent interest in this topic with the advent of new 
opioid antagonists for the treatment of constipation.  
 
1.7.2 Action of opioids on the gastrointestinal tract 
 
Endogenous opioids are thought to play a role in regulating bowel function in healthy 
individuals who are not taking opioids 197. Unlike opioid-analgesia, opioid-induced 
constipation is thought to be mediated predominately by peripheral rather than central 
mechanisms 198:  
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• In vitro experiments have demonstrated inhibitory effect of opioids on isolated 
gut muscle preparations 199.  
• The constipating effects of centrally administered morphine are abolished in 
animals in which the intestine has been rendered refractory to central 
influences through vagal resection. In the same animals however, 
subcutaneous morphine still produced anti-diarrhoeal action 200.  
• Peripherally restricted opioid agonists such as loperamide which do not cross 
the blood-brain barrier also cause a reduction in gut transit 201. 
  
MOR, KOR and DOR are found throughout the gastrointestinal tract and are involved 
in gastrointestinal function 202;203. In humans MOR are found primarily in the 
submucosal and myenteric plexuses and also in cells of the lamina propria. KOR are 
confined to the myenteric plexus and are also found in mucle cells. DOR in humans 
are localised on both the myenteric and submucosal plexuses, in the muscle and in the 
mucosa 202.  Morphine is thought to act directly on these peripheral opioid receptors in 
the bowel.  
 
Opioids cause constipation by increasing gut transit time and reducing gut luminal 
fluid content. Opioid receptor activation results in an overall reduction in neuronal 
excitability through an increase in membrane potassium permeability204, an inhibition 
of voltage-gated calcium channels205 and a reduction in cAMP production 206. This 
causes a disruption in the integrated propulsive gut contractions and enhances non-
propulsive contractions which may also lead to tonic spasm and abdominal cramping 
207
. The stool remains in the gut for longer due to increased transit time resulting in 
more water re-absorption and thus the stool becomes hard and dry. Opioid receptor 
activation also has an indirect inhibitory effect on secretomotor neurones which 
results in less fluid in the gut lumen 208. 
 
Opioid receptor activation results in changes in some of the key hormones, receptors 
and molecules involved in gastrointestinal function. Release of acetylcholine, an 
important excitatory neurotransmitter in the gastrointestinal tract, is reduced. 
Serotonin is released which acts through 5HT2 receptors to increase the release of 
noradrenaline. Noradrenaline plays a role in the inhibition of intestinal secretion 208. 
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1.7.3 Current management of constipation in patients taking opioids 
 
Published studies suggest that constipation in cancer patients is generally poorly 
managed 209. There may be a number of reasons related to definition, assessment and 
treatment.  There is currently no gold standard for the management of constipation in 
cancer and palliative care patients because robust clinical trials in this area are lacking 
210
. 
 
The management of constipation has traditionally been based around oral and rectal 
laxative use. There are a number of different agents available but to date there is no 
evidence that any one laxative is superior to another, mainly because there have been 
few studies in this area 210;211. All laxatives, given in sufficient quantities, are capable 
of normalising bowel function in most constipated patients 194;212 Drug compliance is 
often an issue in cancer patients, not least because of poly-pharmacy. Most symptom 
control guidelines recommend prescribing concurrent laxatives for all patients taking 
opioids. In cancer patients the use of combination laxatives (a softening agent and a 
stimulant) is recommended in order to maximise efficacy and minimise side-effects 
213
. It has been suggested that it is not possible to define accuarately any fixed opioid-
laxative dose relationship because of inter-individual variation in terms of bowel 
function and response to medications 195. It is also recommended that laxative 
treatment is titrated according to individual patient need and symptoms 196;214, rather 
like opioids are titrated to pain.  
 
1.7.4 Opioid antagonists for opioid-induced constipation 
 
In recent years there has been increased interest in the use of opioid receptor 
antagonists for the management of opioid induced constipation.  Theoretically opioid 
receptor blockade by an agent which does not cross the blood brain barrier would 
inhibit peripherally mediated gastrointestinal side-effects without interruption of 
centrally-mediated opioid analgesia. The main three opioid receptor antagonists which 
have been studied for this purpose: naloxone, methylnaltrexone and alvimopan.   
Naloxone is a pan-opioid receptor antagonist with a high affinity for mu-opioid 
receptors. Systemically administered naloxone is used to reverse life-threatening 
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opioid toxicity and acts both peripherally and centrally. Oral naloxone however 
undergoes significant hepatic first pass glucuronidation to produce inactive 
metabolites 215, resulting in a very low (2%) oral bioavailability 216.  The role of oral 
naloxone as a peripheral opioid antagonist in cancer patients has been examined in a 
number of small early studies with good effect 217-219. These studies however all 
demonstrated that the risk of precipitating pain or opioid withdrawal is substantial. 
Recently there has been increased interest in the use of fixed dose combination of 
prolonged release (PR) oral oxycodone / naloxone as a method to provide analgesia 
while preventing opioid-induced constipation.  A multicentre prospective placebo-
controlled randomized double-blind phase II trial of 202 patients with severe chronic 
pain concluded that a 2:1 oxycodone:naloxone ratio was optimal in terms of safety 
and efficacy. Only 2.5% of study participants in this study had a cancer diagnosis 220. 
There was no significant difference in the mean pain intensities between treatment 
groups but there was an improvement in bowel function according to naloxone dose 
(p<0.05). Opioid withdrawal was not formally assessed in this study. Similar studies 
with 12 week follow-up periods comparing oxycodone / naloxone (2:1 ratio) PR with 
oxycodone PR alone demonstrated a significant improvement in bowel function in 
those taking the oxycodone/naloxone combination (p<0.0001) 221;222. The maximum 
oxycodone dose (as part of the oxycodone/naloxone combination) in these studies was 
80mg/day. Studies involving higher opioid doses with longer follow-up are warranted. 
Large studies of this combination of oxycodone / naloxone combination in a 
predominately cancer population have not yet been published.   
 
Methylnaltrexone is a quaternary opioid antagonist which does not readily cross the 
blood brain barrier because of its reduced lipid solubility and increased polarity 223. It 
is a non-selective opioid antagonists with preferential mu-opioid receptor binding 207. 
Methylnaltrexone was originally studied in healthy volunteers who were given 
intravenous placebo, placebo + morphine or methylnaltrexone + morphine. 
Methylnaltrexone significantly prevented morphine-induced increase in oral-caecal 
transit time but did not affect morphine analgesia 224. A randomized placebo-
controlled trial was carried out involving 22 subjects who were enrolled on a 
methadone maintainance programme. All subjects who received methylnaltrexone 
(intravenous) had a laxation response without opioid withdrawal or significant side-
effects 225.  
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A large randomized placebo-controlled phase III study using subcutaneous 
methylnaltrexone in 133 patients with advanced illness has been carried out 226. Study 
subjects were administered 0.15mg/kg methylnaltrexone SC or placebo every second 
day for two weeks. The primary endpoints of this study were the proportion of 
subjects who had a rescue-free laxation (without the use of an enema or suppository) 
within four hours of the first dose and the proportion that had a rescue-free laxation 
within four hours after two or more of the first four doses. Subjects were also assessed 
for overall pain scores and opioid withdrawal. Forty eight percent of patients 
receiving methylnaltrexone had a rescue-free laxation within the first four hours after 
the first dose, compared to 15% who received placebo (p<0.001). Approximately 50% 
of patients who had a rescue-free laxation within four hours had a response within 
30minutes, suggesting a rapid onset of action. There were no differences in pain 
scores between the methylnaltrexone and placebo groups and there was no evidence 
of significant opioid withdrawal. Only 59% (78/133) of study patients had a cancer 
diagnosis 226. A similar study in 154 patients with advanced illness receiving a single 
dose of 0.15 or 0.3mg/kg SC methylnaltrexone or placebo demonstrated a laxation 
within 4 hours for 58-62% of patients, depending on the dose administered 227. SC 
methylnaltrexone is licensed in the UK for palliative care patients as either 8 or 12mg 
depending on body weight 228. Large studies evaluating the safety of methylnaltrexone 
are warranted 211. 
 
Alvimopan is a large oral peripherally restricted opioid antagonist with high affinity 
for mu-opioid receptors 229. It is metabolised in the gut 230. Systemic absorption ranges 
from 0.03% in dogs to 6% in humans 231. Studies in non-cancer and post-operative 
patients are encouraging 232-235. A large study in patients with cancer pain has been 
carried out but the final results have not yet been published fully. Concern about 
cardiovascular side-effects have been raised 236-238. 
 
Just as patients have a variable response to the constipating effects of opioid agonists 
such as morphine, there also appears to be inter-individual variation in response to 
opioid-antagonists. The study of 133 patients taking methylnaltrexone for opioid-
induced constipation demonstrated a 48% response rate 226. Although highly 
significant as compared to placebo, these results suggest that, as with opioid agonists, 
response to opioid antagonists may vary at an individual level. The authors theorised 
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that the lack of response in some patients may have been attributable to centrally-
mediated constipation or to other non-opioid constipating factors 226.  
 
Endogenous opioids are thought to play a role in the physiological regulation of gut 
function 239-241. Studies with opioid receptor antagonists support this idea. Early 
studies on isolated pieces of human ileum demonstrated increased muscle contraction 
when bathed in methylnaltrexone, even in the absence of morphine 242. Furthermore, 
in the absence of morphine, repeated intravenous administration of methylnaltrexone 
in healthy human volunteers demonstrated a significant reduction in gut transit time 
(as measured by the hydrogen breath test) 243. Oral naloxone has been shown to 
improve gut function in patients with chronic idiopathic constipation, although the 
numbers of patients studied was small 244. In vitro studies using guinea pig ileum 
demonstrated that alvimopan increases contractions and mechanical activity in 
morphine-naïve animals 245. 
 
The development of opioid receptor antagonists is exciting; however a recent 
Cochrane review urges some caution 238. These agents have not been directly 
compared against each other and they have not been compared to best current clinical 
practice with oral and rectal laxatives. In some of the larger studies, as constipation 
was a pre-requisite to entering the study, these individuals were clearly on an 
inadequate laxative regimen from the outset 226;246. Most data suggest that these agents 
are more efficacious than placebo in improving opioid-induced bowel dysfunction. 
Long term safety data however is warranted. Animal studies suggest that chronic use 
of opioid-receptor antagonists may actually result in an increase in the number of 
opioid receptors, which in turn may lead to increased sensitivity to the constipating 
effect of opioid agonists and a resultant dependence on opioid antagonists 247. It has 
also been suggested that the effects of opioid-antagonists may in fact be proportional 
to the degree of opioid agonist tolerance and that patients on higher doses of opioid 
agonists may in fact be more at risk of adverse effects from drugs such as naloxone 
248
. 
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1.7.5 Assessment of constipation in cancer and palliative care patients 
 
Assessment of constipation has been reported to be poor in palliative care patients 249. 
This may be for a number of reasons. Firstly there is no standardised definition of 
constipation in cancer patients, which makes objective assessment difficult. Secondly, 
constipation often means different things to different people 250, which makes 
interpretation of subjective assessment difficult. Finally, few constipation assessment 
tools have been specifically designed and validated for use in cancer patients and such 
tools are not in general use in UK hospitals.   
 
Two dimensions of constipation definition in palliative care have been proposed: 1) 
measurable objective symptoms i.e. frequency of bowel movements and 
characteristics of defaecation and 2) the patient’s subjective perception of 
constipation251. 
 
1.7.5.1 Constipation: subjective assessment 
 
Constipation in cancer and palliative care patients differs from constipation in 
gastroenterology clinics in that in the former it should be treated as a symptom while 
in the latter it may be a disease process in its own right. The scale of distress caused 
by symptoms (including constipation) and the perception of severity of the symptom 
are largely subjective assessments 252. In gastroenterology, subjective assessment of 
the presence of constipation does not correlate with the presence of constipation as 
defined by standardised criteria 253. The same appears to be true in cancer and 
palliative care 254. In cancer and palliative care patients therefore, the symptom of 
constipation from the patient’s subjective perspective is as important as the more 
objective medical assessment.  
 
1.7.5.2 Constipation: objective assessment 
 
Unlike other symptoms in palliative care, with regards to constipation, there are some 
dimensions which may be objectively assessed 250. Incorporating an objective measure 
into constipation assessment may be useful in order to facilitate rational 
pharmacological management.  
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On review of the literature, three key aspects of objective constipation assessment 
appear to be frequency of bowel movements, ease of defecation and stool consistency.  
There are many different sources which support the choice of these key features: 
 
• Firstly, a suggested definition of constipation is the “passage of small, hard faeces 
infrequently and with difficulty” 251. Data from studies of bowel function suggest 
that the key characteristics in defining constipation are faeces that are difficult to 
pass, infrequency of bowel movements compared to normal, smaller bowel 
movements compared to normal and hard stools 255.  
 
• Secondly, in gastroenterology, the disorder of constipation may be classified into 
three categories: disorder of rectal evacuation, slow transit or a combination of 
both 256. Although constipation in cancer and palliative care patients is often 
secondary to illness or medications rather than being a primary disorder, this 
classification is also useful for this group of patients in order to guide assessment 
of constipation as a symptom.  Assessment of stool frequency, stool form and the 
need to strain provides information on both of these parameters. Increased gut 
transit time may be demonstrated by decreased stool frequency 256 and by 
assessment of stool form 257. Difficulty in rectal evacuation may be assessed by 
stool consistency or the need to strain 256.  
 
• Finally, as laxative therapies are either stool softeners or stool stimulants, detailed 
assessment of frequency, stool consistency and straining may provide adequate 
information to prompt rational laxative use.  
 
1.7.5.3 Constipation assessment tools 
 
Many different constipation assessment tools exist however there is no such tool 
which has been designed, validated and is commonly used in cancer and palliative 
care patients.  
 
Although a heterogeneous group, cancer and palliative care patients have different 
needs and burdens compared to other patient populations. Many are undergoing 
rigorous chemotherapy, have multiple co-morbidities, and it is likely that constipation 
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is only one of many symptoms. Most existing tools are not suitable for this group of 
patients e.g. recall period may be too long (leading to error or bias) or the tool may 
take too long to complete (thus possibly decreasing the accuracy and completeness of 
the answers) 258. Other constipation tools are not suitable for cancer and palliative care 
patients as they include questions which would be non-discriminatory in this 
population. For example abdominal distension / bloating may be due to disease / 
comorbidities and may not be solely related to the presence of constipation. A suitable 
constipation assessment tool for the cancer and palliative care population needs to be 
brief, easy to understand and non-invasive. Recall period must be brief enough to 
limit recall burden (taking into account the nature of cancer and palliative care 
patients), yet long enough to pick up sufficient occurrences of relatively infrequent 
bowel movement events 258.  
A constipation symptom measurement scale is essential for the adequate management 
of constipation as it will provide the means for detecting symptoms, grading their 
severity and assessing effectiveness of management 259. 
 
Table 1.3 summarises a number of the other available constipation assessment tools. 
Some of these are stand alone tools, others form part of general symptom assessment 
tools. As can be seen, few studies combine objective and subjective assessments of 
constipation.  
 
Two constipation assessment tools were proposed for use in palliative care. The first 
was a bowel score which required patients to recall details about their bowel 
movements over the preceding three days. The score was made up of a composite of 
a) frequency and b) stool consistency196. The second was a bowel function score 
based on frequency (current compared to usual), stool consistency and ease of passing 
stool 260;261. Unfortunately neither of these was tested in large prospective studies. 
 
Mundipharma recently devised a novel constipation assessment tool, the Bowel 
Function Index (BFI) which is based on both subjective and objective assessment 
measures: ease of defaecation, sensation of incomplete bowel evacuation and 
subjective assessment of constipation. The patient scores each parameter on a 
numerical rating scale 0-100 and the BFI is the mean of the three scores. This tool was 
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validated against the Pac-Sym. This tool however does not include any assessment of 
frequency or stool consistency 262. 
 
A Bowel Function Diary has recently been validated in a non-cancer population who 
were started on opioids. The results of this study suggest that assessing the number of 
spontaneous bowel movements (SBM, bowel movements without the use of laxatives 
etc) can differentiate between patients who are constipated or not on opioids 263. The 
use of SBM per week however does not take into account the usual bowel habit of the 
study subject and the mean number of SBM per week is very varied. In the validation 
study (N=238), patients who reported that they were constipated had a mean SBM of 
5.6 +/- 4.3 compared to 7.3 +/-3.6. A further limitation of this tool is that the 
assessment diary includes a number of items e.g. abdominal pain and lack of appetite 
which are non-discriminatory in cancer patients, therefore its use in a palliative care 
population is likely to be limited. 
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Table 1.3 Summary of available Constipation Assessment Tools 
Note: this is not an exhaustive list 
Questionnaire Subjective 
assessment 
Objective 
assessment 
Tested in cancer or 
palliative care 
patients 
Scoring system Comments 
Clinical constipation assessment tools 
Bristol Stool Chart 264 X √ √ Descriptive scoring 
system (verbal and 
visual descriptives) 
 
Constipation Assessment Scale 265 X √ √ 3 point VRS: no 
problem, some problem, 
severe problem. 
2 minutes to complete 
Constipation Scoring System (Cleveland 
Clinic Score)266 
X √ X Structured questionnaire, 
each question scoring 
0-2 or 0-4 marks 
 
PAC-SYM (Patient Assessment of 
Constipation Symptoms)267 
X √ X 5 point VRS (absent, 
mild, moderate, 
severe, very severe) 
2 week recall period, 4 
minutes to complete 
KESS (Knowles-Eccersley-Scott 
Symptom Questionnaire)268;269 
X √ X Structured questionnaire, 
each question scoring 
0-3 or 0-4 marks.  
5 minutes to complete 
Rome Criteria 270-272 X √ X Presence of certain 
criteria 
Developed for diagnosis 
of functional 
constipation. Symptoms 
need to be present for at 
least 12 weeks in the 
preceding 12 months. 
Bowel Function Index 273 √ √ X 0-100 NRS 3-item questionnaire: 
ease of defaecation, 
incomplete bowel 
evacuation and 
subjective assessment  
Bowel Function Diary263 X √ X Adjectival Likert scales Validated in non-cancer 
patients on a variety of 
opioids for two weeks. 
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General symptom assessment tools incorporating constipation assessment * 
EORTC (European Organisation for 
Research and Treatment of Cancer 
QLQ-C30)274-276 
√ X √ 4 point VRS: Not at all, 
a little, quite a bit, 
very much. 
 
Rotterdam Symptom Checklist 277;278 √ X √ 4 point VRS: Not at all, 
a little, quite a bit, 
very much. 
 
Constipation assessment tools in palliative care research 
Bowel function scores 260 X √ √ Numerical score 0-2 or 
0-3 for 3 items 
 
Bowel score196  X √ √ Numerical score for 2 
items 
 
* Note some general symptom assessment scales do not incorporate any question about constipation e.g. ESAS (the Edmonton Symptom Assessment System) 
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1.8 Aims of the thesis: 
 
The overall objective of this thesis was to test the following hypotheses: 
 
1. Inter-individual variation in response to morphine may be clinically defined. 
2. Inter-individual variation in response to morphine is associated with genetic 
variation.     
 
It is hoped that the data presented in this thesis may contribute towards building a tool 
to allow prospective prediction of response to morphine for cancer pain.  
 
My original aims for this thesis were: 
 
• To identify genetic factors associated with inter-individual variation in 
response to morphine in patients with cancer pain using candidate gene assays. 
 
• To explore the prevalence and management of constipation in cancer patients 
taking morphine. 
 
Preliminary results and data analyses, together with developments in 
pharmacogenetics in terms of techniques and approaches, allowed the generation of 
new hypotheses resulting in the following additional aims: 
 
• To develop a clinically relevant and robust method of defining “response” to 
morphine 
• To explore how multiple clinical and genetic factors may interact together to 
influence response to morphine  
• To carry out an exploratory genome wide association study to identify genetic 
factors associated with inter-individual variation in response to morphine in 
patients with cancer pain 
• To examine the clinical assessment of constipation in cancer patients taking 
morphine 
• To develop a constipation assessment tool  
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1.8.1 Clinical data presented in this thesis: 
 
The clinical data were derived from two clinical trials: 
 
• The Prospective Morphine Study: A prospective observational study of 
morphine responders and non-responders. Clinical and genetic data from a 
smaller number of patients (N=228) in this study have been previously 
published 31;95;113;279. Data from the final completed study (N=298) are 
presented in this thesis. 
• A Prospective Randomized Controlled Trial of Morphine versus Oxycodone 
for Cancer Pain. This study is ongoing and therefore the final clinical results 
are not available for this thesis. Interim results for the primary aims and 
objectives of this study form part of another PhD thesis 280. Interim data 
pertaining to constipation assessment are presented in this thesis.  
 
The clinical data were interrogated to: 
 
• Explore the influence of clinical and environmental factors on inter-individual 
variation in response to morphine 
 
• Develop a robust and meaningful definition (phenotype) of clinical response to 
morphine for cancer pain which would be used in further genetic association 
studies 
 
• Constipation as a side-effect of opioids was chosen for in-depth analysis in 
terms of phenotype definition, prevalence, management and assessment.  
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1.8.2 Genetic data presented in this thesis 
 
Genetic analysis was carried out on samples from the Prospective Morphine Study.  
 
• Candidate genes were analysed on the whole study population.  
• A genome-wide association study was carried out on a subset of the study 
population. This is the first GWA in patients taking morphine for cancer pain 
that we know of.  
 
1.8.2.1 Candidate genes 
 
The hypothesis tested in this study was that polymorphisms in genes coding for 
proteins and enzymes involved in biological pathways which interact with opioids and 
their receptors play a role in inter-individual variation in morphine response in cancer 
patients. A number of candidate genes were chosen for investigation based on known 
biological pathways involved in pain and morphine response and also on previously 
published animal studies in this area. Twelve genes were investigated in the palliative 
medicine department, comprising the Royal Marsden Hospital / Imperial College 
“Pain Plate”. I optimised, ran and analysed the assays for “Pain Plate 1” which 
included the following genes: OPRK (Kappa opioid receptor gene), OPRD (Delta 
opioid receptor gene), TRPV1 (capsaicin receptor gene), ADORA1 (A1-adenosine 
receptor gene), ADRA2A (α2A adrenergic receptor gene) and ALOX12 (arachidonate 
12-lipoxygenase gene). “Pain Plate 2” included BDNF (Brain derived neurotropic 
factor), CSEN (Calsenilin gene), GRIN1 (Glutamate receptor subunit 1), GRIN2A 
GRIN1 (Glutamate receptor subunit 2a), GCH1 (GTP cyclooxygenase 1) and MC1R 
(Melanocortin 1 receptor), which were designed and tested on the study population by 
Dr Gretton and presented in her PhD thesis 280.  I also chose two other genes which 
had been run on a smaller sample of the study population to be included for more in-
depth analysis, OPRM (mu-opioid receptor gene) and ARRB2 (B-arrestin 2 gene), as 
well as SLC6A4 (serotonin reuptake transporter gene).  For each of the genes 
presented in this thesis there is a biologically plausible association with pain 
perception and response to morphine, as detailed in relevant results chapters.  
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1.9 Thesis outline 
 
Chapter 2: This chapter contains details of the two clinical trials (The Prospective 
Morphine Study and the Prospective Randomized Controlled Trial of Morphine versus 
Oxycodone for Cancer Pain) which were carried out to generate clinical and 
laboratory data for this thesis. The laboratory methods for genotyping are described 
including candidate gene and whole-genome testing. The statistical methodologies 
used to interrogate the data are presented. 
 
Chapter 3: The clinical results of the Prospective Morphine Study are described. This 
chapter focuses on the results of data exploration in terms of phenotype definition. 
The clinical phenotypes to be used in the subsequent genetic association studies are 
proposed.  
 
Chapter 4: This chapter describes the results of the candidate gene association study 
involving genes coding for the opioid receptors. This study was carried out using data 
from the Prospective Morphine Study.  
 
Chapter 5: This chapter describes the results of the candidate gene association study 
involving other genes involved in pain and analgesia (ADORA1, TRPV1, ADRA2A, 
ALOX12, ARRB2 and SLC6A4). This study was carried out using data from the 
Prospective Morphine Study.  
 
Chapter 6: This chapter presents the results of the genome-wide association study 
which was carried out on a subset of patients from the Prospective Morphine Study. 
 
Chapter 7: This chapter presents the results of a number of studies investigating 
constipation in cancer patients taking oral morphine. An exploration of the current 
management of constipation is presented using data from the Prospective Morphine 
Study. The results of a retrospective audit of documentation of constipation 
assessment which was carried out on a subset of the patients in the Prospective 
Morphine Study are detailed. A definition of a working phenotype of constipation in 
cancer patients on morphine is presented. The results of a genetic association analysis 
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are detailed. Finally the results pertaining to the development of a constipation 
assessment tool as part of the Prospective Randomized Controlled Trial of Morphine 
versus Oxycodone for Cancer Pain are reported.  
 
Chapter 8: The findings of this thesis are discussed with particular emphasis on future 
challenges and opportunities for research in this area.   
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2 Chapter 2 Methods 
  
The work presented in this thesis involved the integration of carefully collected 
clinical data with genetic data to explore inter-individual variation in response to  
morphine. This chapter contains detailed descriptions of the clinical studies and 
laboratory and analytical methods used. 
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2.1 Clinical studies 
 
The clinical data were collected as part of two clinical studies: 
• The Prospective Morphine Study  
• A Prospective Randomized Controlled Trial of Morphine versus Oxycodone 
for Cancer Pain 
 
I was involved in running both of these studies along with a fellow PhD student, Dr 
Sophy Gretton, and a number of research nurses. My involvement in both studies 
included: 
• Study participant recruitment. This included screening, identification, 
consenting and follow up of patients as appropriate  
• Biological specimen collection, storage (as appropriate) and analysis 
• Maintenance of study specific databases and data entry 
• Clinical trial governance. This included including liaison with research 
governance bodies; Research Ethics Committee (REC), Research and 
Development Committee (R&D) and the Medicines and Healthcare Products 
Regulatory Agency (MHRA). 
 
Both studies were carried out in accordance with the principles of Good Clinical 
Practice (GCP) 281. Material Transfer Agreements were set up for the transfer of 
material from the Royal Marsden Hospital to external organisations, in accordance 
with the Human Tissue Act 2004 282.   
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2.1.1 Prospective Morphine Study 
 
2.1.1.1 Study design 
 
This study was originally set up in 2002 and some analysis of the first 228 study 
subjects has been published 31;95;279. I was involved in the continued running of the 
trial until it was closed with a final total study population of 298.  
 
The aim of this study was to investigate the effect of genetic variants on the clinical 
outcome of morphine treatment. This was an observational single time-point study. 
Adult patients (over 18 years of age) who were taking oral morphine for cancer pain 
were included.  Patients with predominately neuropathic or incident pain, patients 
with renal impairment (plasma creatinine >1.5 upper limit of normal) and patients 
who were on subcutaneous, intramuscular or intravenous morphine or other regular 
opioids were not included in this study.  
Approval for this study was given by the Research and Ethics Committee and all 
patients signed a written consent form before entering the study. The clinical 
palliative care team titrated morphine dose according to individual response. Patients 
were recruited into one of two cohorts according to patients’ subjective experience 
and the observations of the experienced clinical team. Subjects who had a successful 
outcome on morphine were called “Morphine responders”. These were patients who 
had been on morphine for at least one month and who were experiencing adequate 
analgesia without problematic side-effects. “Morphine non-responders” were defined 
clinically as those patients who did not have a satisfactory clinical outcome i.e. those 
who failed to achieve adequate analgesia despite escalating morphine doses and/or 
who experienced subjectively intolerable side-effects. Morphine non-responders 
underwent an opioid switch (as determined by the clinical team, but usually to 
oxycodone as the hospital’s second line strong opioid 283). Clinical data on morphine 
non-responders were collected before they underwent the opioid switch. This cohort 
was also followed up after one week to assess the efficacy of the switch.  
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2.1.1.2 Data collection 
 
Pain severity was recorded using the modified Brief Pain Inventory (BPI) 284. This 
pain scoring system has been used in other studies in this area 92;110. Five dimensions 
of pain intensity were assessed; worst pain, least pain and average pain in the previous 
24 hours, current pain and percentage pain relief from morphine. For each of these 
pain modalities, study subjects recorded pain severity on an 11-point numerical rating 
scale (NRS) of 0 – 10 (0 = no pain, 10 = worst pain imaginable).   
 
Morphine side-effects (drowsiness, confusion and hallucinations, constipation, dry 
mouth, myoclonus, itch and nausea) were recorded using a four point Likert scale; 
grade 0 “not at all”, grade 1 “a little”, grade 2 “quite a bit”, grade 3 “very much”. This 
scale is similar to that used in the European Organisation for Research and Treatment 
of Cancer Quality of Life Questionnaire (EORTC-Q30) 276, and is also similar to 
those used in other studies of response to opioids 29;92;112. Demographic data 
(including age, gender and ethnicity), cancer diagnosis, current morphine dose, length 
of time on morphine and concomitant medications were documented. For those 
patients who had died at time of analysis, the number of days between recruitment to 
the study and death were recorded as a measure of prognosis. Details of the study 
questionnaires and proformas are found in Appendix B. 
 
2.1.1.3 Biological samples 
 
Biological samples were collected at the time of recruitment to the study: 
 
• Routine haematology (full blood count) and biochemistry (urea, creatinine, 
electrolytes, calcium, albumin, liver function tests): 3ml blood in EDTA and 
4.5ml in Lithium Heparin tubes respectively. These were processed by the 
laboratories at the Royal Marsden Hospital.  
• Pharmacogenetic analysis: 9mls blood in EDTA tubes for DNA extraction. 
These were processed and stored in Imperial College, as detailed in section 
2.3.1. 
• Immunology (lymphocyte subset analysis): 3ml blood in EDTA tube. This 
sample was processed and analysed in the immunology laboratories of Chelsea 
and Westminster Hospital within 24 hours of the blood being taken. 
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• Morphine metabolites: 9mls blood in Lithium Heparin tubes. These samples 
were centrifuged for 20minutes at 3000rpm within two hours of the blood 
being taken and the plasma stored at -40 degrees for subsequent analysis. 
(Metabolite analysis is presented as part of Dr Gretton’s PhD thesis280). 
• Urine was also collected for future proteomic and metabonomic analysis. This 
was centrifuged at 3000rpm for 30 minutes and the supernatant was stored at 
minus 80 degrees.  
 
 
2.1.1.4 Limitations of the Prospective Morphine Study  
 
 
The data in this study were collected from a single time point which does not reflect 
the dynamic nature of symptoms in cancer patients. Therefore, in order to more 
accurately capture the subjective nature of the symptoms necessitating an opioid 
switch, a prospective follow-up study design, such as in the Prospective Randomized 
Controlled Trial of Morphine versus Oxycodone for Cancer Pain (described in section 
2.1.2), is required.  
 
The decision to switch opioids was made empirically by the palliative care team. This 
was based on the patient’s subjective experience and subjective threshold of 
sensitivity of opioid analgesia and tolerability of side-effects rather than being based 
on pre-determined standardised measures of pain or side-effect intensity. This is in 
keeping with guidelines on opioid switching which emphasise the need for individual 
assessment and flexibility in decision-making based on inter-individual variation 285.  
 
A more standardised definition of when to consider opioid switching might result in a 
homogeneous cohort. Very little work has been carried out in this area. Most studies 
on opioid switching either do not define the switching criteria or define them 
according to the subjective patient experience. A number of studies by Mercadante et 
al have used standardised cut off point in terms of pain and side-effect intensity as 
criteria to define the need for an opioid switch. One prospective study defined patients 
who required an opioid switch in terms of opioid dose escalation and/or intensity of 
opioid side-effects. Patients with unacceptable side-effects were those with symptom 
intensity of ≥2 on a scale of 0-3, which corresponded to a verbal scale of 0 = not at all, 
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1 = slight, 2 = a lot and 3 = awful. Patients experiencing a lack of opioid analgesic 
sensitivity necessitating an opioid switch were defined as those who had a poor 
analgesic response despite having had their opioid dose doubled in one week. Poor 
analgesic response was not defined in terms of pain intensity. In that study, the opioid 
switch was considered successful when the pain intensity or symptom score was 
reduced by 33% within seven days. The authors stated however that although they 
tried to use objective and reproducible assessments, they did not adapt a very rigid 
switching protocol as this would preclude the flexibility which is necessary in 
obtaining a balance between analgesia and opioid side-effects in patients with 
challenging clinical conditions 29. In another study the criteria for switching from 
morphine to methadone included uncontrolled pain (VAS >4) and/or moderate to 
severe opioid side-effects 36.  
 
There has been no study on opioid switching which incorporates objective testing of 
symptoms as a definition of the need to initiate an opioid switch. For example, the 
clock drawing test has been used to determine opioid-related cognitive dysfunction 
286
. There has been one case report of the benefits of opioid switching in a patient with 
an abnormal clock drawing test 287 but such objective assessments have not been used 
in opioid switching studies. As a measure of cognitive function the clock drawing test 
or other assessment may provide objective criteria for opioid switching and an 
objective measure of assessing the efficacy of the switch.  
 
There are little data on the factors which influences a clinician’s decision to initiate an 
opioid switch. The proportion of patients switched due to pain or adverse effects 
varies widely, depending on the study 12. Although guidelines on opioid switching 
recommend assessment of demographics such as age, race, disease status and 
concomitant medications, there is scant evidence as to how these and other factors 
influence decision making. Furthermore there is undoubtedly an element of inter-
clinician variation in terms of when and why opioid switches are initiated. Further 
research in this area would help define the clinical phenotype of morphine responder 
versus morphine non-responder.  
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2.1.2 A Prospective Randomized Controlled Trial of Morphine versus Oxycodone 
for Cancer Pain 
 
This study was designed by Dr Sophy Gretton, Dr Julia Riley and Dr Joy Ross. The 
interim analysis of the primary outcome forms part of Dr Gretton’s PhD280. 
Recruitment to this study is ongoing and therefore any further analysis of clinical 
outcomes is not possible at time of writing this thesis. A brief overview of the study 
design is detailed below. I was involved in running the study until I finished my work 
as a research fellow, at which time 109 study subjects had been recruited. I had a 
specific primary role in amending the protocol to comply with MHRA standards, 
submitting substantial amendments to the research governance agencies (including an 
amendment to include the constipation on opioids assessment tool), designing and 
maintaining the study specific database and maintaining the pharmacovigilance 
records for the study. 
 
2.1.2.1 Study design 
 
The primary aim of this study is to compare the response rates of morphine and 
oxycodone when these drugs are used as first line strong opioids in moderate to severe 
cancer pain. 
 
The eligibility criteria for this study includes adult patients (over 18 years of age) with 
a diagnosis of cancer for whom pain is not controlled on Step 2 (weak opioid) 
analgesics (as defined by the 1996 WHO analgesic ladder) and who clinically require 
a strong opioid. Like in the Prospective Morphine Study, patients with predominately 
neuropathic or incident pain, patients with renal impairment (plasma creatinine >1.5 
upper limit of normal), patients requiring parenteral opioids and patients with a clearly 
defined history of intolerance to morphine or oxycodone are excluded.  
 
Approval for this study was granted by the Royal Marsden Hospital R&D department 
and the REC and the MHRA.  Written consent is obtained from all study participants. 
Potential study participants are recruited from inpatient and outpatient settings at the 
Royal Marsden Hospital.  
 
The study was designed and is conducted out in accordance with the principles of EU 
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Clinical Trials Directive (2001/20/EC), The Medicines for Human Use (Clinical 
Trials) Regulations (2004) and the Human Tissue Act (2004) 282;288;289. 
 
This is a single centre, prospective, randomised controlled trial. On entry to the study, 
participants are randomised via a computer to receive either oral morphine or oral 
oxycodone. Study subjects are titrated on short-acting preparations of oral morphine or 
oral oxycodone as per Palliative Care clinical guidelines in the Trust 283 until pain 
control is achieved or intolerable side-effects are experienced. If the study subject is a 
non-responder to the initial opioid (i.e. he/she experiences inadequate analgesia 
despite escalating doses and/or intolerable side-effects), he/she is switched to the 
alternative opioid (morphine if the patient started on oxycodone and vice versa) and 
this is titrated to effect. Study subjects complete a daily opioid titration diary until 
they are stable on either the initial or second opioid. Once they are stable they are 
converted to the long acting preparation of the opioid if appropriate. Study subjects 
are followed up for a maximum period of 12 months or until they die or withdraw 
from the study.  
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2.1.2.2 Data collection 
 
Clinical data and biological specimens are collected from study subjects at certain 
defined time points during their follow up as detailed in figure 2.1. At each time point 
clinical data are collected about pain character and pain severity (using the Modified 
Brief Pain Inventory, as for the Prospective Morphine Study). Neuropathic pain is 
screened for using the S-LANSS (self-report version of the Leeds Assessment of 
Neuropathic Symptoms and Signs pain scale) 290. Side-effect scores are collected as 
11 point numerical rating scales where 0 represents no symptom and 10 the worst 
symptom severity imaginable. Data about the opioid dose, schedule and breakthrough 
opioid are collected, as well as data about concomitant medications. Demographic 
data including ethnicity, gender, age, tumour diagnosis are also collected at baseline. 
The daily titration diaries include pain and toxicity scores as detailed above. At each 
time point the “Constipation on Opioids Assessment” is completed. Details of the 
study questionnaires and proformas are found in appendix B. 
 
Biological samples are also collected at each time point. These are the same as are 
collected in the prospective Morphine Study (section 2.1.1.3), except that whole blood 
for DNA is only collected once, at time of recruitment.  
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* daily titration diaries collected  
Reasons for study exit include: 
• Non-response to both morphine and oxycodone  
• Subjects converted to parenteral opioids on clinical grounds 
• Subjects unable to take oral opioids on clinical grounds 
• Development of renal failure of >1.5 upper limit of normal 
• Patient dies 
• Subject stops taking step 3 opioid on clinical grounds 
• Subjects have reached one year post recruitment 
• Needing to stop morphine and/or withdraw from the study on clinical 
grounds not specified above 
 
Figure 2.1 Study design for A Prospective Randomized Controlled 
Trial of Morphine versus Oxycodone for Cancer Pain. 
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2.2 Database construction and maintenance 
 
Both the Prospective Morphine Study and Prospective Randomized Controlled Trial 
of Morphine versus Oxycodone for Cancer Pain have study specific databases which I 
was involved in designing and maintaining.  
 
The procedures for collecting, storing and accessing the data collected in these trials 
are in keeping with GCP guidelines 281, the Data Protection Act 291 and Caldicott 
Principles 292. Only members of the research team have direct access to data and 
documents pertaining to this study. The clinical data for each patient are recorded in a 
patient-specific Clinical Research Form (CRF) which is kept in a locked cabinet in a 
secure office in the palliative medicine research department. All patient identifiable 
data are removed from the electronic database. The subjects are pseudo-anonymised 
and a unique study number is assigned to each subject. The electronic databases have 
been constructed using Microsoft Excel. These are stored in a limited access, 
password protected encrypted network folder on the Royal Marsden Hospital Server.  
 
Quality control measures to minimise data error include:  
• Data entry onto the electronic database by two members of the research team 
• The electronic database is checked against the source data (original CRFs /  
laboratory reports / genetic data)  
• Data audit to identify outliers, missing data and unusual data points which 
require verification against source data. Data mining tools such as Knowledge 
Studio (www.Angoss.com) were used to audit the data for accuracy. 
 
Work continues in the department to develop an integrated data management system 
to 1) cope with the vast quantities of data that are being generated by the studies and 
2) aim for zero error in data fields. I was involved in the initial planning to develop an 
InForm Global Trial Management database 293. This database is a web-based 
application which has an easy-to-use interface and simple navigation tools. Online 
edit checks are in place to reduce data entry errors and there is an online query 
process to facilitate efficient data discrepancy resolution. It also has an inbuilt audit 
facility to monitor data entry and data accuracy. This work is being continued by Dr 
Ruth Branford and will be presented as part of her PhD.  
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2.3 Laboratory methods 
 
All biological samples (except for those sent to haematology and biochemistry) were 
labelled with the patient unique study identifier and not patient identifiable details. 
 
2.3.1 DNA extraction from fresh blood 
 
DNA was extracted from whole blood samples (9 mLs, tri-sodium citrate or di-
sodium EDTA vacutainers) using a standard salting out method 294. 9mls of whole 
blood was collected in an EDTA bottle. This was transferred to a 15ml Falcon tube 
and centrifuged at 2500 rpm at room temperature for 20 minutes. This resulted in 
separation of the white cells, red cells and plasma. The white cells were removed 
using a 3ml Pasteur pipette and placed in another Falcon tube. 13ml of Red Cell Lysis 
Buffer (144 mM NH4Cl, 1 mM NaHCO3) was added in order to remove any 
erythrocytes contaminating the sample and the sample shaken well. The sample was 
left at room temperature for approximately 20minutes until complete haemolysis was 
evident. The sample was centrifuged again at 2500 rpm for 20 minutes in order to 
separate out the white cells into a pellet at the bottom of the tube. The supernatant was 
discarded and the pellet was washed gently in Red Cell Lysis Buffer.  
3mls Nuclear Lysis buffer (10 mM Tris-HCl pH 8.2, 400 mM NaCl, 2 mM Na2EDTA 
pH 8.0) was added and the sample shaken in order to re-suspend the pellet. 1ml NaCl 
(Sodium Chloride) and 2mls 24:1 Chloroform / iso-amyl alcohol were then added in 
order to precipitate and separate proteins from the DNA. The sample was shaken well 
to form a milky solution which was then centrifuged at 3000 rpm for 30 minutes. This 
resulted in the separation of the DNA into a phase at the top of the sample, separated 
from the lower layer of debris by a layer of protein. The DNA layer was transferred 
into a Falcon tube and was topped up to 13mls with absolute ethanol. The mixture 
was inverted several times which allowed the DNA to precipitate out as a white 
filament. The DNA was removed from the ethanol and placed in a microfuge tube. 
The ethanol was allowed to evaporate in the fume cupboard and the DNA was re-
suspended in sterile water (Baxter, UK). The sample was allowed to dissolve 
overnight in the fridge (4o C) and then stored at -20oC.  
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2.3.2 DNA amplification of genomic DNA 
 
The yield of DNA from individual patient whole blood samples is limited and 
therefore it is often necessary to amplify existing DNA. This was carried out using 
Repli-g Midi kits and protocol (Qiagen, UK) 295. 
 
2.3.2.1 Preparation of Genomic DNA for amplification 
 
2.5µl template DNA was placed in a microcentrifuge tube. 2.5µl D1 buffer (9µl 
reconstituted DLB buffer and 32µl nuclease-free water per 15 reactions) was added to 
the DNA and mixed by vortexing and centrifuging briefly. The sample was incubated 
at room temperature for 3 minutes. This denatures the DNA: the double-stranded 
DNA unwinds and separates into single-stranded strands.  
2.5µl buffer N1 (Stop solution 12µl and nuclease-free water 68µl per 15 reactions) 
was added to neutralise the reaction and again the samples were mixed by vortexing 
and centrifuging briefly. 10µl of the denatured DNA was placed in another microfuge 
tube to act as a template for amplification as detailed below (section 2.3.2.3). 
 
2.3.2.2 DNA extraction from dried blood spots 
 
Some of our collaborators collected blood on blood spot cards which only contain 
small amounts of DNA. Whole genome amplification from the dried blood spots was 
carried out using Repli-g Midi kits (Qiagen, UK)295.  
 
A 3mm dried blood spot was cut using a Harris unicore cutter™ and placed into a 
microfuge tube containing 500µl TE buffer (10mM Tris CL, 1ml EDTA, pH 8.0). The 
tube was inverted several times to wash the blood spot and was incubated at room 
temperature for 30 minutes. The sample was then centrifuged for 15 seconds and the 
supernatant discarded. The blood spot was rinsed again in 500µl TE buffer, 
centrifuged again for 15 seconds and the supernatant discarded. 40µl TE buffer was 
placed directly onto the blood spot in the microfuge tube. 500 µl Solution A was 
prepared by adding 40 µl 5 M KOH (potassium hydroxide) and 10 µl 0.5 M EDTA 
(pH 8) into 450 µl deionized water. 40µl denaturation buffer (D2) (10µl  DTT 1M and 
110µl Solution A per 3 reactions) was added to the tube in order to lyse the cells and 
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this was mixed by pipetting up and down 3 times before placing it on ice for 10 
minutes. 40µl stop solution was added to neutralise the lysed cells and mixed by 
pipetting up and down 3 times. 10µl of the lysed blood spot solution (containing HCl 
and Tris HCl buffer) was placed in another microfuge tube to act as a template for 
DNA amplification (see below).  
 
2.3.2.3 Amplification of Human Genomic DNA by MDA 
 
Whole genome amplification by Multiple Displacement Amplification (MDA) was 
carried out using Repli-g Midi kits (Qiagen, UK)296. This high fidelity technique is 
reliable and has a low rate of amplification bias 297. Genome amplification is carried 
out using DNA polymerase, an enzyme that catalyzes the polymerization of 
deoxyribonucleotides  into a DNA strand. Random hexamer primers anneal to 
multiple sites along the target molecule and serve as initiation sites for the Phi29 
DNA polymerase-mediated DNA replication. Phi29 DNA polymerase is stable, which 
facilitates many hours of performance, and it can replicate 100kb without dissociating 
from the template 297. As the replication proceeds along the template molecule, it 
reaches the initiation site for other replication events that are processed in parallel. 
These upstream DNA strands are displaced to produce new templates and thus DNA 
replication continues exponentially to produce large numbers of copies of the original 
DNA. This process produces products that are greater than 10 kb in size, thus suitable 
for SSP-PCR genotyping 297;298. The quality of the products of MDA is influenced by 
the quality of the original DNA.  
 
The DNA polymerase was thawed on ice and a master mix was prepared (10µl 
nuclease free water (Baxter, UK), 29µl Repli-g Midi Reaction Buffer and 1µl DNA 
polymerase per reaction, kept on ice and used immediately). 40µl of the master mix 
was added to each microfuge tube containing the template DNA (as detailed above), 
vortexed for 10seconds and centrifuged briefly. The tube was then kept at 30oC for 
16hours in the thermal cycler for isothermal DNA amplification. The DNA 
polymerase was inactivated by heating the sample to 65 oC for 3 minutes and the 
DNA sample was stored at -20oC. 
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2.3.3  DNA quantification 
 
DNA concentration was measured using PicoGreen®, a fluorescent nucleic acid stain 
which binds selectively to dsDNA.  It has an excitation maximum at 480 nm (lesser 
peaks in the short-wave UV range) and an emission peak at 520 nm. The unbound dye 
has practically no fluorescence 299. 
 
A standard DNA concentration curve was constructed by serial dilution of stock DNA 
(A) as shown in table 2.1 and fig 2.2. The standard curve was generated by plotting 
the concentration of the DNA standards on the X-axis and the fluorescence reading 
from the microplate reader on the Y-axis. 
 
Table 2.1 DNA dilution protocol to prepare the standard curve 
 
Standard 
Concentration 
Volume of known 
standard Volume of dH2O 
Final DNA 
standard 
concentration in 
PicoGreen assay* 
(B) 2000 ng/ml 40µl of stock DNA (A) (100 µg/ml) 1960 µl 1000 ng/ml 
(C) 1000 ng/ml 500µl of B (2000 ng/ml) 500 µl 500 ng/ml 
(D) 500 ng/ml 500µl of C (1000 ng/ml) 500 µl 250 ng/ml 
(E) 200 ng/ml 50µl of B (2000 ng/ml) 450 µl 100 ng/ml 
(F) 50 ng/ml 50µl of D (500 ng/ml) 450 µl 25 ng/ml 
(G) 5 ng/ml 50µl of F (50 ng/ml) 450 µl 2.5 ng/ml 
(H) 0 ng/ml 0 500 µl 0 ng/ml 
Stock DNA (A) is supplied at 100µg/mL. 
* The final DNA standard concentration in PicoGreen assay is the standard concentration / 2 
because the DNA standard is diluted 1:1 with the PG stock. 
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Figure 2.2 A DNA standard concentration curve 
 
The PicoGreen dsDNA Quantitation Reagent (PG) is supplied as a 1mL concentrated 
dye solution in anhydrous dimethylsulfoxide (DMSO). 5µl PG was added to 100µl TE 
in 900µl dH2O (Baxter) to make up a 2 µg/mL PG stock solution (PG stock : 2XTE 
1:200). This working PG solution was prepared in a plastic tube as the reagent may 
adsorb to glass surfaces. The tube was kept covered with foil to protect against light 
degradation.  
 
DNA samples to be tested were prepared by diluting 2µl DNA in 500µl dH2O to 
make 1:250 dilution. (A high dilution of the experimental sample ensures that any 
contaminants are maximally diluted.) 
 
10µl of each of the standard concentration DNAs was dispensed into the left lateral 
column (column 1) of wells of a 96-well plate (Griener Bio-One, UK) as 
demonstrated in figure 2.3. 10µl of the test DNA was dispensed into the other wells 
and a paper grid was labelled according to the position of the DNA samples. 10µl of 
the working PG solution was added to each well and the plate was centrifuged briefly. 
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Figure 2.3 96 well plate set up for DNA quantification 
10µl of each of the DNA standards are placed in the wells of column 1 as shown. The 
last well in column 1 is left empty as a negative control. 
 
The fluorescence of the samples measured using a Lambda Fluoro 320 plus 
fluorescence microplate reader (MWG Biotech AG, Milton Keynes, UK). PicoGreen-
stained samples were excited at 485nm and emission at 538nm was recorded. The 
concentration of each individual DNA sample was determined by plotting the 
fluorescence reading of the sample against the standard curve and reading the DNA 
concentration on the X-axis.   
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2.3.4 DNA quality control checks 
 
The quality of DNA was checked in a number of ways: 
• Electrophoresis of a small quantity of DNA (25 ng to 200 ng) on 1% agarose 
gel. Non-degraded DNA will run as a distinct homogenous band of high 
molecular weight (approximately 10-20kb). A smear of lower molecular 
weights that indicate degradation or shearing of the sample.  
 
Figure 2.4 DNA quality control 
RMH 187 (b) is degraded while RMH 191 (b) and RMH 197 (b) are non-degraded 
DNA. 
 
• DNA quality was also checked using DNA-OK! (Microzone Ltd, UK). This is 
a multiplex PCR (polymerase chain reaction) which amplifies from 5 different 
regions of the genome. There is also a positive PCR control. The presence of 6 
amplicons suggests good quality DNA. If the DNA is partially degraded, then 
the largest PCR fragments are lost and one or more of the amplicons are 
missing. If the DNA has been entirely degraded, only the positive control will 
amplify. 
3µl DNA OK primer mix, 5µl Megamix (containing recombinant Taq 
polymerase, dNTPs, reaction buffer and an enzyme stabiliser), 1µl water 
(Baxter, UK) and 1µl of the DNA to be tested were placed in a well of a 96-
well plate. The plate was placed in a thermocycler and the cycling parameters 
were set as: 5 minutes at 950C, followed by 33 cycles of: 950C for 30 seconds, 
630C for 30 seconds, and 720C for 45 seconds. The PCR products were then 
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electrophoresed on an agarose gel containing SYBR® Safe DNA gel stain 
(Invitrogen, UK) and visualised using a UV illuminator. 
 
2.3.5 Sequence-Specific Primers and Polymerase Chain Reaction 
 
In this thesis I used two methods to assess SNPs: 
• SSP-PCR (Sequence-Specific Primers and Polymerase Chain Reaction) 
• Genome-wide genotyping using the Affymetrix microarray platform.  
 
I was involved in sample collection and preparation, assay design and testing and 
genotyping using SSP-PCR, the details of which are outlined below. I carried out the 
sample preparation and data analysis of the Affymetrix study but the genome-wide 
genotyping was carried out in Yale University, USA therefore I have only included a 
basic overview of this process in this thesis (section 2.3.6). 
 
SSP-PCR is a technique which amplifies specifically selected DNA sequences, which 
can then be visualised on an agarose gel. A primer is a short oligonucleotide which 
serves as a starting point for DNA synthesis. The primer base-pairs to a specific 
sequence of DNA to allow initiation of a complimentary strand of DNA by a DNA 
polymerase. The DNA polymerase catalyses the synthesis of DNA by adding free 
nucleotides to the 3’ end of the primer. Therefore the new strand of DNA is elongated 
in a 5’-3’ direction.  
 
In SSP-PCR, in order to test a bi-allelic SNP, two specific primers (known as allele 
specific / sequence specific primers) are designed so that their 3’ ends are 
complimentary to the two allelic variants. Amplification will only take place if the 3’ 
end base-pairs with the DNA sequence. A consensus primer is also designed which is 
a certain distance from the variant. The specific and consensus primers match the 
beginning and the end of the DNA sequence to be replicated and direct replication 
towards each other i.e. amplification of a known length of DNA sequence (amplicon) 
occurs between the two primers (specific and consensus).  The newly synthesised 
stretch of DNA is complementary to the original template and therefore a double 
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stranded piece of DNA is recreated.  SSP-PCR is a self-perpetuating process in which 
the DNA which is generated is used as a template for further amplification.   
 
PCR consists of a series of heating and cooling cycles which are required for any 
DNA synthesis reaction:  
• Denaturation of the template into single strands. This involves heating the 
DNA to 93-95oC to melt the hydrogen bonds joining the two strands.  
• Annealing of primers to each original strand for new strand synthesis. This 
occurs when the temperature is reduced to between 50-70oC. 
• Extension of the new DNA strands from the primers. This occurs between 70-
75oC as this is the optimal temperature at which Taq-polymerase works.  
After 30 cycles of these three steps more than 100,000,000 copies of the original 
sequence are created.  
 
When the PCR products are electrophoresed on an agarose gel, the presence of a PCR 
product of expected size indicates the presence of the specific allele. By using two 
reactions per bi-allelic SNP (one for each allele), the diploid genotype of each study 
subject can be determined.  
 
SSP-PCR is a useful technique to identify SNPs as it is cheap, sensitive and fast.  
 
2.3.5.1 SSP-PCR Primer Design 
 
The DNA sequence around the SNP of interest must be known in order to design 
specific primers. Online databases such as NCBI (National Centre for Biotechnology 
Information) (http://www.ncbi.nlm.nih.gov) and CHIP (Childrens Hospital 
Bioinformatics Programme) (http://snpper.chip.org) 89 were used to identify the 
published genomic sequences for each gene. The location of the SNP of interest was 
identified from the literature and from these databases.  
 
A number of design parameters were taken into consideration: 
• Primer sequences were chosen to uniquely select for a region of DNA in order 
to avoid annealing to a similar sequence nearby. The NCBI BLAST (Basic 
Local Alignment Search Tool) function 
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(http://www.ncbi.nlm.nih.gov/BLAST/) was used to identify all the possible 
regions in the genome to which the primer may bind. 
• Mononucleotide repeats were avoided, as loop formation can occur and 
contribute to mishybridization.  
• The web-based Oligonucleotide properties calculator 
(http://www.basic.nwu.edu/biotools/OligoCalc.html) and FastPCR programme 
(http://www.biocenter.helsinki.fi/bi/bare-1_html/download.htm) were used to 
ensure that primers did not easily anneal with other primers in the mixture as 
this could lead to the production of 'primer dimer' products contaminating the 
mixture. Primers were also designed so that they did not anneal strongly to 
themselves, as internal hairpins and loops could hinder the annealing with the 
template DNA. 
• The optimal GC content (the percentage of nitrogenous bases that are either 
guanine or cytosine) of the primer was 45-55%. A higher GC-content level 
indicates a higher melting temperature.  
• The optimal length of each primer was 17-21 nucleotides. This length is long 
enough for adequate specificity and short enough for primers to bind easily to 
the template at the annealing temperature. 
• The optimal salt adjusted melting point (Tm) was 58-61oC. This was 
calculated using the Oligonucleotide calculator. Primer Melting Temperature 
is the temperature at which DNA denaturation into single strands occurs. This 
is therefore an indication of stability between the two DNA strands. Primers 
with melting temperatures above 65oC have a tendency for secondary 
annealing. 
• Tm is important in determining the annealing temperature (Ta). Too high Ta 
will produce insufficient primer-template hybridization resulting in low PCR 
product yield. Too low Ta may possibly lead to non-specific products caused 
by a high number of base pair mismatches. 
• Amplicon length.  
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Control primers were used as positive controls in order to confirm that the 
amplification procedure was successful. These control primers were chosen 
depending on the length of the expected PCR product: 
• Primers which amplify a constant region of the HLA-DRB1 gene on 
chromosome 6 were used if a PCR product of <450 base pairs was expected. 
These primers (63: 5′-TGC CAA GTG GAG CAC CCA A-3′ and 64: 5′-GCA 
TCT TGC TCT GTG CAG AT-3′) produce band sizes on a gel of 
approximately 650 and 1300 bp, with the former showing preferential 
amplification. Therefore 1 or 2 control bands are visible after electrophoresis.  
• Primers amplifying a smaller product (250 bp) in the adenomatosis polyposis 
coli gene on chromosome 5 were used when the expected PCR was >450 bp, 
(210: 5′- ATG ATG TTG ACC TTT CCA GGG-3′ and 211: 5′- TTC ATC 
AGT TGC TGC CCC TC-3′).  
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2.3.5.2 SNP selection 
 
When designing assays for SSP-PCR, within each of the genes polymorphisms were 
selected to cover alleleic diversity across the gene. Polymorphisms in regions most 
likely to have an impact on gene function were prioritised (promoter region, exons, 
intron-exon boundaries, 3-UTR), as were polymorphisms for which there exists 
published data for the Caucasian population. Intronic polymorphisms were selected at 
intervals spanning the gene to ensure full coverage of the region for haplotype 
analysis. Data on linkage disequilibrium, haploblocks and tag SNPs (see section 2.4.3) 
from the International HapMap Project (http://hapmap.ncbi.nlm.nih.gov) and the 
software programme Haploview (Whitehead Institute for Biomedical Research, USA) 
were used to limit the choice of SNPs.  
 
2.3.5.3 SSP-PCR protocol 
 
Control primer master mix was made up by adding 1ml deionised water (Baxter, UK) 
to 9µl of the loading dye cresol red (Sigma Ltd, Poole, UK) and either 2µl of each of 
the 63/64 control primers or 8µl of each 201/211 control primers.  Cresol red 
undergoes a pH-dependent colour change from orange to purple on addition of DNA. 
5µl primer stock (2000µg/ml) (Sigma Genosys Ltd, Poole, UK) (both allele-specific 
and consensus) was added to 1ml of control primer master mix. The mixture was 
vortexed well. 
 
5µl of the primer mix (allele-specific and consensus primers + control primer) was 
placed in a well of a 96-well plate which contained 10µl mineral oil. To this 8µl a 
PCR reaction mix was added containing PCR buffer ((NH4)2SO4), MgCl2 (50mM), 
dNTP mix (100mM), Taq DNA polymerase (Biotaq TM, Bioline Ltd, London, UK) 
and genomic DNA.  
 
Each 1ml PCR reaction mix contained 749.1µl deionised water, 166.4µl ((NH4)2SO4 
buffer, 65µl MgCl2 , 4.75µl each dNTP; deoxyadenosine triphosphate, 
deoxythymidine triphosphate, deoxyguanosine triphosphate, and deoxycytidine 
triphosphate and 6-8µl Taq DNA Polymerase. The dNTPs are the single units of DNA 
which are added to the primer by DNA polymerase. Magnesium acts as a cofactor for 
DNA ploymerase and the Mg2+ concentration can affect primer annealing; Tm of the 
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DNA template, product and primer-template associations and PCR product 
specificity. Each reaction in the 96-well plate required 0.08µg DNA. 
 
Each 13µl reaction underwent PCR amplification in a MJ Research PTC200V thermal 
cycler (GRI, Braintree, UK). Cycling parameters were set at: 1 minute at 96oC; 
followed by 5 cycles at 96 oC for 20 seconds, 70 oC for 45 seconds, and 72 oC for 25 
seconds; followed by 21 cycles at 96 oC for 25 seconds, 65 oC for 50 seconds, and 72 
oC for 30 seconds; followed by 4 cycles at 96 oC for 25 seconds, 55 oC for 60 seconds, 
and 72 oC for 120 seconds. 
 
2.3.5.4 Gel electophoresis 
 
When DNA amplicons (or other molecules) are placed in a gel connected to a power 
source, the DNA migrates from the negative towards the positive electrode. Larger 
molecules move more slowly through the gel while the smaller molecules move faster 
and therefore further. 
 
To determine the presence or absence of the specific allele, the PCR amplified 
products were electrophoresed for 20 minutes on a 1.5% agarose gel made up with 
500mls x 0.5% Tris Borate EDTA (TBE) (Sigma, Poole, UK) and 7.5g agarose 
(Bioline, UK). This was stained with 20µL SYBR® Safe DNA gel stain (Invitrogen, 
UK). 10mls of orange G loading buffer, a color marker for monitoring the process of 
agarose gel electrophoresis (150 mls glycerol (Sigma, Poole, UK), 350 mls 0.5 x 
TBE, 0.125 g Orange G (Sigma, Poole, UK)) was added to each sample before they 
were loaded into the wells of the gel. The PCR products were visualised using 
ultraviolet light and photographed. The presence of a band indicated the presence of 
that particular allele at that position. The presence of the control band for each 
reaction acted as a positive control. 
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Figure 2.5 SSP-PCR products on an agarose gel using 63/64 and 210 / 211 control 
primers. 
R1 (63/64) tests for the G allele, R2 (63/64) tests for the A allele of SNP X.  
DNA A is positive for R1 (G) but negative for R2 (A), therefore the genotype is GG. 
Likewise the genotype for DNA B is GG.  
R1 (210/211) tests for the C allele and R2 (210/211) tests for the T allele of SNP Y. 
DNA A is negative for R1 (C) but positive for the R2 (T), therefore the genotype at 
this position is TT. DNA B is positive for both R1 and R2 therefore the genotype is 
CT. 
 
2.3.5.5 SSP-PCR primer setup, titration and optimisation 
 
The high sensitivity of PCR makes it susceptible to false positives from 
contamination. Such false-positives can be avoided through judicious laboratory set-
up (e.g. maintaining a physical seperation between DNA samples and the PCR 
reaction area), using separate laboratory equipment and consumables (including 
disposable gloves) for pre- and post-SSP-PCR work and dividing the reagents into a 
number of aliquots 300. 
  
False positive reactions (and false negatives) may also be seen in the presence of 
excess or inadequate primer. Titration of primers (specific and consensus) to 
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concentrations which minimise the likelihood of false positive and negative reactions 
is important in setting up the primer assay. In a false positive reaction, there is uneven 
intensity of the reaction products, whereby a true positive (heterozygous) reaction is 
indicated by the presence of both alleles with bands of equal intensity on 
electrophoresis. 
 
2.3.5.6 Primer titration for primer concentration optimisation 
 
5µl of the allele-specific and  5µl of the consensus primer stock (2000µg/ml) were 
added to 1ml of control primer master mix (as described above) and used to run PCR 
on 20 test DNA samples. Likely homozygous and heterozygous samples were 
identified. The allele-specific and consensus primers were titrated at different 
concentrations (table 2.2) and tested on the probable homo- and heterozygous DNA 
samples. 1ml primer mix containing control primer mix and either allele-specific or 
consensus stock primer in the volumes given below were made. 2.5µl of each allele-
specific primer was dispensed along with 2.5µl of consensus primer, therefore the 
final primer volume was 5µl.   
 
Table 2.2 SSP-PCR primer titration grid 
Cons Cons  Allele 
1 
Allele 
2 
Allele 
1 
Allele 
2 
Allele 
1 
Allele 
2 
Allele 
1 
Allele 
2 
Allele 
1 
Allele 
2 
Volume (µl)  
of stock 
primer to use 
in 1ml 
2 2 4 4 6 6 8 8 10 10 
 Final 
vol 1 1 2 2 3 3 4 4 5 5 
2 1 1/1 1/1 2/1 2/1 3/1 3/1 4/1 4/1 5/1 5/1 
4 2 1/2 1/2 2/2 2/2 3/2 3/2 4/2 4/2 5/2 5/2 
6 3 1/3 1/3 2/3 2/3 3/3 3/3 4/3 4/3 5/3 5/3 
8 4 1/4 1/4 2/4 2/4 3/4 3/4 4/4 4/4 5/4 5/4 
10 5 1/5 1/5 2/5 2/5 3/5 3/5 4/5 4/5 5/5 5/5 
Cons = consensus primer 
Final vol refers to the final volume of primer in 1ml of control primer mix.   
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Figure 2.6 SSP-PCR primer titration 
False positive reactions can be seen for allele 2 at the higher primer concentrations, as 
shown by the arrow heads. (The control primer for this experiment was 63/64). The 
combination of 2µl allele specific primer with 4µl consensus primer (highlighted) was 
chosen as the optimum primer concentration.  
 
 106
2.3.5.7 SSP-PCR for deletion-insertion polymorphism 
 
The polymorphism in the promoter region of  SLC6A4, (known as SERTPR), is a 
deletion-insertion (DIP) rather than a SNP. This DIP is a 20-23bp repeating unit. The 
allelic variants are named short (S) and long (L) depending on the presence or absence 
of the DIP. There are 3 possible allelic combinations: L (homozygous for the long 
form), S (homozygous for the short form) and LS (heterozygous). The L allele has 14 
repeats and the S allele 16 repeats respectively 301. Primers flanking this region which 
have been described in the literature 302;303 were used in this study to generate a 
484bp302 / 528bp303 fragment (S allele) or a 528 bp302 / 572bp303 fragment (L allele). 
Therefore the two common alleles differ in length by 44 base pairs.  
 
In order to visualise the SERTP insertion-deletion polymorphism (as detailed in 
chapter 5), the PCR products were electrophoresed for a longer period (60-90minutes) 
on a thicker 2% agarose gel. This ensured increased separation of the smaller DNA 
products.  A 100bp DNA molecular weight standard ladder (Invitrogen, UK) was 
included during the gel electrophoresis.  
 
 
 
Figure 2.7 SERTP deletion-insertion polymorphism 
This representative photo of an agarose gel shows the 3 possible allelic combinations 
for the SERTP deletion/insertion polymorphism. The 100bp DNA ladder is seen on 
the right hand side of the gel. On this ladder the 600bp band is 2-3 times brighter than 
the other bands.  
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2.3.6 Affymetrix genome wide SNP array 
 
A genome-wide SNP array was carried out using the Affymetrix DNA micorarray 5.0, 
a multiplex assay that simultaneously tests for 440,794 SNPs. 
 
Before the sample DNA can be added to the array it is digested using restriction 
enzymes (Nsp I and Sty I). Restriction enzymes cut double-stranded or single stranded 
DNA at specific recognition nucleotide sequences known as restriction sites. The 
digested DNA is then ligated to adaptors. These adaoptor-ligated DNA fragments are 
ampified using PCR, with preferential amplification of fragments in the 200-1,100 bp 
size range. The PCR products are purified and the amplified DNA is then fragmented, 
labeled, and hybridized to a Genome-Wide Human SNP 5.0 Array.  
 
The SNP array consists of an orderly collection of microscopic spots (called features), 
each of which has a specific probe (a fragment of DNA, usually 100-1000 bases long 
of known sequence), which is attached to a solid surface (the chip). When these 
probes are exposed to labelled sample DNA, complementary strands will hybridise by 
forming non-covalent hydrogen bonds between complementary nucleic acids. 
Fluorescently labeled DNA sequences which bind to a probe sequence generate a 
signal which is used to generate the genotype data 304. 
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2.4 Preliminary genetic analyses and genetic data management 
 
In order to be able to use genetic data in a genetic association study, there are a 
number of analyses and quality control checks which must be first carried out in order 
to ensure that the data are in the correct format for analyses and to minimise the 
likelihood that apparent SNP-phenotype associations are chance rather than true 
associations. These include: 
 
• Calculating allele carriage, allele frequency and genotype frequency 
• Hardy-Weinberg equilibrium testing 
• Linkage disequilibrium analysis 
• Inferrence of phase 
• Haploblock and haplotype construction 
 
A genetic database was set up in Microsoft Excel into which the genetic data was 
added in allele carriage format, as read from the presence or absence of bands on the 
agarose gels. The genotype was determined depending on the diploid allele carriage 
data at that position. Study subjects were considered heterozygous if they carried two 
different alleles at the same position or homozygous if they carried two copies of the 
same allele at that position.  
Allele carriage and allele frequency were calculated. 
Allele carriage is a sum of the number of subjects homozygous for that allele plus the 
number of heterozygotes, divided by the total number of individuals in the study.  
Allele frequency is calculated by the following equation: 
 [(2 x number of homozygotes) + number of heterozygotes] / total number of alleles  
Allele frequencies and genotype frequencies were used to compare genetic data in this 
study population to previously published data (e.g. HapMap CEU data) 90 as a quality 
control measure. 
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2.4.1 Genetic modelling 
 
There are a number of genetic models under which a genetic variant may be assumed 
to influence phenotype: 
 
• Dominant: Subjects who are either homozygous for the variant allele or 
heterozygous have the same phenotype i.e. subjects need only one copy of the 
variant allele to display the phenotype. 
 
• Recessive: Subjects who are homozygous for the variant allele have a different 
phenotype to those who are homozygous for the alternative allele or 
heterozygous. In other words, under the recessive model, a subject requires 
both copies of the variant allele to demonstrate the phenotype. 
 
• Codominant: This model assumes some quantitative measure of the 
phenotype. In a co-dominant model, the heterozygous mean differs from both 
homozygous means. The phenotype associated with each of the three 
genotypes is separated. 
 
• Additive: This is a variant of the co-dominant model in which each copy of the 
variant allele has an effect. If the heterozygous mean is equal to the average of 
the homozygous means, then the model is co-dominant but also additive. In 
this situation a gene dose effect (where there is an intermediate phenotype 
when the heterozygous genotype may be demonstrated): AA vs AB vs BB 
 
Ideally, the choice of statistical association test would depend on the genetic model 
underpinning the phenotype. It is rarely possible to know the likely genetic model in 
advance and therefore it is challenging to choose the best model to use in statistical 
analyses 305;306.  
 
In this candidate gene association study I used two different approaches to test for 
SNP-phenotype associations: comparisons of allele carriage and genotype frequency. 
These analyses were exploratory, one of the aims being to establish the SNP-
phenotype genetic model. Therefore no correction for multiple testing was included. 
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Allele carriage:  
Using allele carriage assumes a dominant (or recessive) model of association 307. 
When the phenotype being tested is a complex trait such as response to morphine, it is 
usually not known whether the variant allele is a risk-enhancing allele (increases the 
likelihood of a poor outcome) or a protective allele (increases the likelihood of a good 
outcome). Therefore assuming the dominant model for testing one allele in a bi-allelic 
SNP is the same as assuming the recessive model for the alternative allele, as shown 
below. 
 
Table 2.3 Allele carriage in genetic association tests assumes a dominant / 
recessive mode of SNP-phenotype inheritance 
Model Genetic association test Genotypes 
compared 
Dominant for allele A Carriage of A versus non-carriage of A AA + AB vs BB 
Recessive for allele A Non-carriage of B versus carriage of B AA vs AB + BB 
   
Dominant for allele B Carriage of B versus non-carriage of B BB + AB vs AA 
Recessive for allele B Non-carriage of A versus carriage of A BB vs AA + AB 
Consider two alleles: A and B 
A subject is said to be “carrying” the A allele if the genotype is AA or AB. A subject 
is said to be “carrying” the B allele if the genotype is BB or AB.  
 
 
Genotype frequency: 
The genotypes were recoded as 0 (homozygous for minor allele), 1 (heterozygous), 2 
(homozygous for major allele) and a linear trend analysis was carried out which tested 
for a linear trend of increasing effect across the three genotype groups. The genotypes 
were entered into regression analyses as non-categorical data. This assumes a co-
dominant additive model. This was the preferred model in this thesis because: 
• When the allele under investigation is assumed to be in linkage disequilibrium 
(LD) with the true susceptibility allele, then testing genotype frequencies using 
an additive model is recommended, especially if the genetic effect is likely to 
be small, as LD is likely to “dilute” the true effect size 306.  
 111
• It is thought that the model of SNP-phenotype associations in complex traits is 
usually additive 305. 
 
A “per-allele” analysis is often carried out in genetic analyses in which the allele 
frequencies are compared. In this type of analysis the sample size is doubled as each 
subject has two alleles, therefore increasing the power of the study. However this 
approach is prone to false-positives and false negatives, especially when Hardy-
Weinberg deviations are present 307, see section 2.4.2. Furthermore it is difficult to 
interpret the results of per-allele analyses in terms of biological risks 306. Therefore 
allele frequency was only used in this thesis to compare our data with published 
frequency data. 
 
2.4.2 Hardy-Weinberg Equilibrium 
 
The Hardy-Weinberg Equilibrium (HWE) states that alleles are independent and that 
the allele and genotype frequencies should remain constant (in equilibrium) from one 
generation to the next.  
 
For any bi-alleleic SNP, consider the frequency of allele A = p, and the frequency of 
allele B = q. The frequency of genotype AA is p2, AB is 2pq and BB is q2. If the 
population is in HWE, then the sum of both allelic frequencies equals 100% i.e.   
p + q  = 1 
and 
p2 + 2pq + q2 = 1 
 
The HWE model is based on a number of assumptions, departure from which can 
result in deviations from HWE: 
• Large population. In a small population chance alone may alter allele 
frequencies in situations where there are only a few copies of a certain allele 
within that population (genetic drift). 
• Random mating. Departures from random mating e.g. inbreeding causes an 
increase in the homozygosity of genes. 
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• Negligible mutations with little effect on allele frequencies. Mutations may 
have a greater effect on allele frequencies in smaller populations. 
• No gene flow between populations (e.g. through migration). 
• Natural selection is not operating on the population i.e. no selection of certain 
alleles over other alleles. 
 
In order to test for whether the population is in HWE, the difference between expected 
genotype frequencies and observed genotype frequencies were compared using a Chi-
squared test.  Significant (p <0.05) differences between expected and observed 
genotype frequencies indicate that the study population was not in HWE. If the 
population was not in HWE for a particular SNP, the raw data were rechecked for 
genotyping errors. 
 
2.4.3 Linkage Disequilibrium and Haplotypes  
 
Linkage disequilibrium (LD) is the non-random association of genetic variants within 
a population. LD refers to the idea that certain alleles occur on the same haplotype 
more often than is expected by chance. A haplotype is a combination of alleles that 
are transmitted together. 
 
The human genome is thought to be comprised of areas of strong LD interspersed 
with areas of LD breakdown, presumably recombination hotspots. (Recombination is 
the generation of new combinations of genetic material as a result of crossover during 
meiosis). A haploblock (also known as a haplotype block) is a genomic region which 
is inherited without substantial historical recombination. The size of haplotype blocks 
in humans can range from a few kb to more than 100 kb 308.  Haplotypes are 
combinations of markers in LD together which are often defined within the 
haploblock structure. Within each haploblock there are only a few common 
haplotypes. Instead of analysing each SNP individually, these common haplotypes 
may be used to analyse genetic variation across sizable regions by testing only a small 
number of haplotype tag SNPS. This is the basis of the International HapMap Project 
79;309
. Haplotype blocks may vary in different populations. The HapMap Project 
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characterised SNPs and LD in four different populations: 90 subjects of northern and 
western European origin (denoted CEU), 45 Han Chinese (CHB), 
44 from Tokyo (JPN) and 90 subjects from the Yoruba in Ibadan, Nigeria (YRI). In 
Phase 1 of the International HapMap Project, over 1 million SNPs were genotyped 79. 
In Phase 2, over 3.1 million SNPs have been included 309.The HapMap project has 
identified only approximately 1% of common variants which are “untagggable” as 
they lie within areas of low LD, usually recombination hotspots 309. Another benefit of 
haplotype analysis is that it may provide information about the cumulative effect of a 
number of genetic variants on the study outcome 310. 
 
LD can be affected by a number of genetic processes including selection and genetic 
drift. Changes in population size (e.g. population bottlenecks) and the exchange of 
individuals among populations with resultant mixing of individuals from 
subpopulations that have different allele frequencies can both alter LD 308. The 
strength of LD between pairs of markers decreases as a function of the genetic 
distance between markers. LD around an allele decays due to recombination breaking 
down ancestral haplotypes 311. However, LD patterns may be surprising with pairs of 
loci at considerable distances from each other being in complete LD 310. These areas 
of long-range LD are thought to have occurred when the population was so small that 
the amount of genetic variation was limited e.g. during a population bottleneck (i.e. 
when there was a temporary reduction in the size of the population resulting in a loss 
of genetic variation) or due to an extreme founder effect. Long-range LD may also 
arise from population admixture, the mixing of genetically distinct populations 312. 
 
There are many different measures of LD. Most measure the degree of LD between 
pairs of markers. For any two biallelic loci (Aa and Bb), there are four possible 
haplotypes: Ab, AB, aB and ab. The frequency of haplotype AB may be denoted as 
piAB and the frequencies of the alleles piA, piB, pia and pib. 
 
One of the early measures of LD was D, the coefficient of linkage disequilibrium. D is 
the difference between the frequency of gametes carrying the pair of alleles A and B 
at two loci (piAB) and the product of the frequencies of those alleles (piA and piB). 
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DAB= piAB- piApiB 313  
 
This measure is limited by its dependence on allele frequencies. To avoid (or at least 
minimise) this problem, D’ was proposed as the coefficient of linkage disequilibrium 
(D), standardised to the maximum possible value of D at the given allele frequencies  
313
.  
 
DAB’ = DAB/ DAB, max311 
 
The absolute value of D’, |D’|   is usually used. 
If all four haplotypes are present, historical recombination has occurred between the 
two loci and therefore |D’| < 1. If even one haplotype is not observed, |D’|  =1 314. |D’|  
= 1 represents the situation where no recombination has occurred between the two 
markers. Therefore D’ is also a measure of historical recombination. |D’|  values may 
be inflated when rare alleles are examined or when the sample size is small. If a SNP 
has a low minor allele frequency, it is quite possible that it is carried on a rare 
haplotype which may not be observed in a small study population. Therefore, all four 
haplotypes will not be present in the study population. This results in |D’|  =1, 
irrespective of the level of linkage disequilibrium. 
 
r
2
 is another commonly used  marker of LD and represents the correlation coefficient 
between pairs of markers. Like D, r2 is allele frequency dependent. 
 
r2= (DAB)2/ piApiBpia pib = (piAB- piApiB)2 / piApiBpia pib315 
 
|D’| and r2 values range from 0 to1. |D’| or r2 =1 represents complete LD while |D’|  or 
r2 =0 represents no LD.  
 
In this study, LD (D’ and r2) was measured between pairs of alleles using the 
programme, Haploview 316.  
 
Haploblocks were identified using Haploview which is based on the Confidence 
Interval algorithm described by Gabriel et al 315.   Each pair of markers was defined as 
being in “strong LD”, “inconclusive” or “strong evidence for recombination” 
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depending on the confidence intervals (CI) for D’. For markers to be in “strong LD”, 
the upper CI must be >0.98 and the lower CI >0.7. A haploblock was created if 95% 
of the informative markers (minor allele frequency >0.2) were in “strong LD”. This 
method was chosen as it avoids the changes in absolute D’ values which are 
associated with small numbers of samples.  
 
The genotype of an individual will not tell us anything about the haplotype i.e. 
genotype data alone will not tell us about the pairwise relationship between alleles at 
each locus. Consider two bi-allelic loci on the same chromosome. If the first locus, A, 
has alleles p and q and the second locus B, alleles w and y, then the possible genotype 
combinations at locus A are pp, pq and qq and at locus B, ww, wy and yy. There are 
therefore nine possible configurations for the genotypes at these two loci. In order to 
resolve the haplotype phase (that is to determine haplotypes from genotype 
information), in a sample of unrelated individuals, statistical programmes are used 
which infer haplotypes from genotype data. The inferred haplotypes can then be 
treated as data. There are a number of such programmes available, all based on 
slightly different theoretical backgrounds. I used the software programme PHASE, a 
probability based Bayesian method, 
(http://www.stat.washington.edu/stephens/software.html) 317 to construct haplotypes 
within each haploblock which had been defined using Haploview.  
 
When carrying out haplotype analysis, a very low rate of genotyping error is essential 
in order to avoid the identification of false rare haplotypes. Therefore if rare 
haplotypes were identified, the samples were regenotyped to ensure accuracy of 
genetic data. 
 
Like allele frequencies, haplotype frequencies are calculated as the total number of 
haplotypes present in the population on both chromosomes [(2 x number of subjects 
with two copies) + number of subjects with one copy] divided by the total number of 
chromosomes in that population (total study population x 2). The sum of the 
haplotype frequencies adds up to 100%. Haplotype frequencies were calculated to 
allow comparisons with published data. 
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The combination of haplotypes in a pair of chromosomes is known as a diplotype. 
Haplotype carriage frequencies were calculated as the sum of the number of subjects 
with one or two copies of the haplotype, divided by the total number of subjects in the 
study. The haplotypes on each chromosome making up a diplotype may be dissimilar. 
In this way the sum of haplotype carriage frequencies in the study often add up to 
>100%. Haplotype carriage frequency was used in the association analyses. 
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2.5 Statistical analyses 
 
Statistical analyses and plots were performed using SPSS (SPSS, Chicago, IL) and 
GraphPad. (GraphPad Prism version 4.02 for Windows, GraphPad Software, San 
Diego California USA). 
 
Means and standard deviation (SD) values (or median and range if non-parametric) 
were used to describe continuous clinical data, with counts and percentages used for 
discrete variables. Normality of continuous data was checked by analysing skewness 
and kurtosis (both of which describe the shape of the data distribution) and by 
application of the Shapiro-Wilk test. Where appropriate, non-parametric data were 
transformed using logarithmic transformation.  
 
Correlation coefficients may be calculated using a number of correlation coefficients. 
Spearman’s correlation coefficient was used in this thesis as it is the test of choice if 
the data are non-parametric or if the sample size is small. Kendall-tau was used for 
non-parametric and non-interval scaled ordinals. A correlation coefficient of +/- 0.1 
represents a small effect, +/- 0.3 a medium effect and +/- 0.5 a large effect 318. 
 
Categorical variables were compared between using the Chi-square (χ2) or Fisher’s 
exact test if the sample sizes were small. Continuous data were analysed using 
Student t-test / 1-way ANOVA for parametric data and Man-Whitney U / Kruskal-
Wallis for non-parametric data. Paired data were compared using paired t-test 
(parametric) / Wilcoxon signed rank test (non-parametric). 
 
2.5.1 Regression 
 
The relationships between the clinical and genetic variables and the defined clinical 
phenotypes were determined using regression analyses; linear for continuous outcome 
variables and logistic for binary outcome variables. Regression analyses were used to 
demonstrate the level of change in the dependent variable (outcome variable) 
according to variance in each of the predictor variables, when all other predictor 
variables were held fixed.  
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Univariate regression was initially carried out to screen for an association between 
individual clinical and genetic variables and the outcome variables. Multiple 
regression was used to investigate the joint effect of predictor variables (clinical and 
genetic) on the clinical phenotype (dependent variable). The dependent variable was 
transformed to ensure parametric distribution when necessary for linear regression. 
Candidate clinical predictor variables included age, gender, time on morphine (days), 
dose of morphine (mg in 24 hours) and time to death (days), concomitant medications, 
biochemical and haematological parameters and tumour diagnosis. Clinical and 
genetic factors with p<0.1 on univariate analysis were included in the multivariate 
modelling. Variables with p>0.1 were excluded in order to reduce the number of 
predictor variables.  Variable selection was carried out using a stepwise method, with 
p<0.05 and p>0.1 as criteria for entry and removal respectively.  Only factors with 
p<0.05 were retained in the final model.   
 
The following test statistics were generated: 
Linear regression: 
• R2: The proportion of the variability in the outcome variable that can be 
explained by its relationship with the predictor variables. This value represents 
an assessment of goodness of fit.  
• B (the regression coefficient), standard error of B, CI (B): This value 
represents the change in the outcome variable associated with a unit change in 
the predictor variable. A regression coefficient of 0 means that a unit change 
in the predictor variable is associated with no change in the outcome. In a 
multivariate regression analysis, the correlation coefficient provides 
information about the extent to which the predictor variable affects the 
outcome variable, if the effects of all of the other predictor variables are held 
constant 318. The value of B is dependent on the unit of measurement of the 
variable. The relationship between the predictor and outcome variable may be 
positive or negative, as demonstrated by the sign of the B value. Confidence 
Intervals (CI) of B are provided in SPSS. If the model is a good model, the CI 
should not cross 0.  
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•  T-test p-value. This is based on the null hypothesis that B = 0. If p<0.05, then 
the predictor variable is making a significant contribution to the model. 
• β  is a standardised version of B. This represents the change in the outcome 
variable (in terms of number of standard deviations) due to one standard 
deviation change in the predictor. In a multivariate regression model the 
different β values may be compared.  
• ANOVA F-test: A significant result (p<0.05) indicates that there is a linear 
relationship between the outcome variable and at least some of the predictor 
variables i.e. that the model overall is a good predictor of the outcome 
variable.  
• Variable Inflation Factor (VIF). This assesses whether the predictors are 
correlated together. An average VIF of >1 suggests that there may be multiple 
collinearity which may introduce bias into the model.  
 
Logistic regression: 
• Wald statistic: This provides information about whether the B value 
(regression coefficient) is significantly different from zero, i.e. whether a 
change in the predictor variable is associated with a significant change in the 
outcome variable.  
• Exp (B) This represents a change in the odds associated with a unit change in 
the predictor variable. A value >1 suggests that as the predictor increases, then 
the odds of the outcome occurring increase and vice versa. (Therefore in a 
good model, the 95% CI for Exp(B) should not cross 1). In multivariate 
logistic regression, this value represents an estimate of the odds ratio for the 
predictor and outcome variable when all other predictor variables are held 
fixed.  
• Nagelkerke’s R2: This value is used in logistic regression and is an adjusted 
square of the partial correlation between the outcome variable and each of the 
predictor variables,  
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2.5.2 Principal Components Analysis (PCA) 
 
Principal components analysis was used to identify groups / clusters of variables 
within the dataset. Using this technique a number of uncorrelated artificial variables, 
known as components, are identified which account for most of the variance in the 
data. PCA is a variable reduction procedure. Although the number of components 
identified equals the number of variables, only the first few are retained in subsequent 
analyses as these account for most of the variance in the data.  The first component 
extracted in a principal component analysis accounts for a maximal amount of total 
variance in the observed variables. The second component accounts for the maximum 
amount of variance in the data set that was not accounted for by the first component. 
In this study all components with eigenvalues >1 were retained 319. The variables 
making up each component were determined by assessing the component loadings of 
each variable. The component loadings represent the importance of the variable to the 
component. The significance of a component loading depends on the sample size. A 
value >0.4 was considered significant in this thesis as the sample size was between 
100 and 200 318. 
 
The appropriateness of PCA was determined using Kaiser-Meyer-Olkin measure of 
sampling adequacy (KMO). This generates a value between 0 and 1. Values above 0.7 
suggest a statistically adequate sample size 318. Individual variables with KMO values 
of <0.5 were excluded from further analysis. A significant value (<0.05) for Bartlett’s 
test of sphericity suggests that there are relationships between the variables, which is 
required for PCA to be successful.  
 
Individual component scores (log transformed) for each study subject were used as 
outcome variables in subsequent linear regression in the clinical and genetic 
association studies. 
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3 Chapter 3: Results from Prospective Morphine Study 
and Definition of the clinical phenotype 
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3.1 Summary of the rationale behind this study 
 
• In the published literature there is little consensus with respect to definition of 
outcome measures in pain and analgesia studies. Therefore comparison and 
replication of results is challenging.  
Previously published reports have chosen one dimension of analgesic response 
or opioid side-effects as the outcome measure in genetic association studies.   
• Response to morphine is determined by the subjective experience of pain 
control and side-effects. There may be many other clinical factors contributing 
to these subjective experiences.  
 
3.1.1 Aim 
 
The aim of this part of the study was to explore the clinical data to establish clinically 
relevant methods of defining the clinical phenotype of response to morphine. The 
resulting phenotype/s would then be used in the subsequent genetic association 
studies.  
 
In this chapter I present two distinct clinical phenotypes of morphine response: 
 
1. Composite scores of analgesic response and central side-effects as distinct 
outcome measures, defined by principal components analysis (PCA). 
2. The daily dose of morphine required to achieve adequate analgesia.  
 
A further clinical phenotype of constipation on morphine is presented in chapter 7. 
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3.2 Subjects and methods 
 
Clinical data from the Prospective Morphine Study were used in these analyses.  
 
The data were initially explored using descriptive statistics. Most continuous variables 
were not normally distributed and were described using medians and ranges. The 
reasons for morphine non-response were examined. The pain and side-effect scores 
for all study subjects were examined for correlation. Logistic regression with 
morphine non-responder (switcher) as the dependent variable was used to determine 
which pain / side-effects scores were predictors of morphine response / non-response.  
 
Principal components analysis (PCA) was used to explore response to morphine 
morphine using a comprehensive assessment of five patient reported pain intensity 
scores and seven side-effect scores. PCA (or a similar factor analysis approach) has 
been used previously to examine relationships between different pain scores and 
thresholds 320;321. This is the first time in which it has been used to identify clusters of 
variables defining the underlying dimensions of morphine response.  
 
Principal components analysis (PCA) was carried out in order to examine the 
components of morphine response / non-response which account for the variability in 
the clinical data. All of the subjective symptom scores (pain and side-effects) were 
entered into the model as numeric data. As this part of the study represents a move 
away from the clinical phenotype of “morphine responder” versus “morphine non-
responder”, all subjects were included in the analysis together without making the 
distinction between responders and non-responders. Component scores were 
calculated using the regression method and rotation was carried out using an oblique 
method (direct oblimin). All components with eigenvalues >1 were retained 319. 
 
The individual component loading scores were used as dependent / outcome measures 
in subsequent linear regression modelling. This was carried out to identify other 
clinical factors predictive of the outcome. The clinical factors included in the 
modeling included age, gender, dose of morphine, time on morphine, diagnosis, 
concomitant medications and haematological / biochemical parameters.  
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3.2.1 Maintaining a tight clinical phenotype  
 
In order to maintain as tight a clinical phenotype as possible, the clinical data were 
examined in terms of 1) length of time on morphine at recruitment to the study and 2) 
pain scores in the morphine “responder” and “non-responder” groups.  
 
Titration of morphine dose to achieve optimal pain control may take a variable length 
of time. One study demonstrated that the median time to achieve stable pain control 
ranged from 4 days for mild pain to 8 days for moderate pain to 22 days for severe 
pain 322. In our study, subjects who had been on morphine for less than 1 week (N=19) 
were therefore excluded from analysis as it was felt that this may not have been 
adequate time to allow optimal dose titration.  
 
Many sources agree that pain intensity of 4 or less on an 11 point NRS represents 
either mild pain or good analgesia 181;323-326. An average pain of ≤ 4/11 has been 
considered to be adequate or acceptable pain control 92. In this study there were a 
number of patients whose pain was well controlled according to both the patient and 
the clinical palliative care team but whose scores on the modified BPI did not reflect 
this. These patients were categorised clinically as “morphine responders” by the 
palliative care team yet their pain scores suggested that they were either inadequately 
titrated on their morphine dose or that they were simply unable to fill in the numerical 
rating scale accurately. In order to maintain a very tight clinical phenotype these 
patients (N=38) were also excluded from analysis.  
 
89% (264) study subjects were Causacian, with 4% (13) Black / Black British, 2% (7) 
Asian / Asian British, and 5% (14) each Mixed or Other ethnicity.  The study 
population was compared to all new patients attending the Royal Marsden Hospital in 
a defined 12 month period (2006-2007). The proportion of patients with different 
ethnicities in the study was representative of the ethnicities of patients attending the 
Royal Marsden Hospital (see figure 3.1).  
 
The main aim of this study was to examine the genetic factors associated with opioid 
response. As the number of non-caucasian subjects was small in the study (N=34), in 
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order to avoid population stratification, these were also excluded from further 
analysis. 
 
Figure 3.1 Ethnicity data 
Number of patients shown on top of bars 
A total of 207 study subjects were included in subsequent analyses.  
 
 
Figure 3.2 Study population used in thesis (Prospective Morphine Study) 
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3.3 Results 
 
Prospective Morphine study: demographic data 
 
The characteristics of the total study population are shown in table 3.1.  
 
145 (70%) of the 207 subjects included in the analyses were morphine responders and 
62 (30%) morphine non-responders. 
 
3.3.1 Morphine responders versus morphine non-responders 
 
The reasons for switching to an alternative opioid are presented in table 3.2. The most 
common reason for a patient to be considered a “morphine non-responder” was 
intolerable drowsiness (66%), followed by inadequate pain control (47%) and 
confusion or hallucinations (37%).  
 
 
 
 
Figure 3.3 Morphine dose and Length of time on morphine  
There was no statistical difference between the daily dose of morphine taken by non-
responders (median 120mg, range 15-1280mg), compared to responders (median 
100mg, range 10-720mg). Non-responders had been on morphine a shorter time than 
responders (median 59, range 8-1369 days and median 106, range 7-4455 days 
respectively, p<0.0001).   
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Table 3.1 Patient characteristics for total study population (N=207) 
 
 
Median (range) 
Age (years) 60 (19-85) 
Daily morphine dose (mg/24hours)  100 (10-1280) 
White blood cell count (x109 /L) 8.6 (0.3-68.1) 
Serum sodium (mmol/L) 136 (120-143) 
Serum albumin (g/L) 30 (11-48) 
Serum calcium (mmol/L, corrected for albumin) 2.24 (1.52-2.94) 
Days to death (days) 131 (5-2147) 
Days on morphine (days) 89 (7-4455) 
 N (%) 
Sex  
   Male 108 (52)  
   Female  99 (48)  
Diagnosis  
   Gynaecological 18 (9)  
   Lung (including mesothelioma) 27 (13)  
   Breast 36 (17)  
   Urogenital (renal and bladder) 21 (10)  
 Upper gastrointestinal tract 16 (8) 
 Lower  gastrointestinal tract  18 (9) 
   Head & Neck 12 (6) 
   Sarcoma 28 (14) 
   Prostate 17 (8) 
Concomitant medications  
   Antibiotic 54 (26) 
   Anticonvulsant 44 (21)  
   Anticoagulant 49 (24) 
   Anti-diabetic medication 11 (5.3) 
   Antiemetic  99 (48)  
   Aspirin 21 (10)  
   B Blocker 17 (8)  
   Diuretic 24 (12)  
   Laxative 136 (66) 
   NSAID 74 (36)  
   Paracetamol 83 (40) 
   Proton Pump Inhibitor 139 (67) 
   SSRI, SNRI antidepressants 23 (11)  
   Statin 11 (5.3) 
   Steroid 82 (40) 
   Tricyclic antidepressants 27 (13)  
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Table 3.2 Reason for morphine "non-response" (N=62) 
 
 N (%) 
Uncontrolled pain 29 (47) 
Intolerable side-effects  
  Nausea 18 (29) 
  Vomiting 5 (8) 
  Constipation 6 (10) 
  Drowsiness 41 (66) 
  Confusion / hallucinations 23 (37)  
  Nightmares 9 (15)  
  Pruritus 4 (6)  
* Other 6 (10)  
62 out of 207 patients were “morphine non-responders” 
*Other reasons for switching included: myoclonus, fatigue, 
feeling “spaced out”, lethargy, sweating and poor concentration. 
All of these symptoms were also accompanied by another 
reason for non-response. 
Patients usually had >1 reason for morphine “non-response” 
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3.3.2 Prospective Morphine Study: Pain scores  
 
There was a clear difference between the pain experienced by morphine responders 
and non-responders as shown in table 3.3. 
 
Table 3.3 Pain scores, shown as median (range) 
 
 All study 
subjects 
N=207 
Responders 
N=145 
Non-
responders 
N=62 
P value* 
Worst pain  5 (0-10) 4 (0-9) 7 (2-10) <0.0001 
Least pain  0 (0-9) 0 (0-4) 2 (0-9) 0.01 
Average pain  2.5 (0-9) 2 90-4) 5 (0-9) <0.0001 
Pain now 1.5 (0-9) 0 (1-6) 4 (0-9) <0.0001 
% pain relief  80 (0-100) 90 (30-100) 60 (0-100) <0.0001 
*Man-Whitney-U 
 
Correlations between the different pain scores are shown in table 3.4. The strongest 
correlation is between average pain and worst pain (r = 0.737). There is also moderate 
to strong correlation between average pain and all pain scores. Pain relief, average 
pain and worst pain were identified in this study as independent predictors of 
morphine non-response by multivariate regression analysis as shown in Table 3.5. 
 
Table 3.4 Correlation between pain scores 
 
 
Worst 
pain 
Least 
pain 
Average 
pain 
Pain 
now 
% pain relief 
in last 24hours 
Worst pain  1.000 0.495 0.737 0.574 -0.610 
Least pain  0.495 1.000 0.654 0.675 -0.528 
Average pain  0.737 0.654 1.000 0.675 -0.725 
Pain now 0.574 0.675 0.675 1.000 -0.640 
% pain relief in last 
24hours -0.610 -0.528 -0.725 -0.640 1.000 
All pain scores NRS 0-10 
% Pain Relief NRS 0-100 
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Table 3.5 Pain scores predictive of morphine response 
Multivariate logistic regression with morphine non-responder as dependent variable. 
  
 B  S.E. Wald p value OR (95% CI) 
Worst pain  0.267  0.112 5.715 0.017 1.306(1.049, 1.626) 
Least pain -0.256  0.194 1.738 0.187 0.774(0.529, 1.133) 
Average pain 0.568  0.198 8.219 0.004 1.765(1.197, 2.603) 
Pain now 0.214  0.134 2.538 0.111 1.238(0.952, 1.611) 
% Pain Relief  -0.024  0.011 4.837 0.028 0.976(0.955, 0.997) 
Constant  -2.611 1.168 5.000 0.025 0.073 
 
 
3.3.3 Prospective Morphine study: Side-effect scores  
 
Drowsiness (80%) and constipation (73%) were the most common opioid side-effects 
experienced by the total study population. There were a higher proportion of subjects 
experiencing nausea, drowsiness, confusion, bad dreams and myoclonus in the “non-
responder” group. However a substantial proportion of subjects in the “responder” 
group also experienced these symptoms. (Table 3.6: Side-effects on morphine: 
Morphine responders versus non-responders) 
 
Table 3.7 shows the correlations between the side-effects of morphine. The highest 
correlations were between confusion/hallucinations and drowsiness (r = 0.38) and 
confusion/hallucinations and bad dreams (r = 0.309). Constipation was not 
significantly correlated with any other side-effect.  
 
A multivariate logistic regression model defined drowsiness, confusion/hallucinations 
and bad dreams as independent predictors of morphine non-response (table 3.8). 
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Table 3.6 Side-effects on morphine. 
 
Morphine responders versus non-responders  
Total N= 207 
% (N) 
     Chi-squared test* 
Symptom Grade Total study 
population 
Responder 
(N=145) 
Non-
responder 
(N=62) 
X2 P value 
Nausea All 49 (102) 44 (64) 61 (38) 5.1 0.02 
 0 51 (105) 55.9 (81) 38.7 (24) 
  
 1 30 (63) 29.7 (43) 32.3 (20)   
 2 11 (23) 10.3 (15) 12.9 (8)   
 3 8 (16) 4.1 (6) 16.1(10)   
Constipation All 71 (148) 71 (103) 73 (45) 0.8 0.05 
 0 29 (59) 29.0 (42) 27.4 (17)   
 1 27 (55) 29.0 (42) 21.0 (13)   
 2 24 (50) 23.4 (34) 25.8 (16)   
 3 43 (20) 18.6 (27) 25.8 (16)   
Drowsiness All 80 (166) 75 (109) 92 (57) 7.7 0.006 
 0 20 (41) 24.8 (36) 8.1 (5) 
  
 1 31 (64) 37.9 (55) 14.5 (9)   
 2 29 (60) 31.0 (45) 24.2 (15)   
 3 20 (42) 6.2 (9) 53.2 (33)   
Confusion / 
hallucination 
All 40 (83) 28 (40) 69 (43) 32 <0.001 
 0 60 (124) 72.4 (105) 30.6 (19) 
  
 1 20 (41) 20.7 (30) 17.7 (11)   
 2 14 (30) 5.5 (8) 35.5 (22)   
 3 6 (12) 1.4 (2) 16.1 (10)   
Nightmares All 23 (48) 14 (20) 45 (28) 24 <0.001 
 0 77 (159) 86.2 (125) 54.8 (34) 
  
 1 13 (27) 9.7 (14) 21.0 (13)   
 2 9 (18) 4.1 (6) 19.4 (12)   
 3 1 (3) 0 (0) 4.8 (3)   
Dry mouth All 12 (25) 10 (14) 18 (11) 2.7 0.1 
 0 88 (182) 90.3 (131) 82.3 (51) 
  
 1 2 (4) 2.1 (3) 1.6 (1)   
 2 8 (16) 6.9 (10) 9.7 (6)   
 3 2 (5) 0.7 (1) 6.5 (4)   
Pruritus All 4 (9) 3 (5) 6 (4) - 0.5 
 0 96 (198) 96.6 (140) 93.5 (58)   
 1 3 (7) 2.8 (4) 4.8 (3)   
 2 1 (2) 0.7 (1) 1.6 (1)   
 3 0 (0) 0 (0) 0(0)   
Myoclonus All 4 (8) 1 (2) 10 (6) - 0.01 
 0 96 (199) 98.6 (143) 90.3 (56) 
  
 1 2 (4) 1.4 (2) 1.6 (1)   
 2 2 (4) 0(0) 6.5 (4)   
 3 0 (0) (00) 0(0)   
* Chi-squared test  (or Fisher’s exact test) performed on binary data: presence or absence of 
symptom 
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Table 3.7 Correlation between side-effects on morphine  
 
 Nausea Constipation Drowsiness Confusion Bad dreams Dry mouth Itch Myoclonus 
Nausea Correlation 
Coefficient 1.000 0.083 0.139 0.201 0.159 0.141 0.093 0.020 
  
P 
 0.164 0.021 0.001 0.012 0.029 0.154 0.765 
Constipation Correlation 
Coefficient 0.083 1.000 0.034 0.033 0.120 0.019 -0.006 0.033 
  
P 0.164  0.563 0.582 0.053 0.759 0.930 0.601 
Drowsiness Correlation 
Coefficient 0.139 0.034 1.000 0.380 0.227 0.071 -0.035 0.061 
  
P 0.021 0.563  1x 10-6 0.0002 0.261 0.583 0.339 
Confusion Correlation 
Coefficient 0.201 0.033 0.380 1.000 0.309 0.081 0.016 0.122 
  
P 0.001 0.582 1x 10-6  1.4 x 10-6 0.211 0.803 0.064 
Bad dreams Correlation 
Coefficient 0.159 0.120 0.227 0.309 1.000 0.017 0.091 0.025 
  
P 0.012 0.053 0.0002 1.4x 10-6  0.793 0.178 0.711 
Dry mouth Correlation 
Coefficient 0.141 0.019 0.071 0.081 0.017 1.000 0.066 -0.068 
  
P 0.029 0.759 0.261 0.211 0.793  0.334 0.319 
Itch Correlation 
Coefficient 0.093 -0.006 -0.035 0.016 0.091 0.066 1.000 0.091 
  
P 0.154 0.930 0.583 0.803 0.178 0.334  0.190 
Myoclonus Correlation 
Coefficient 0.020 0.033 0.061 0.122 0.025 -0.068 0.091 1.000 
  
P 0.765 0.601 0.339 0.064 0.711 0.319 0.190  
Binary data (presence or absence of symptom) used in analysis 
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Table 3.8 Side-effects predictive of morphine response 
 
 B S.E. Wald p value OR (95% CI) 
Nausea 0.199 0.209 0.915 0.339 1.221(0.811, 1.837) 
Constipation 0.104 0.182 0.331 0.565 1.110(0.778, 1.585) 
Drowsiness 0.938 0.233 16.207 5.7x10-7 2.554 (1.618, 4.032) 
Confusion 0.733 0.224 10.754 0.001 2.082(1.343, 3.228) 
Bad dreams 0.750 0.280 7.156 0.007 2.116(1.222, 3.666) 
Dry mouth 0.228 0.299 0.585 0.444 1.256(0.700, 2.255) 
Itch 0.836 0.771 1.175 0.278 2.308(0.509, 10.464) 
Myoclonus 2.064 1.237 2.785 0.095 7.880(0.698, 89.007) 
Constant -3.879 0.598 42.094 0.000 0.021 
Multivariate logistic regression. Dependent variable: Morphine non-responder 
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3.3.4 Phenotype 1: Composite scores of analgesic response and central side-
effects on morphine, as defined by PCA 
 
The sample size was statistically adequate to carry out principal components analysis 
(Overall Kaiser-Meyer-Olkin (KMO) value 0.852, Bartlett’s test of sphericity 
<0.001).  Constipation, dry mouth and myoclonus were excluded from analysis as the 
individual KMO values were 0.404, 0.531 and 0.468, which are only borderline for 
sampling adequacy 318. 
 
Two principal components emerged with eigenvalues >1 (Figure 3.4 and table 3.9). 
The first component, which carried high loadings from all the pain intensity scores, 
explained nearly 40% of the total variance. This component represents analgesic 
response to morphine. Component 2, accounting for 15% of the total variance, 
received high loadings from the central side-effects of confusion / hallucinations, 
drowsiness, bad dreams and nausea. Itch was not retained in either of the principal 
components. The final pattern matrix (table 3.9) demonstrates the loadings of each 
variable onto each component after rotation.  
 
Component 1 (analgesia) and component 2 (central side-effects) were only mildly 
correlated, Spearman r = 0.18.  
 
The principal components were transformed as they were not normally distributed. A 
higher log10Component 1 score was associated with higher average, least, worst and 
pain now scores and lower pain relief scores (correlation coefficients 0.889, 0.764, 
0.803, 0.836and -0.834 respectively), as shown in Figure 3.5. Similarly a higher 
log10Component 2 score (central side-effect) score was associated with a higher 
individual symptom severity score (table 3.10). Confusion and hallucinations was 
associated with the highest loading of individual factors onto log10Component 2 
(central side-effects). Therefore a higher log10Component 1 or log10Component 2 
scores represents a worse outcome in terms of analgesia or central side-effects on 
morphine respectively. 
 
Patients who were defined as being morphine responders had much lower analgesic 
and central side-effects components scores than morphine non-responders (p<0.0001).   
 135
 
Figure 3.4 Principal Components of morphine response 
The co-ordinates of the variables along the axes (components) represent a measure of 
the strength of the relationship between the variable and the component. Worst pain, 
average pain, least pain, pain now and pain relief scores correlate highly with 
component 1 (x-axis). Therefore component 1 appears to represent analgesic 
response.  Confusion, drowsiness, nausea and bad dreams are correlated with 
component 2 (y-axis). Therefore component 2 appears to represent central side-
effects. The variables which are highly correlated with component 1 (analgesic 
response: red circle) have a low correlation with component 2. Similarly variables 
which are highly correlated with component 2 (central side-effects: blue circle) have a 
low correlation with component 1.   
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Table 3.9 Pattern matrix showing the loading of each variable onto each 
component after rotation 
 
  Component 
  1 2 
Eigenvalue (after rotation)* 3.683 2.026 
% variance explained 39.7 14.6 
Average pain score 0.865 0.191 
Pain now 0.853 0.021 
Least pain score 0.812 -0.010 
% Pain relief -0.801 -0.043 
Worst pain score 0.734 0.188 
Itch -0.267 0.242 
Confusion** 0.213 0.711 
Bad dreams 0.130 0.629 
Drowsy 0.138 0.619 
Nausea -0.109 0.609 
*Rotation Method: Direct oblimin with Kaiser Normalization. 
** confusion includes hallucinations 
 
 
Figure 3.5 Correlations between pain scores and component analgesic response 
score  
Component analgesic response scores are presented as log10Component 1. Spearman 
correlation coefficient presented for each pain score. 
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Table 3.10 Comparing component central side-effect scores with symptom 
severity scores 
 
 
Grade of 
severity 
Total study 
population            
% (N) 
 Component central side-
effect score                            
Mean (SEM) 
Nausea 0 51 (105) 0.3217 (0.013) 
 1 30 (63) 0.4279 (0.016) 
 2 11 (23) 0.5226 (0.024) 
 3 8 (16) 0.6043 (0.028) 
Drowsiness 0 20 (41) 0.2402 (0.02) 
 1 31 (64) 0.3575 (0.016) 
 2 29 (60) 0.4394 (0.014) 
 3 20 (42) 0.5655 (0.017) 
Confusion** 0 60 (124) 0.3124 (0.01) 
 1 20 (41) 0.4628 (0.017) 
 2 14 (30) 0.5742 (0.017) 
 3 6 (12) 0.6347 (0.02) 
Bad dreams 0 77 (159) 0.3476 (0.01) 
 1 13 (27) 0.5253 (0.02) 
 2 9 (18) 0.6044 (0.02) 
 3 1 (3) 0.6908 (0.04) 
* Component central side-effect score represents Log10Component2 in PCA 
** includes hallucinations 
Total N = 207 
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The component scores were used in the subsequent genetic association studies 
(chapter 4 and 5). They were also used in linear regression analysis to determine the 
clinical factors predictive of variability in pain and central side-effect scores, as 
shown in tables 3.11 and 3.12.  
 
Being on an antiemetic was associated with lower pain scores (log10component1 
scores) while being on a B-blocker, a diuretic or paracetamol was associated with 
higher pain scores. Diagnosis and length of time on morphine were not found to be 
predictive of pain scores on univariate analysis. 
 
Length of time on morphine was inversely correlated with central side-effect scores 
(log10component2 scores). Being on an antiemetic or a selective serotonin reuptake 
inhibitor (SSRI) was associated with higher central side-effect scores. Being on a 
steroid or a tricyclic antidepressant was associated with lower side-effect scores. 
Having a tumour of the pancreas or biliary tree was associated with higher central 
side-effect scores, but the numbers of patients in this group was very small so this 
variable was omitted from further analysis. Having prostate cancer was associated 
with lower central side-effect scores.  
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Table 3.11 Clinical factors predictive of variability in analgesic response 
Univariate linear regression. Log10Component1 dependent variable (pain scores) 
Variable B Std. Error B β P value Median (range) Spearman’s r 
Age 0.001 0.001 0.065 0.358 60 (19-85) 0.013 
Daily morphine dose (mg) <0.001 <0.001 0.131 0.062 102.5 (10-1280) 0.089 
Days to death <-0.001 <0.001 -0.049 0.49 122.5 (5-2590) -0.041 
Days on opioids <-0.001 <0.001 -0.045 0.523 91 (7-4455) -0.129 
Total White Cell Count 0.001 0.001 0.054 0.441 8.6 (0.3-68.1) 0.019 
     % (N) Mean 
      Yes* No* 
Gender -0.027 0.02 -0.094 0.18 F 47.8 (99) / M 52.2 (108)  F 0.39 (0.049) M 0.4 (0.048) 
Diagnosis        
 Upper gastrointestinal tract 0.011 0.038 0.021 0.765 7.7 (16) 0.31 (0.12) 0.4 (0.036) 
 Lower  gastrointestinal tract  0.015 0.037 0.029 0.68 8.7 (18) 0.41 (0.123) 0.39 (0.036) 
 Gynaecological -0.093 0.036 -0.18 0.10 8.7 (18) 0.22 (0.101) 0.41 (0.036) 
 Urogenital (renal and bladder) -0.001 0.035 -0.001 0.988 10.1 (21) 0.4 (0.112) 0.39 (0.036) 
 Breast -0.01 0.027 -0.027 0.707 17.4 (36) 0.36 (0.081) 0.4 (0.038) 
 Sarcoma -0.03 0.03 -0.71 0.314 13.5 (28) 0.39 (0.094) 0.39 (0.037) 
 Lung (including mesothelioma) 0.007 0.031 0.016 0.826 13 (27) 0.38 (0.097) 0.39 (0.037) 
 Skin 0.119 0.066 0.127 0.071 2.4 (5) 0.8 (0.2) 0.38 (0.035) 
Medications        
   Anticonvulsant 0.024 0.025 0.066 0.347 21.3 (44) 0.44 (0.077) 0.38 (0.038) 
   Antiemetic   -0.044 0.02 -0.149 0.033 49 (99) 0.43 (0.015) 0.47 (0.014) 
   Aspirin 0.001 0.034 0.002 0.973 10.1 (21) 0.43 (0.111) 0.39 (0.036) 
   B Blocker 0.089 0.037 0.169 0.016 8.2 (17) 0.71 (0.114) 0.36 (0.035) 
   Diuretic 0.066 0.032 0.146 0.037 11.6 (24) 0.54 (0.104) 0.37 (0.036) 
   NSAID 0.011 0.022 0.037 0.604 35.7 (74) 0.39 (0.058) 0.39 (0.042) 
   Paracetamol 0.046 0.021 0.155 0.027 40.1 (83) 0.48 (0.056) 0.34 (0.043) 
   SSRI, SNRI antidepressants  0.045 0.032 0.097 0.168 11.1 (23) 0.48 (0.106) 0.38 (0.036) 
   Steroid 0.021 0.021 0.071 0.313 39.6 (82) 0.43 (0.055) 0.37 (0.044) 
   Tricyclic antidepressants 0.002 0.031 0.005 0.938 13 (27) 0.38 (0.097) 0.39 (0.037) 
Other drugs included in analysis but non-significant: ACE-inhibitor, Antibiotic,   Anticoagulant, Benzodiazepine, Brochodilator, H2 Antagonist, Proton Pump 
Inhibitor. Other diagnoses included but not significant: tumours of pancreas and biliary tree, haematological tumour, head and neck, prostate 
*Yes / No represents being on the drug or not or having the diagnosis or not 
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Table 3.12 Clinical factors predictive of central side-effects on morphine 
Univariate linear regression 
Log10Component2 as dependent variable (central side-effects) 
Variable B Std. Error B β P value Median (range) Spearman’s r 
Age 0.001 0.001 0.111 0.115 60 (19-85) 0.118 
Daily morphine dose (mg) <0.001 <0.001 -0.043 0.542 102.5 (10-1280) -0.013 
Days to death <0.001 <0.001 -0.16 0.13 122.5 (5-2590) -0.212 
Days on opioids <0.001 <0.001 -0.163 0.02 91 (7-4455) -0.294 
Total White Cell Count 0.002 0.001 0.083 0.238 8.6 (0.3-68.1) 0.016 
Plasma sodium -0.006 0.003 -0.134 0.057 136 (120-143) -0.137 
Plasma calcium 0.012 0.067 0.013 0.858 2.24 (1.52-2.94) 0.039 
     
 Mean 
     % (N)  Yes* No* 
Gender 0.01 0.022 0.032 0.65 F 47.8 (99) / M 52.2 (108)  F 0.29 (0.046) 0.35 (0.047) 
Diagnosis        
 Pancreas and biliary 0.168 0.06 0.195 0.005 3.4 (7) 0.71 (0.184) 0.3 (0.033) 
 Gynaecological -0.015 0.039 -0.028 0.694 8.7 (18) 0.28 (0.109) 0.32 (0.034) 
 Haematological 0.028 0.057 0.035 0.621 3.9 (8) 0.25 (0.164) 0.32 (0.033) 
 Sarcoma -0.061 0.032 -0.134 0.056 13.5 (28) 0.21 (0.079) 0.34 (0.036) 
 Head and Neck -0.084 0.047 -0.126 0.072 5.8 (12) 0.17 (0.112) 0.33 (0.034) 
 Prostate -0.083 0.04 -0.146 0.037 8.2 (18) 0.29 (0.114) 0.32 (0.034) 
Medications        
   Anticonvulsant 0.008 0.027 0.02 0.771 21.3 (44) 0.35 (0.074) 0.31 (0.037) 
   Antiemetic  0.044 0.022 0.14 0.046 47.8 (99) 0.38 (0.049) 0.26 (0.043) 
   Benzodiazepine 0.004 0.019 0.009 0.894 16.9 (35) 0.26 (0.075) 0.33 (0.036) 
   B Blocker 0.032 0.04 0.057 0.422 8.2 (17) 0.35 (0.119) 0.32 (0.034) 
   NSAID -0.032 0.023 -0.098 0.163 35.7 (74) 0.23 (0.05) 0.37 (0.042) 
   SSRI, SNRI antidepressants  0.078 0.035 0.157 0.025 11.1 (23) 0.43 (0.106) 0.3 (0.034) 
   Steroid -0.044 0.022 -0.136 0.053 39.6 (82) 0.27 (0.05) 0.35 (0.043) 
   Tricyclic antidepressants -0.065 0.033 -0.138 0.05 13 (27) 0.19 (0.079) 0.34 (0.036) 
Other drugs included in analysis but non-significant: Antibiotic,   Anticoagulant, Aspirin, Benzodiazepine, Brochodilator, Diuretics H2 Antagonist, Paracetamol, Proton Pump 
Inhibitor. Other diagnoses included but not significant: tumours of skin,breast, lung, upper and lower gastrointestinal tract and urogenital tumours.  
*Yes / No represents being on the drug or not or having the diagnosis or not 
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3.3.5 Phenotype 2: Daily morphine dose requirements 
 
This phenotype of response to morphine examines the dose of morphine required to 
achieve adequate pain control i.e. the dose of morphine required to achieve an average 
pain of ≤ 4 in the preceding 24 hours. This method has been used previously in 
genetic association studies of response to morphine in cancer pain 92;135. This 
phenotype was included in this thesis to allow some comparison with previous 
studies.  
 
All patients who were “morphine responders” were included in this analysis (N=183). 
This was in order to stratify this phenotype to represent a well defined group of 
patients who had their dose of morphine titrated up until they achieved good pain 
control without intolerable side-effects. In the total Caucasian morphine-responder 
population (N=183), 79% (N=144) of patients achieved an average pain of ≤ 4 
compared to 21% (N=38) who did not. (There was one patient with incomplete pain 
scores) 
 
The clinical factors predictive of variability in morphine dose to achieve adequate 
pain control are shown in table 3.13. The strongest clinical predictor was being on an 
anticonvulsant medication. Patients who were taking anticonvulsants required much 
higher doses of morphine (median 195mg, range 30-610mg) compared to those not 
taking these drugs (median 90mg, range 30-610mg), p= 4.6 x 10-5. Being on an 
anticoagulant medication was also predictive of requiring a higher dose while being 
on a bronchodilator was predictive of a lower dose. Older subjects required lower 
doses of morphine.  
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Table 3.13 Clinical factors predictive of variability in daily morphine dose requirements 
Univariate linear regression. Log10daily morphine dose (mg) as dependent variable 
Variable B Std. Error B β P value R2 % (N) / median (range) Spearmans r 
Age -0.005  0.002 -0.187 0.025 0.035 58 (19-85) -0.186 
Gender -0.098 0.059 -0.138 0.098 0.019 F 49.3 (71)  / M 50.7 (73) -0.137 
Days to death <-0.0001 <0.0001 -0.005 0.953 <0.0001 145.5 (6-2590) 0.109 
Days on opioids <0.0001 <0.0001 0.026 0.761 0.001 104.5 (7-4455) 0.168 
Total White Cell Count -0.003 0.005 -0.558 0.578 0.002 8.7 (0.3-37.6) -0.117 
Serum albumin 0.005 0.005 0.084 0.317 0.007 29 (11-43) 0.074 
Serum calcium 0.179 0.175 0.088 0.307 0.008 2.2 (1.52-2.94) 0.11 
       Mean (log10dailymorphinedose) 
Diagnosis       Yes* No* 
 Upper gastrointestinal tract 0.037 0.101 0.031 0.713 0.001 9.7 (14) 2.03 (0.08) 2.0 (0.03) 
 Lower  gastrointestinal tract  0.034 0.112 0.025 0.764 0.001 7.6 (11) 2.03 (0.12) 2.0 (0.03) 
 Pancreas and biliary 0.034 0.209 0.014 0.871 <0.001 2.1 (3) 2.03 (0.16) 2.0 (0.03) 
 Gynaecological -0.102 0.097 -0.087 0.298 0.008 10.4 (15) 1.9 (0.11) 2.01 (0.03) 
 Urogenital (renal and bladder) 0.044 0.108 0.034 0.684 0.001 8.3 (12) 2.04 (0.06) 2.0 (0.03) 
 Haematological -0.198 0.148 -0.111 0.184 0.012 4.2 (6) 1.8 (0.13) 2.0 (0.03) 
 Breast -0.098 0.077 -0.106 0.206 0.011 18.1 (26) 1.92 (0.06) 2.02 (0.03) 
 Sarcoma 0.128 0.079 0.134 0.108 0.018 16.7 (24) 2.11 (0.07) 1.98 (0.03) 
 Lung  0.065 0.095 0.057 0.496 0.003 11.1 (16) 2.06 (0.08) 1.99 (0.03) 
 Head and Neck 0.057 0.13 0.037 0.664 0.001 4.2 (6) 2.05 (0.1) 2.0 (0.03) 
 Prostate -0.101 0.108 -0.078 0.35 0.006 8.3 (12) 1.91 (0.14) 2.01 (0.03) 
Skin 0.073 0.209 0.029 0.728 0.001 2.1 (3) 2.07 (0.06) 2.0 (0.03) 
Drugs         
   Anticoagulant 0.142 0.07 0.168 0.045 0.028 22.9 (33) 2.11 (0.06) 1.97 (0.03) 
   Anticonvulsant 0.308 0.073 0.333 4.6 x 10-5 0.111 18.1 (26) 2.25 (0.06) 1.9 (0.03) 
   Aspirin 0.114 0.108 0.088 0.293 0.008 8.3 (12) 2.1 (0.06) 2.0 (0.03) 
   B Blocker 0.057 0.149 0.032 0.701 0.001 4.2 (6) 2.06 (0.16) 2.0 (0.03) 
  Bronchodilator -0.225 0.102 -0.181 0.03 0.033 9 (13) 1.8 (0.08) 2.02 (0.03) 
   NSAID 0.097 0.062 0.13 0.12 0.017 35.4 (51) 2.06 (0.05) 1.97 (0.04) 
   Paracetamol 0.003 0.062 0.004 0.961 <0.001 35.4 (51) 2.0 (0.05) 2.0 (0.04) 
   SSRI, SNRI antidepressants  0.081 0.097 0.07 0.406 0.005 10.4 (15) 2.07 (0.07) 2.0 (0.03) 
   Steroid -0.027 0.061 -0.037 0.658 0.001 41 (59) 1.98 (0.04) 2.0 (0.04) 
   Tricyclic antidepressants 0.05 0.09 0.046 0.582 0.002 12.5 (18) 2.04 (0.06) 2.0 (0.03) 
Other drugs included in analysis but non-significant: ACE-inhibitor, Antibiotic,   Antiemetic Antihistamine,   Haloperidol, Antiemetic  5HT4 agonist, Antiemetic 5HT3 antagonist, Antiemetic 
Phenothiazine, Antifungal, Benzodiazepine, Diuretic, H2 Antagonist, Proton Pump Inhibitor 
*Yes / No represents being on the drug or not or having the diagnosis or not 
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3.4 DISCUSSION 
 
3.4.1 Main Findings 
 
The 2 phenotypes for response to morphine as presented here are: 
 
• Phenotype 1: Composite scores of analgesic response and central side-effects 
as distinct outcome measures, defined by principal components analysis 
(PCA). 
• Phenotype 2: Daily morphine dose required to achieve adequate pain control.  
The daily dose of morphine in morphine responders with an average pain of 
≤4 is examined. 
 
The main findings from this study are: 
 
• There is inter-individual variation in response to morphine in terms of 
analgesia and side-effects and also in the dose of morphine required to achieve 
adequate pain control. 
 
• Analgesic response, central side-effects on morphine and the dose of morphine 
required to achieve adequate pain control appear to be distinct clinical 
outcomes. There is little correlation between these outcomes. The clinical 
factors contributing to variability in these measures are dissimilar.  
 
3.4.2 Study design 
 
The design of the Prospective Morphine Study is such that response to morphine may 
be explored and defined. One of the main strengths of this study is the abundant 
clinical data that has been collected from each patient which allows in-depth analysis 
of individual factors contributing to morphine response / non-response.  
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Particular attention has been focused on maintaining an accurate clinical database in 
this study. This is why a number of subjects were excluded, including those who were 
categorised clinically as “morphine responders” by the palliative care team but whose 
pain scores suggested that they were either inadequately titrated on their morphine 
dose or that they were simply unable to fill in the numerical rating scale accurately. 
This finding reflects other studies which demonstrated that some patients, for a variety 
of reasons cannot complete pain assessment tools 327;328. It was felt that inclusion of 
these patients in the analyses would permit unacceptable inaccuracy and bias. Unlike 
other studies in this area which rely solely on pain and side-effect scores and doses of 
morphine used, the additional clinical distinction of patients into morphine responders 
or non-responders in this study allowed refinement of the study population to include 
only those with as accurate clinical data as possible. 
 
The wide-range of clinical, drug and laboratory data collected from each patient also 
allowed investigation of the other non-opioid factors which may influence response. 
Other studies have also included such data analysis 92;93;112. In this study there were a 
wide number of different cancer diagnoses and the study subjects are on a variety of 
different concomitant medications.  
 
3.4.3 Phenotype definition 
 
In this study a validated tool, the brief pain inventory was used to collect pain scores 
328
. This tool has also been used by other researchers in this field 92;112. Although the 
BPI is a commonly used pain assessment tool, there is no consensus as to which of the 
five pain intensity variables is most clinically relevant. “Pain now” may be influenced 
by any number of factors including 1) the time since the last dose of morphine, 2) 
recent activity and 3) other psychological issues including desire to please the 
attending physician 329. “Worst” and “least” pain scores may be altered by the 
presence or absence of incident pain i.e. the patient has pain which is exacerbated by 
activity. Average pain has been used in other genetic association studies of response 
to morphine 92;93;110;112. Pain relief ratings have been shown to be sensitive to the 
effects of treatment 330. Pain relief, average pain and worst pain were identified in this 
study as independent predictors of morphine non-response (Table 3.5). In a recent 
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large study investigating variables to include in an international pain classification 
system, average and worst pain and pain relief were chosen as dependent variables on 
the basis of expert opinion 331.  
 
This is the first study that we are aware of in which a number of different pain 
intensity and side-effect scores have been included in the analysis. Instead of 
analysing each pain score (or side-effect score) separately, or instead of choosing one 
single dimension of pain intensity to study, in this study all actual pain and side-effect 
scores were included in the PCA modelling. PCA was used to develop a mathematical 
model of morphine response, incorporating as much clinical data on morphine 
response as possible. Two components, representing analgesic response and central 
side-effects respectively were identified which accounted for most of the variability in 
the data. The finding that pain and central side-effect scores loaded onto separate 
components and the lack of significant correlation between these two components 
suggests two separate dimensions of morphine response.  
 
Principal components analysis has been used in validation studies of the Brief Pain 
Inventory and in most of these studies pain intensity scores loaded highly onto the 
same component 328;332. In a more recent study, pain intensity and pain interference 
scores were explored using factor analysis (which is similar to PCA). In that study, 
like in ours, the pain intensity scores loaded onto the same factor 333. 
 
Previous work in our department has used morphine responder versus morphine non-
responder as the study outcome. In this study we found that although a higher 
proportion of morphine non-responders experienced morphine-related side-effects, a 
substantial proportion of subjects in the “responder” group also experienced these 
symptoms, especially constipation, drowsiness and nausea, although these appear not 
to have been dose-limiting. In order to capture the subjective experiences of all study 
subjects, we used all pain scores and side-effect scores in the PCA, regardless of 
whether the subjects were clinically defined as responders or non-responders.   
 
In this study the different side-effects were separated out to examine which in 
particular were most problematic. Drowsiness, confusion/hallucinations and bad 
dreams were identified as being independent predictors of morphine non-responders. 
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These same variables loaded onto the same component in the PCA, along with nausea, 
making up a component representative of central side-effects.  
 
The strongest correlations in this study were between the centrally mediated side-
effects of drowsiness, confusion and bad dreams. In particular constipation was not 
well correlated with any of the other side-effects. Consistent with this was the fact that 
it did not meet the criteria for inclusion in the PCA modeling. Constipation was not 
included in the modelling, perhaps because it is mediated primarily by peripheral 
mechanisms 334. The number of subjects with dry mouth or myoclonus was low, 
perhaps explaining why these factors were not included in the final model. Further 
consideration should be given to these side-effects in future studies.  
 
In order to be able to compare our findings with other published genetic association 
studies, we also examined the variability of morphine dose required to achieve 
adequate pain control, as defined by average pain less than 4/10. This method has 
been used by the Norweigan group in some of their genetic association studies 92;135. 
In some of their later studies they did not stratify according to pain scores and just 
examined variability in morphine dose, regardless of individual pain scores 110;112. The 
Norweigan studies also did not take into account whether the patient had the opioid 
dose adequately titrated according to the individual level of pain. We adopted their 
initial approach as it provides a tighter model to explore individual variation in 
response to morphine.  In this study we included only those patients who we knew to 
respond well to morphine. Thus these patients represent a well defined group of 
patients who had their dose of morphine titrated up until they achieved good pain 
control without intolerable side-effects. One of the main disadvantages to this 
approach was that the substratification required significantly reduced the numbers of 
study subjects, with the potential influence on the power of the study. The final 
number however (N=145) was larger that in the original Norweigan study (N=99). 
 
This definition of morphine response potentially reflects variability in sensitivity to 
morphine for cancer pain. It may however also represent variability in pain 
perception. In clinical practice morphine is titrated according to individual patient 
response in terms of pain and side-effects. It is therefore unlikely that the dose of 
morphine for an individual patient will be predicted solely on such population data. 
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The PCA model of morphine response appears to be more clinically relevant and 
therefore more meaningful for use in genetic association studies.  
 
3.4.4 Clinical factors influencing morphine response 
 
Although to date no clinical factor except for renal impairment has been shown to 
consistently alter morphine response, it has been suggested that there are a number of 
factors which may influence opioid handling and pain perception. In this study 
different clinical factors appear to be associated with the different clinical phenotypes 
i.e. the clinical factors associated with pain scores (component 1 in PCA) are distinct 
to those associated with central side-effect scores (component 2) or those associated 
with morphine dose requirements. This further supports the proposal that pain, central 
side-effects and morphine dose requirements may be discrete end points in morphine 
response. This may be one reason why previous genetic association studies have 
failed to replicate in this field, namely because the outcomes were not the same. 
 
In our study, gender was not associated with either pain or side-effect scores but there 
was a trend towards an association with variation in morphine dose (p=0.098), with 
men requiring a median dose of 120mg morphine per day to achieve adequate 
analgesia, compared to women who required a median dose of 90mg per day. 
 
In our study there was an inverse relationship between age and dose of morphine: 
older patients required less daily morphine to achieve adequate analgesia. We found 
no association between age and analgesic or central side-effect scores.  
 
We demonstrated an inverse relationship between central side-effects and length of 
time on morphine. This may suggest that tolerance to these central side-effects occurs 
with time, something which is recognized clinically11 . Length of time on morphine 
did not influence either analgesic response to morphine or variability in morphine 
dose requirements.   
 
Concomitant medications were found to account for some of the variability in 
morphine response. Our data show that cancer patients on morphine are often on a 
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large number of other medications. Many of these drugs increase the likelihood of 
opioid side-effects through a variety of mechanisms 335. In our study drugs acting on 
beta-adrenergic receptors in particular were predictive of morphine response / non-
response. Being on a bronchodilator (B-agonist) was associated with lower morphine 
requirements and being on a B-blocker was associated with less analgesia from 
morphine. There have been some reports previously of interaction between the 
adrenergic and opioidergic systems in terms of morphine response, tolerance and 
dependence 336;337. The data presented here are in contrast to other studies in which 
beta-blockers have been shown to reduce analgesic requirements and improve pain 
scores in post-operative pain conditions 338;339. One animal study however suggested 
that the effects of beta-blockade on opioid response was determined in part by the site 
of administration of the drugs 340. Another study demonstrated that beta-blockers 
altered the morphine dose-response curve after chronic but not after acute morphine 
treatment 341. There may be differential interactions between beta-blockers and 
opioids depending to the length of time on opioids and the method and frequency of 
opioid and beta-blocker administration. There have been some animal data suggesting 
specific interactions and even dimerisation between beta-adrenergic and opioid 
receptors 342-344. Therefore it is biologically plausible that drugs which act on 
adrenergic receptors may alter morphine response. Antiemetics were associated with 
better analgesic response, which is plausible as some of these agents, especially 
phenothiazine antiemetics are purported to have intrinsic analgesic properties 345. 
Being on an antiemetic may also facilitate improved analgesia because it may allow 
adequate dose escalation through avoidance of dose-limiting nausea.  
 
Some of the findings are difficult to interpret. Antidepressants, paracetamol and 
NSAIDs are often used as adjunct analgesic agents when patients are on morphine. In 
this study however, being on paracetamol with higher pain scores i.e. a worse 
outcome in terms of analgesic response. It may be that patients taking these 
medications had more severe or complex pain. This finding mirrors another study in 
which paracetamol was an independent predictor for failure of analgesia for acute 
pain in a prehospital setting 346.  
 
Anticonvulsants are used as analgesic agents, especially for neuropathic pain, 
therefore again, intuitively one would expect their use to be associated with decreased 
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opioid requirements. Instead, in this study, being on an anticonvulsant is associated 
with higher morphine dose requirements. This group of patients may represent those 
with pain which was not morphine responsive e.g. neuropathic pain. Patients with 
predominately neuropathic pain were excluded from the study on the basis that 
neuropathic pain is usually treated with non-opioid medications. However, in this 
study (unlike the subsequent Randomised Controlled Trial), a specific neuropathic 
pain assessment tool was not used. It is possible that there is a cohort of patients with 
mixed cancer pain with a significant neuropathic element which was not identified. 
 
Antiemetics and SSRIs were associated with higher central side-effect scores. This is 
not surprising as these medications also have the potential to cause side-effects such 
as drowsiness. A previous study found that psychotropic medications 
(benzodiazepines, anxiolytics or SSRI antidepressants) were associated with higher 
morphine dose requirements post-operatively 50. This was not replicated in our study.  
Tricyclic antidepressants, which are commonly associated with drowsiness, were 
associated with less central side-effects in our study.  
 
It is unclear why certain tumour groups would be associated with differences in 
morphine response. There are two possible reasons why prostate cancer was found to 
be associated with lower central side-effect scores: 1) pain in prostate cancer is 
usually bone pain, which often responds well to opioid-sparing NSAIDs, and 2) 
prostate cancer is rarely associated with organ involvement, therefore there are less 
non-opioid reasons why this cohort would experience the symptoms of nausea, 
confusion and hallucinations or drowsiness. In a larger study, sub-stratification 
according to diagnosis would allow further exploration of this finding. 
 
 The data presented here suggest that the dose of the original opioid at which an 
opioid switch is required varies widely. Similarly the duration of the initial opioid 
therapy is variable. These data may suggest that there may be two broad groups of 
patients which undergo opioid switching. The first group require switching shortly 
after initiation of the initial opioid, when the opioid dose is relatively low. The second 
group appear to become non-responsive to the initial opioid at either higher doses or 
after some time has elapsed, perhaps due to changes in the underlying painful state, 
disease, tolerance or some other contributing factor. These data support a recent 
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proposal that there is a pharmacodynamic difference between initial failure of 
response to an opioid shortly after opioid initiation and alteration of response after 
initial good effect 35. It was not possible to explore this potential difference further in 
this study. 
3.4.5 Limitations 
 
Although we attempted to account for as many clinical confounders as possible, it is 
likely that there are a large number of other clinical and environmental factors which 
may influence pain perception or opioid response, which are not included in this study 
including psychological state (anxiety and depression) 347, social status and diet348. 
The latter two factors have not been included in any study of opioid response, perhaps 
because of challenges in measuring and quantifying such variables. Psychological 
distress has been associated with pain intensity and treatment response 331 and this 
factor has been included in one previous opioid genetic study 124. 
 
As this study was carried out at a single time point we were not able to control for 
factors such as pain intensity at initiation of morphine therapy, the development of 
morphine tolerance or the fact that cancer pain is likely to change in location, 
character and severity with time. Data pertaining to the exact cause of the cancer pain 
(treatment, tumour, metastases) were not collected.  
 
This study (and further studies presented in this thesis) was carried out in Caucasian 
subjects. Further studies are needed to explore the applicability of these findings to 
other ethnic populations. This is discussed in more detail in chapter 8. 
 
The findings presented in this chapter have not yet been replicated and we have not 
adjusted the results for multiple testing. Thus the PCA and regression modelling must 
be considered preliminary and hypothesis generating. However in terms of correcting 
for multiple testing, the use of PCA component scores in the genetic association study 
does reduce the multiplicity of analyses which would be necessary if each score was 
examined separately, while retaining as much clinical information as possible. In 
addition, although the findings presented here require testing in larger, prospective 
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studies, biologically sound hypotheses may be proposed to explain the association of 
most factors retained in the modelling. 
3.5 Conclusion 
 
Future work requires confirmation and validation of the applicability of these 
definitions or morphine response in other adequately powered prospective studies. 
Larger studies may facilitate more accurate sub-stratification according to diagnosis 
and concomitant medications. Prospective follow-up studies may allow exploration of 
the issues of tolerance and changing pain. A larger study would also facilitate 
examination of “extremes” i.e. subjects in both groups experiencing either no 
symptoms or severe symptoms of opioid side-effects.  
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4 Chapter 4: Results from candidate gene association 
study: Opioid receptors 
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4.1 Introduction and summary of the rationale behind this study 
 
 
Morphine acts on opioid receptors, therefore the genes coding for opioid receptors are 
natural candidates for genetic association studies. Opioid receptors are found 
throughout the nervous system. Three different opioid receptors have been identified: 
mu (MOR), delta (DOR) and kappa (KOR). These receptors have been cloned 349-351 
and are encoded by different genes: OPRM (mu opioid receptor), OPRD (delta opioid 
receptor) and OPRK (kappa opioid receptor). 
 
Morphine acts primarily via the mu opioid receptor (MOR). In this study I tested the 
hypothesis that polymorphisms in any of the three opioid receptor genes may 
influence response to morphine for cancer pain because:  
 
• Morphine also binds, albeit with a weaker affinity, to delta and kappa opioid 
receptors 24;158. 
• Opioid receptors are thought to interact with each other and form heterodimers 
with altered function potentially affecting opioid response 159-162;352;353. 
• Activation of MOR, DOR and KOR elicits different responses both in terms of 
response to morphine and also non-morphine effects. Although MOR are 
essential for morphine analgesia, as demonstrated by studies involving MOR 
knockout mice 354, DOR and KOR play a role in the modulation of certain 
aspects of morphine response and are also involved in nociception in general. 
MOR are involved in respiratory function and regulation of the gastrointestinal 
tract. DOR have been shown to play a role in morphine tolerance 163, 
depressive and anxiety-states 355, and in alcohol abuse 356. KOR have been 
shown to mediate dysphoria to opioid and non-opioid drugs 356. 
• MOR, DOR and KOR are all involved in nociception. There is well 
documented inter-individual variation in pain perception and pain sensitivity. 
Inter-individual variation in response to morphine is the result of a complex 
interplay between variability in nociception as well as sensitivity to the drug 
itself. MOR are involved in perception of thermal and irritant chemical pain 
356;357
. DOR modulate mechanical, neuropathic and inflammatory pain 357;358 
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and although the data are controversial, some authors suggest that KOR maybe 
involved in mediating chemical visceral (and thermal) pain 357;359. More recent 
data have suggested that these opioid receptors may be distinct in both 
physical location and also mode of pain transmission, calling into question the 
idea of mu- delta dimers 360. Cancer pain however is likely to be a mixed pain 
and therefore it remains biologically plausible that all three opioid receptors 
play a role in both cancer pain perception and morphine response. 
 
The association of genetic polymorphisms in mu-opioid receptor gene, OPRM and 
variability in both pain perception and sensitivity to opioids has been a focus of a 
number of studies 83;87;92;94, as discussed in chapter 1. OPRM is located on 
chromosome 6 (6q52.2) and spans 79865 bp. There are 13 exonic SNPs located in the 
coding region of the gene but most have minor allele frequencies (MAF) of 1% or 
less. Over 800 polymorphisms in OPRM have been described 89. OPRD is located on 
chromosome 1 (1p35.3) and spans 51556 bp. It consists of three exons and there are 
currently 344 known SNPs.  The kappa opioid receptor gene, OPRK, is located on 
chromosome 8 (8q11.23) and spans 25919 bp.  
 
Pain and response to morphine are complex traits and are likely to be under the 
influence of a number of genes and environmental factors. There have been some 
attempts to explore the influence of combinations of SNPs in OPRM and other genes 
on response to morphine for cancer pain. These studies have been limited to 
examining at most the interaction of two SNPs at a time. In each case these SNPs 
were chosen on the basis of previous candidate gene studies confirming a proposed 
clinical significance. This is the first study in cancer patients taking opioids in which 
multiple SNPs and multiple genes are systematically considered together, along with 
other clinical confounders which may influence the clinical outcome. 
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4.1.1 Aim 
 
The aim of this study was to examine the influence of genetic variation in the opioid 
receptor genes on inter-individual variation in morphine response.  
 
The clinical phenotypes defined in chapter 3 (analgesic response, central side-effects 
on morphine and variability in dose of morphine required to achieve adequate 
analgesia) were used in a hypothesis-generating genetic association study examining 
the effect of interaction between multiple polymorphisms in genes coding for the 
opioid receptors and other confounding clinical variables on morphine response. 
 
4.2 Subjects and methods 
 
Each of the genes were tested on all clinical phenotypes presented in chapter 3 i.e. 
analgesic response to morphine, central side-effects on morphine and variation in the 
daily morphine dose required to achieve adequate analgesic response.  
 
The genetic assays were run on DNA from the Prospective Morphine Study.  
 
4.2.1 Genetic Marker inclusion 
 
Details of the primers used are found in appendix B. Seven polymorphisms in OPRM 
(rs621029, rs1799971, rs589046, rs563649, rs9479757, rs2075572, rs533586), eight 
in OPRK (rs10504151, rs7836120, rs6473799, rs1365098, rs7016778, rs7824175, 
rs16918875, rs963549) and five in OPRD (rs1042114, rs533123, rs419335, 
rs2236857, rs2234918) were included in the study. 
Primers for OPRK and OPRD were designed by Dr Sophy Gretton. I optimised and 
ran these primers on all 264 Caucasians. 7 SNPs across the OPRM gene were 
included in this study. 5 of these SNPs (rs6912029, rs1799971, rs9479757, rs589046 
and rs2075572) had been designed previously by Dr Joy Ross and run on a smaller 
cohort of this population (N=193).  I ran these primers on the remaining patients in 
the final cohort (N=264). I designed, tested and optimised primers for 2 new SNPs in 
OPRM rs563649 and rs533586. I ran these new primers and also rs589046 on all 264 
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Caucasians. Details of the SNPs tested, including location on the gene, call rate and 
minor allele frequencies are found in tables 4.1 - 4.3.  
 
4.2.2 Statistical analysis 
 
Each SNP was tested individually using univariate regression analysis. Both the 
dominant and additive models were used to assess whether the association was due 
primarily to allele carriage or whether there was a gene dose effect. Univariate 
regression was used to screen for an association between individual clinical and 
genetic variables and the outcome variables. 
 
Multivariate stepwise regression analysis was carried out to assess the effect of 
genetic and clinical factors on variability in the clinical phenotype. Clinical factors 
known from univariate analysis to predict the clinical phenotype (as detailed in 
chapter 3) were also included in this analysis. Clinical and genetic factors significant 
at the level of 10% (p<0.1) on univariate analysis were introduced simultaneously into 
the model using a stepwise approach.  
 
No corrections for multiple testing are presented here. The data presented in the tables 
represents the raw unadjusted data as the data are considered exploratory until 
replication studies are performed. Tables containing significant results are presented 
in this chapter. Tables containing mainly non-statistically significant results are 
located in appendix c. 
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4.3 Results 
 
4.3.1 Genetic marker data 
 
All SNPs were in Hardy-Weinberg equilibrium. 
 
All SNPs were comparable to published data from the HapMap northern and western 
European ancestry group (CEU) in term of allele and genotype frequencies. (Tables 
4.1 - 4.3) 
 
The haplotype data are presented in tables 4.4 - 4.6 and figures 4.1 – 4.3. 
 
One haploblock was identified in OPRM, spanning 1670 bp and three haplotypes were 
constructed within this block.  
 
Two haploblocks were identified across OPRD, consisting of six haplotypes in total. 
Three haploblocks comprised of two SNPs each were identified. The finding that 
OPRD rs2234918 is not in LD with the other SNPs is similar to the OPRD LD pattern 
found in another study 361.  
 
Three haploblocks were identified across OPRK. Nine haplotypes were constructed 
within the haploblocks. There was a region in the middle of the gene spanning 
approximately 10 kbp which was not included in any of these haploblocks  
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Table 4.1 OPRM marker data 
 
N=249* 
SNP Position (bp) 
Locus 
on gene 
Allele 
Major:minor MAF 
Published 
MAF HWp 
Call 
rate 
AA 
change 
rs6912029 154402201 Exon 1 G:T 0.05 0.05 1.0 1.0 Gln-His 
rs1799971 154402490 Exon 1 A:G 0.15 0.167 0.2985 1.0 Asn-Asp 
rs589046 154434831 Intron 1 C:T 0.27 0.246  0.5629 1.0 - 
rs563649 154449660 Intron 1 C:T 0.1 0.08  0.21 1.0 - 
rs9479757 154453037 Intron 2 G:A 0.11 0.117 0.9122 1.0 - 
rs2075572 154453697 Intron 2 C:G 0.43 0.425 0.7319 0.996 - 
rs533586 154455367 Intron 3 T:C 0.33 0.34 G 0.7819 1.0 - 
Published genotype and allele frequencies from HapMap CEU 
* rs6912029, rs1799971, rs9479757, rs9479757 N=249 
rs589046, rs563649, rs533586 N=243 
Reference sequence NT_025741.14 
 
 
Table 4.2 OPRK marker data 
 
N=244 
SNP Position (bp) 
Locus 
on gene 
Allele 
major:minor MAF 
Published 
MAF HWp              
Call  
rate AA change 
rs10504151 54320793 Intron 2 T:C 0.11  0.05 0.27 1.0 - 
rs7836120 54320092 Intron 2 A:G 0.18  0.108 0.42 1.0 - 
rs6473799 54315676 Intron 2 T:C 0.22  0.192 0.84 1.0 - 
rs1365098 54315236 Intron 2 G:T 0.31  0.212 1.0 1.0 - 
rs7016778 54312658 Intron 2 T:A 0.14  0.1 0.23 1.0 - 
rs7824175 54306727 Intron 3 G:C 0.11  0.092 0.56 1.0 - 
rs16918875 54304707 Exon 4 C:T 0.08  0.018 1.0 1.0 Val-Val 
rs963549 54304377 3UTR G:A 0.18  0.133 0.8 1.0 - 
Published genotype and allele frequencies from HapMap CEU 
Reference sequence NT_008183.18 
 
 
Table 4.3 OPRD marker data 
 
N=243 
SNP Position (bp) 
Locus  
On 
gene 
Allele        
Major:minor MAF 
Published
MAF HWp              
Call 
rate AA change 
rs 1042114 29011562 Exon 1 T:G 0.15 0.12 0.779 1.0 Cys-Phe 
rs 533123 29013742 Intron 1 A:G 0.21 0.15 0.5678 1.0 - 
rs 419335 29024431 Intron 1 A:G 0.29 0.34 1 1.0 - 
rs 2236857 29034196 Intron 1 T:C 0.24 0.27 0.7799 1.0 - 
rs 2234918 29062184 Exon 3 T:C 0.42 0.5 1 1.0 Gly-Gly 
Published genotype and allele frequencies from HapMap CEU  
Reference sequence NT_004610.18 
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Table 4.4 OPRM haplotypes 
 
 
Haploblock 1 % (N) 
SNP rs 6912029 rs 1799971 rs589046 rs563649 rs 94797571 rs 2075572 rs533586 Frequency  Carriage frequency  
position 154402201 154402490 154434831 154449660 154453037 154453697 154455367 
1 - - - - - C T 0.57 (275) 0.81 (195) 
2 - - - - - G C 0.32 (156) 0.53 (129) 
3 - - - - - G T 0.11 (52) 0.2 (48) 
Data shown for total Caucasian population (N=243) 
 
 
Figure 4.1 LD Plots for OPRM 
(Haploview version 4.0, Broad Institute, Cambridge, USA). See List of Abbreviations for explanation of colour scheme. 
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Table 4.5 OPRD haplotypes 
 Haploblock 1 Haploblock 2  % (N) 
 SNP rs1042114 rs533123 rs419335 rs2236857 rs2234918 Frequency  Carriage 
frequency  position 29011562 29013742 29024431 29034196 29062184 
1 T A - - - 0.79 (382) 0.95 (230) 
2 T G - - - 0.06 (33) 0.13 (32) 
3 G G - - - 0.15 (71) 0.28 (67) 
1 - - A T - 0.7 (340) 0.91 (222) 
2 - - G T - 0.06 (30) 0.12 (30) 
3 - - G C - 0.23 (113) 0.4 (98) 
Data shown for total Caucasian population (N=243) 
 
 
Figure 4.2 LD Plots for OPRD  (Haploview version 4.0, Broad Institute, Cambridge, USA). 
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Table 4.6 OPRK haplotypes 
 Haploblock 3 Haploblock 2  Haploblock 1 % (N) 
SNP rs 10504151 rs 7836120 rs 6473799 rs 1365098 rs 7016778 rs 7824175 rs 16918875 rs  963549 Frequency  Carriage 
frequenc
y  position 54320793 54320092 54315676 54315236 54312658 54306727 54304707 54304377 
1 - - - - - - C G 0.82 (339) 0.96 (235) 
2 - - - - - - C A 0.1(50) 0.2 (49) 
3 - - - - - - T A 0.08 (39) 0.16(38) 
1 - - T G - - - - 0.69 (336) 0.9 (220) 
2 - - T T - - - - 0.09 (43) 0.17 (42) 
3 - - C T - - - - 0.2 (109) 0.4 (98) 
1 T A - - - - - - 0.82 (401) 0.96 (234) 
2 T G - - - - - - 0.07 (34) 0.13 (31) 
3 C G - - - - - - 0.11 (53) 0.2 (48) 
Data shown for total Caucasian population (N=244) 
 
Figure 4.3 LD Plots for OPRK 
(Haploview version 4.0, Broad Institute, Cambridge, USA). 
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4.3.2 Analgesic response 
 
Univariate analysis 
 
On univariate analysis, there was an association with analgesic response as defined by 
PCA component 1 (see chapter 3) with SNPs in OPRK, rs1365098, rs7824175 and 
rs963549, (tables 4.8 and 4.9). These SNPs are not located in the same haploblock but 
they are in LD with each other (D’ 0.92-0.94).  
 
The strongest association was with intronic OPRK rs7824175. Carriers of the C allele 
(genotype CC or CG) at OPRK rs7824175 had a worse outcome in terms of analgesic 
response i.e. higher pain scores (p=0.001, R2 = 0.054). Conversely carriers of the G 
allele (genotype GG or CG) had lower pain scores (p=0.016, R2 = 0.031). Although 
the numbers of patients who were homozygous for the variant allele (CC) was low 
(N=4), this SNP demonstrates a clear gene-dose effect in terms of analgesic response 
(p=0.0004, R2 = 0.065), as demonstrated in figure 4.4. 
 
Carriers of the A allele (genotype AA or GA) at rs963549 had higher pain scores than 
non-carriers (GG p=0.005, R2 = 0.042) and again there was a clear gene-dose effect 
(p=0.001, R2 = 0.055). There was a similar pattern seen with rs1365098 although the 
association was not as strong (p=0.021, R2 = 0.023). 
 
Haplotypes 1-2 in OPRK Haploblock 1 are significantly associated with variability in 
analgesic response (p=0.019 and 0.005 respectively) but this association is no stronger 
than the association with OPRK rs963549 (data not shown). 
 
There was a weak association between two OPRM SNPs, rs589046 (p=0.02, R2 = 
0.029) and rs9479717 (p=0.034, R2 = 0.024) and analgesic response. This association 
was found with allele carriage only, (table 4.7). There was no association between 
analgesic response and OPRM haplotypes or OPRD SNPs / haplotypes. 
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 Table 4.7 Effects of OPRM on analgesic response to morphine (dominant model) 
 
Allele carriage (Dominant model) 
  
Carrying allele Not carrying allele Univariate linear regression 
Log10Component1 (pain scores) as dependent variable 
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P 
value 
rs6912029 G 100 (194) 0.45 (0.01) 0 - - - - - 
 T 8.2 (16)  0.45 (0.04) 91.8 (178) 0.45 (0.01) -0.004 0.038 -0.008 0.911 
rs1799971  A 95.9 (186)  0.44 (0.01) 4.1 (8) 0.49 (0.06) -0.043 0.052 -0.06 0.411 
 
G 25.3 (49)  0.44 (0.02) 74.7 (145) 0.45 (0.01) -0.008 0.024 -0.025 0.727 
rs589046 C 93.7 (177)  0.45 (0.01) 6.3 (12) 0.35 (0.04) 0.1 0.042 0.171 0.02 
 
T 49.7 (94)  0.45 (0.01) 50.3 (95) 0.45 (0.02) -0.002 0.021 -0.006 0.933 
rs563649  C 97.9 (185)  0.45 (0.01) 2.1 (4) 0.45 (0.09) <-0.001 0.073 <-0.001 0.998 
 
T 19.6 (37)  0.45 (0.02) 80.4 (152) 0.45 (0.01) 0.006 0.027 0.017 0.816 
rs9479757 A 22.2 (43)  0.43 (0.02) 77.8 (151) 0.45 (0.01) -0.026 0.025 -0.075 0.299 
 G 99 (192)  0.45 (0.01) 1.0 (2) 0.23 (0.01) 0.219 0.102 0.154 0.034 
rs2075572 C 81.9 (158)  0.44 (0.01) 18.1 (35) 0.46 (0.02) -0.012 0.027 -0.032 0.659 
 G 64.8 (125)  0.45 (0.01) 35.2 (68) 0.45 (0.02) -0.002 0.022 -0.007 0.923 
rs533586 T 89.4 (169)  0.45 (0.01) 10.6 (20) 0.44 (0.03) 0.01 0.034 0.021 0.78 
 
C 51.3 (97) 0.44 (0.01) 48.7 (92) 0.45 (0.02) -0.006 0.021 -0.021 0.779 
* mean (SEM) of log10Component1 scores 
R2 rs589046C = 0.029, rs9479757G = 0.024 
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Table 4.8 Effects of OPRK on analgesic response to morphine (dominant model) 
 
  
Carrying allele Not carrying allele Univariate linear regression 
Log10Component1 (pain scores) as dependent variable 
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P 
value 
r10504151 T 97.9 (186) 0.45 (0.01) 2.1 (4) 0.51 (0.08) -0.063 0.073 -0.034 0.385 
 C 20 (38) 0.46 (0.02) 80 (152) 0.44 (0.01) 0.011 0.026 0.032 0.666 
rs 7836120 A 96.3 (183) 0.45 (0.01) 3.7 (7) 0.48 (0.05) -0.036 0.055 -0.048 0.513 
 G 30 (57) 0.46 (0.02) 70 (133) 0.44 (0.01) 0.019 0.023 0.06 0.418 
rs 6473799 T 94.7 (180) 0.45 (0. 01) 5.3 (10) 0.48 (0.05) -0.03 0.047 -0.046 0.529 
 C 40.5 (77) 0.47 (0.02) 59.5 (113) 0.43 (0.01) 0.036 0.021 0.123 0.093 
rs 1365098 G 89.5 (170) 0.44 (0.01) 10.5 (20) 0.5 (0.03) -0.054 0.034 -0.117 0.111 
 T 54.2 (103) 0.47 (0.01) 45.8 (87) 0.42 (0.02) 0.044 0.021 0.152 0.038 
rs 7016778 T 98.9 (188) 0.45 (0.01) 1.1 (2) 0.57 (0.14) -0.119 0.102 -0.086 0.245 
 
A 26.3 (50) 0.47 (0.02) 73.7 (140) 0.44 (0.01) 0.032 0.024 0.098 0.182 
rs 7824175 G 97.9 (186) 0.44 (0.01) 2.1 (4) 0.62 (0.04) -0.175 0.072 -0.176 0.016 
 C 21.6 (41) 0.51 (0.02) 78.4 (149) 0.43 (0.01) 0.08 0.025 0.232 0.001 
rs16918875 C 99.5 (189) 0.45 (0.01) 0.5 (1) - -0.257 0.143 -0.131 0.074 
 
T 16.3 (31) 0.48 (0.03) 83.7 (159) 0.44 (0.01) 0.033 0.029 0.085 0.25 
rs 963549 G 96.3 (183) 0.44 (0.01) 3.7 (7) 0.57 (0.05) -0.131 0.055 -0.173 0.018 
 A 35.3 (67) 0.49 (0.02) 64.7 (123) 0.42 (0.01) 0.062 0.022 0.205 0.005 
* mean (SEM) of log10Component1 scores 
R2 rs1365098T = 0.023, rs7824175G = 0.031, rs7824175C = 0.054, rs963549G = 0.03, rs963549A = 0.042 
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Table 4.9 Effects of OPRK on analgesic response to morphine (additive model) 
 
    
Univariate linear regression 
Log10Component1 (pain scores) as dependent variable 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β 
P 
value 
rs10504151 TT 80 (152) 0.51 (0.08)     
 TC 17.9 (34) 0.45 (0.03) -0.015 0.023 -0.047 0.52 
 CC 2.1 (4) 0.44 (0.01)     
rs7836120 AA 70 (133) 0.44 (0.01)     
 AG 26.3 (50) 0.46 (0.02) -0.017 0.019 -0.067 0.365 
 GG 3.7 (7) 0.48 (0.05)     
rs6473799 TT 59.5 (113) 0.43 (0.01) 
    
 TC 35.3 (67) 0.47 (0.02) -0.029 0.018 -0.119 0.104 
 CC 5.3 (10) 0.78 (0.05) 
    
rs1365098 GG 45.8 (87) 0.42 (0.02)     
 GT 43.7 (83) 0.46 (0.02) -0.036 0.016 -0.169 0.021 
 TT 10.5 (20) 0.5 (0.03)     
rs7016778 TT 73.7 (140) 0.44 (0.01)     
 TA 25.3 (48) 0.47 (0.02) -0.034 0.022 -0.111 0.131 
 AA 1.1 (2) 0.57 (0.14)     
rs7824175 GG 7834 (149) 0.43 (0.01)     
 GC 19.5 (37) 0.5 (0.02) -0.777 0.021 -0.256 0.0004 
 CC 2.1 (4) 0.62 (0.04)     
rs16918875 CC 83.7 (159) 0.44 (0.01)     
 CT 15.8 (30) 0.47 (0.02) -0.039 0.027 -0.105 0.152 
 TT 0.5 (1) -     
rs963549 GG 64.7 (123) 0.42 (0.01)     
 GA 31.6 (60) 0.48 (0.02) -0.06 0.018 -0.234 0.001 
 AA 3.7 (7) 0.57 (0.05)     
* mean (SEM) of log10Component1 scores  
R2 rs1365098 = 0.028, rs7824175 = 0.065, rs963549 = 0.055 
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Figure 4.4 OPRK rs7824175 and analgesic response  
 
The analgesic response scores on the y-axis are log10Component1 scores (ref. chapter 
3) Higher scores represent worse analgesic response. There is a significant association 
between variation in analgesic response and OPRK rs7824175 (genotype CC versus 
CG versus GG), p=0.0004, R2 = 0.065. Red line demonstrates mean value. (Univariate 
linear regression uncorrected for other clinical and genetic factors)  
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Analgesic response: Gene-gene and gene-environment interactions 
 
Using log10Component1as the dependent variable, multivariate logistic regression was 
used to model factors predictive of analgesic response to morphine (Tables 4.10 and 
4.11).  
 
Four factors were retained as independent predictors of analgesic response: OPRK 
rs7824175, use of a beta-blocker, taking an anti-emetic and the total daily morphine 
dose. Being on a beta-blocker was found to be associated with a worse outcome in 
terms of analgesic response (as evidenced by higher PCA scores), whereas being on 
an anti-emetic was associated with a better outcome (lower PCA scores). Daily 
morphine dose only contributes slightly to the model. On univariate analysis total 
morphine dose accounted for less than 2% of variability in analgesic response. Daily 
morphine dose and analgesic score are not correlated to any significant degree (r = 
0.08). The multivariate model comprising OPRK rs7824175, being on a beta-blocker 
or an antiemetic and the total daily morphine dose accounted for 15.9% of variability 
in analgesic response to morphine.  
 
The same four factors were retained in both the dominant (allele carriage) and 
additive (genotype) regression models. 
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Table 4.10 Clinical and genetic factors predictive of analgesic response to morphine (additive model) 
Multivariate stepwise linear regression   
Log10Component1 (pain scores) as dependent variable 
  B Std. Error Beta P 
(Constant) 0.587 (  0.509, 0.664) 0.039  <0.001 
OPRK1 rs7824175 -0.080 (-0.121, -0.039 ) 0.021 -0.265 0.00015 
B Blocker 0.118 (  0.045, 0.192) 0.037 0.218 0.002 
Antiemetic -0.055 (-0.094, -0.016 ) 0.020 -0.192 0.006 
Daily morphine dose (mg)  <0.001 (<0.001, <0.001 ) <0.001 0.140 0.042 
ANOVA F = 8.6, p=2.4 x 10-6 ,R2 = 15.9 
All genotype and clinical variables p<0.1 included in analysis 
 
Table 4.11 Clinical and genetic factors predictive of response to morphine, dominant model (allele carriage) 
Multivariate stepwise linear regression   
Log10Component1 (pain scores) as dependent variable  
  B 
Std. 
Error Beta P  
(Constant) 0.426 (0.392, 0.460) 0.017  <0.001 
OPRK1 rs7824175 CC / CG 0.083 (0.036, 0.131) 0.024 0.239 0.001 
B Blocker 0.117 (0.043, 0.191) 0.038 0.215 0.002 
Antiemetic -0.054 (-0.093, -0.015) 0.020 -0.187 0.008 
Daily morphine dose (mg) <0.001 (<0.001,<0.001) <0.001 0.140 0.045 
ANOVA F = 7.7, p=9.8 x 10-6 ,R2 = 14.6 
All allele carriage and clinical variables p<0.1 included in analysis 
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4.3.3 Central side-effects  
 
Univariate analysis 
 
The strongest association with central side-effects (log10Component2 scores) was 
with OPRK rs1054151. Carriers of the C allele (genotype CC or CT) had lower 
central side-effect scores than non-carriers (p=0.009, R2 = 0.037). This finding 
remained significant on testing the individual genotypes (p=0.014, R2 = 0.033) but the 
association is stronger for allele carriage (Tables 4.14 and 4.15). 
 
There was also an association with OPRM rs2075572. Here carriers of the C allele 
(genotype CC or CG) had higher central side-effect scores (p=0.034, R2 = 0.023). 
Again, this SNP demonstrated a gene-dose effect (Tables 4.12 and 4.13). 
 
There was no association between SNPs in OPRD and central side-effects on 
morphine. There was no significant association with haplotypes in OPRK, OPRM or 
OPRD.  
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Table 4.12 Effects of OPRM on central side-effects of morphine (dominant model) 
 
  
Carrying allele Not carrying allele Univariate linear regression 
Log10Component2 (central side-effect scores) as 
dependent variable 
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P 
value 
rs6912029 G 100 (194) 0.39 (0.01) 0 - - - - - 
 T 8.2 (16)  0.39 (0.03) 91.8 (178) 0.39 (0.01) -0.005 0.04 -0.01 0.894 
rs1799971  A 95.9 (186)  0.39 (0.01) 4.1 (8) 0.46 (0.07) -0.06 0.056 -0.078 0.28 
 G 25.3 (49)  0.42 (0.02) 74.7 (145) 0.39 (0.01) 0.026 0.026 0.073 0.313 
rs589046 C 93.7 (177)  0.4 (0.01) 6.3 (12) 0.38 (0.05) 0.014 0.045 0.023 0.754 
 T 49.7 (94)  0.38 (0.020 50.3 (95) 0.41 (0.02) -0.027 0.022 -0.09 0.224 
rs563649  C 97.9 (185)  0.4 (0.01) 2.1 (4) 0.32 (0.08) 0.081 0.077 0.078 0.293 
 T 19.6 (37)  0.36 (0.02) 80.4 (152) 0.4 (0.01) -0.037 0.028 -0.095 0.197 
rs9479757 A 22.2 (43)  0.38 (0.02) 77.8 (151) 0.4 (0.01) -0.023 0.027 -0.062 0.391 
 G 99 (192)  0.4 (0.01) 1.0 (2) 0.24 (0.09) 0.16 0.109 0.106 0.143 
rs2075572 C 81.9 (158)  0.4 (0.01) 18.1 (35) 0.35 (0.03) 0.061 0.029 0.154 0.034 
 G 64.8 (125)  0.38 (0.01) 35.2 (68) 0.42 (0.02) -0.033 0.023 -0.102 0.162 
rs533586 T 89.4 (169)  0.4 (0.01) 10.6 (20) 0.34 (0.04) 0.057 0.036 0.116 0.114 
 C 51.3 (97) 0.39 (0.02) 48.7 (92) 0.4 (0.02) -0.018 0.022 -0.058 0.428 
* mean (SEM) of log10Component2 scores 
R2 rs2075572C = 0.023 
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Table 4.13 Effects of OPRM on central side-effects of morphine (additive model) 
 
    
Univariate linear regression 
Log10Component2 (central side-effect scores) as dependent 
variable 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β 
P 
value 
rs6912029 GG 91.8 (178) 0.39 (0.01)     
 GT 8.2 (16) 0.39 (0.04) -0.005 0.04 -0.01 0.894 
 TT 0 -     
rs1799971  AA 74.7 (145) 0.39 (0.01)     
 AG 21.1 (41) 0.41 (0.02) 0.025 0.021 0.088 0.225 
 GG 4.1 (8) 0.46 (0.07)     
rs589046 CC 50.3 (95) 0.41 (0.02)     
 CT 43.4 (82) 0.38 (0.02) -0.02 0.018 -0.082 0.264 
 TT 6.3 (12) 0.38 (0.05)     
rs563649  CC 80.4 (152) 0.4 (0.01)     
 CT 17.5 (33) 0.37 (0.03) -0.035 0.024 -0.106 0.15 
 TT 2.1 (4) 0.32 (0.08)     
rs9479757 AA 1.0 (2) 0.24 (0.09)     
 AG 21.1 (41) 0.38 (0.03) -0.028 0.025 -0.082 0.258 
 GG 77.8 (151) 0.4 (0.01)     
rs2075572 CC 35.2 (68) 0.42 (0.02)     
 CG 46.6 (90) 0.4 (0.02) -0.033 0.016 -0.152 0.036 
 GG 35.2 (68) 0.35 (0.03)     
rs533586 TT 48.7 (92) 0.4 (0.02)     
 CT 40.7 (77) 0.4 (0.02) 0.022 0.017 0.097 0.186 
 
CC 10.6 (20) 0.34 (0.04)     
* mean (SEM) of log10Component2 scores  
R2 rs2075572 = 0.023 
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Table 4.14 Effects of OPRK on central side-effects of morphine (dominant model) 
 
  
Carrying allele Not carrying allele Univariate linear regression 
Log10Component2 (central side-effect scores) as 
dependent variable 
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P 
value 
r10504151 T 97.9 (186) 0.4 (0.01) 2.1 (4) 0.34 (0.06) 0.052 0.077 0.049 0.505 
 C 20 (38) 0.33 (0.03) 80 (152) 0.41 (0.01) -0.073 0.028 -0.19 0.009 
rs 7836120 A 96.3 (183) 0.39 (0.01) 3.7 (7) 0.42 (0.05) -0.025 0.059 -0.032 0.666 
 G 30 (57) 0.38 (0.02) 70 (133) 0.4 (0.01) -0.023 0.024 -0.071 0.338 
rs 6473799 T 94.7 (180) 0.4 (0.01) 5.3 (10) 0.34 (0.05) 0.055 0.05 0.082 0.264 
 C 40.5 (77) 0.41 (0.02) 59.5 (113) 0.38 (0.14) 0.034 0.023 0.11 0.135 
rs 1365098 G 89.5 (170) 0.4 (0.01) 10.5 (20) 0.35 (0.03) 0.053 0.036 0.107 0.145 
 T 54.2 (103) 0.4 (0.02) 45.8 (87) 0.39 (0.02) 0.014 0.022 0.004 0.547 
rs 7016778 T 98.9 (188) 0.39 (0.01) 1.1 (2) 0.36 (0.06) 0.031 0.109 0.021 0.777 
 A 26.3 (50) 0.4 (0.02) 73.7 (140) 0.39 (0.01) 0.002 0.025 0.006 0.931 
rs 7824175 G 97.9 (186) 0.39 (0.01) 2.1 (4) 0.42 (0.08) -0.022 0.007 -0.021 0.771 
 C 21.6 (41) 0.4 (0.02) 78.4 (149) 0.39 (0.01) 0.001 0.027 0.003 0.969 
rs16918875 C 99.5 (189) 0.39 (0.01) 0.5 (1) - 0.086 0.153 0.041 0.575 
 T 16.3 (31) 0.35 (0.03) 83.7 (159) 0.4 (0.01) -0.055 0.03 -0.132 0.072 
rs 963549 G 96.3 (183) 0.4 (0.01) 3.7 (7) 0.33 (0.05) 0.064 0.059 0.079 0.28 
 A 35.3 (67) 0.38 (0.02) 64.7 (123) 0.4 (0.01) -0.03 0.023 -0.093 0.206 
* mean (SEM) of log10Component2 scores 
R2 rs10504151 = C 0.036 
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Table 4.15 Effects of OPRK on central side-effects of morphine (additive model) 
 
    
Univariate linear regression 
Log10Component2 (central side-effect scores) as dependent 
variable 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β 
P 
value 
rs10504151 TT 80 (152) 0.41 (0.01)     
 TC 17.9 (34) 0.33 (0.03) 0.059 0.024 0.179 0.014 
 CC 2.1 (4) 0.34 (0.06)     
rs7836120 AA 70 (133) 0.4 (0.01)     
 
AG 26.3 (50) 0.37 (0.02) 0.013 0.02 0.048 0.513 
 
GG 3.7 (7) 0.42 (0.05)     
rs6473799 TT 59.5 (113) 0.38 (0.14)     
 
TC 35.3 (67) 0.42 (0.02) -0.015 0.019 -0.06 0.418 
 
CC 5.3 (10) 0.34 (0.05) 
    
rs1365098 GG 45.8 (87) 0.39 (0.02)     
 
GT 43.7 (83) 0.41 (0.02) 0.004 0.017 0.017 0.822 
 
TT 10.5 (20) 0.35 (0.03)     
rs7016778 TT 73.7 (140) 0.39 (0.01)     
 
TA 25.3 (48) 0.4 (0.02) <0.001 0.024 -0.001 0.984 
 
AA 1.1 (2) 0.36 (0.06)     
rs7824175 GG 7834 (149) 0.39 (0.01)     
 
GC 19.5 (37) 0.39 (0.02) -0.003 0.024 -0.009 0.902 
 
CC 2.1 (4) 0.42 (0.08)     
rs16918875 CC 83.7 (159) 0.4 (0.01)     
 
CT 15.8 (30) 0.35 (0.03) 0.052 0.029 0.133 0.069 
 
TT 0.5 (1) -     
rs963549 GG 64.7 (123) 0.4 (0.01)     
 GA 31.6 (60) 0.38 (0.02) 0.029 0.02 0.106 0.147 
 AA 3.7 (7) 0.3 (0.05)     
* mean (SEM) of log10Component2 scores  
R2 rs10504151 C = 0.032 
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Central side-effects: Gene-gene and gene-environment interactions 
 
Using log10Component2as the dependent variable (representing central side-effect 
scores), multivariate logistic regression was used to model clinical and genetic factors 
predictive of central side-effects on morphine. A better outcome in terms of central 
side-effect was represented by lower PCA component 2 scores while a worse response 
was represented by higher scores. 
 
Two SNPS (OPRK rs10504151 and OPRM rs2075572) and a number of clinical 
factors (tumour diagnosis and concomitant medications) were retained in the 
multivariate model as independent predictors of developing central side-effects on 
morphine. (Tables 4.16 and 4.17) The same SNPs remained significant in both the 
additive and dominant model but the clinical variables varied slightly. In the dominant 
model (allele carriage), being on a tricyclic antidepressant was independently 
predictive of lower central side-effect scores. In the additive model however, being on 
a tricyclic antidepressant did not remain independently significant. Instead, having a 
sarcoma diagnosis or being on steroids was predictive of lower scores. These models 
of genetic and clinical factors account for 9-10% of variability in central side-effects 
on morphine.  
 
  176
Table 4.16 Clinical and genetic factors predictive of central side-effects on morphine (dominant model) 
 
Multivariate stepwise linear regression   
Log10Component2 (central side-effect scores) as dependent variable  
  B (95% CI) Std. Error Beta P  
(Constant) 0.364 (0.314, 0.413) 0.025  <0.001 
OPRK1 rs10504151 CC / CT -0.074 (-0.128, -0.020 ) 0.027 -0.194 0.007 
OPRM rs2075572 CC / CG 0.067 (0.013, 0.122) 0.028 0.174 0.016 
Tricyclic antidepressant -0.072 (-0.135, -0.010 ) 0.032 -0.163 0.024 
ANOVA F = 5.7, p=0.001 ,R2 = 8.7 
All allele carriage and clinical variables p<0.1 included in analysis 
 
Table 4.17 Clinical and genetic factors predictive of central side-effects on morphine (additive model) 
 
Multivariate stepwise linear regression   
Log10Component2 (central side-effect scores) as dependent variable 
  B (95% CI) Std. Error Beta P  
(Constant) 0.325 (0.238, 0.412) 0.044  <0.001 
OPRK1 rs10504151 0.069 (0.023, 0.115) 0.023 0.211 0.004 
OPRM rs2075572 -0.035 (-0.065, -0.006 ) 0.015 -0.167 0.020 
Sarcoma -0.066 (-0.128, -0.003) 0.031 -0.148 0.039 
Steroid -0.045 (-0.089, -0.001 ) 0.022 -0.144 0.045 
ANOVA F = 4.9, p=0.001 ,R2 = 9.9 
All allele carriage and clinical variables p<0.1 included in analysis 
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4.3.4 Variation in daily morphine dose to achieve adequate analgesia 
 
Univariate analysis 
 
Variation in daily morphine dose was associated with SNPs in OPRM, OPRD and 
OPRK. The strongest association was with OPRM rs1799971. Carriers of the G allele 
(genotype GG or GA) required higher morphine doses to achieve adequate pain 
control (p=0.027, R2 = 0.036). Although the number of subjects homozygous for the 
minor allele was low (N=4), this association remained significant when the additive 
model was used (p=0.017, R2 = 0.042 (figure 4.5). OPRM rs589046 and rs2075572 
were also associated with variation in daily morphine dose (p=0.02 and 0.046 
respectively), (Tables 4.18 and 4.19). These SNPs are not located on the same 
haploblock. 
 
There were also associations with OPRK rs7016778 (p = 0.045), OPRK rs7836120 (p 
= 0.031), OPRD rs419335 (p = 0.019) and OPRD rs2236857 (p = 0.038), (Tables 
4.20 and 4.21). None of these exhibited a gene-dose effect. There was a statistically 
significant association between OPRK haploblock 3 haplotype 1 (rs10504151 T, 
rs7836120 A, p=0.031) but this is no stronger than the association with the individual 
SNPs. The same is true for OPRD haploblock 2 hapolotype 1 (rs419335 A, rs2236857 
T, p=0.019). 
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Table 4.18 Effects of OPRM on daily morphine dose (dominant model) 
 
  
Carrying allele Not carrying allele Univariate linear regression 
log10 Daily morphine dose (mg) as dependent variable 
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P 
value 
rs6912029 G 100 (135) 2.0 (0.03) 0 - - - - - 
 T 8.9 (12) 2.08 (0.11) 91.1 (123) 2.0 (0.03) 0.087 0.105 0.071 0.410 
          
rs1799971  A 97 (131) 1.99 (0.03) 3 (4) 2.26 (0.14) -0.268 0.176 -0.131 0.130 
 G 23.7 (32) 2.12 (0.06) 76.3 (103) 1.95 (0.03) 0.156 0.069 0.191 0.027 
          
rs589046 C 93.3 (125) 2.01 (0.03) 6.7 (9) 1.7 (0.09) 0.277 0.118 0.2 0.02 
 T 5.07 (68) 2.0 (0.04) 49.3 (66) 2.0 (0.04) 0.001 0.06 0.001 0.987 
          
rs563649  C 97 (130) 2.0 (0.28) 3 (4) 2.0 (0.03) 0.011 0.204 0.005 0.957 
 T 19.4 (26) 1.9 (0.08) 80.6 (108) 2.0 (0.03) -0.089 0.075 -0.104 0.234 
          
rs9479757 A 23.7 (32) 1.99 (0.05) 76.3 (103) 2.0 (0.04) 0 0.071 0 0.998 
 G 98.5 (133) 2.0 (0.03) 1.5 (2) 1.55 (0.23) 0.455 0.245 0.159 0.066 
          
rs2075572 C 81.3 (109) 2.02 (0.03) 18.7 (25) 1.89 (0.06) 0.136 0.077 0.152 0.08 
 G 64.9 (87) 1.95 (0.03) 35.1 (47) 2.1 (0.06) -0.126 0.062 -0.172 0.046 
          
rs533586 T 88.8 (119) 2.0 (0.03) 11.2 (15) 1.9 (0.07) 0.09 0.095 0.082 0.344 
 C 5.07 (68) 1.97 (0.04) 49.3 (66) 2.02 (0.05) -0.057 0.060 -0.082 0.347 
* mean (SEM) of Log10 Daily morphine dose(mg) 
R2 rs1799971G = 0.036, rs589046C = 0.04, rs2075572G = 0.03 
 
 
  179
Table 4.19 Effects of OPRM on daily morphine dose (additive model) 
 
    
Univariate linear regression 
log10 Daily morphine dose (mg) as dependent variable 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β 
P 
value 
rs6912029 GG 91.1 (123) 1.99 (0.03)     
 GT 8.9 (12) 2.06 (0.12) 0.087 0.105 0.071 0.41 
 TT 0 -     
rs1799971  AA 76.3 (103) 1.95 (0.03)     
 AG 20.7 (28) 2.1 (0.07) 0.141 0.058 0.205 0.017 
 GG 3 (4) 2.3 (0.14)     
rs589046 CC 49.3 (66) 2.0 (0.04)     
 CT 44 (59) 2.03 (0.05) -0.045 0.049 -0.08 0.357 
 TT 6.7 (9) 1.74 (0.09)     
rs563649  CC 80.6 (108) 2.01 (0.03)     
 CT 16.4 (22) 1.89 (0.08) -0.067 0.064 -0.09 0.299 
 TT 3 (4) 1.99 (0.29)     
rs9479757 AA 1.5 (2) 1.55 (0.23)     
 AG 22.2 (30) 2.02 (0.05) 0.03 0.064 0.041 0.639 
 GG 76.3 (103) 2.0 (0.04)     
rs2075572 CC 35.1 (47) 2.08 (0.06)     
 CG 46.3 (62) 1.97 (0.04) -0.096 0.042 -0.198 0.022 
 GG 18.7 (25) 1.89 (0.06)     
rs533586 TT 49.3 (66) 2.02 (0.05)     
 CT 39.6 (53) 1.98 (0.04) 0.05 0.044 0.099 0.257 
 
CC 11.2 (15) 1.92 (0.07)     
* mean (SEM) of Log10 Daily morphine dose(mg) 
R2 rs1799971 = 0.042, rs2075572 = 0.039 
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Table 4.20 Effects of OPRD on daily morphine dose (dominant model) 
 
  
Carrying allele Not carrying allele Univariate linear regression 
log10 Daily morphine dose (mg) as dependent variable 
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P 
value 
rs 1042114 T 97.7 (130) 1.99 (0.03) 2.3 (3) 2.04 (0.16) -0.48 0.204 -0.20 0.815 
 G 28.6 (38) 2.02 (0.05) 71.4 (95) 1.98 (0.04) 0.39 0.067 0.05 0.566 
          
rs 533123 A 94.7 (126) 1.99 (0.03) 5.3 (7) 2.1 (0.08) -0.104 0.135 -0.067 0.442 
 G 38.3 (51) 1.97 (0.05) 61.7 (82) 2.0 (0.04) -0.035 0.062 -0.05 0.571 
          
rs 419335 A 90.2 (120) 1.97 (0.03) 9.8 (13) 2.21 (0.1) -0.238 0.100 -0.204 0.019 
 G 54.1 (72) 2.01 (0.05) 45.9 (61) 1.97 (0.04) 0.041 0.061 0.058 0.504 
 
         
rs 2236857 C 42.9 (57) 2.01 (0.05) 57.1 (76) 1.98 (0.04) 0.033 0.061 0.048 0.587 
 T 94 (125) 1.98 (0.03) 6 (8) 2.24 (0.15) -0.263 0.125 -0.181 0.038 
 
         
rs 2234918 C 66.9 (89) 2.02 (0.04) 33.1 (44) 1.94 (0.05) 0.08 0.064 0.109 0.212 
 T 81.2 (108) 1.99 (0.03) 18.8 (25) 2.0 (0.07) -0.007 0.078 -0.008 0.924 
* mean (SEM) of Log10 Daily morphine dose(mg) 
R2 rs419335A = 0.042, rs2236857T = 0.033 
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Table 4.21 Effects of OPRK on daily morphine dose (dominant model) 
 
  
Carrying allele Not carrying allele Univariate linear regression 
log10 Daily morphine dose (mg) as dependent variable 
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P 
value 
r10504151 T 98.5 (132) 2.0 (0.03) 1.5 (2) 1.5 (0.24) 0.463 0.245 0.162 0.061 
 C 21.6 (29) 1.98 (0.08) 78.4 (105) 2.0 (0.03) -0.019 0.073 -0.023 0.792 
          
rs 7836120 A 96.3 (129) 2.0 (0.03) 3.7 (5) 1.5 (0.13) 0.341 0.156 0.187 0.031 
 G 30.6 (41) 1.97 (0.06) 69.4 (93) 2.0 (0.03) -0.021 0.065 -0.028 0.751 
          
rs 6473799 T 94.8 (127) 2.0 (0.03) 5.2 (7) 2.0 (0.12) -0.003 0.136 -0.002 0.985 
 C 38.1 (51) 1.92 (0.05) 61.9 (83) 2.04 (0.04) -0.120 0.061 -0.169 0.052 
          
rs 1365098 G 90.3 (121) 2.0 (0.03) 9.7 (13) 1.89 (0.11) 0.121 0.101 0.103 0.236 
 T 52.2 (70) 1.95 (0.05) 47.8 (64) 2.0 (0.04) -0.77 0.060 -0.111 0.202 
 
         
rs 7016778 T 99.3 (133) 2.0 (0.03) 0.7 (1) - 0.700 0.345 0.174 0.045 
 
A 25.4 (34) 1.96 (0.07) 74.6 (100) 2.0 (0.03) -0.036 0.069 -0.045 0.606 
 
         
rs 7824175 G 99.3 (133) 1.99 (0.03) 0.7 (1) - -0.485 0.348 -0.121 0.165 
 C 18.7 (25) 1.97 (0.07) 81.3 (109) 2.0 (0.03) -0.028 0.077 -0.032 0.715 
 
 
        
rs16918875 C 100 (134) 1.99 (0.03) 0 - - - - - 
 T 16.4 (22) 1.97 (0.1) 83.6 (112) 2.0 (0.03) 0.03 0.081 -0.032 0.712 
          
rs 963549 G 97.8 (131) 1.99 (0.03) 2.2 (3) 2.1 (0.25) -0.059 0.204 -0.025 0.774 
 A 32.8 (44) 1.98 (0.06) 67.2 (90) 2.0 (0.03) -0.022 0.064 -0.03 0.733 
* mean (SEM) of Log10 Daily morphine dose(mg) 
R2 rs7016778T = 0.03 
  182
 
 
Figure 4.5 OPRM rs1799971 and morphine dose requirements 
There is a significant association between analgesic response and OPRM rs1799971, 
p=0.017, R2 = 0.042. Red line represents median value. (Univariate linear regression 
uncorrected for other clinical and genetic factors) 
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Variation in daily morphine dose to achieve adequate analgesia: Gene-gene and 
gene-environment interactions  
 
Using log10 (daily morphine dose (mg)) as the dependent variable, multivariate 
logistic regression was used to model factors predictive of variation in morphine dose 
required to achieve adequate analgesia (Tables 4.22 and 4.23).  
 
Similar to central side-effects, when multivariate regression analysis was carried out 
using the dominant and additive models, the resulting models were slightly different.  
The additive model identified OPRM rs1779971, being on an anticonvulsant or a 
bronchodilator as being independent predictors of variation in morphine dose 
requirements. Together these factors accounted for 22% of variability in morphine 
dose. When the dominant model was used, OPRM rs1779971 was not retained. 
Instead OPRM rs207572, OPRM rs589046 and OPRK rs7836120 were included as 
independent predictors. Being on an anticonvulsant and taking a bronchodilator 
remained independent predictors of variability in the dose of morphine required to 
achieve adequate pain control in both models.  
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Table 4.22 Clinical and genetic factors associated with variability in daily morphine dose requirements (dominant model) 
 
Multivariate stepwise linear regression 
Dominant model (allele carriage) 
   B (95% CI) Std. Error Beta P value 
(Constant) 1.437 (1.052, 1.821) 0.194  <0.001 
Anticonvulsant 0.317 (0.174, 0.459) 0.072 0.339 2.26 x10-5 
Brochodilator -0.198 (-0.376, -0.020) 0.090 -0.169 0.029 
OPRK rs7836120 AA/AG  0.406 (0.098, 0.714) 0.156 0.200 0.010 
OPRM rs2075572 GG / GC -0.119 (-0.230, -0.008) 0.056 -0.164 0.035 
OPRM rs589046 CC/CT  0.222 (0.010, 0.434) 0.107 0.161 0.041 
ANOVA F = 9.5, p = 1 x10-7 , R2 = 0.27  
All clinical and genetic factors p<0.1 on univariate analysis included in analysis 
 
Table 4.23 Clinical and genetic factors associated with variability in daily morphine dose requirements (additive model) 
 
Multivariate stepwise linear regression 
Additive model (genotypes) 
  B (95% CI) Std. Error Beta P value 
(Constant) 1.918 (1.85, 1.985) 0.034  <0.001 
Anticonvulsant 0.344 (0.202, 0.486) 0.072 0.374 4.57 x10-6 
Brochodilator -0.191 (-0.372, -0.010) 0.091 -0.163 0.039 
OPRM rs1799971 0.138 (0.033, 0.244) 0.053 0.202 0.010 
ANOVA F = 12.1, p = 4.7 x10-7 , R2 = 0.22 
All clinical and genetic factors p<0.1 on univariate analysis included in analysis 
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4.4 Discussion 
 
4.4.1 Main findings 
 
The results of this study suggest that: 
 
1. SNPs in the genes coding for the mu and kappa (and possibly delta) opioid 
receptors are associated with variability in morphine response.  
 
2. Analgesia, central side-effects and variability in morphine dose are influenced 
by different genes / SNPs. This supports the hypothesis presented in Chapter 3 
i.e. that these are distinct dimensions of morphine response. 
 
3. Genetic variation in the genes coding for the opioid receptors account for 
some, but certainly not all of the variability in clinical response to morphine. 
 
Previous studies of the influence of genetic variation in opioid receptors on morphine 
response have tended to focus exclusively on OPRM. Although some non-cancer 
studies have examined the association between SNPs in all three opioid receptor 
genes and alcohol dependence 362;363, this is the first study to include a comprehensive 
analysis of SNPs in OPRM, OPRK and OPRD in cancer patients taking morphine for 
pain.  
 
4.4.2 Analgesic response to morphine 
 
The dominant factor predicting analgesic response to morphine was a SNP in OPRK 
(rs7824175). This SNP has not been studied in terms of opioid response or pain 
sensitivity previously. Concomitant β-blocker therapy or the use of anti-emetics was 
also found to be independently predictive of analgesic response (as discussed in 
Chapter 3), with beta-blocker use associated with higher pain scores and anti-emetic 
use associated with lower pain scores. It is biologically plausible that drugs which act 
on adrenergic receptors may alter morphine response in association with genetic 
variation in OPRK.  
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OPRK rs963549 was also significantly associated with analgesic response on 
univariate analysis. It was not retained in multivariate analysis possibly because it is 
in LD with OPRK rs7824175 (D’0.92, R2 0.45). Previous studies have suggested that 
OPRK rs963549 may be of functional importance 362;364. Its location in the 3-UTR 
suggests that may be involved in regulating translational efficacy. One study has 
suggested differential OPRK expression associated with this region 365.  
 
4.4.3 Central side-effects on morphine 
 
Central side-effects were predicted by a model comprised of two polymorphisms 
(OPRM rs2075572 and OPRK rs10504151), diagnosis and concomitant medications.  
OPRK rs10504151 has not been studied in terms of opioid response or pain sensitivity 
previously. Haplotypes containing OPRM rs2075572 have been found to be 
associated with variability in experimental pain sensitivity 148 but this SNP has not 
previously been associated with response to opioids. 
Only 10% of the variability in the central side-effects on morphine is explained by the 
regression model. This suggests that central side-effects as a clinical phenotype may 
be quite complex, perhaps confounded by phenotypic variability (i.e. variability in 
onset / severity of symptoms) which is not captured by the study data or simply 
difficulty in subjectively scoring these symptoms. Complexity may also arise from the 
fact that a number of these symptoms may also be contributed to by other non-opioid 
factors. Therefore although nausea, confusion, drowsiness and bad dreams are central 
side-effects of morphine, the other clinical factors confounding this phenotype may be 
quite varied.  
4.4.4 Morphine dose required to achieve adequate pain control 
 
Modeling of the genetic and environmental factors associated with variability in daily 
morphine dose requirements is not conclusive. OPRM rs1799971 which has been 
associated with this phenotype in other cancer and non-cancer pain studies,82;83;92 
remained an independent predictor when the additive model was used but not the 
dominant model. This finding may be reflective of the relatively weak associations 
between dose and OPRM rs1799971, both in our study and in other studies in this 
area. The findings may also suggest that since the SNPs and indeed genes are different 
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in both models, that the only true associations with morphine dose are the clinical 
variables which remain consistent i.e. being on a bronchodilator or an anticonvulsant 
medication.  
 
4.4.5 OPRM, OPRK and OPRD 
 
Although the primary site of action of morphine is the mu-opioid receptor, in this 
study no SNP in OPRM remained independently significant for analgesic response in 
the multivariate analysis. Instead a SNP in OPRK appeared to be more influential in 
determining analgesic response to morphine. In humans there is much less evidence 
regarding the influence of polymorphisms in OPRD and OPRK than OPRM in pain 
sensitivity or opioid response. Quantitative Trait Loci (QTL) analysis influencing 
morphine antinociception in four populations of mice revealed four significant QTLs. 
One of these mapped to the same region as OPRM and another mapped to the same 
region as OPRK 366. In a study of 500 normal participants, a polymorphism in OPRD 
rs2234918 was associated with a gender specific difference in thermal pain sensitivity 
108
.   However OPRD haplotype analysis in a similar study by the same researchers 
did not show any association 367.  OPRD did not appear to influence analgesia or 
central side-effects in our study.  
 
In our study the OPRK and OPRM SNPs which appear to be predictive of analgesic 
response and central side-effects on morphine are found in intronic regions of the 
genes. Although the exact role of these intronic SNPs in opioid response is not yet 
known, it is possible that they may alter protein function through linkage 
disequilibrium, whereby these polymorphisms may represent markers for true 
susceptibility polymorphisms.80 Alternatively these intronic SNPs may be involved in 
the production of functionally variable opioid receptor subtypes through the 
mechanism of alternative pre-mRNA splicing.  
 
A recent study has analysed the impact of SNPs on the mRNA and translational 
activity of OPRM isoforms. 148 An intronic SNP, OPRM rs563649 was found to be 
located within an internal ribosomal binding site in an alternative exon of OPRM. The 
authors suggest that allelic variation at this site results in altered expression of a 
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corresponding mu-opioid receptor isoform, MOR-1K and differential pain sensitivity 
but not analgesic response to morphine 148. I did include OPRM rs563649 in this 
analysis but it was not found to be associated with any of the clinical phenotypes 
tested.  
 
4.5 Conclusion 
 
The data presented in this study suggest that SNPs across the opioid receptor genes do 
appear to play a role in determining variability in response to morphine, be it 
analgesic response, the development of central side-effects or variation in the daily 
morphine dose required to achieve adequate analgesia. Further studies with larger 
numbers are required to facilitate in-depth analysis of these factors and also to 
validate these findings. However, even the multivariate regression models only 
explain at a proportion of this variability. 16% of variation in analgesic response was 
explained by our model in this study and 10% of variation in central side-effects. It is 
highly likely that there are other genes and biological pathways which play a role in 
this phenomenon of inter-individual variation in response to morphine.  
 
These data also support the hypothesis presented in Chapter 3, that analgesia and side-
effects on morphine and morphine dose requirements to achieve adequate pain control 
appear to be distinct dimensions of response to morphine. Analgesic response and 
side-effects on morphine scores load onto separate components in PCA, and all three 
outcome variables are associated with different genetic and clinical predictors.  
 
In Chapter 5 the analysis of genes other than those coding for the opioid receptors is 
presented. These data have been used to build on the regression models presented here 
to build up a more comprehensive model of clinical and genetic factors predictive of 
response to morphine.  
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5 Chapter 5: Results from candidate gene association 
study: Other genes 
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5.1 Introduction and Summary of the rationale behind this study 
 
There are significant animal data to support the hypothesis that pain and to morphine 
may be under genetic control. To date research in this area has focused on a small 
number of genes with mixed results.  The analysis of polymorphisms in the genes 
coding for the opioid receptors is described in Chapter 4. Like other complex traits, it 
is likely that there are many genes involved in pain perception and analgesic response 
and that the clinical outcomes are polygenic, resulting from multiple gene-gene and 
also gene-environment interactions 172. 
 
The hypothesis tested in this part of the study was that polymorphisms in genes 
coding for proteins and enzymes involved in biological pathways which interact with 
opioids and their receptors play a role in inter-individual variation in morphine 
response in cancer patients.  
 
For this part of the study a number of candidate genes were chosen for investigation 
based on known biological pathways involved in pain and morphine response and also 
on previously published animal studies in this area.  
 
The following genes were chosen for inclusion in this study: TRPV1 (capsaicin 
receptor gene), ADORA1 (A1-adenosine receptor gene), ADRA2A (α2A adrenergic 
receptor gene) and ALOX12 (arachidonate 12-lipoxygenase gene), ARRB2 (β-
arrestin2) and SLC6A4 (serotonin reuptake transporter gene).  For each of the genes 
presented in this thesis there is a biologically plausible association with pain 
perception and response to morphine. This is discussed in detail in the following 
sections.  
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5.1.1 Aim 
 
The aim of this part of the study was to examine the influence of genetic variation in 
genes other than those coding for opioid receptors on inter-individual variation in 
morphine response.  
 
• Initially the influence of single SNPs / genes was tested.  
 
• Combining these data with date presented in chapters 3 and 4 pertaining to 
clinical factors and opioid receptors, gene-gene and gene-environment 
interactions were explored. 
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5.2 Subjects and methods 
 
Each of the genes were tested on all clinical phenotypes presented in chapter 3 i.e. 
analgesic response to morphine, central side-effects on morphine, variation in the 
daily morphine dose required to achieve adequate analgesic response.  
 
The genetic assays were run on DNA from the Prospective Morphine Study.  
 
Details of the primers used are found in Appendix C. The assays for ADORA1, 
ADRA2A, TRPV1 and ALOX12 were designed by Dr Sophy Gretton. (REF) I tested 
and optimised each reaction and ran the assays on the study samples and carried out 
the analyses. Details of the SNPs tested, including location on the gene, call rate and 
minor allele frequencies are presented. 
 
Each SNP was tested individually using univariate regression analysis. Both the 
dominant and additive models were used to assess whether the association was due 
primarily to allele carriage or whether there was a gene dose effect.  
 
Where there was a biologically plausible link between two genes (including the opioid 
receptor genes), e.g. heterodimer formation, multivariate stepwise regression analysis 
was carried out to assess the effect of SNPs in both genes on variability in the clinical 
phenotype. Clinical factors known from univariate analysis to predict the clinical 
phenotype were also included in this analysis. Clinical and genetic factors significant 
at the level of 10% (p<0.1) on univariate analysis (as presented in chapter 3) were 
introduced simultaneously into the model using a stepwise approach.  
 
No corrections for multiple testing are presented here. The data presented in the tables 
represents the raw unadjusted data as the data are considered exploratory until 
replication studies are performed. Tables containing significant results are presented 
in this chapter. Tables containing mainly non-significant results are located in 
Appendix D. 
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5.3 ADORA1 
 
Adora1, the gene coding for the A1-adenosine receptor is located on chromosome 1 
(1q32.1) and spans 76752bp. It is made up of 6 exons, containing 383 known SNPs 89 
(http://snpper.chip.org, accessed 05/01/2010). This gene codes for a seven 
transmembrane G-protein coupled receptor. The second extracellular loop is 
important in ligand binding 368;369. Two separate promoters, 600bp apart regulate A1-
adenosine receptor expression 370.  
 
Adenosine acts on a number of different adenosine receptors, A1, A2A, A2B and A3. 
The activation of A1-adenosine receptors in particular is thought to play a role in 
modulation of pain transmission 371. A1-adenosine receptors are found on the cell 
bodies of the dorsal root ganglion and on central terminals of afferent nociceptors 372. 
They are highly expressed in the brain, especially the cortex, cerebellum and 
hippocampus 370. Activation of these receptors inhibits adenylate cyclase in the spinal 
cord 373.  
 
Adenosine agonists have antinociceptive properties. Intrathecal adenosine was studied 
in a small number of patients with neuropathic pain with good effect, although  
intraveneous adenosine was not effective 374. A link between adenosine and opioid 
systems has been established. Animal studies have demonstrated that A1-adenosine 
agonists increase while caffeine (an adenosine receptor antagonist) decreases 
morphine analgesia, morphine tolerance and dependence 375;376. There is some 
contradictory evidence however that caffeine (perhaps at varying doses and in varying 
species) may actually enhance morphine analgesia 377;378. There is also debate about 
the influence of adenosine agonists on morphine tolerance and dependence. There 
may be differences in terms of acute and chronic drug exposure 372. Theophylline, an 
adenosine receptor antagonist was shown to inhibit the analgesic but not the 
gastrointestinal effects of morphine administered intrathecally or intraventricularly 379.  
 
Mu-opioid receptor knockout mice have reduced binding to A1-adenosine receptors, 
again providing evidence for a functional interaction between the opioid and 
adenosine receptor systems 380. A1-adenosine receptor knockout mice have reduced 
analgesia from morphine administered intrathecally, but not systemically 381.  
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5.3.1 ADORA1 Results 
 
 
Table 5.1 ADORA1 marker data 
 
Name Position 
Location in 
gene 
Allele 
major: 
minor MAF 
Published 
MAF HWpval Call rate 
AA 
change 
rs2364571 201327167 Promoter C:G 0.305 0.32 0.7896 100 - 
rs9660662 201335343 Intron 2 T:C 0.32 0.32 0.8376 100 - 
rs11590405 201346887 Intron 2 T:C 0.318 0.31 0.7645 100 - 
rs903361 201357897 Intron 2 A:G 0.322 0.32 0.9122 100 - 
rs10920568 201364898 Exon 5 T:G 0.311 0.34 0.7748 100 Ala-Ala 
rs10800901 201377927 Intron 5 G:A 0.332 0.28 0.7154 100 - 
rs3766560 201385017 Intron 5 C:T 0.174 0.19 0.0626 99.2 - 
rs10920576 201395802 Intron 5 C:T 0.148 0.19 1 100 - 
Reference sequence NM_000674 
Published frequencies HapMap CEU 
 
 
There are 5 validated SNPs occurring in coding exons, however only one of these was 
polymorphic in Caucasians, rs10920568. This SNP is located in exon 5 of the gene 
and was included in the analysis. Eight SNPS across ADORA1 were investigated in 
this study. All SNPs were in Hardy-Weinberg equilibrium and the allele frequencies 
were similar to those published (table 5.1). 
 
Three haploblocks were identified and haplotypes were constructed within each of 
these blocks (table 5.2 and figure 5.1).  
 
In our study SNPs in ADORA1 were found to be predictive of both variation in 
analgesic response to morphine and also in dose of morphine required to achieve 
adequate analgesia. There was no significant association between SNPs in ADORA1 
and central side-effects on morphine.  
 
In terms of variation in morphine dose, exonic SNP rs10920568 and intronic 
rs903361 had the strongest association, both p=0.004., R2 =0.06.  These SNPs are in 
close LD together, R’0.91 and are found on the same haploblock. Carriers of the 
rs10920568 T allele (genotype TT or TG) required higher daily morphine doses than 
individuals with genotype GG, median 100mg versus 80mg respectively (figure 5.2). 
Intronic SNPs rs2364571, rs9660662, rs11590405 which are also in LD with the two 
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previously mentioned SNPs were also associated with such variation. All of these 
intronic SNPs are located in the 5’ untranslated region of the gene. A further intronic 
SNP, rs10800901, located in the coding region of the gene, and not in tight LD with 
any of the other SNPs tested was also associated with variation in morphine dose, 
p=0.014, R2 0.045 .  There was no gene dose effect for any of the associations (Table 
5.3 and 5.4). 
 
Haplotype carriage which was also associated with variability in daily morphine dose, 
however this was no stronger than the association with individual SNPs (figure 5.2).   
 
ADORA1 rs903361 was also associated with variability in overall analgesic response 
to morphine (p= 0.031) with patients homozygous for the minor allele (genotype GG) 
having lower pain scores. This association demonstrates a gene-dose effect. There was 
also a trend towards significance with a number of the SNPs tested, including exonic 
rs10920568, p=0.09 (Appendix D). 
 
 
 
 
Figure 5.1 ADORA1 rs10920568 and daily morphine dose 
There is a significant association between ADORA1 rs10920568 and haploblock 2 / 
haplotype 3 and variation in morphine dose required to achieve adequate analgesia. 
Red line represents median value. 
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Table 5.2 ADORA1 Haplotypes 
 Haploblock 1 Haploblock 2  Haploblock 3 % (N) 
 rs2364571 rs9660662 rs11590405 rs903361 rs10920568 rs10800901 rs3766560 rs10920576 Frequency Carriage  
frequency 
1 C C C - - - - - 1 (7) 2.5 (6) 
2 C T T - - - - - 68 (328) 89.3 (216) 
3 G C C - - - - - 31 (148) 51.2 (124) 
           
1 - - - G T - - - 1 (7) 2.5 (6) 
2 - - - G G - - - 31 (150) 52.1 (126) 
3 - - - A T - - - 67 (325) 88.8 (215) 
           
1 - - - - - - C C 83 (400) 95 (230) 
2 - - - - - - T C 2 (12) 5 (12) 
3 - - - - - - T T 15 (72) 27.7 (67) 
Data shown for total Caucasian population. 
 
Figure 5.2 LD Plots for ADORA1  
(Haploview version 4.0, Broad Institute, Cambridge, USA). See List of Abbreviations for explanation of colour scheme. 
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Table 5.3 Effects of ADORA1 on morphine dose (dominant model) 
 
  
Carrying allele Not carrying allele Univariate linear regression 
log10 Daily morphine dose (mg) as dependent variable 
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P value 
rs 2364571  C 86.6 (116) 2.026 (0.032) 13.4 (18) 1.787 (0.084) 0.241 0.086 0.237 0.006 
 
G 56.7 (76) 1.994 (0.04) 43.3 (58) 1.994 (0.047) -0.005 0.061 -0.007 0.932 
rs 9660662  T 85.1 (114) 2.023 (0.032) 14.9 (20) 1.828 (0.081) 0.197 0.083 0.202 0.019 
 
C 59 (79) 1.999 (0.034) 41 (55) 1.986 (0.049) 0.007 0.061 0.01 0.904 
rs 11590405  T 85.1 (114) 2.023 (0.032) 14.9 (50) 1.828 (0.081) 0.197 0.083 0.202 0.019 
 
C 58.2 (78) 1.998 (0.039) 41.8 (56) 1.988 (0.048) 0.005 0.061 0.007 0.938 
rs 903361  A 85.8 (115) 2.028 (0.032) 14.2 (19) 1.787 (0.078) 0.244 0.084 0.245 0.004 
 
G 58.2 (78) 2.011 (0.04) 41.8 (56) 1.968 (0.047) 0.037 0.061 0.052 0.547 
rs 10920568  T 86.6 (116) 2.027 (0.318) 13.4 (18) 1.78 (0.082) 0.249 0.086 0.245 0.004 
 
G 56 (75) 2.021 (0.041) 44 (59) 1.958 (0.046) 0.057 0.061 0.082 0.348 
rs 10800901  G 89.6 (120) 2.019 (0.031) 10.4 (14) 1.787 (0.096) 0.239 0.096 0.211 0.014 
 
A 61.9 (83) 1.988 (0.037) 38.1 (51) 2.004 (0.05) -0.022 0.062 -0.031 0.724 
rs 3766560  C 95.5 (126) 1.985 (0.031) 4.5 (6) 2.171 (0.095) -0.185 0.146 -0.111 0.206 
 
T 31.1 (41) 1.964 (0.05) 68.9 (91) 2.007 (0.037) -0.043 0.066 -0.057 0.514 
rs 10920576  C 99.3 (133) 1.992 (0.031) 0.7 (1) - -0.152 0.35 -0.038 0.666 
 
T 28.4 (38) 1.961 (0.056) 71.6 (96) 2.007 (0.036) -0.049 0.067 -0.063 0.466 
* mean (SEM) of log10 Daily morphine dose (mg)  
rs2364571 C ANOVA P= 7.878, R2 = 0.056 
rs9660662 T ANOVA P= 5.635, R2 = 0.041 
rs11590405 T ANOVA P= 50635, R2 = 0.041 
rs903361 A ANOVA P= 8.046, R2 = 0.06 
rs10920568 T ANOVA P= 8.44, R2 = 0.06 
rs10800901 G ANOVA P= 6.167, R2 = 0.045 
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Table 5.4 Effects of ADORA1 on morphine dose (additive model) 
    
Univariate linear regression 
log10 Daily morphine dose (mg)as dependent variable 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β P value 
rs 2364571  CC 43.3 (58) 1.994 (0.047)     
 
CG 43.3 (58) 2.058 (0.043) 0.061 0.043 0.122 0.159 
 
GG 13.4 (18) 1.787 (0.084)     
rs 9660662  TT 41 (55) 1.986 (0.049)     
 
TC 44 (59) 2.057 (0.042) 0.047 0.043 0.095 0.272 
 
CC 14.9 (20) 1.828 (0.081)     
rs 11590405  TT 41.8 (56) 1.987 (0.048)     
 
TC 43.3 (58) 2.056 (0.043) 0.048 0.043 0.098 0.261 
 
CC 14.9 (20) 1.828 (0.081)     
rs 903361  AA 41.8 (56) 1.968 (0.047)     
 
AG 44 (59) 2.084 (0.043) -0.043 0.043 -0.086 0.324 
 
GG 14.2 (19) 1.787 (0.048)     
rs 10920568  TT 44 (59) 1.958 (0.046)     
 
TG 42.5 (57) 2.097 (0.042) 0.031 0.043 0.062 0.476 
 
GG 13.4 (18) 1.78 (0.082)     
rs 10800901  GG 38.1 (51) 1.781 (0.096)     
 
GA 51.5 969) 2.029 (0.041) -0.067 0.047 -0.124 0.152 
 
AA 10.4 (14) 2.004 (0.05)     
rs 3766560  CC 68.9 (91) 2.007 (0.037)     
 
CT 26.5 (35) 1.928 (0.058) 0.004 0.054 0.006 0.945 
 
TT 4.5 (6) 2.171 (0.095)     
rs 10920576  CC 71.6 (96) 2.007 (0.036)     
 
CT 27.6 (37) 1.956 (0.058) 0.04 0.064 0.054 0.536 
 
TT 0.7 (1) 0     
* mean (SEM) of log10 Daily morphine dose (mg)  
No statistically significant associations found 
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5.4 ADRA2A 
 
ADRA2A is located on chromosome 10 (10q25.2) and spans 3651 bp. 
(http://snpper.chip.org, accessed 09/01/2010)89. It is an intronless gene and contains 1 
exons and 101 known SNPs. Of these there are 6 validated SNPs occuring in the 
coding exon but four of these are non-polymorphic and for two, frequency data are 
not known. 
 
ADRA2A codes for the α2A adrenergic receptor (α2A AR), one of three α2 adrenergic 
receptors. These are seven transmembrane G-protein coupled receptors which play a 
role in regulating neurotransmitter release (including noradrenaline and adrenaline) 
from sympathetic and central adrenergic neurons 382. 
 
The α2A AR mediates analgesic effects of α2 adrenergic receptor agonists 383. α2 
adrenergic agonists, e.g. clonidine have analgesic properties 384;385. 
 
α2A AR agonists act synergistically with either MOR or DOR agonists, including 
morphine 383;386;387. The mechanism for this synergy is poorly understood. Mice 
lacking α2A AR demonstrate elevated concentrations of plasma noradrenaline 382. 
Mice carrying a point mutation D79N, in which functional α2A AR binding is reduced 
by 80%, exhibit a markedly increased ED50 for spinally administered morphine, 
suggesting that α2A ARs may mediate some of the effects of morphine 383. This point 
mutation also blocks the synergy between α2 adrenergic agonists and either µOR or 
δOR agonists 383. 
 
Knockout studies have shown that α2A AR mediates the sympathetic inhibition of 
intestinal motility. α2A AR knockout mice have reduced gastrointestinal transit time as 
compared to wild-type animals 388. 
 
α2A AR and DOR have been shown to colocalise in the superficial dorsal horn and 
also in peripheral nerve terminals, leading to the hypothesis that these receptors may 
form heterodimers together with altered function 387. There is further evidence 
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suggesting that this synergy is mediated by protein kinase C 389. Physical receptor-
receptor interactions have also been proposed for α2A AR and MOR 390.  
 
5.4.1 ADRA2A Results 
 
 
Table 5.5 ADRA2A marker data 
 
Name Position 
Location in 
gene 
Alleles 
major: 
minor MAF 
Published 
MAF HWpval 
Call 
rate 
AA 
change 
rs638019 112821819 promoter G:A 0.238 0.354 0.993 99.6 - 
rs11195418 112825149 promoter A:G 0.045 0.02 1 99.6 - 
rs1800544 112826493 promoter C:G 0.266 0.205 0.4302 99.2 - 
rs11195419 112829358 3UTR C:A 0.098 0.142 0.3496 98.8 - 
rs3750625 112829591 3UTR C:A 0.048 0.067 0.8443 99.6 - 
rs602618 112833075 Downstream A:C 0.261 0.283 0.7488 100 - 
Reference sequence NM_000681 
Published frequencies HapMap CEU except rs638019 (AFD Eur Panel )and rs1800544 (PGA Ceph) 
 
 
Six SNPs across ADRA2A were investigated. All SNPs were in Hardy-Weinberg 
equilibrium and the allele frequencies were similar to those published, (table 5.5). 
 
Within the ADRA2A region covered by the SNPs in this study a single haplotype 
block spanning 4674bp and including the three SNPs in the promoter region of the 
gene was identified (Table 5.6 and figure 5.3). This haploblock definition is different 
to that published by Belfer et al which includes a number of the same SNPs and which 
identifies a single haploblock spanning the entire gene. There were much fewer study 
subjects in that study (N=96 Caucasians) 391. There was no association between the 
haplotypes and any of the clinical phenotypes in this study.  
 
There was a weak association between a SNP in the promoter region, rs11195418 and 
variation in daily morphine dose, p=0.039, R2 0.032. Subjects carrying the G allele 
(genotype GG or GA) required less morphine to achieve adequate pain control than 
non-carriers of G (genotype AA). In this study no subject was homozygous for the 
minor allele (Appendix C). 
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There was no association between SNPs in ADRA2A and either pain scores or central 
side-effects on morphine (Appendix C). 
 
Table 5.6 ADRA2A haplotypes 
 
 
 
   
Frequency Carriage  
frequency 
 Haploblock 1    % (N) 
 rs638019 rs11195418 rs1800544 rs11195419 rs3750625 rs602618   
1 A A G - - - 19 (92) 36 (85) 
2 A G G - - - 4 (20) 8 (20) 
3 G A C - - - 74 (352) 95 (225) 
4 G A G - - - 2 (12) 4.6 (11) 
Data shown for total Caucasian population.  
  
 
Figure 5.3 LD plot for ADRA2A 
(Haploview version 4.0, Broad Institute, Cambridge, USA). 
 
 
 
 
.
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5.5 TRPV1 
 
TRPV1 codes for transient receptor potential cation channel, subfamily V, also known 
as the vanilloid or capsaicin receptor. This gene is located on chromosome 17 
(17p13.3) and spans 43964 base pairs. It contains 426 known SNPs. 
(http://snpper.chip.org, accessed 10/01/2010) 89. One of the SNPs included in this 
analysis, TRPV1 rs222747, occurs in a region of the gene which codes for a part of 
the receptor involved in protein-protein interactions392. 
 
The capsaicin receptor is a non-selective cation channel. It is expressed in the dorsal 
root ganglion and peripheral nociceptors. It is activated by capsaicin (the active 
ingredient of hot chilli peppers), protons and noxious heat 393. Capsaicin receptors are 
also activated by 12-lipoxygenase metabolites including 12(S)-HPETE. 12(S)-HPETE 
and capsaicin are very similar structurally 394.  
 
There are many studies demonstrating the role of the capsaicin receptor in pain 
sensation and also response to opioids. Mice lacking the capsaicin receptor have 
impaired responses to painful heat 395. As well as causing pain, prolonged exposure to 
capsaicin results in analgesia due to desensitisation of nociceptors 393;396.  
 
MOR and capsaicin receptors co-localise on the dorsal root ganglion (DRG) 397. 
Chronic morphine treatment is associated with an increase in TRPV1 expression in 
the DRG. TRPV1 blockade has been shown to attenuate morphine tolerance in animal 
studies 397. Knockout studies have shown that TRPV1 is involved in morphine-
induced nociception and also in the development of morphine-induced hyperalgesia 
398;399
. The use of TRPV1 antagonists potentiates the analgesic effects of morphine in 
some pain states 400.  
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5.5.1 TRPV1 Results 
 
Table 5.7 TRPV1 marker data 
 
SNP Position Location  
Allele  
major:minor MAF 
Published 
MAF 
HW  
p value 
Call 
rate 
AA 
change 
rs877610 3422240 Exon 15 G:A 0.054 0.026 1 98.8 - 
rs2277679 3427524 Intron 12 C:G 0.334 0.42 0.3285 100 - 
rs222745 3435620 Intron 9 C:T 0.087 0.09 0.2849 99.2 - 
rs161393 3436263 Intron 8 A:G 0.337 0.25 0.5747 99.6 - 
rs222747 3439949 Exon 7 C:G 0.264 0.18 0.6389 100 Met-Ile 
rs3744683 3460211 Promoter A:G 0.025 0.004 0.2628 98.4 - 
Published allele frequencies from HapMap CEU 
Reference sequence NM_080704 
 
TRPV1 is comprised of 17 exons and there are ten known SNPs located in coding 
exons. Of these, four have either unknown frequency data or else the frequency of the 
minor allele is less than 0.05. Four others were included for investigation initially, 
rs877610, rs222747, rs224534 and rs222748. The latter two however were not in 
Hardy Weinberg equilibrium and were not included in the final analysis.  
 
Six SNPs across TRPV1 were included in the final analysis. All were in Hardy-
Weinberg equilibrium. 
 
One haploblock was identified, spanning 643 base pairs (Table 5.8 and figure 5.4). 
There was no significant association between the haplotypes and any of the clinical 
phenotypes tested.  
 
In this study there was no association between any of the TRPV1 SNPs and analgesic 
response or central side-effects on morphine. Two SNPs, rs877610 (exonic) and 
rs2277679 were associated with variability in daily morphine dose. Carriers of the A 
allele of rs877610 (genotype AA or AG) had a lower dose requirement than non-
carriers (genotype GG), p=0.047, R2 0.03. Carriers of the G allele of rs2277679 
(genotype GG or CG) also required less morphine to achieve adequate analgesia, 
p=0.026, R2 0.037 (Tables 5.9 and 5.10).There was no gene dose effect for either of 
these SNPs. 
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Table 5.8 TRPV1 haploblocks and haplotypes 
 
   Haploblock 1   Frequency Carriage frequency 
 
rs877610 rs2277679 rs222745 rs161393 rs222747 rs3744683 % (N) 
1 - - C A - - 66 (314) 88 (204) 
2 - - C G - - 25 (120) 44 (104) 
3 - - T G - - 8 (40) 17 (40) 
Data shown for total Caucasian population. 
 
 
Figure 5.4 LD Plots for TRPV1 
(Haploview version 4.0, Broad Institute, Cambridge, USA). 
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Table 5.9 Effects of TPRV1 on morphine dose (dominant model) 
 
Univariate linear regression 
Log10 Daily morphine dose(mg) as dependent variable  
  Carrying allele Not carrying allele     
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P 
value 
rs877610  G 99.2 (131) 1.99 (0.031) 0.8 (1) - -0.33 0.352 0.082 0.35 
 
A 12.9 (17) 1.838 (0.086) 87.1 (115) 2.016 (0.033) -0.181 0.09 -0.174 0.047 
 
         
rs2277679  C 85.8 (115) 1.999 (0.035) 14.2 (19) 1.950 (0.063) 0.053 0.086 0.053 0.54 
 
G 53 (71) 1.931 (0.039) 47 (63) 2.063 (0.048) -0.133 0.059 -0.192 0.026 
 
         
rs222745  C 100 (133) 1.992 (0.031) 0 - - - - - 
 
T 15.8 (21) 1.996 (0.067) 84.2 (112) 1.992 (0.035) 0.017 0.083 0.018 0.839 
 
         
rs161393  A 92.5(123) 1.998 (0.032) 7.5 (10) 1.923 (0.121) 0.069 0.115 0.053 0.548 
 
G 52.6 (70) 1.984 (0.044) 47.4 (63) 2.002 (0.045) -0.017 0.061 -0.024 0.783 
 
         
rs222747  C 94.8 (127) 2.0 (0.032) 5.2 (7) 1.832 (0.127) 0.125 0.135 0.08 0.357 
 
G 44.8 (60) 1.971 (0.52) 55.2 (60) 2.01 (0.038) -0.041 0.061 -0.059 0.498 
 
         
rs3744683  A 100 (131) 1.992 (0.031) 0 - - - - - 
 G 3.1 (4) 1.774 (0.274) 96.9 (126) 1.999 (0.031) -0.226 0.178 -0.111 0.207 
* mean (SEM) of Log10 Daily morphine dose 
rs877610 A ANOVA F = 4.036, R2 = 0.03 
rs2277679 G ANOVA F = 5.058, R2 = 0.037 
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Table 5.10 Effects of TPRV1 on morphine dose (additive model) 
 
Univariate linear regression 
Log10 Daily morphine dose(mg) as dependent variable  
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β P value 
rs877610  GG 87.1 (115) 2.016 (0.033)     
 
GA 12.1 (16) 1.807 (0.086) 0.134 0.083 0.14 0.11 
 
AA 0.8 (1) -     
rs2277679  CC 47 (63) 2.063 (0.048)     
 
CG 38.8 (52) 1.924 (0.049) 0.079 0.049 0.161 0.063 
 
GG 14.2 (19) 1.950 (0.063)     
rs222745  CC 84.2 (112) 1.992 (0.035)     
 
CT 15.8 (21) 1.996 (0.067) 0.017 0.083 0.018 0.839 
 
TT 0 -     
rs161393  AA 47.4 (63) 2.002 (0.045)     
 
AG 45.1 (60) 1.993 (0.047) 0.023 0.049 0.041 0.636 
 
GG 6.9 (10) 1.923 (0.121)     
rs222747  CC 55.2 (74) 2.01 (0.038)     
 
CG 39.6 (53) 1.987 (0.056) -0.046 0.051 -0.079 0.362 
 
GG 5.2 (7) 1.832 (0.127)     
rs3744683  AA 96.2 (126) 1.999  (0.031)     
 AG 3.5 (5) 1.774 (0.274) 0.158 0.16 0.087 0.324 
 GG 0 -     
* mean (SEM) of Log10 Daily morphine dose  
No statistically significant associations found 
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5.6 ALOX12 
 
ALOX12, the gene which codes for arachidonate 12-lipoxygenase is located on 
chromosome 17 (17p13.1) and spans 14650 base pairs. It contains 178 known SNPs. 
(http://snpper.chip.org, accessed 10/01/2010)89. This enzyme is found in a number of 
regions including platelets and human leucocyte cells. A non-expressed 12-
lipoxygenase pseudogene also exists on chromosome 17 401. 
 
Arachidonate 12-lipoxygenase is a key enzyme in arachidonic acid metabolism, 
producing 12(S)-HPETE (12(S)-hydroperoxy-5,8,10,14-eicosatetraenoic acid). 
Arachidonic acid and its metabolites, including 12(S)-HPETE are involved in cell 
signalling and act as second messengers 402. In the brain, suppression of the inhibitory 
effects of GABA (gamma-Aminobutyric acid) on the descending antinociceptive 
pathways by opioids has been shown to occur through a pathway involving 
arachidonic acid and its metabolites 403. 
 
12-lipoxygenase knockout mice have enhanced analgesia from morphine in the acute 
stage, but this effect diminished with chronic morphine treatment. This suggests that 
with long-terms morphine use, alternative second messangers that are not dependent 
on 12-lipoxygenase may be involved 404. Furthermore, spinal inhibition of 12-
lipoxygenase attenuates morphine withdrawal in animals treated with naloxone 405. 
There is also evidence that 12-lipoxygenase metabolites activate TRPV1, the 
capsaicin receptor, which is implicated in nociception.  
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5.6.1 ALOX12 Results 
 
Table 5.11 ALOX12 marker data 
 
Name Position 
Locus on 
gene 
Alleles 
major:minor MAF 
Published 
MAF HWpval 
Call 
rate 
AA 
change 
rs6502999 6833363 Promoter A:G 0.373 0.45 0.6911 100 - 
rs1126667 6843484 Exon 6 G:A 0.382 0.44 0.798 100 Gln-Arg 
rs434473 6845658 Exon 8 A:G 0.384 0.43 0.4891 100 Asn-Ser 
Published frequencies HapMap CEU 
Reference sequence NM_000697 
 
 
ALOX12 contains 14 exons,406 in which there are 12 SNPs in coding regions. Of these 
8 are non-polymorphic in Caucasians or have a very low minor allele frequency.  Of 
those exonic SNPs which were not included for investigation, rs1042356 was in tight 
LD with rs1126667 (which was included) and rs1042357 was not included in 
Hapmap data. 
 
Three SNPs were included in the final analysis. These were all in Hardy-Weinberg 
equilibrium. One haploblock which included all three SNPs was identified (Table 5.12 
and figure 5.5). There was no association between the ALOX12 SNPs or haplotypes 
and any of the clinical phenotypes tested.  
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Table 5.12 ALOX12 haplotypes 
 
 
 Frequency Carriage frequency 
 
 % (N) 
 rs6502999 rs1126667 rs434473   
1 A A G 2 (8) 3 (8) 
2 A G A 60 (299) 84 (205) 
3 G A G 36 (178) 59 (145) 
Data shown for total Caucasian population. 
 
 
 
Figure 5.5 LD plots for ALOX12 
(Haploview version 4.0, Broad Institute, Cambridge, USA). 
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5.7 SLC6A4 
 
Serotonin is a key signaling molecule in both the central nervous system and the 
gastrointestinal tract. Serotonin is inactivated by SERT, the serotonin reuptake 
transporter, which is coded for by SLC6A4, (solute carrier family 6, member 4). 
SLC6A4 is located on chromosome 17 (17q11.2) and spans 37798 base pairs.  
 
SERT has been associated with variability in morphine response. This involvement is 
somewhat complicated however and is dependent on a number of factors including 
the site and dose of morphine used 407. One study demonstrated that SERT knockout 
mice have 64% reduction in morphine-induced analgesia, as compared to wild-type 
animals, p = 0.014 408. Furthermore, the use of SSRIs appears to attenuate naloxone-
induced morphine withdrawal in rats 409. There is some evidence that serotonin 
receptors, specifically 5-HT(1A) inhibit endogenous opioid release in the spinal cord 
410
. 
 
The data pertaining to SERT and nociception are less clear. Serotonergic pathways are 
involved in both pronociception and antinociception 407. One study demonstrated that 
SERT -/- mice developed reduced inflammatory pain after inflammation 411. Another 
study however showed no difference in nociception (thermal, mechanical or formalin-
induced) between SERT -/- and wild-type animals 412. 
 
The 5’ promoter region of SLC6A4 contains a 44-base pair deletion-insertion 
polymorphism (DIP) known as SERTPR or 5HTTLPR 413. The allelic variants are 
named short (S) and long (L) depending on the presence or absence of the DIP. The 
short allele (S) has been associated with reduced transcriptional activity, a lower level 
of SERT-P expression and therefore reduced re-uptake and inactivation of serotonin 
413;414
. 
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5.7.1 SLC6A4 Results 
 
Table 5.13 SLC6A4 marker data 
 
Name 
Chr 
Position 
(bp) 
Locus 
on gene 
Alleles 
major:minor MAF 
Published 
MAF HWpval 
Call 
Rate 
AA 
change 
rs4583306 25500441 Intron 9 A:G 0.43 0.4 0.884 99.6 - 
rs140700 25405115 Intron 6 C:T 0.108 0.1 0.2452 98.4 - 
rs6354 25411612 5UTR T:G 0.215 0.21 0.0978 98.8 - 
rs25528 25411692 Intron 1 T:G 0.224 0.18 0.305 96.7 - 
rs7214991 25433987 promoter A:G 0.363 0.35 0.1493 98.4 - 
SERTP**  DIP L / S 0.16 0.18* 0.2 97.5 - 
Reference sequence NW_926750 
Published allele frequencies from HapMap CEU  
*refers to published genotype frequencies for 193 white US subjects 415 
**Contig position SERTP 3292128-3292610 302 
 
SLC6A4 contains 15 exons and 348 known SNPs. (http://snpper.chip.org, accessed 
10/01/2010)89. It contains nine validated SNPs in coding exon regions. Of these eight 
are non-polymorphic in Caucasians. The remaining exonic SNP rs2228673 was 
included in this study but was found to be non-polymorphic in this study population 
and was therefore omitted from the final analysis.  
Five SNPs and one deletion-insertion polymorphism were tested. All were in Hardy-
Weinberg equilibrium. 
 
One haploblock was identified which included two SNPs, rs6354 and rs25528, 
spanning 80 base pairs (Table 5.14 and figure 5.6). 
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Table 5.14 SLC6A4 haploblock and haplotypes 
 
 
 Haploblock 1   % (N) 
 
 rs 7214991 rs25528 rs6354 rs 140700 rs4583306 Frequency 
 
Carriage  
frequency  
1 - T T - - 0.77 (352) 0.93 (212) 
2 - G G - - 0.22 (99) 0.37 (85) 
Data shown for total Caucasian population.  
 
 
 
 
Figure 5.6 LD Plots for SLC6A4 
Haploview version 4.0, Broad Institute, Cambridge, USA 
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Intronic SNP, SLC6A4 rs140700, was associated with analgesic response to morphine 
on univariate analysis. Carriage of the C allele (genotype CC or CT) at this position 
was associated with lower pain scores than non-carriage (genotype TT) p=0.009, R2 
0.037 (figure 5.7). This SNP exhibited a clear gene dose effect (Tables 5.15 and 5.16, 
figure 5.7). 
 
Rs22528 was also associated with variation in pain scores, carriers of the T allele 
(genotype TT or TG) having lower pain scores than non-carriers (genotype GG), 
p=0.02, R2 0.03. Again there was a gene dose effect, but this was borderline 
significant, p=0.052.  
 
SNPs in SLC6A4 were not found to be associated with variation in daily morphine 
dose or central side-effects on morphine.  
 
The deletion-insertion polymorphism SERTP was not statistically associated with any 
of the clinical phenotypes tested.  
 
Figure 5.7 SLC6A4 and analgesic response 
SLC6A4 rs140700 is associated with variation in analgesic response to morphine. The 
analgesic response scores on the y-axis are log10Component1 scores (ref chapter 3) 
Higher scores represent worse analgesic response. The red line represents the mean 
value. 
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Table 5.15 SLC6A4 and analgesic response to morphine (dominant model) 
 
Univariate linear regression 
Log10Component1 (pain scores) as dependent variable  
  Carrying allele Not carrying allele     
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P value 
rs 7214991 A 90 (171) 0.45 (0.012) 10 (19) 0.39 (0.035) 0.06 0.035 0.125 0.088 
 
G 59.8 (113) 0.44 (0.014) 40.2 (76) 0.46 (0.017) -0.025 0.022 -0.084 0.253 
rs 22528 T 94.6 (174) 0.44 (0.011) 5.4 (10) 0.55 (0.034) -0.108 0.046 -0.173 0.02 
 
G 36.2 (67) 0.47 (0.018) 63.8 (118) 0.44 (0.014) 0.029 0.022 0.099 0.184 
rs6354 T 93.7 (177) 0.44 (0.011) 6.3 (12) 0.52 (0.033) -0.082 0.043 -0.14 0.057 
 
G 34.2 (65) 0.47 (0.018) 65.8 (125) 0.43 (0.014) 0.035 0.022 0.117 0.111 
rs 140700 C 97.9 (183) 0.44 (0.011) 2.1 (4) 0.61 (0.032) -0.189 0.071 -0.193 0.009 
 
T 18.2 (34) 0.49 (0.026) 81.8 (153) 0.44 (0.012) 0.057 0.027 0.154 0.037 
rs 4583306 A 78.9 (150) 0.44 (0.012) 21.1 (40) 0.46 (0.027) -0.012 0.026 -0.033 0.649 
 
G 71.1 (135) 0.45 (0.013) 28.9 (55) 0.45 (0.021) -0.008 0.023 -0.025 0.731 
SERTP  S 69 (126) 0.46 (0.012) 31 (56) 0.42 (0.2) -0.03  0.028 -0.081 0.275 
 
L 82 (149) 0.44 (0.012) 18 (33) 0.47 (0.023) 0.43 0.023 0.139 0.062 
* mean (SEM) of log10Component1 scores 
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Table 5.16 SLC6A4 and analgesic response to morphine (additive model) 
 
Univariate linear regression 
Log10Component1 (pain scores) as dependent variable  
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β 
P 
value 
rs 7214991 AA 40.2 (76) 0.46 (0.017)     
 
AG 49.7 (94) 0.45 (0.016) -0.028 0.016 -0.123 0.094 
 
GG 10.1 (19) 0.39 (0.035)     
rs 22528 TT 63.9 (117) 0.44 (0.014)     
 
TG 30.6 (56) 0.45 (0.019) -0.035 0.018 -0.145 0.052 
 
GG 5.5 (10) 0.55 (0.034)     
rs 6354 TT 66.1 (125) 0.43 (0.014)     
 
TG 27.5 (52) 0.46 (0.02) -0.035 0.017 -0.147 0.045 
 
GG 6.3 (12) 0.52 (0.033) 
    
rs 140700 CC 81.8 (153) 0.44 (0.012)     
 
CT 16 (30) 0.48 (0.028) 0.061 0.023 0.193 0.009 
 
TT 2.1 (4) 0.61 (0.032) 
    
rs 4583306 AA 28.9 (55) 0.45 (0.021)     
 
AG 50 (95) 0.44 (0.015) 0.001 0.015 0.003 0.968 
 
GG 21.1 (40) 0.46 (0.027)     
SERTP SS 17.8 (33) 0.48 (0.024)     
 LS 51.4 (95) 0.45 (0.015) -0.023 0.015 -0.139 0.062 
 LL 30.8 (57) 0.42 (0.022)     
* mean (SEM) of log10Component1 scores  
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5.8 ARRB2 
 
ARRB2 is the gene coding for intra-cellular B-arrestin 2 proteins.  These proteins act 
as inhibitors to receptor coupling and are negative regulators of opioid receptor 
signalling 125. B-arrestin2 knockout mice have been shown to experience prolonged 
analgesia from morphine, even at doses which are normally subanalgesic 126. 
Desensitization and tolerance to morphine does not occur in these knock-out animals 
416
. Morphine analgesia is also improved by inhibition of B-arrestin 2 expression in 
the periaqueductal grey matter of mice 417. Conversely rats with over-expression of B-
arrestin2 have little or no analgesia from morphine 418. B-arrestin2-knockout mice 
also demonstrated reduced constipation and respiratory depression on morphine 419. 
 
Opioid receptors are thought to interact and dimerise with each other and with other 
receptors in regulation of receptor function 420. Mu-delta opioid receptor heterodimers 
can alter B-arrestin recruitment and so modulate opioid receptor signalling 421.  
 
5.8.1 ARRB2: Results  
 
Table 5.17 ARRB2 marker data 
 
Name 
Position 
(bp) 
Locus on 
gene 
Alleles 
major:minor MAF 
Published 
MAF HWpval 
Call 
Rate 
AA 
change 
rs1973555 4552636 Promoter C:T 0.321 0.29 0.7661 100 - 
rs3786047 4561847 Intron 1 G:A 0.366 0.283 0.3746 99.3 - 
rs4522461 4568522 Intron 9 C:T 0.223 0.217 0.6781 99.6 - 
rs1045280 4569387 Exon 11 T:C 0.361 0.31 0.2448 96.8 Ser-Ser 
Published allele frequencies from HapMap CEU 
 
 
This gene is located on chromosome 17p13.2 and spans approximately 11007bp. It is 
comprised of 15 exons and contains 226 SNPs (http://snpper.chip.org, accessed 
02/01/2010) 89. Of these, three are located in coding exons, rs1045280, rs9915175 and 
rs34750256. The latter two are non-polymorphic and were not included. Dr Joy Ross 
originally tested seven SNPs across this gene on the smaller subset of the study 
population 279. A number of these were in tight LD together and therefore four were 
chosen for further investigation:  rs1973555 rs3786047, rs4522461, rs1045280. The 
primers for these SNPs were designed by Dr Joy Ross 279 who also ran them on 199 
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caucasian patients who were included in this study. I ran these primers on the 
remaining 66 Caucasian patients. All were in Hardy-Weinberg equilibrium. 
 
One haploblock was identified which included two of the SNPs and spanned 6675 
base pairs (table 5.18 and figure 5.8). 
 
Carriers of the T allele of rs4522461 (genotype TT or TC) also had lower central side-
effect scores compared to non-carriers (genotype CC), p=0.024. There was no gene 
dose effect for this SNP.  There was also an association between Haplotype 2 and 
central side-effects, p=0.03. There was an association between exonic SNP rs1045280 
and central side-effects on morphine, p=0.039 (Tables 5.19 and 5.20). 
 
None of the SNPs tested were associated with variation in analgesic response or 
morphine dose requirements.  
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Figure 5.8 LD plots for ARRB2 
Haploview version 4.0, Broad Institute, Cambridge, USA 
 
Table 5.18 ARRB2 haplotypes 
 
 
    % (N) 
 rs1973555 rs3786047 rs4522461 rs1045280 Frequency  Carriage  
frequency  
 
 Haploblock 1   
 
1 - A C - 23 (53) 14 (66) 
2 - A T - 42 (98) 22 (105) 
3 - G C - 84 (199) 63 (298) 
4 - G T - 1 (3) 1 (3) 
Data shown for total Caucasian population. 
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Table 5.19 ARRB2 and central side-effects on morphine (dominant model) 
 
Univariate linear regression 
Log10Component2 (central side effect scores) as dependent variable  
  Carrying allele Not carrying allele     
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P 
value 
rs1973555 C 92.1 (176) 0.4 (0.012) 7.9 (15) 0.4 (0.041) <0.001 0.043 <0.001 0.997 
 T 52.9 (101) 0.38 (0.016) 47.1 (90) 0.42 (0.017) -0.042 0.022 -0.135 0.065 
          
rs3786047 G 87.8 (166) 0.4 (0.013) 12.2 (23) 0.39 (0.027) 0.009 0.035 0.018 0.805 
 A 57.9 (110) 0.42 (0.018) 42.1 (80) 0.38 (0.015) -0.035 0.023 -0.112 0.128 
          
rs4522461 C 95.8 (182) 0.4 (0.012) 4.2 (8) 0.44 (0.052) -0.033 0.06 -0.041 0.578 
 T 41.6 (79) 0.37 (0.018) 58.4 (111) 0.42 (0.015) -0.052 0.023 -0.165 0.024 
          
rs1045280 T 89.2 (165) 0.4 (0.012) 10.8 (20) 0.36 (0.032) 0.048 0.037 0.096 0.2 
 
C 54.6 (101) 0.38 (0.015) 45.4 (84) 0.42 (0.017) -0.045 0.023 -0.144 0.052 
* mean (SEM) of log10Component2 scores 
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Table 5.20 ARRB2 and central side-effects on morphine (additive model) 
 
Univariate linear regression 
Log10Component2 (central side-effect scores) as dependent variable  
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β 
P 
value 
rs1973555 CC 47.1 (90) 0.42 (0.017)     
 CT 45 (86) 0.38 (0.017) 0.027 0.018 0.108 0.14 
 TT 7.9 (15) 0.4 (0.041)     
rs3786047 GG 42.3 (80) 0.42 (0.018)     
 GA 45.5 (86) 0.38 (0.017) 0.021 0.017 0.09 0.222 
 AA 12.2 (23) 0.39 (0.027)     
rs4522461 CC 58.4 (111) 0.42 (0.015) 
    
 CT 37.4 (71) 0.36 (0.019) 0.035 0.02 0.13 0.077 
 TT 4.2 (8) 0.44 (0.052)     
rs1045280 TT 45.4 (84) 0.42 (0.017)     
 
TC 43.8 (81) 0.39 (0.018) 0.036 0.017 0.153 0.039 
 
CC 10.8 (20) 0.36 (0.032)     
* mean (SEM) of log10Component2 scores  
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5.9 Gene-gene interaction / gene-environment interaction 
 
The main positive findings from the univariate analyses are summarized in table 5.21. 
 
Table 5.21 Summary of positive associations of genes with clinical outcomes 
 
Gene 
Analgesic 
response 
Central side-
effects 
Morphine dose  
(mg/24 hours) to 
achieve 
adequate pain 
control 
OPRM √  √ 
OPRK √ √ √ 
OPRD   √ 
ADORA1 √  √ 
ADRA2A   √ 
TRPV1   √ 
ALOX12    
SLC6A4 √   
ARRB2  √  
 
As discussed earlier in this chapter, there is evidence to suggest interaction between 
the following genes: 
• OPRM / ADORA1 
• OPRM / ADRA2A 
• OPRM / ALOX12  
• OPRM / TRPV1  
• OPRM / ARRB2 
• ALOX12 / TRPV1 
• ADRA2A / OPRD 
• ADORA1 / ADRA2A / OPRM 
• Opioid receptors/SLC6A4 
 
Multivariate regression modeling was used to examine these gene-gene interactions 
and also gene-environment interactions. Clinical and genetic factors significant at the 
level of 10% (p<0.1) on univariate analysis (as presented in chapter 3) were 
introduced simultaneously into the model using a stepwise approach.  
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(For some of these combinations there were no genetic factors with p<0.1 therefore it 
was not possible to carry out multivariate regression analyses.) 
 
5.9.1 Analgesic response to morphine 
 
5.9.1.1 SLC6A4 and opioid receptor genes  
 
In chapter 4, I described the results of a multivariate regression analysis which 
identified OPRK rs7824175, daily morphine dose, being on a b-blocker and taking an 
antiemetic as independent predictors of variability in analgesic response to morphine, 
accounting for approximately 16% of variability in the clinical phenotype. 
 
The main association with variation in analgesic response to morphine in this chapter 
was with SNPs in SLC6A4. Therefore SNPs in the opioid receptor genes together with 
SNPs in SLC6A4 and clinical factors which were significant on univariate analysis 
(p<0.1) were entered into a multivariate regression model. 
 
When SLC6A4 SNPs were added, OPRK rs7824175, SLC6A4 rs140700, SERTP and 
being on a B-blocker, antiemetic and taking paracetamol were included in the final 
model. Daily morphine dose was no longer included. This new model predicted 
23.4% of variance in analgesic response to morphine (Table 5.22). In this model, the 
association between analgesic response and OPRK rs7824175 became stronger, with 
the p value increasing from 0.00015 to 7.68x10-5. When the dominant model was 
used, a similar result was obtained. In the dominant model SERTP was not included 
and SLC6A4 rs25528 rather than SLC6A4 rs140700 was included. These latter SNPs 
are in LD together (D’ 0.97, R2 0.39).  
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Table 5.22 OPRM, OPRD, OPRK and SLC6A4 and analgesic response (additive 
model) 
Multivariate regression model (using log10Component 1 (Pain scores) as dependent 
variable) of clinical and genetic factors associated with analgesic response to 
morphine.  
 
  B (95% CI) 
Std. 
Error Beta P 
(Constant) 0.610 (0.527, 0.693) 0.042  <0.001 
OPRK1 rs7824175 -0.083 (-0.123, -0.043) 0.020 -0.280 7.68 x 10-5 
SLC6A4 rs140700  0.062 (0.017, 0.107) 0.023 0.194 0.007 
SERTP  -0.035 (-0.064, -0.006 ) 0.015 -0.171 0.020 
Antiemetic -0.043 (-0.084, -0.003) 0.020 -0.151 0.035 
B Blocker 0.124 (0.048, 0.200) 0.039 0.222 0.002 
Paracetamol 0.044 (0.005, 0.084) 0.020 0.152 0.029 
Additive (genotype) model 
All SNPs (OPRM, OPRK, OPRD, SLC6A4)and clinical variables p<0.1 on univariate 
analysis included 
ANOVA F = 8.3, p = 8 x 10-8, R2 = 23.4 
 
 
Table 5.23 OPRM, OPRD, OPRK and SLC6A4 and analgesic response 
(dominant model) 
 
  B (95% CI) Std. Error Beta P 
(Constant) 0.514 (0.426, 0.601) 0.044 
 
<0.001 
OPRK1 rs7824175 CC/CG 0.087 (0.040, 0.135) 0.024 0.253 0.0004 
SLC6A4 rs25528 TT/TG -0.096 (-0.182, -
0.010) 0.043 -0.156 0.028 
Antiemetic -0.050 (-0.090, -
0.009) 0.020 -0.171 0.016 
B Blocker 0.121 (0.042, 0.199) 0.040 0.213 0.003 
Paracetamol 0.041 (0.000, 0.082) 0.021 0.140 0.048 
Dominant (allele carriage) model 
All SNPs (OPRM, OPRK, OPRD, SLC6A4) and clinical variables p<0.1 on 
univariate analysis included 
ANOVA = 7.6, p = 1.7 x 10-6, R2 = 18.7 
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5.9.1.2 ADORA1 and opioid receptor genes  
 
ADORA1 was also associated with variability in analgesic response to morphine on 
univaraite analysis. When SNPs in ADORA1, OPRM, OPRD and OPRK and clinical 
variables were included in the multivariate analysis, the final model (additive) 
consisted of four independent variables including ADORA rs903361. OPRK 
rs7824175, being on a B-Blocker and taking an antiemetic remained independent 
predictors of variation in analgesic response to morphine. This model however only 
explained 16% of variability in the clinical outcome, similar to the model which did 
not included the ADORA1 SNPs (data not shown).  
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5.9.2 Variation in central side-effects on morphine 
 
The only gene with any association with central side-effects on morphine in this 
chapter was ARRB2. When this gene was added to the multivariate analysis described 
in chapter 4, no ARRB2 SNPs remained independent predictors of the clinical 
outcome. 
 
 
5.9.3 Variation in daily morphine dose to achieve adequate analgesia   
 
5.9.3.1 ADORA1 and opioid receptor genes 
 
In chapter 4, I described the results of a multivariate regression analysis which 
identified OPRK rs7836120, being on a bronchodilator and taking an anticonvulsant 
and OPRM rs2075572 and OPRM rs589046 as independent predictors of variability 
in analgesic response to morphine, accounting for approximately 27% of variability in 
the clinical phenotype. 
 
This model was built on to incorporate SNPs in ADORA1. Multivariate analysis of 
ADORA1 and OPRM and OPRK with clinical factors associated with the clinical 
phenotype resulted in a regression model consisting of four independent variables 
which also predicted 27% of variability in morphine dose (table 5.23). OPRM 
rs2075572, OPRK rs7836120 and being on an anticonvulsant were retained in the 
model, along with ADORA rs10920568. Being on a bronchodilator and OPRM 
rs589046 were no longer included in the model.  
 
Carriage of the T allele at ADORA rs10920568 (genotype TT or TG), or carriage of 
the OPRK1 rs7836120 A allele (genotype AA or AG) or being on an anticonvulsant 
are predictive of a need for higher daily morphine dose to achieve adequate analgesia. 
Carriage of the G allele OPRM rs2075572 (genotype GG or GC) is predictive of 
lower morphine dose requirements. This model is similar to that developed using 
clinical factors and SNPs in the opioid genes alone. 
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When the additive model was used (genotype) no ADORA1 SNPs were retained in 
the final model.  
 
 Table 5.24 OPRM, OPRD, OPRK and ADORA1 and daily morphine dose 
(additive model) 
Stepwise multivariate linear regression model (using Log10 Daily morphine dose as 
dependent variable) of clinical and genetic factors associated with variability in daily 
morphine dose requirements. 
 
  B Std. Error Beta P value 
(Constant) 1.467 (1.136, 1.797) 0.167  <0.001 
Anticonvulsant 0.325 (0.183, 0.467) 0.072 0.348 1.3 x 10-5 
OPRK rs7836120 AA/AG  0.394 (0.086, 0.701) 0.155 0.194 0.012 
ADORA1 rs10920568 
TT/TG 0.208 (0.054, 0.363) 0.078 0.205 0.009 
OPRM rs2075572 GG/GC -0.137 (-0.247, -0.028) 0.055 -0.189 0.015 
ANOVA F = 11.6, p = 5 x10-8 , R2 = 0.267  
All clinical and genetic factors OPRM, OPRK and ADORA1 p<0.1 on univariate 
analysis included 
 
 
5.9.3.2 ADRA2A and opioid receptor genes 
 
Multivariate analysis of ADRA2A and OPRM, OPRK and OPRD with clinical factors 
associated with the clinical phenotype resulted in a regression model consisting of 
three independent variables which predicted 26% of variability in morphine dose 
(Tables 5.24 and 5.25). Both the additive and dominant models are similar including 
being on an anticonvulsant and OPRM rs1799971 and ADRA2A rs11195418. The 
dominant model also includes a SNP in OPRK . These models do not predict any 
more variance in this clinical phenotype than the model including the opioid receptor 
genes alone.  
 
5.9.3.3 Other gene combinations 
 
When multivariate analysis of ADORA1, ADRA2A, OPRM, OPRD and OPRK was 
carried out, no ADRA2A genetic data was retained. The final model resembled that 
for OPRM, OPRD, OPRK and ADORA1 alone (table 5.23).  
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When multivariate analysis of ALOX12 and OPRM, ARRB2 and OPRM and TRPV1 
and OPRM was carried out, no ALOX12 / ARRB2 / TRPV1 genetic data were 
retained.   
 
 
Table 5.25 OPRM, OPRD, OPRK and ADRA2A and daily morphine dose 
(dominant model) 
 
In tables 5.24 and 5.25 stepwise multivariate linear regression model, using Log10 
Daily morphine dose as dependent variable was carried out to determine the influence 
of clinical and genetic factors on variability in daily morphine dose requirements. 
 
  B (95% CI) 
Std. 
Error Beta  P 
(Constant) 1.477 (1.171, 1.783) 0.155 
  
0.000 
Anticonvulsant 0.324 (0.176, 0.471) 0.075 0.340 2.9x10-5 
OPRK rs7836120 AA/AG 0.456 (0.145, 0.767) 0.157 0.225 0.004 
OPRM rs1799971 GG/GA  0.171 (0.042, 0.300) 0.065 0.205 0.010 
ADRA2A rs11195418 GG/GA -0.225 (-0.422, -0.028) 0.100 -0.178 0.026 
All SNPs (OPRM, OPRD, OPRK, ADRA2A) and clinical variables p<0.1 on univariate 
analysis included 
ANOVA F = 10.9, p = 13 x 10-7, R2 = 25.9 
 
 
 
 
Table 5.26 OPRM, OPRD, OPRK and ADRA2A and daily morphine dose 
(additive model) 
 
 
  
B (95% CI) 
Std. 
Error Beta P  
(Constant) 1.912 (1.844, 1.979) 0.034 
 
<0.001 
Anticonvulsant 0.348 (0.198, 0.498) 0.076 0.365 1 x 10-5 
OPRM rs1799971 0.159 (0.050, 0.269) 0.055 0.229 0.005 
ADRA2A rs11195418 -0.213 (-0.414, -0.012) 0.101 -0.169 0.038 
ANOVA F = 11.9, p = 6.2 x10-7 , R2 = 22.1  
All clinical and genetic factors OPRM, OPRK, OPRD, ADRA2A p<0.1 on univariate 
analysis included 
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5.10 General Discussion 
 
5.10.1 Main findings 
 
The main findings from the analyses presented in this chapter are:  
 
• Response to morphine in terms of pain, central side-effects and morphine dose 
requirements are mediated by different polymorphisms in different genes with 
little overlap. This supports the argument that morphine response is a 
heterogeneous clinical outcome and adds more weight to the hypothesis 
presented in chapter 3 that these clinical phenotypes are separate and discreet.  
 
• SLC6A4 appears to play a role in analgesic response. 
 
• OPRK (rs7824175), SLC6A4 rs140700 and being on a B-blocker/anti-
emetic/paracetamol are independent predictors, accounting for 23% of 
variability in analgesic response to morphine. 
 
• Being on an anticonvulsant remains the strongest predictor of variability in 
morphine dose requirements on multivariate analysis, regardless of the genes 
included in the modeling. 
 
• OPRM, OPRK and ADORA1 also appear to play a role in variability in the 
dose of morphine required to achieve adequate pain control. 
  
In chapter 4, models predicting response to morphine in terms of clinical factors and 
the opioid receptor genes were presented. The aim of this chapter was to explore the 
influence of other genes and to use these data to build up more comprehensive 
predictive models. Although each SNP was studied individually, one of the main aims 
of this chapter was to build multivariate regression models to explore the influence of 
gene-gene and gene-environment interactions on morphine response.  
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5.10.2 Models predicting analgesic response to morphine 
 
In this study SLC6A4 appears to be associated with variability in analgesic response. 
Two SNPs in SLC6A4 were included in the final additive multivariate regression 
model, SERTP (the DIP in the promoter region) and rs140700. The SERTP short 
allele (S) has been associated with reduced transcriptional activity, a lower level of 
SERT-P expression and therefore reduced re-uptake and inactivation of serotonin. 414 
413
. There has only been one small study investigating this DIP in pain. In that study 
43 healthy volunteers found that remifentanil, a short acting opioid, was more 
effective in subjects carrying the short (S) allele at this position 422. SLC6A4 rs140700 
is an intronic SNP. This SNP may be in LD with a true marker SNP which may alter 
function of the serotonin reuptake transporter protein, thus altering response to 
opioids. 
 
A multivariate regression model predicting 16% of variability in analgesic response to 
morphine had been described in chapter 4 in which clinical factors and SNPs in the 
opioid receptor genes were included. When SNPs in SLC6A4, the serotonin reuptake 
transporter gene were added, the model got significantly stronger, predicting 23% of 
variance in this clinical phenotype. OPRK rs7824175 and being on a B-blocker / 
antiemetic were retained in the new model but daily morphine dose was not, 
suggesting that the former three factors are more likely to be true predictors of 
analgesic response to morphine. The fact that morphine dose was removed from the 
multivariate model is consistent with 1) the finding in this study that morphine dose 
only accounted for a very small proportion of the variance in analgesic response on 
univariate analysis and 2) the clinical finding of significant variation in morphine dose 
requirements for similar painful stimuli.  
Therefore the model presented here suggests that increased serotonin levels in 
addition to variation in OPRK and being on paracetamol/β-blockers and antiemetic 
medications are predictive of analgesic response to morphine in cancer patients. 
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5.10.3 Models predicting central side-effects on morphine 
 
The genetic associations with central side-effects are less significant. ARRB2 
rs1045280, in the B-arrestin 2 gene, was previously found to be associated with 
morphine non-responders 95. In that study (which was carried out on a subset of this 
study population) morphine non-responders were more likely to carry the T allele at 
this position (p=0.036). In this study this SNP was weakly associated with central 
side-effects but it is unlikely that these results would withstand any corrections for 
multiple testing.  
 
In chapter 4 a model predicting 8-10% of variability in central side-effects on 
morphine was presented including SNPs in OPRM and OPRK and clinical variables. 
Despite testing more genes, OPRK rs10504151 remains the strongest predictor on 
univariate analysis (p=0.009). ARRB2 SNPs were not retained on multivariate testing.  
 
 
5.10.4 Models predicting morphine dose requirements 
 
Variability in morphine dose requirements to achieve adequate analgesia was 
associated with genetic variation in ADORA1, ADRA2A and TRPV1 on univariate 
analysis. The most significant association was with SNPs in ADORA1, the gene 
coding for the A1-adenosine receptor. In chapter 4 a multivariate model consisting of 
SNPs in OPRK and OPRM and being on a bronchodilator or anticonvulsant 
medication was developed which predicted 27% of variance in daily morphine dose 
requirements. In this chapter SNPs in ADORA and ADRA2A were added to the 
model. Different models were generated depending on which genes were included in 
the analysis. However, throughout all, being on an anticonvulsant medication remains 
the single most consistent and significant predictor of variability in morphine dose 
requirements.  
 
The lack of consistency among the SNPs in each of the multivariate models is likely 
to suggest that these models need further testing to eliminate false positive and false 
negative findings. However the models presented are biologically plausible. 
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In the spinal cord morphine produces a dose-dependent release of adenosine which is 
thought to mediate some of the antinociceptive effects of morphine 373;423.  MOR 
(much more so than DOR or KOR) activation increases adenosine release 424. There 
also appears to be a synergistic antinociceptive action when adenosine receptor 
agonists are administered with delta or kappa opioid receptor agonists 425. This 
supports the multivariate model of morphine dose requirements which includes SNPs 
in OPRM, OPRK and ADORA1.  
 
ADORA1 rs10920568 is the most significant ADORA1 SNP and remains an 
independent predictor of variation in morphine dose on multivariate linear regression 
with OPRM, OPRK and clinical factors. This SNP is located in exon 5, which is in the 
coding region of the gene.  It is not associated with an amino acid change. There was 
also an association with a SNP in intron 5, rs10800901 which is downstream to and 
not in LD with rs10920568. The LD plot for this gene demonstrates a disintegration 
of LD within intron 5. Intron 5 interrupts the coding sequence in a region which 
corresponds to the second intracellular loop of the receptor 370;426. The second 
intracellular loop is involved in G-protein coupling 427. The region of the gene 
upstream and including this region of LD disintegration (represented by haploblocks 1 
and 2 in this study) is associated with the clinical phenotype of variation in morphine 
dose requirements and the region downstream to this (haploblock 3) is not.  This LD 
block structure is similar to that presented in HapMap 90. There were also associations 
with intronic SNPs located in the untranslated 5’ region of the gene. Alternative 
splicing in A1-adenosine receptors is thought to occur in this region 426. The data 
presented in this study suggests that the SNPs included may represent marker SNPs 
for the true susceptibility SNP which is located somewhere upstream to haploblock 3 
and that the DNA variation may influence receptor function through post-
transcriptional modification.  
 
ADRA2A, the α2A adrenergic receptor gene was also associated with variability in 
morphine dose. Although the association on univariate analysis was weak (p=0.039), 
a SNP in ADRA2A rs11195419 remained an independent predictor of morphine dose 
when multivariate regression was carried out using clinical factors and SNPs in 
OPRM, OPRK and OPRD as co-variables. A multivariate predictive model was built 
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which included OPRM, and ADRA2A and being on an anticonvulsant in both the 
additive model and dominant model.  Therefore, although this model again accounts 
for approximately 22-26% of variance in the clinical phenotype, it may represent a 
more robust model to that including ADORA1 or just the opioid receptor genes as the 
genetic data are more consistent regardless of the method of modelling used. This 
SNP was also significantly associated with morphine dose requirements in the test 
group (N= 1475) in the large EPOS study, but did not remain significant in the 
validation study 135. 
 
In animal models the analgesic effects of clonidine (α2-adrenoceptor agonist) were 
blocked by PACPX and naloxone, which act as antagonists at the A1-adenosine 
receptor and mu-opioid receptors respectively 428. This suggests that A1-adenosine 
receptors may exist as multi-receptor complexes with mu-opioid receptors and α2-
adrenoceptors. All three receptors are located on the same primary afferent neurons 
and physical coupling may be involved in antinociception. Alternatively agonism of 
all three receptors may result in nociception through a common second messenger 
system 428. In this study, when SNPs in OPRM, OPRK, ADORA1 and ADRA2A were 
included in a multivariate regression analysis however, ADRA2A SNPs were not 
retained.  
 
An exonic SNP in TRPV1, rs877610 was also associated with variability in daily 
morphine dose but this SNP was not retained in any multivariate modeling including 
other genes. It is disappointing that there was no stronger association between our 
clinical phenotypes and TRPV1, especially since MOR in TRPV1-expressing neurons 
are thought to be involved in thermal nociception 360. It may be that the pain 
experienced by our patients was mediated by different mechanisms or that this 
analysis failed to identify the associated polymorphisms. Two exonic SNPs in TRPV1 
were not investigated in this study, rs8065080 and rs222749, both of which are 
associated with an animo acid change. The MAF of the former is 0.36 and of the latter 
is 0.06 89. Neither of these SNPs is in LD with the SNPs included in this analysis. 
TRPV1 rs8065080 is thought to affect the area of the receptor which is involved in 
response to capsaicin and rs 222749 affects the intracellular amino tail 392. Neither of 
these SNPs however has been associated with variability in pain perception or 
response to opioids. 
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Multivariate regression to explore gene-gene and gene-environment interactions 
 
The concept of epistasis (gene-gene interaction) is discussed in chapter 8.  
 
5.11 Conclusion 
 
Analgesia, central side-effects on morphine and variability in dose of morphine 
required to achieve adequate pain control appear to be distinct clinical phenotypes. 
This hypothesis is supported by the fact that the clinical and genetic variables 
associated with these clinical outcomes are dissimilar. 
 
The data presented are exploratory and serve to present a method of defining clinical 
outcomes and approaching genetic analyses in studies of response to opioids. The 
findings from this study have not yet been replicated and as the findings are merely 
hypothesis-generating, we have not adjusted the results for multiple testing.  
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6 Chapter 6: Results from a Genome-Wide Association Study  
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6.1 Introduction and Summary of the rationale behind study 
 
• Inter-individual variation in response to morphine is likely to be influenced by 
multiple genes. 
 
• The choice of genes to include in candidate gene studies is limited by current 
understanding of biological and genetic pathways.  
 
• Analysis of SNPs across the entire genome may identify novel genes which 
are associated with response to morphine. 
 
6.1.1 Aim 
 
The aim of this study was to use DNA micro-array technology to carry out a Genome-
Wide Association Study (GWAS) to explore inter-individual variation in response to 
morphine. The following data represent the first genome wide association study in 
cancer patients taking morphine.  
This study is a preliminary hypothesis-generating study. 
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6.2 Subjects and Methods 
 
This study was carried out on a subset of patients from the Prospective Morphine 
Study.  
 
6.2.1 Clinical Phenotype / outcome 
 
This study was carried out before PCA was used to build a mathematical model of 
response to morphine. Therefore the clinical phenotypes used in this study are 
different to those presented in chapters 3-5.  
 
In this study the variables “average pain” and “pain relief from morphine” in the past 
24 hours were used to define the clinical outcomes. These parameters were chosen to 
best reflect what is clinically thought to be an acceptable analgesic response (see 
section 3.4.3). These parameters were subsequently included in a different study as 
the most clinically relevant pain intensity variables, based on the opinion of 16 
experts. 331 
 
As discussed in chapter 3 (section 3.2.1), an average pain of ≤ 4/11 is considered to be 
adequate or acceptable pain control. Using average pain score ≤4 as the dependent 
variable, two clusters of scores for pain relief in the preceding 24hours were 
identified: pain relief <70% and pain relief ≥70%.Therefore 2 binary clinical 
phenotypes were used in the association analysis:  
• Average pain ≤ 4  
• Pain relief ≥ 70% 
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6.2.2 Experimental design 
 
Figure 6.1 shows the experimental design for the genetic association study.  
 
This study was carried out in a series of sequential stages. 
 
Stage 1: Genome-wide-association study: A subset of samples from the Prospective 
Genetics Study was sent to Yale for genotying using Affymetrix Genome-Wide 
Human SNP Array 5.0. technology. In subsequent discussion, this dataset is known as 
the “Affy dataset”. These genetic data were analysed for associations with clinical 
outcomes i.e. average pain ≤ 4 or pain relief ≥ 70%.  
 
Stage 2: Replication study using SSP-PCR: Significant SNPs / genes from the 
“Affy dataset” were identified and these were run using SSP-PCR on a second, 
independent data set comprised of the remaining samples in the Prospective Genetics 
Study (“SSP-PCR dataset”). This second set were also analysed for associations with 
the relevant clinical phenotypes.  
 
Stage 3: The “Affy” and “SSP-PCR” datasets were compared in terms of  
• Accuracy of the data generated with both methods 
• Significance of the associations with clinical outcomes  
• Structure of the both datasets (genetic and clinical) 
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Figure 6.1 Experimental design for genetic association study 
*132 samples in total run on Affymetrix5.0 chip but only Caucasians (N=115) 
included in analysis (see results section).  
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6.2.2.1 Stage 1: Genotyping using Affymetrix 5 gene chip and analysis of the 
resulting “Affy dataset” 
 
132 DNA samples from the Prospective Genetics Study were genotyped using the 
Affymetrix Genome-Wide Human SNP-Array 5.0. The DNA was sent on ice to Yale 
University for this to be carried out under the supervision of Professor Josephine Hoh, 
Professor of Epidemiology and Public Health, and Professor A. DeWan, Assistant 
Professor of Epidemiology, Yale School of Medicine, Yale University, US. 
 
DNA samples were chosen for analysis using Affymetrix on the basis of 
 
• DNA quality checks:  
o Amplified samples were excluded (although genomic DNA amplified 
with the QIAGEN Repli-G Kit has been tested successfully with the 
Genome-Wide Human SNP 5.0 Assay). 
o 100ng of genomic DNA was run on a 1% agarose gel.  Samples 
lacking a significant band of >10kb were excluded as this suggested 
that the sample was of insufficient quality for Affymetrix SNP 
genotyping. (Personal correspondence with Professor A. DeWan). 
Ligation and successful PCR will not occur in degraded DNA lacking 
intact restriction sites 304. 
o DNA quality was also checked using DNA-OK! (Microzone Ltd, UK) 
as detailed in Chapter 2.  
 
• DNA quantity: 
o At least 3ug/sample of DNA was required at a minimum concentration 
of 50ng/ul. The DNA was quantified using picogreen (Invitrogen) and 
the concentration adjusted with Baxter H20.  
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Before analysis, the GWAS data also underwent quality checks. SNPS were excluded 
from further analysis if: 
• The Minor Allele Frequency < 0.05 
• They were not in Hardy-Weinberg equilibrium  
• There were a lot of missing genetic data i.e. the call rate < 95%. 
 
440,794 SNPs were included in the Affymetrix Genome-Wide Human SNP-Array 
5.0, of which 348,477 were included in the genetic association analysis.  
 
Three data files were used to analyse the Affymetrix data: 
 
1. The Affymetrix genetic data (.txt)  
This is the data file provided by Yale University. The Affymetrix output data 
was provided as a .txt file in which the genetic data was presented in a non-
delimited form i.e. AA,AB,BB. Missing values were represented by NC (No 
Call). This data set is a tall data set i.e. the individual patient IDs are in 
columns and the SNP data are in rows. 
In order for this file to be used in R and STATA, the genetic data was split up 
into chromosomes and the format was changed from AA, AB, BB to 0, 1 and 
2 respectively, where the numbers represent allele counts for the total number 
of B alleles. NC cells were changed to blank cells. The data were then split up 
into chromosomes using R to allow easier data manipulation.  
 
2. The “Annotation data set” (Affy5 SNP list) which was downloaded from the 
Affymetrix website 429. This file contains details about the each of the SNPs 
including chromosome, base pair position and rs number and facilitates 
alignment with the individual study subject data using the unique Affymetrix 
id.   
 
3. The clinical dataset. This had a column which corresponded to the Affy ID 
and also had the corresponding clinical trial patient study number. 
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The association analysis was carried out using logistic regression. The additive / co-
dominant model (using genotype frequency) was used for the genetic data and the 
analyses were carried out using R and STATA (www.r-project.org and 
www.stata.com). Gender was postulated as a possible influence on pain perception 
and analgesic response and was thus included as a predictor variable in the initial 
analysis. This initial analysis was run by Dr Saffron Willis-Owen, Research 
Associate, Molecular Genetics, National Heart and Lung Institute, Imperial College, 
London.  
 
 
6.2.2.2 Stage 2: Chosing Affy SNPs to genotype on the second population using 
SSP-PCR 
 
In order to choose SNPs from the Affy dataset to run on the SSP-PCR dataset, the 
results were examined in terms of:  
 
• SNPs with the highest p values in the genome-wide association study.  
 
In many multi-stage genetic association studies, SNPs are chosen from the 
first stage for replication in the second stage on the basis of the strength of 
statistical association. A p-value threshold of <5.67x10-8 was calculated for 
this study using the conservative Bonferroni multiple test correction (440,794 
SNPs x 2 tests). In the “Affy dataset”, the most significant p value was 1 x   
10-5.  Taking into account the exploratory nature of this study and the fact that 
the study size was relatively small, in order to minimise the chance of false 
negatives, a threshold for significance was not used to define the SNPs to be 
included in subsequent analysis. Instead SNPs with p<0.001 (i.e. –log10P 
values >3) on genotype-phenotype analysis of the “Affy” dataset were 
considered for SSP-PCR genotyping.  
 
• Genes in which there was >1 SNP associated with the clinical outcome. 
 
• SNPs which were located in genes with a biologically plausible association 
with pain and opioid response. 
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For each gene in which there was a SNP which was chosen for inclusion in the SSP-
PCR dataset, the genetic data for all of the SNPs included on the Affy array with 
p<0.01 (–log10p >2) were examined for linkage disequilibrium using Haploview 
(Whitehead Institute for Biomedical Research, USA). This was used to identify and 
choose other SNPs in haploblocks surrounding the SNPs of interest. SNPs were 
chosen for inclusion in the SSP-PCR dataset on the basis of p value, whether they 
were in LD (R2>0.8) with other SNPs, and whether they were included in a 
haploblock. The methodology used to design SSP-PCR assays is described in Chapter 
2. 
 
Analysis of the second SSP-PCR dataset (Stage 2) 
 
Logistic regression and Chi-squared tests were used to assess odds ratios, confidence 
intervals and significance of association with the clinical outcome. As for stage 1, an 
additive inheritance model was assumed. Genotype data were examined for evidence 
of a gene-dose effect.  
 
Adjustment for multiple testing was carried out using the Bonferroni formula. 9 SNPs 
in total were tested on a maximum of 2 clinical phenotypes therefore p < 0.0027 was 
considered significant in the SSP-PCR dataset (stage 2). The p values presented in the 
tables and results sections represent unadjusted p values.  
 
6.2.2.3 Stage 3: Comparison of the “Affy” and SSP-PCR methods and datasets     
 
• Correlations between the data generated with the Affymetrix 5.0 array and the 
SSP-PCR data were carried out in order to check validity and accuracy of both 
techniques. 
o All of the new SSP-PCR SNP assays were run on 16 DNA samples 
which were initially genotyped using the Affymetrix 5.0 array. 
o The SSP-PCR PRKD3 rs1158219 assay was run on all samples i.e. 
both the “Affy” set and “SSP-PCR” set (Total N for comparison =115).  
 
• As there were some differences in the genetic associations with the clinical 
phenotype between the “Affy” and “SSP-PCR” datasets, the datasets were 
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compared in terms of genotype frequencies, pairwise LD and clinical factors 
in order to examine why these differences might have occurred. Logistic 
regression was used to assess the contribution of clinical factors to the clinical 
outcome.  
 
 
Figure 6.2 Comparing methods and results from different datasets 
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6.3  Results 
 
Refining analysis dataset according to ethnicity 
 
132 samples were analysed using Affymetrrix5.0 array, of which 115 were Caucasian. 
Principal components analysis demonstrated clear separation between Caucasians and 
non-Caucasians. In order to minimise population stratification bias 430, only 
Caucasians were included in further analysis. (Figure 3) 
 
 
 
Figure 6.3 PCA demonstrating separation of genotypes according to ethnicity in 
two chromosomes 
 
6.3.1 Stage 1: Genome-wide-association study results (N=115)  
 
Many of the SNPs which were found to have an association with either of the clinical 
phenotypes were intragenic. 3 genes, ZDHHC14, PRKD3 and NTRK3, were 
associated with the clinical outcomes on analysis of the “Affy” data. These genes 
were therefore chosen to take forward to the second step in the study i.e. genotyping 
using SSP-PCR. 
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6.3.1.1 Average pain ≤ 4 
 
The strongest association with average pain (highest p value / highest –log10p value) 
for the phenotype “average pain ≤ 4” was with a SNP, PRKD3 rs1158219 on 
chromosome 2, p = 9.7x10-5 (figure 6.4). PRKD3 codes for protein kinase D3, which 
is activated by G-protein coupled receptors and is involved in signal transduction and 
membrane trafficking. Therefore PRKD3 is a gene which has a biologically plausible 
role in pain and opioid response. The next strongest associations were with SNPs in 
PWP2H (periodic tryptophan protein homolog) and TMEM1 (Transmembrane protein 
1), neither of which are not known to be associated with pain or response to opioids 
and also with SNPs on Chromosomes 4, 5, 7, 8, 18 and 21 which were intragenic. A 
SNP in NTRK3 (neurotrophic tyrosine kinase, receptor, type 3) rs8026216 on 
chromosome 15 has also one of the strongest associations with average pain in this 
dataset (p=0.0003). NTRK3 is a nerve growth factor receptor. These receptors are 
important in regulating the development of the central and peripheral nervous 
systems.  
 
 
Figure 6.4 Results for genome-wide association testing with the clinical outcome, 
average pain ≤4  
Manhattan plot for 348,477 SNPs from the step 1 genome-wide association analysis.  
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6.3.1.2 Pain Relief ≥ 70% 
 
The strongest association with pain relief ≥70% was with a SNP, ZDHHC14 
rs17165436 on chromosome 6, p = 0.000013 (figure 6.5). The function of this gene, 
Zinc finger, DHHC-type containing 14, is as yet unknown. The next strongest 
associations were with SNPs in ST6GALNAC3 (alpha-N-acetyl-neuraminyl-2,3-beta-
galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 3), FBN2 
(Fibrillin 2) and NRXN1 (Neurexin 1). ST6GALNAC3 is associated with smoking 
cessation, FBN2 with Marfan’s syndrome and NRXN1 with autism. None of these 
genes has been associated with pain sensation or response to opioids. NTRK3 
(neurotrophic tyrosine kinase, receptor, type 3) was also associated with pain relief 
≥70%, p = 0.0003. Although NTRK3 (neurotrophic tyrosine kinase receptor type 3) 
did not have the highest p values, it has a biologically plausible role in pain and opioid 
response and was found to be associated with both clinical phenotypes, therefore was 
included for SSP-PCR genotyping of the second step of the study.  
 
 
Figure 6.5 Results for genome-wide association testing with the clinical outcome, 
pain relief ≥70%. 
Manhattan plot for 348,477 SNPs from the step 1 genome-wide association analysis.  
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6.3.2 Stage 2: Replication study using SSP-PCR  
 
6.3.2.1 Chosing SNPS and designing primers for SSP-PCR set (N=125) 
 
The primer details are found in Appendix 
E```````````````````````````````````````````````````````````. 
  
PRKD3 primers for SSP-PCR 
 
There are 17 PRKD3 SNPs on the AFFY 5.0 array. There were 2 SNPs with p<0.001, 
rs1158219 and rs11124574). There were 2 SNPS with p<0.01, rs10177970 and 
rs6730503 (Table 6.1). Three of these 4 SNPs made up one haploblock. The other 
SNP, rs1158219, lay outside this haploblock (figure 6.6).  
 
Of these 4 SNPs, only 1, rs1158219 was retained for analysis. It was not possible to 
design SSP-PCR primers for rs10177970 as the GC content was too high. 
Rs11124574 and rs6730503 were omitted from analysis because the SSP-PCR assay 
failed.  
 
Table 6.1 PRKD3 SNPS (p<0.01) chosen from the “Affy dataset” as candidates 
for SSP-PCR 
 
“Affy” marker rs number MAF Call rate HW p value P value*                                           
snp_a2257376 rs11124574 37.06897 100 0.319915 0.0008 
snp_a4193911 rs10177970 37.93103 100 0.692834 0.003 
snp_a1818533 rs6730503 37.5 100 0.552423 0.004 
snp_a2037703 rs1158219 36.84211 98.27586 0.841542 9.75x10-5 
* association with average pain ≤ 4 on analysis of the “Affy” data set 
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Figure 6.6 LD plots for PRKD3 in the “Affy” dataset 
SNPs with p<0.001 with clinical phenotypes are highlighted 
 
(Haploview version 4.0, Broad Institute, Cambridge, USA). See List of Abbreviations 
for explanation of colour scheme. 
 
ZDHHC14 primers for SSP-PCR 
 
There are 63 ZDHHC14 SNPs on the AFFY 5.0 array. There were 2 SNPs with 
p<0.001, rs4463281 and rs17165436. There were 8 SNPS with p<0.01 (Table 5). 
Both rs4463281 and rs17165436 were in the same haploblock (Figure 6.7). Therefore 
one other SNP in this block was chosen for SSP-PCR analysis, rs17165429 (Table 
6.2) 
Of these 3 SNPs, rs4463281 and rs17165436 were retained for analysis. Rs17165429 
was omitted from analysis because the SSP-PCR assay failed. 
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Figure 6.7 LD plots for ZDHHC14 in the “Affy” dataset 
SNPs with p<0.001 with clinical phenotypes are highlighted 
(Haploview version 4.0, Broad Institute, Cambridge, USA). SNPS with –log10P>3 
highlighted 
 
Table 6.2 ZDHHC14 SNPS (p<0.01) chosen from the “Affy dataset” as 
candidates for SSP-PCR 
 
marker rs_number MAF Call rate HW p value P * 
snp_a1838804 rs9457715 47.41379 100 0.71307 0.003 
snp_a1881342 rs17165436 45.17544 98.27586 0.707516 1.32x10-5 
snp_a1921155 rs735756 35.34483 100 0.545133 0.004 
snp_a1927701 rs4463281 48.27586 100 0.35188 9.25x10-5 
snp_a2049841 rs17165429 28.01724 100 0.488516 0.002 
snp_a2255670 rs17297221 14.22414 100 1 0.003 
snp_a4202034 rs885536 26.57658 95.68965 0.470077 0.002 
snp_a4246797 rs2135210 44.78261 99.13793 0.344902 0.002 
* association with pain relief ≥70% on analysis of the “Affy” data set 
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NTRK3 primers for SSP-PCR 
 
There are 166 NTRK3 SNPs on the AFFY 5.0 array. There were 2 SNPs with 
p<0.001, rs8026216 and rs1075891, for both clinical phenotypes (average pain ≤ 4 
and pain relief ≥70%). There were 2 further SNPs (rs1559822 and rs17755717) 
associated with pain relief ≥70%, p<0.001. . There were 13 SNPS in total with p<0.01 
from the “Affy” set for either pain relief or average pain.  
 
Rs8026216 and rs1075891 made up one haploblock and rs1559822 was part of a 
second haploblock. These 3 SNPs were included in stage 2 of the study using SSP-
PCR. Rs4887383 and rs1863482 were also chosen as they were part of the latter 
haploblock. Rs17755717 was also included as it was not in either of these haploblocks 
(Fig 6.8). 
 
All NTRK3 SNPs which were chosen to run using SSP-PCR were analysed using 
both clinical phenotypes. 
 
Table 6.3 NTRK3 SNPS (p<0.01) chosen from the “Affy dataset” as candidates 
for SSP-PCR 
 
marker 
rs_numbe
r 
MAF 
Call 
rate 
HW p 
value 
P 
value* 
P 
value** 
snp_a217389
2 rs1559822 
9.29203
5 97.4138 0.594337 
0.02 0.0009 
snp_a230321
0 
rs1775571
7 
19.8275
9 100 0.042478 
0.05 0.0004 
snp_a230339
1 rs8026216 
11.6379
3 100 0.648292 
0.0003 0.0005 
snp_a230339
4 rs1075891 
11.7391
3 
99.1379
3 1 
0.0006 0.0003 
snp_a420491
4 rs4887382 
10.4347
8 
99.1379
3 0.607016 
0.003 0.002 
snp_a430356 rs1863482 9.91379 100 0.598687 0.02 0.003 
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6 4 
*association with average pain ≤ 4 on analysis of the “Affy” data set 
**association with pain relief ≥70% on analysis of the “Affy” data set 
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Figure 6.8 L D plots for NTRK3 in the “Affy” dataset 
SNPs with p<0.001 with clinical phenotypes are highlighted.  
(Haploview version 4.0, Broad Institute, Cambridge, USA). SNPS with –log10P>3 highlighted.
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6.3.2.2 Stage 2: Analysis of “SSP-PCR” dataset 
 
All SSP-PCR SNPs were in Hardy-Weinberg equilibrium. The call rates using SSP-
PCR were 100% except for PRKD3 rs1158219 which was 99.2%.  
 
As can be seen from tables 6.4 – 6.7 below, none of the associations between SNPs 
and clinical outcomes in the “Affy dataset” were replicated in the “SSP-PCR” 
datasets. 
 
Three SNPs in NTRK3 remained significantly associated with average pain in the 
SSP-PCR datasets; rs1559822, rs4887382 and rs1863482. However, the direction of 
the genetic association with the clinical phenotype is the opposite i.e. the odds ratio 
changes direction / crosses 1 between the “Affy” and the “SSP-PCR” datasets. This 
change in odds ratio is mirrored by differences in genotype frequencies between the 
“Affy” and “SSP-PCR” datasets (Figure 6.9 and table 6.6).  
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Figure 6.9 NTRK3 Flip-Flop 
 
Figure A demonstrates the apparent “flip-flop” phenomenon in NTRK3. The 
association between rs4887382 with average pain is the opposite of that between 
snpa_4204914, even though these are the same genetic variant. In the “Affy” dataset 
(snpa_4204914), a higher proportion of patients with average pain ≤ 4 have the AA 
genotype than patients with average pain> 4.  In the “SSP-PCR” population 
(rs4887382), a lower proportion of patients with average pain ≤ 4 have the AA 
genotype than patients with average pain > 4.  
 
Figure B demonstrates the difference in Odds Ratio between the two datasets for the 
same SNP. 
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Table 6.4 ZDHHC14 and Pain relief 
Data presented as % (N) 
  “Affy” dataset (N=115) SSP-PCR dataset (N=125) 
rs number 
/genotype 
Pain relief ≥ 70% 
(N=75) 
Pain relief < 70% 
(N=39) 
P OR Pain relief ≥ 70% 
(N=88) 
Pain relief < 70% 
(N=34) 
P OR 
  
        
rs17165436 CC 0.16 (12) 0.59 (23)   0.19 (17) 0.29 (10) - - 
 CT 0.57 (43) 0.36 (14) 1.47 x 10-5 4.9 (2.41-10.4) 0.58 (51) 0.47 (16) - - 
 TT 0.27 (20) 0.05 (2)   0.23 (20) 0.24 (8) - - 
          
rs4463281 GG 0.09 (7) 0.44 (17)   0.11 (10) 0.15 (5) - - 
 GT 0.59 (44) 0.46 (18) 9.4 x 10-5 4.108 (2.02-8.35) 0.57 (50) 0.5 (17) - - 
 TT 0.32 (24) 0.1 (4)   0.32 (28) 0.35 (12) - - 
- represents non-significant association 
Unadjusted p values presented.  
 
Table 6.5 PRKD3 and average pain ≤ 4 
Data presented as % (N) 
  “Affy” dataset (N=115) SSP-PCR dataset (N=125) 
rs number 
/ genotype 
Average pain ≤ 4 
(N=74) 
Average pain > 4 
(N=41) 
P OR Average pain  ≤ 4            
(N=93) 
Average pain > 4 
(N=30) 
P OR 
 
         
rs1158219 AA 0.04 (3) 0.32 (13)   0.11 (10) 0.23 (7) - - 
 AT 0.45(33) 0.46 (19) 7.7 X 10-5 3.7 (1.94-7.1) 0.46 (43) 0.43 (13) - - 
 TT 0.51(38) 0.22 (9)   0.43 (40) 0.33 (10) - - 
- represents non-significant association 
Unadjusted p values presented.  
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Table 6.6 NTRK3 and Average Pain 
 
Data presented as % (N) 
rs number 
/ genotype 
“Affy” dataset (N=115) SSP-PCR dataset (N=125) 
Average pain ≤ 4 
(N=74) 
Average pain > 4 
(N=41) P OR 
Average pain ≤ 4 
(N=93) 
Average pain > 4 
(N=31) P OR 
rs17755717 GG 0.55 (41) 0.73 (30) - - 0.67 (62) 0.61 (19) - - 
 GA 0.45 (33) 0.27 (11) - - 0.31 (29) 0.36 (11) - - 
 AA 0(0) 0(0) - - 0.02 (2) 0.03 (1) - - 
rs1559822 AA 0 (0) 0.07 (3)   0.01 (1) 0 (0)   
 AG 0.12 (9) 0.29 (12) 0.002 4.0 (1.7-9.6) 0.24 (22) 0.07 (2) 0.043 0.22 (0.05-0.96) 
 GG 0.88 (65) 0.63 (26)   0.75 (70) 0.93 (29)   
rs8026216 TT 0 (0) 0.05 (2)   0.02 (2) 0 (0)   
 TG 0.11 (8) 0.37 (15) 0.0003 5.6 (2.2-14.1) 0.22 (20) 0.1 (3) - - 
 GG 0.89 (66) 0.58 )24)   0.76 (71) 0.9 (28)   
rs1075891 AA 0.01 (1) 0.02 (1)   0.02 (2) 0 (0)   
 AG 0.12 (9) 0.39 (16) 0.003 3.6 (1.6-8.5) 0.22 (20) 0.1 (3) - - 
 GG 0.87 (64) 0.59 (24)   0.76 (71) 0.9 (28)   
rs4887382 GG 0 (0) 0 (0)   0 (0) 0 (0)   
 GA 0.12 (9) 0.37 (15) 0.003 4.2 (1.6-10.7) 0.25 (23) 0.07 (2) 0.043 0.21 (0.05-0.95) 
 AA 0.88 (65) 0.63 (26)   0.75 (70) 0.94 (29)   
rs1863482 TT 0 (0) 0 (0)   0 (0) 0 (0)   
 TC 0.14 (10) 0.32 (13) 0.023 2.97 (1.2-7.6) 0.75 (70) 0.94 (29) 0.043 0.21 (0.05-0.95) 
 CC 0.86 (64) 0.68 (28)   0.25 (23) 0.07 (2)   
- represents non-significant association 
Unadjusted p values presented.  
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Table 6.7 NTRK3 and Pain Relief 
 
Data presented as % (N) 
rs number 
/ genotype 
“Affy” dataset (N=115) SSP-PCR dataset (N=125) 
Pain relief  ≥ 70% 
(N=74) 
Pain relief  < 70% 
(N=41) P OR 
Pain relief   ≥ 70%  
(N=88) 
Pain relief  < 70% 
(N=34) P OR 
rs17755717 GG 0.49 (37) 0.85 (33)   0.63 (55) 0.74 (25) - - 
 GA 0.51 (38) 0.15 (6) 0.001 0.177 (0.066-0.472) 0.35 (31) 0.23 (8) - - 
 AA 0 (0) 0 (0)   0.02 (2) 0.03 (1) - - 
rs1559822 AA 0.03 (2) 0.03 (1)   0.01 (1) 0 (0) - - 
 AG 0.09 (7) 0.36 (14) 0.009 2.992 (1.312-6.821) 0.22 (19) 0.12 (4) - - 
 GG 0.88 (66) 0.62 (24)   0.77 (68) 0.88 (30) - - 
rs8026216 TT 0 (0) 0.05 (2)   0.02 (2) 0 (0) - - 
 TG 0.12 (9) 0.36 (14) 0.001 4.896 (1.977-12.122) 0.21 (18) 0.12 (4) - - 
 GG 0.88 (66) 0.59 (23)   0.77 (68) 0.88 (30) - - 
rs1075891 AA 0.01 (1) 0.03 (1)   0.02 (2) 0 (0) - - 
 AG 0.12 (9) 0.41 (16) 0.002 3.982 (1.689-9.386) 0.21 (18) 0.12 (4) - - 
 GG 0.87 (65) 0.56 (22)   0.77 (68) 0.88 (30) - - 
rs4887382 GG 0 (0) 0 (0)   0 (0) 0 (0) - - 
 GA 0.12 (9) 0.39 (15) 0.002 4.583 (1.774-11.843) 0.23 (20) 0.12 (4) - - 
 AA 0.88 (66) 0.62 (24)   0.77 (68) 0.88 (30) - - 
rs1863482 TT 0 (0) 0 (0)   0 (0) 0 (0) - - 
 TC 0.12 (9) 0.36 (14) 0.004 4.107 (1.579-10.678) 0.23 (20) 0.12 (4) - - 
 CC 0.88 (66) 0.64 (25)   0.77 (68) 0.88 (30) - - 
- represents non-significant association 
Unadjusted p values presented.  
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6.3.3 Stage 3: Comparing “Affy” and “SSP-PCR” datasets 
 
6.3.3.1 Assessing validity of genotyping methods 
 
Validating “Affy” results against SSP-PCR data for 16 samples 
 
All of the new SSP-PCR SNP assays were run on 16 DNA samples which were 
initially genotyped using the Affymetrix 5.0 array. The genotype data generated with 
the Affymetrix 5.0 array was compared to SSP-PCR data using Kendall’s correction. 
 
There was one data point out of 144 (0.7%) which differed between the “SSP-PCR” 
data and the “Affy” data (See table 6.8). In this instance the genotype for PRKD3 
rs1158219 was heterozygous using SSP-PCR but “Affy” designated it homozygous. 
This resulted in a correlation coefficient of 0.897.  
 
Table 6.8 Comparing “Affy” results against SSP-PCR data for 16 samples 
 
Gene SNP name “Affy” name Correlation 
coefficient 
(Kendall) 
ZDHHC14 rs17165436 SNP_A.1881342 1.0 
 
rs4463281 SNP_A.1927701 1.0 
PRKD3 rs1158219 SNP_A.2037703 0.897 
NTRK3 rs17755717 SNP_A.2303210 1.0 
 
rs1559822 SNP_A.2173892 1.0 
 
rs8026216 SNP_A.2303391 1.0 
 
rs1075891 SNP_A.2303394 1.0 
 
rs4887382 SNP_A.4204914 1.0 
 
rs1863482 SNP_A.4303566 1.0 
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Validating “Affy” results against SSP-PCR data for PRKD3 rs1158219 
 
PRKD3 rs1158219 was run on all Caucasian subjects in the Prospective Morphine 
study to check validity of the “Affy” data against the SSP-PCR data. There was one 
case in which SSP-PCR data was not available. Out of 114 samples, there were 4 
samples in which the “Affy” data did not matchup with the SSP-PCR data (correlation 
coefficient 0.959). In this instance, the genotype is clearly heterozygous on SSP-PCR 
(rerun twice) but on “Affy”, 2 patients are designated homozygous for the major allele 
and 2 homozygous for the minor allele. 
 
 
Figure 6.10 Comparing Affymetrix and SSP-PCR genotype results 
PRKD3 rs1158219 genotypes generated by Affymetrix 5.0 compared to SSP-PCR in 
114 study subjects. 
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6.3.3.2 Comparing “Affy” and “SSP-PCR” datasets 
 
Because there were differences in the genetic associations with the clinical 
phenotypes between the “Affy” and SSP-PCR datasets in terms of significance of the 
findings and direction of association, the underlying structure of these datasets were 
compared in terms of genetic data (frequencies and LD) and clinical factors.  
 
Comparing genotype frequencies 
 
The overall genotype frequencies of the “Affy” and “SSP-PCR” datasets were 
compared (Table 6.9). The overall direction of allele frequencies were similar i.e. the 
minor allele was the same in all datasets and corresponds to the minor allele in 
previously published data in the HapMap CEU population.   
 
Although there were no statistically significant differences between these overall 
genotype frequencies (tested using Chi2 test), there were some apparent trend 
differences, especially in ZDHHC14 rs4463281. For this SNP, there was a higher 
proportion of patients homozygous for T and a lower proportion of patients 
homozygous for G in the SSP-PCR dataset than in the “Affy” dataset.  
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Table 6.9 Comparing genotype frequency data 
 
Rs number Genotype Published 
genotype 
frequency 
(HapMap CEU) 
“Affy” 
dataset 
(N=115) 
SSSP-PCR 
dataset 
(N=125) 
ZDHHC14 
rs17165436 CC 0.383 0.3 (35) 0.23  (29) 
 CT 0.433 0.5 (58) 0.54 (68) 
 TT 0.183 0.19 (22) 0.22 (28) 
rs4463281** GG 0.217 0.21 (24) 0.13 (16) 
 TG 0.483 0.55 (63) 0.54  (68) 
 TT 0.3 0.24 (28) 0.33 (41) 
PRKD3 
rs1158219 TT 0.417 0.41 (47) 0.4 (50) 
 TA 0.383 0.45 (52) 0.45 (56) 
 AA 0.2 0.14 (16) 0.15 (18) 
NTRK3 
rs17755717 AA 0.017 0 (0) 0.02 (3) 
 AG 0.283 0.38 (44) 0.33 (41) 
 GG 0.7 0.62 (71) 0.65 (81) 
rs1559822 AA 0.033 0.03 (3) 0.01 (1) 
 AG 0.183 0.18 (21) 0.2 (25) 
 GG 0.783 0.79 (91) 0.79 (99) 
rs8026216 GG 0.767 0.78 (90) 0.79 (99) 
 TG 0.2 0.2 (23) 0.19 (24) 
 TT 0.033 0.02 (2) 0.02 (2) 
rs1075891 AA 0.017 0.02 (2) 0.02 (2) 
 GA 0.203 0.22 (25) 0.19 (24) 
 GG 0.78 0.76 (88) 0.79 (99) 
rs4887382 AA 0.783 0.79 (91) 0.79 (99) 
 GA 0.183 0.21 924) 0.21 (26) 
 GG 0.033 0 (0) 0 (0) 
rs1863482 CC 0.783 0.8 (92) 0.79 (99) 
 TC 0.183 0.2 (23) 0.21 (26) 
 TT 0.033 0 (0) 0(0) 
**rs4463281 ““Affy”” vs “Second set” p=0.15 
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Comparing Linkage disequilibrium  
 
Pairwise linkage disequilibrium (LD) was calculated between SNPs in each gene 
using Haploview. (Whitehead Institute for Biomedical Research, USA).  
The main differences in LD are seen between: 
• ZDHHC14 rs4463281 and rs17165436. The % LD is less in the “SSP-PCR” 
dataset than in the “Affy” dataset. (R2 51% vs 71% and D’ 88% vs 97% 
respectively) 
• NTRK3 rs17755717 and rs8026216. The D1 between these markers in the 
“Affy” dataset is 100% but in the “SSP-PCR” dataset is 2.4%.  
• NTRK3 rs1863482 and rs17755717. The D’ between these markers in the 
“Affy” dataset is 100% but in the “SSP-PCR” dataset is 60%. 
There are also other differences between NTRK3 SNPs in terms of D’ (Table 
6.10). The haploblock structure however, as defined by CI for D’ 315, is similar in 
both the “Affy” and “SSP-PCR” datasets, as shown in figure 6.11. 
 
Table 6.10 Pairwise LD between SNPs in NTRK3 
 
  "Affy" dataset “SSP-PCR” dataset 
SNP 1 SNP 2 D' R2 D' R2 
rs17755717 rs4887382 1 0.028 0.603 0.01 
rs17755717 rs1863482 1 0.026 0.603 0.01 
rs17755717 rs1559822 0.546 0.009 0.718 0.014 
rs17755717 rs8026216 1 0.031 0.024 0 
rs17755717 rs1075891 0.383 0.005 0.024 0 
rs4887382 rs1863482 0.951 0.862 1 1 
rs4887382 rs1559822 1 0.876 1 0.959 
rs4887382 rs8026216 0.903 0.715 0.912 0.765 
rs4887382 rs1075891 0.901 0.656 0.912 0.765 
rs1863482 rs1559822 0.95 0.753 1 0.959 
rs1863482 rs8026216 0.847 0.599 0.912 0.765 
rs1863482 rs1075891 0.844 0.548 0.912 0.765 
rs1559822 rs8026216 0.786 0.617 0.873 0.731 
rs1559822 rs1075891 0.782 0.563 0.873 0.731 
rs8026216 rs1075891 0.957 0.844 1 1 
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Figure 6.11 Comparing pairwise LD and haploblock structure in NTRK3 
D’ values are shown. 
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Comparing clinical factors 
 
The “Affy” and SSP-PCR clinical datasets were compared (table 6.11). The study 
subjects in the “Affy” set had been on morphine for a shorter time than those in the 
SSP-PCR datasets, p=0.01. There was a higher proportion of morphine non-
responders in the “Affy” dataset, p=0.003 and the “Affy” dataset had higher central 
side-effect scores, drowsiness and confusion/hallucinations, p=0.002 and 0.0001 
respectively. There was a slight difference in albumin levels and the proportion taking 
a non-steroidal anti-inflammatory (NSAID) but the latter was not statistically 
significant. There was no difference in overall pain scores (analysed as both 
continuous and binary categorical data) between the “Affy” and “SSP-PCR” datasets.  
 
Logistic regression was carried out on both “Affy” and “SSP-PCR” datasets to take 
into account any variability in the clinical phenotype which might have been 
accounted for by time on morphine, serum albumin or gender (the latter as this was 
included in the original analysis of the “Affy” dataset”). This however did not make 
any appreciable difference to the genetic association results (data not shown). 
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Table 6.11 Comparing Affymetrix and SSP-PCR data sets in terms of clinical factors 
 Median (Range) 
 Affymetrix dataset 
(N=115) 
SSP-PCR second set (N=125) 
Age 60 (29-89) 59 (23-85) 
Daily morphine dose (mg) 100 (10-1280) 100 (15-820) 
Days to death 108 (5-1926) 182.5 (7-2147) 
Days on morphine 65 (1-2178)* 105 (2-4455)* 
Total White Cell Count 8.9 (0.3-68.1) 8.75 (2.8-30.6) 
Serum albumin level 29 (14-48)** 31.5 (11-43)** 
Serum urea level 4.5 (0.5-19.7) 5.05 (0.8-20.7) 
Serum calcium level 2.23 (1.81-2.94) 2.24 (1.52-2.83) 
Side-effect scores (0-3)   
   Drowsiness 2 (0-3)+ 1 (0-3)+ 
   Confusion/hallucination 1 (0-3)++ 0 (0-3)++ 
   Bad dreams 0 (0-3) 0 (0-3) 
Pain scores (NRS 0-10)   
   Worst pain score 5 (0-10) 5 (0-10) 
   Least pain score 1 (0-8) 0 (0-8) 
   Average pain score  3 (0-9) 3 (0-8) 
   Pain now score 2 (0-10) 1.5 (0-9) 
   Pain relief 80 (0-100) 80 (0-100) 
 % (N) 
Pain scores (categorical)   
   Average pain ≤ 4/10 0.64 (74) 0.75 (93) 
   Pain relief ≥ 70% 0.66 (75) 0.72 (88) 
   Average pain ≤ 4/10 and Pain relief ≥ 
70% 
0.54 (62) 0.63 (77) 
Gender   
   Male 0.55 (63) 0.44 (55) 
   Female 0.45 (52) 0.56 (70) 
Morphine response   
   Morphine responder 0.61 (70)¥ 0.78 (98) ¥ 
   Morphine non-responder 0.39 (45) ¥ 0.22 (27) ¥ 
Diagnosis    
 Upper gastrointestinal tract 0.14 (16) ¥¥ 0.06 (8) ¥¥ 
 Lower  gastrointestinal tract  0.1 (11) 0.06 (8) 
 Pancreas and biliary 0.02 (3) 0.04 (4) 
 Gynaecological 0.05 (6) ¥¥ 0.12 (15) ¥¥ 
 Urogenital (renal and bladder) 0.09 (10) 0.1 (12) 
 Haematological 0.08 (9) 0.03 (4) 
 Breast 0.17 (19) 0.18 (23) 
 Lung (including mesothelioma) 0.11 (13) 0.17 (21) 
Other medications   
   B Blocker 0.06 (8) 0.08 (9) 
   Brochodiator 0.08 (9) 0.1 (12) 
   NSAID 0.3 (34) ¥¥ 0.42 (52) ¥¥ 
   Paracetamol 0.38 (44) 0.41 (51) 
   Steroid 0.37 (43) 0.34 (42) 
Other drugs and diagnoses included in analyses but not significant: Aspirin Anticonvulsant 
Anticoagulant ACE Inhibitor, Antibiotic, Haloperidol, antiemetics, Benzodiazepines, Proton Pump 
Inhibitor, Tricyclic, SSRI and SNRI antidepressants, H2 Antagonist , Tumours  of Skin, Unknown 
primary, Prostate, Head and Neck, Sarcoma. 
* Days on morphine p=0.01  
** Serum albumin level p=0.049 
+drowsy score p=0.002, ++ confusion/hallucinations score p=0.0001 
¥morphine responder / non-responder p=0.003, X2 8.77 
¥¥Trend towards significance 0.5< p<0.1 
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6.4 Discussion 
 
6.4.1 Main Findings 
 
• NTRK3 and PRKD3 were found to be associated with variability in average 
pain while NTRK3 and ZDHHC14 were associated with pain relief in the 
genome-wide association study. These findings were not replicated in the 
second patient sample using SSP-PCR. 
 
• No single “pain” or “morphine response” gene was identified in this study. 
 
• Genotype data generated by Affymetrix is comparable to that generated by 
SSP-PCR, thus validating both techniques. 
 
 
6.4.2 Identification of novel candidate genes 
 
To date studies examining association between genetic variation and response to 
morphine have focused on specific candidate genes which are known to play a 
biologically relevant role in morphine pharmacodynamics and kinetics including 
OPRM, the gene coding for the mu-opioid receptor and COMT (Catechol-O-
methyltransferase gene) which codes for an enzyme involved in catecholamine 
metabolism. This is the first genome-wide association study (GWA) examining 
response to morphine in cancer pain. Neither OPRM nor COMT were identified in this 
study as being significantly associated with analgesic response to morphine. As 
discussed in chapter 3, variability in phenotype classification is a common reason for 
replication failure in genetic association studies 431. It is not surprising therefore that 
commonly studied genes including OPRM and COMT were not found to be 
significant in this study. The phenotypes used in the OPRM and COMT studies have 
tended to be variability in daily morphine dose requirements, which, as demonstrated 
in chapters 3-5,  is a distinct clinical phenotype to pain and side-effect scores.  
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In our study three novel genes were identified from the initial GWA as being possible 
candidates for association with analgesic response: ZDHHC14, PRKD3 and NTRK3.  
 
Both PRKD3 and NTRK3 are biologically plausible genes. PRKD3 (protein kinase 
D3) codes for one of the protein kinase C family which is involved in cell signalling. 
432
. NTRK3 (Neurotrophic tyrosine kinase 3 receptor) is involved in the development 
of proprioceptive sensory neurones 433. NTRK3 mRNA levels change with chronic 
opioid exposure and withdrawal 434. NTRK3 is also thought to play a role in opioid-
plasticity of the locus coeruleus, which in turn is involved in opioid dependence 434. 
The function of ZDHHC14 is as yet unknown. It is expressed throughout the body but 
has a higher expression in some areas including the spinal cord 435. It is thought to 
probably code for palmitoyltransferase 436. Palmitoylation is a process which increases 
the hydrophobicity of proteins and thus impacts on subcellular protein trafficking and 
protein-protein interactions 437. Many proteins are known to undergo palmitoylation, 
including some G-protein coupled receptors 438. ZDHHC14 was identified as being 
possibly involved in the pathogenesis of post-transplant lymphoproliferative disorders 
and B-cell lymphoms 435. ZDHHC14 per se has not to date been associated with 
morphine response. However a recent mouse model of opioid tolerance demonstrated 
that repeated administration of morphine resulted in increased activity of spinal cord 
serine palmitoyltransferase 439. This paper suggests that ceramide is involved in the 
development of morphine antinociceptive tolerance. One of the ways in which 
ceramide is generated involves serine palmitoyltransfease 439. Palmitoylation has 
further been linked to pain through the identification of mutations in SPTLC1, the 
gene coding for serine palmitoyltransferase, in patients with hereditary sensory 
neuropathy 440.  
 
Despite these three genes being associated with variability in the clinical outcome in 
the genome-wide-association analysis, these findings were not replicated in the 
validation SSP-PCR study. Therefore overall our study fails to identify a definitive 
“morphine response gene”.  What this study does do however is highlight a number of 
challenges associated with all genetic association studies, challenges which are worth 
considering and taking into account if further research into the pharmacogenomics of 
morphine is to be carried out.  
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The most likely reasons why this study failed to identify any single gene associated 
with morphine response are 1) inadequate sample size and 2) the complexity of 
morphine response as a clinical trait. 
 
As discussed in chapters 3-5, pain perception and analgesic response to opioids are 
complex phenomena, influenced by not only by genetic factors but also by multiple 
physical, psychological, environmental and social factors. Similar to other complex 
diseases / traits, it is likely that pain perception and analgesic response are oligogenic, 
resulting from multiple gene-gene interactions. In this study we focused on 
identification of single independent associations. Epistasis was neither accounted for 
nor examined. The importance of epistasis is discussed in detail in chapter 8. 
 
6.4.3 Sample size influences power to detect associations 
 
A formal power calculation was not carried out for this genetic association study as 
the genotyping was carried out on samples that had been previously collected. The 
post hoc analysis of the genetic factors associated with clinical outcome variability in 
the GWA presented in this thesis can only be considered hypothesis generating 441. It 
is likely that the sample size used in this study was simply too small to identify true 
associations with the clinical outcome. Such small numbers have been used 
previously and have been considered adequate, but in each case the clinical phenotype 
was well defined rather than the complex trait presented here. For example, in a study 
of statin-induced myopathy, a GWA of 318,237 SNPs was performed on 85 subjects 
and 90 controls using Illumina BeadChip. 2 SNPs were then chosen for replication in 
a cohort of 16,664 patients, of which 21 had myopathy (cases) and 16,643 did not 
(controls). 
 
Some of the factors influencing sample size for a genetic association study include:  
• The frequency of the susceptibility allele and the allelic odds ratio442.  
• The prevalence of the disease / trait in the general population.  
• The number of SNPs to be tested. 
These are discussed in more detail in chapter 8.  
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We used a multi-stage approach in our genetic association study as this has previously 
been proposed as a method to minimise required sample size 443. In the first sample of 
patients in a multi-stage study, all SNPs are tested and a liberal p value is used to 
identify possible susceptibility SNPs. These SNPs are then tested in another 
population of similar or larger size, using a more stringent p value. A multi-stage 
approach is associated with little loss of power because of the low false-negative rate 
at stage 1 444. This multi-stage approach has been used successfully in a number of 
settings but there is no standard method to define significance thresholds. Some 
authors have proposed p< 10-8  or p<10-9 as evidence of strong association in GWAs 
445;446
. It has been acknowledged that a strict Bonferroni correction, as was used in our 
study, may be too conservative, because it does not take into account the LD between 
SNPs. Therefore such a correction may dictate impossibly low p-values 443.  
 
In the study of statin-induced myopathy, p-values < 5 x 10-7 were considered to 
provide strong evidence and p< 5 x 10-5 moderate evidence of association in the first 
stage. The significance of the association in the initial study set was p = 4 x 10-9 but in 
the second set was p=0.004 447. Another study examining genetic variants associated 
with height used a meta-analysis of GWA data on 13,665 individuals to choose 39 
SNPs to genotype in a second population of 16,482 individuals. The data from the 
first and second groups were combined for final analysis. The significance threshold 
for the first group was set at p < 1 x 10-5. However SNPs were also included for 
genotyping in the second set if p < 1 x 10-4 and the SNP was in a region previously 
shown to be associated with either length in mouse studies or extreme changes in 
stature in human studies 448. We adopted this approach in our study.  
 
In general it is thought that the threshold for significance in the first sample should be 
set to ensure that 1) the power to detect genetic variants which account for a small 
proportion of the phenotypic variance is maintained, 2) genetic markers which do not 
meet significance are unlikely to achieve significance in the whole sample and 3) true 
positives are not rejected 443;444. In our study, since 1 x 10-5 was the most significant p 
value in the initial screen of the first stage of the study (“Affy” dataset), we did not set 
a defined p value threshold for the first stage. This is a limitation of this study as it 
increased the risk of false-positive findings. Instead we chose SNPs to genotype in the 
second stage (SSP-PCR dataset) on the basis of: 
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• The lowest P values 
• Occurring in genes in which there was more than one SNP with p < 0.001 
• Occurring in genes in which there was a plausible biological explanation for 
involvement in morphine response  
• Genes which appeared to have significant associations with >1 clinical 
phenotype 
 
In multi-stage studies, there are no defined rules as to the genotyping techniques to be 
used in the second stage. It has been recommended that alternative methods to GWA 
be used because 1) these might be more suitable for genotyping smaller SNP sets and 
2) this ensures that errors from technical genotyping issues are not replicated 443. We 
used SSP-PCR to genotype the patients in the second sample set. The results of both 
methods demonstrated near 100% correlation in our data and allowed us to conclude 
that data generated from these methods was valid and comparable.  
 
6.4.4 The genetic association results fail to replicate in the “Affy” and the “SSP-
PCR” datasets 
 
In our data there were differences in the strength of associations found in the first 
(“Affy”) and the second (“SSP-PCR”) datasets. Apart from the possibility that the 
initial findings were type 1 errors, other possible explanations for these disparities 
include a) differences in allele frequency and LD between the two populations and b) 
sample stratification bias due to some other factor.  
 
We have previously mentioned how the power of a study is determined by the 
frequency and effect of the susceptibility allele 442. One of the underlying premises of 
genetic association studies is that the observed allelic association may often represent 
a marker which is in some degree of LD with the true susceptibility allele.   
 
Therefore power of the study to identify an association may be influenced by effect 
size of the marker allele. The effect size (odds ratio) of the marker allele in turn 
depends on 4 factors 80: 
• The effect size (OR) of susceptibility allele 
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• The extent of LD between the marker and susceptibility allele 
• Marker allele frequency (mAF) 
• Susceptibility allele frequency (sAF) 
 
When mAF = sAF, the marker allele effect size is approximately equal to the 
susceptibility allele effect size multiplied by the LD between the 2 80. Therefore when 
mAF = sAF and when the LD between the 2 is complete, the effect size of the marker 
allele is similar to that of the susceptibility allele. However, if the susceptibility allele 
is either uncommon (frequency <0.1) or very frequent, no matter what the LD 
between the 2 markers, the dominant factor affecting marker effect is marker allele 
frequency. In this case even slight differences between the mAF and sAF can result in 
more marked differences between the effect size of the marker and susceptibility 
allele 80. A change in mAF of <0.1 can result in a drop in power to detect the true 
susceptibility allele from 80 to 20% 431. 
 
In terms of statistical power to detect an association, variation in LD between the 
marker and susceptibility alleles and discrepancies between mAF and sAF can be 
influential. If the effect size of the susceptibility allele is moderate, an association may 
only be detected if the susceptibility allele is common (>0.1) and either a) mAF is 
similar to SAF and / or b) the marker allele is in high LD with the susceptibility allele. 
80
. If the effect of the susceptibility allele is high, these factors are less influential. If 
the effect size of the susceptibility allele is very low, the power to detect an 
association will remain low, despite high LD and similar mAF and SAF.   
 
In our study we know neither the OR of the true susceptibility allele nor the true 
susceptibility allele frequency. By assuming that these remain stable, we can presume 
that if the effect size of the susceptibility allele is moderate or low (as is likely to be 
associated with common variants 80), then a change in the marker allele frequency 
between the first and second datasets could certainly influence the power to detect an 
association with the clinical phenotype (Figure 6.13). This in turn could plausibly 
explain the perceived loss in significance of association with the clinical phenotype 
between the “Affy” and “SSP-PCR” datasets. 
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The change in LD between ZDHHC14 and NTRK3 markers in the “Affy” and SSP-
PCR datasets might reflect differences in LD with the true susceptibility allele which 
may impact on the power of the study.  
 
Figure 6.12 LD values may be determined by marker frequency values 
A change in the frequency of the marker allele can change the LD between the marker 
allele and the susceptibility allele therefore changing the chances of detecting an 
association using the marker allele. (This is discussed in detail in chapter 2). 
 
6.4.4.1 NTRK3 appears to be associated with a flip-flop 
 
The most striking difference between the data for the NTRK3 SNPs in the “Affy” 
dataset and the “SSP-PCR” datasets is the occurrence of an apparent “flip-flop” 
phenomenon when these datasets are examined according to clinical phenotype. For 
most SNPs in this gene the direction of the genetic association with the clinical 
phenotype appears to change between the two datasets. Conflicting genetic 
associations are not uncommon in the published literature. As discussed in Chapter 1, 
the G allele of OPRM A118G has usually been associated with higher opioid 
requirements for pain relief. One study however suggested that the A allele was 
associated with higher opioid dose requirements 85. Variation in influences on 
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outcome by other non-characterised variants has been proposed as an explanation for 
this flip-flop phenomenon 449. This occurs in two situations: 
• When the SNPs being tested are merely markers for the true susceptibility 
SNP. Differences in correlation of the observed marker allele (which may 
or may not play a role in determining outcome) and another unobserved 
susceptibility allele (which may be either a protective or risk allele) may 
cause a change in the direction of allelic association. This is especially true 
if the susceptibility allele is common and there is weak LD between the 
unobserved susceptibility allele and the observed marker allele 449. Flip-
flop in genetic association may also occur when LD remains apparently 
stable 450.  This occurs because it is a change in the frequencies of 
haplotypes designated by the observed and unobserved susceptibility 
variants that brings about the flip-flop, rather than a change in LD itself.  
 
• When multiple variants act together to bring about a particular outcome. The 
flip-flop may represent varying effects of the causal susceptibility SNP due to 
differences in genetic background and environment 449. This is particularly 
relevant in genetic association studies of pain and analgesia since these traits 
are so complex and multi-factorial in nature.  
 
Other common reasons for the flip-flop phenomenon include: 
• Genotyping errors. This is unlikely in our study as the phenomenon is 
observed across multiple markers. In addition, the genetic data data was 
exactly the same when two genotyping platforms (Affymetrix and SSP-PCR) 
were used. 
• Differences in LD patterns across different ethnic groups. Again this risk has 
been minimised as much as possible by only including white Caucasians in the 
study. However it is likely that even defining ethnicity in this manner results 
in inclusion of a somewhat heterogenous group of subjects because of 
population drift. 
• Sampling variation. The “Affy” and “SSP-PCR” datasets were examined and 
compared in terms of clinical factors which might influence or be associated 
with pain and analgesia, but no striking differences were seen. However it is 
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extremely likely that there are other untested genetic and environmental 
factors contributing to sampling variation, of which we are simply unaware. 
(This is discussed further in chapter 3). 
 
6.5 Conclusions 
 
This study has identified a number of challenges in carrying out genetic association 
studies in pain and analgesic response, namely study size, study design, phenotype 
definition and data analysis. These challenges are not unique to studies of pain and 
neither are they insurmountable. Collaborations of investigators researching the same 
outcome would improve study power. Such collaboration has been proved possible in 
the EPOS study (European Pharmacogenetic Opioid Study) in which over 2000 
cancer patients were recruited from 17 centres in 11 countries 135. These factors must 
be considered when designing any genetic association study. Exploration of 
underlying biological interactions and epistasis will enrich the search for genetic 
associations. Correlation of genetic data with functional studies will be a further step 
towards validation of genetic findings. Identification of and focused study of 
biologically plausible interactions between genes and environment might yield more 
significant and useful results 451. Hypothesis-free testing of hundred of thousands of 
genetic polymorphisms brings us closer to finding the true “pain genes” but do not 
negate the findings of other hypothesis-driven studies.   
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7 Chapter 7: Constipation in cancer patients taking 
morphine 
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7.1 Summary of the rationale behind this study 
 
• Constipation is a significant problem in cancer patients. 
• Opioids including morphine are a common cause of constipation in cancer and 
palliative care patients. 50-100% on patients taking opioids experience 
constipation 189;190.  
• There has been relatively little study to date of assessment, management and 
risk factors for constipation on opioids. 
7.1.1 Aims 
 
The aims of this chapter were: 
 
• To explore the prevalence and management of constipation in cancer patients 
taking morphine 
• To present a clinically meaningful classification and definition of the 
phenotype of constipation on morphine 
• To explore the clinical and genetic factors associated with constipation on 
morphine in cancer patients 
• To examine the clinical assessment of constipation in cancer patients taking 
morphine 
• To begin to develop a constipation assessment tool  
 
The following chapter consists of a series of studies carried out in cancer patients 
taking morphine. The subjects and methods for each study are described briefly, as 
well as the main clinical findings. There is an overall discussion of all of the data at 
the end of the chapter.  
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7.2 Study 1: Examination of the prevalence and management of 
constipation in cancer patients taking morphine 
 
7.2.1 Subjects and Methods 
 
This part of the study was carried out using data collected as part of the Prospective 
Genetics Study (see chapter 2). In this study, patient subjective assessment of 
constipation during the preceding week was carried out using a four point adjectival 
scale: “not at all” (grade 0), “a little” (grade 1), “quite a bit” (grade 2), and “very 
much” (grade 3). This constipation assessment question is similar to that used in the 
validated European Organisation for Research and Treatment of Cancer Quality of 
Life Questionnaire 452. Current medications including morphine and laxatives (type 
and dose) were also recorded. 
 
Laxative dose groups (LDGs): 
Patients who reported constipation were analysed according to their laxative use. In 
this study laxatives taken by the study subjects were classified in terms of Laxative 
Dose Groups (LDGs) (Table 7.1). The concept of LDGs is based on current 
recommendations that laxatives should be titrated according to individual patient 
response 453. As with any other medication, individuals may vary in their sensitivity 
and tolerance of laxatives 195. In some patients dose-limiting side-effects may 
necessitate rotation to an alternative laxative 454. 
 
It is well known that palliative care patients are often prescribed medications at 
different (usually higher) doses that many other groups of patients. Taking this into 
account, LDGs were devised for each laxative using dosing information obtained 
from therapeutics manuals 455, reviews of laxatives 453 and symptom control 
guidelines specific for this patient group 456;457.  It was acknowledged that in general 
guidelines for the management of constipation in cancer patients are based on expert 
opinion as to date there is currently no evidence to support the use of one laxative 
over another. It was noted that in some studies and reports of laxatives, higher doses 
than those in the LDGs were used 212;458. These higher doses were not incorporated 
into the LDGs because they were either being used under experimental conditions or 
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they are greater than those commonly used in cancer patients. It is possible that the 
use of vast doses of laxatives may be associated with an increased risk of side-effects. 
Similarly if the pill or liquid volume of laxatives is too great there is an increased risk 
of non-compliance in a palliative care and cancer population 459.  
 
In this study laxative use by constipated patients was analysed in terms of LDGs in 
order to determine: 
• The proportion of patients with inadequately treated constipation. These were 
defined as those patients who were constipated but were not on maximum 
recommended doses of laxatives. It is suggested that these patients could have 
their dose of laxatives increased in an attempt to alleviate the symptom of 
constipation. These patients were thought to have sub-optimally treated 
constipation. 
• The proportion of patients who were constipated despite being on high / 
maximal laxative treatment. It is suggested that increasing the dose of that 
particular laxative in these patients would probably offer little added benefit. 
These patients were thought to have constipation which was resistant to that 
particular laxative.  
 
Inter-individual response to the constipating effects of opioids was explored by 
looking for associations with the cancer diagnosis, factors associated with opioid 
therapy and concomitant factors which may be hypothesised to play a role in the 
pathogenesis of constipation.  
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Table 7.1 Laxative Dose Groups (LDG) for each laxative 
For application to patients reporting constipation only 
All doses are per 24 hours 
 Laxatives  Milpar 
(ml)  
Senna 
(mg)  
Danthron 
(mg)  
Docusate 
(mg)  
Bisacodyl 
(mg)  
Movicol 
(Sachets)  
Lactulose 
(ml) 
 
 
0 
 
 
None 
 
0 0 0 0 0 0 0 
 
 
 
Suboptimally  
treated  
constipation 
 
 
 
Laxative dose  
could be  
increased 
1  
Subtherapeutic 
 
Below usual 
starting dose 
 
1-10 
 
1 – 7.5 
 
1 - 25 
 
≤100 
 
<5 
 
1/2 
 
1-10 
2 
 
 
Low 
therapeutic 
 
 
 
 
 
Within 
recommended 
dose 
 
 
 
 
>10 ≤20 
 
> 7.5 ≤15 
 
> 25≤50 
 
>100≤200 
 
5 - 10 
 
1 
 
>10≤20 
3  
Moderate 
therapeutic 
 
>20 ≤40 
 
>15 ≤ 30 
 
>50 ≤100 
 
>200 ≤400 
 
>10 ≤20 
 
2 
 
>20 ≤ 40 
4 
 
 
High 
therapeutic 
 
 
>40 ≤60 
 
> 30≤67.5 
 
>100≤300 
 
>400 < 
600 
 
>20 ≤ 40 
 
3-4 
 
> 40 ≤60 
Resistant  
onstipation 
 
Uncertain  
benefit to  
increasing  
laxative dose 
5 Above usual 
therapeutic 
dose 
Above normal 
recommended 
dose 
 
>60 
 
>67.5 
 
>300 
 
≥600 
 
> 40 
 
5-8 
 
> 60 
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7.2.2 Results 
 
274 patients were included in this study. 72% (197 / 274) of patients had mild to 
severe constipation (grade 1 – 3); 28% (77/274) had no constipation. 
Of those who were not constipated, 53% (41/77) were not taking any laxatives.  
Of the patients who said that they were constipated, 73% (144/197) were already 
taking laxatives but 27% (53/197) were not taking any laxatives.  
 
Table 7.2 shows the proportion of patients with different degrees of constipation and 
the proportion of each group which is on laxatives.  
 
Laxatives taken by the study population varied widely (Table 7.3). These were 
divided into predominately softening and predominately stimulating laxatives. Of the 
constipated patients in the study, 71% (139/197) were taking a softening agent and 
53% (104/197) were taking a stimulating laxative. Only 50% (99/197) of constipated 
patients were taking a combination of a softener and a stimulant. (Figure 7.1) 
 
75% (104/139) of constipated patients taking a stool softener and 77% (80/104) of 
those taking stimulant laxatives were on suboptimal laxative doses (LDG 0 to 3).  
78% (77/99) of constipated subjects taking combination laxatives were also on a 
suboptimal dose. Therefore only 11% (22/197) of the study subjects who reported 
constipation had been titrated onto maximum recommended doses of combination 
laxatives (LDG 4 or 5). 
In the total study population, 8% (22/274) were constipated despite being on high 
doses of laxatives. These were clinically deemed to have “resistant constipation” i.e.  
constipation that had not resolved on maximally titrated doses of that particular 
laxative / combination of laxatives.    
 
89% (175/197) of constipated patients in this study group were on inadequate 
treatment for their constipation (no laxatives or suboptimal doses of laxatives).  
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Overall the results of this study demonstrate a distinct inter-individual variation in 
constipation on opioids with three main subgroups: 
• Patients who do not experience constipation and do not need to take laxatives   
(No constipation No laxatives). This group comprises 15% (41/274) of study 
population.  
• Patients who do not experience constipation because they are being adequately 
treated with laxatives (No constipation On laxatives). This group comprises 
13% (36/274) of study population. 
• Patients who experience constipation despite being on high dose combination 
laxatives (Constipation On laxatives). This group comprises 8% (22/274) of 
study population 
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Table 7.2 Proportion of patients on laxatives and not on laxatives according to 
the reported severity of constipation 
 
% (N) 
 Grade 0 
“Not at all” 
Grade 1 
“A little”  
Grade 2 
“Quite a bit” 
Grade 3 
“Very 
much
” 
Total 
Not on laxatives 53 (41)  41 (28) 31 (21) 6  (4) 34 (94) 
On laxatives 47 (36) 59 (40) 69 (46) 94 (58) 66 (180) 
Total (77)  (68) (67) (62) (274) 
 
Table 7.3 Laxatives used by study population 
 
N (%) 
 All study subjects  
 
(N=274) 
Constipated study 
subjects  
(N=197) 
Non constipated 
study subjects 
on laxatives 
(N=36) 
Predominantly 
softening 
   
Milpar (magnesium 
hydrochloride 
and liquid 
paraffin 
emulsion) 
57 (21) 49 (25) 8 (22) 
Docusate Sodium 12 (4) 11 (6) 1 (3) 
Lactulose 14 (5) 12 (6) 2 (6) 
Movicol 
(polyethylene 
glycol) 
37 (14) 28 (14) 9 (25) 
Predominantly 
stimulating 
   
Senna 57 (21) 43 (22) 14 (39) 
Danthron 
containing 
laxatives 
(codanthramer, 
co-danthrusate)* 
72 (27) 61 (31) 11 (31) 
Bisacodyl 3 (1) 3 (2) 0  
* docusate is classified as a stimulant in some refenences 455and a softener in others 
456
. 
** codanthramer and codanthrusate are combination of softener and stimulant 
laxatives 
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Figure 7.1 Type of laxatives taken by patients reporting constipation (N = 197)
  
 
• Laxative Dose Group 0,1,2,3: Sub-optimally treated constipation:         
Laxative dose could be increased 
• Laxative Dose Group 4,5: Constipation resistant to that laxative / 
combination of laxatives:  
Uncertain benefit to increasing laxative dose 
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7.3 Study 2: Constipation on morphine in cancer patients: Clinical 
phenotype definition 
 
7.3.1 Subjects and Methods 
 
As previously, this part of the study was carried out using data collected as part of the 
Prospective Genetics Study (see chapter 2). Details about a number of other clinical 
variables were collected including demographic data, cancer diagnosis, concurrent 
medications (including laxatives), daily dose of morphine and length of time on 
morphine.  
 
The study population was refined in order to define a tight clinical phenotype. Patients 
taking morphine for less than 1 week were excluded from the analysis because 1) 
most definitions of constipation are based around the period of a week and 2) the 
questionnaire about constipation in the study related symptoms experienced during 
the preceding week.  Nine patients had incomplete data about concurrent laxatives and 
were therefore excluded from analysis. As the clinical phenotype was defined for use 
in the genetic association study, only Caucasian patients were included in order to 
reduce the risk of population stratification (discussed in chapter 8) in the genetic 
association analysis.  
 
In our previous study, we identified three distinct groups of cancer patients taking 
morphine: 1) patients who did not experience constipation and who were taking no 
laxatives, 2) patients who did not experience constipation because they were on 
adequate laxative treatment and 3) patients who did experience constipation despite 
laxative treatment. The third group were further subdivided into those who were on 
suboptimal laxative treatment and those who remained constipated despite high dose 
combination laxatives.  
 
In this study we re-classified these groups to allow comparison between subjects with 
bowel problems on morphine (N=199) those with no bowel problems (N=37). Patients 
who reported being constipated were included in the “bowel problems” group, 
whether they were on laxatives or not. There were a number of patients who felt that 
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they were not constipated but were taking laxatives. It was assumed that these patients 
required laxatives to maintain normal bowel function on morphine thus these patients 
were also included in the “bowel problems” group. The small group of patients 
(N=37) who were defined as having no bowel dysfunction on opioids were those who 
were not subjectively constipated and did not need to take any laxatives (Figure 7.2).  
 
 
During the past week have you had 
constipation?
During the past week have you had 
constipation?
Yes constipated                  
(subjective 
symptom)
Yes constipated                  
(subjective 
symptom)
Not constipated 
(subjective 
symptom)
Not constipated 
(subjective 
symptom)
On 
laxatives
Not on 
laxatives
A little  
j
A little  
j Quite a bit
Quite a 
bit
Very 
much
Very 
much
Not at 
all
Not at 
all
On 
laxatives
Not on 
laxatives
Bowel problems on 
morphine
No bowel problems on 
morphine
 
Figure 7.2 Defining the “Constipation on opioids” clinical phenotype 
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7.3.2 Results 
 
236 Caucasian patients who had been taking oral morphine for at least one week were 
included in the analysis.  
 
The subjective patient-reported severity of constipation is shown in table 7.4 together 
with details about laxative use.  
 
The two clinical groups (those with bowel problems on morphine and those without) 
were compared in terms of clinical variables which might be associated with 
constipation (Table 7.5).  There was no difference in terms of age, gender, time on 
morphine or dose of morphine between those who had bowel problems on morphine 
and those who did not. There was no difference in the proxy measure of disease status 
(time to death) between the 2 groups. Proxy measures of hydration (urea and 
haematocrit) did not differ between the 2 groups. There was no difference between the 
two groups in terms of cancer diagnosis except for tumours of the lower 
gastrointestinal tract. A smaller proportion of patients with bowel problems on 
morphine had a diagnosis of a tumour of the lower gastrointestinal tract compared to 
those without bowel problems (p=0.008). There was no difference between the groups 
however when all tumours involving the abdominal cavity were assessed together. 
The two groups were compared in terms of proportion of subjects taking medications 
(including chemotherapy within the preceding 4 weeks) which might alter bowel 
function but again there was no significant difference between the 2 groups.  
 
Table 7.4 Severity of constipation and laxative use in study population 
 
% (N) 
 Grade 0 
“Not at 
all” 
Grade 1 “A 
little” 
Grade 2 
“Quite a 
bit” 
Grade 3 
“Very 
Much” 
Total 
Not on 
laxatives 
54 (37) 45 (27) 26 (15) 4 (2) 81 
On laxatives 46 (31) 55 (33) 74 (42) 96 (49) 155 
Total 68 60 57 51 236 
Note: this table differs from table 7.2 as the study population has been refined to 
define a tight clinical phenotype for use in the genetic association study. 
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Table 7.5 Other clinical factors associated with constipation 
 
Data presented as N (%) or median (range) 
 
No bowel problems on 
morphine (n=37) 
Bowel problems on 
morphine(n=199) 
Male 19 (51.4) 98 (49.2) 
Female 18 (48.6) 101 (50.8) 
Morphine dose                
(mg / 24 hours) 
95 (10-720) 110 (15-1280) 
Time to death (days) 151 (18 – 2126) 121 (5 – 2590) 
Days on morphine 120 (10 – 4455) 84 (7 – 4319) 
Age 61 (29-83) 59 (19-85) 
Urea 4.2 (1.1-11.1) 4.8 (0.5-20.7) 
Haematocrit 0.341 (0.264-0.504) 0.344 (0.237-0.518) 
Serum calcium (corrected 
for serum albumin)  
2.25 (1.52 – 2.56) 2.23 (1.61 – 2.94) 
Other constipating 
medications* 
9 (24) 48 (24) 
Chemotherapy that may 
cause constipation ** 
6 (16) 29 (15) 
Chemotherapy that may 
cause diarrhoea*** 
8 (22) 32 (16) 
Diagnosis ¥¥ 
  
 Upper gastrointestinal 
tract 
4 (11) 17 (9) 
 Lower  gastrointestinal 
tract ¥ 
7 (19) 12 (6) 
 Pancreas and biliary 2 (5) 5 (3) 
 Gynaecological 2 (5) 20 (10) 
 Urogenital (renal and 
bladder) 
2 (5) 20 (10) 
 Haematological 2 (5) 12 (6) 
 Breast 5 (14) 37 (19) 
 Sarcoma 2 (5) 26 (13) 
 Lung (including 
mesothelioma) 
6 (16) 24 (12) 
 Head and Neck 4 (11) 14 (7) 
Melanoma 0 (0) 6 (3) 
 Prostate 2 (5) 15 (8) 
 Other 1 (3) 6 (3) 
Lower gastrointestinal tract 
/ gynaecological / 
pancreas 
11 (30) 37 (19) 
* includes 5HT3 antagonists, antimotility / antispasmodic / antimuscarinic agents, tricyclic 
antidepressants 
** Vinca alkaloids, platinums, thalidomide 
***5-fluorouracil, methotrexate, irinotecan, taxanes 
¥¥ Some patients have more than 1 tumour diagnosis 
¥ p=0.008, X2 7 
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7.4 Study 3: Constipation on morphine: genetic association study 
 
This is the first study of pharmacogenetic factors associated with constipation as a 
side-effect of an opioid. Other genetic association studies of response to morphine for 
cancer pain have tended to focus primarily on variation in the level of pain control or 
the dose of morphine required 92;94;124. Some of these studies did include a 
constipation assessment score in secondary analysis however the number of genetic 
variants tested has been limited and no genetic association was found 92;110. In this 
study the follwing genes were tested against the clinical phenotype of constipation in 
cancer patients taking morphine: OPRM, OPRD, OPRK, ADRA2A, ADRB2 and 
SLC6A4. Full details about these genes are found in Chapters 4 and 5.  
 
Since morphine and other opioids cause constipation by acting as agonists at 
peripheral opioid receptors, the genes coding for the opioid receptors were the most 
obvious candidates for inclusion in this study. Mu, delta and kappa opioid receptors 
are found throughout the gastrointestinal tract and are involved in gastrointestinal 
function 202;203.  
 
ARRB2, the gene coding for intra-cellular B-arrestin 2 proteins was also chosen. 
These proteins act as inhibitors to receptor coupling and are negative regulators of 
opioid receptor signalling 125. B-arrestin2 knockout mice have reduced constipation on 
morphine 460. These data suggest that B-arrestin2 plays an important role in mediating 
constipation on opioids 461.  
 
ADRA2A codes for the α2A adrenergic receptor (α2A AR). Knockout studies have 
shown that α2A AR mediates the sympathetic inhibition of intestinal motility. α2A AR 
knockout mice have reduced gastrointestinal transit time as compared to wild-type 
animals 388. 
 
Serotonin is synthesized in enterochromaffin cells in the GIT and plays a number of 
important roles in gut function. It is a key signalling molecule in GI motility, secretion 
and sensation. A study examining human colonic samples demonstrated reduced 
availability of serotonin in the mucosa of patients with Ulcerative Colitis (UC) and 
Irritable Bowel Syndrome (IBS) compared to healthy controls 462. Serotonin is 
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inactivated by SERT, the serotonin reuptake transporter, encoded by the gene 
SLC6A4. All enterocytes express SERT. Treatment with mice with paroxetine, a 
known inhibitor of SERT, resulted in delayed GI transit and reduced stool output 463. 
SERT -/- mice demonstrate increased gut water and motility and have alternating 
diarrhea and constipation 464.  
 
High serotonin levels can cause increased bowel motility and secretion 465. Cisapride 
and tegaserod are 5HT4-receptor agonists which are effective in the treatment of 
constipation through prokinetic activity. Unfortunately both these drugs are associated 
with cardiovascular side-effects. Prucalopride is a newer 5HT4-receptor agonist 
which does not appear to be limited by these side-effects  466;467. Prucalopride has been 
recently granted UK marketing authorisation for the symptomatic treatment of chronic 
constipation in women in whom laxatives fail to provide adequate relief 468. Due to 
some conflicting functional data however, some authors have suggested that in fact 
increased synaptic serotonin levels can result in a down-regulation in serotonin 
receptors with reduced serotonergic effect therefore slowing gut motility 302.  
 
There have been a number of studies examining the role of this polymorphism in IBS 
but the results have been conflicting, especially in terms of the association either 
diarrhoea or constipation predominant disease. In one study the presence of the S/S 
genotype was associated with constipation-predominant IBS and the L/L genotype 
with the diarrhoea-predominant variant 302. In other studies the S/S genotype was 
associated with diarrhoea-predominant IBS 303 301. This polymorphism did not 
withstand a recent meta-analysis in this area 465. This polymorphism has also been 
studied in relation to anxiety 414. 
 
7.4.1 Subjects and methods 
 
This part of the study was carried out using data collected as part of the Prospective 
Genetics Study. Subjects with bowel problems on morphine (N=199) were compared 
to those with no bowel problems (N=37) as defined in the previous section. 
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7.4.2 Results  
 
Overall there were no highly significant genetic associations between constipation on 
morphine and SNPs in OPRM, OPRD or OPRK. There was a weak association with 
an intron in OPRD, rs2236857. A higher proportion of patients with bowel problems 
on morphine carried the T allele at this position (genotype TT or CT), p=0.035. 
Logistic regression analysis was carried out to examine any possible association 
between the constipation phenotype and SNPs in the opioid receptor genes while 
controlling for the variability accounted for by a diagnosis of a lower GI tract tumour 
(Tables 7.6 – 7.8). OPRD rs2236857 was also significant in this model. This 
association however does not remain statistically significant after correcting for 
multiple testing. 
 
There were no significant associations with haplotypes in any of these genes (not 
shown).  
 
There was no significant association between constipation on morphine and any of the 
polymorphisms or haplotypes in SLC6A4, ADRA2A or ADRB2 (Appendix F). 
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Table 7.6 OPRM and Bowel problems on morphine 
 
  Allele carriage (dominant model) Genotype frequency (additive model) 
  Bowel problems on 
morphine  
OR (95% CI) P value 
 Bowel problems on 
morphine  
OR (95% CI) P value SNP name Allele 
No 
 (N=37) 
Yes 
(N=199) Genotype 
No  
(N=37) 
Yes 
(N=199) 
rs6912029 G 1.0 (35) 1.0 (186) - - GG 0.86 (30) 0.92 (171)   
 
T 0.14 (5) 0.08 (15) 0.484 (0.161-1.46) 0.198 GT 0.14 (5) 0.08 (15) 2.065 (0.685-6.23) 0.198 
 
     TT 0 (0) 0 (0)   
rs1799971  A 0.97 (34) 0.96 (179) 0.677 (0.077-5.963) 0.725 AA 0.77 (27) 0.74 (138)   
 
G 0.23 (8) 0.26 (48) 1.014 (0.463-2.632) 0.823 AG 0.2 (7) 0.22 (41) 0.893 (0.435-1.833) 0.757 
 
     GG 0.03 (1) 0.04 (7)   
rs589046 C 0.94 (32) 0.95 (172) 1.28 (0.265-6.187) 0.759 CC 0.44 (15) 0.54 (98)   
 
T 0.56 (19) 0.46 (84) 0.708 (0.334-1.501) 0.368 CT 0.5 (17) 0.41 (74) 1.312 (0.712-2.419) 0.384 
 
     TT 0.06 (2) 0.06 (10)   
rs563649  C 1.0 (34) 0.97 (177) <0.001 0.999 CC 0.74 (25) 0.82 (149)   
 
T 0.27 (9) 0.18 (33) 0.555 (0.232-1.326) 0.185 CT 0.26 (9) 0.15 (28) 1.385 (0.656-2.925) 0.393 
 
     TT 0 (0) 0.03 (5)   
rs9479757 A 0.23 (8) 0.2 (37) 0.808 (0.334-1.954) 0.636 AA 0.03 (1) 0.005 (1)   
 
G 0.97 (34) 0.995 (185) 6.407 (0.389-105.5) 0.194 AG 0.2 (7) 0.195 (36) 1.365 (0.611-3.049) 0.448 
 
     GG 0.77 (27) 0.8 (149)   
rs2075572 C 0.74 (26) 0.83 (153) 1.711 (0.72-4.068) 0.224 CC 0.34 (12) 0.34 (62)   
 
G 0.66 (23) 0.66 (123) 1.031 (0.475-2.239) 0.939 CG 0.4 (14) 0.49 (91) 1.179 (0.702-1.978) 0.534 
 
    
 
GG 0.26 (9) 0.17 (32)   
rs533586 T 0.88 (30) 0.89 (162) 1.077 (0.336-3.449) 0.9 TT 0.5 (17) 0.46 (84)   
 
C 0.5 (17) 0.54 (98) 1.138 (0.539-2.402) 0.734 CT 0.38 (13) 0.43 (78) 1.057 (0.605-1.846) 0.847 
 
     CC 0.12 (4) 0.11 (20)   
Logistic regression corrected for clinical factors (lower GI tumour) 
Data are given as % (N) 
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Table 7.7 OPRK and Bowel problems on morphine 
 
  Allele carriage (dominant model) Genotype frequency (additive model) 
  Bowel problems on 
morphine  
OR (95% CI) P value 
 Bowel problems on 
morphine  
OR (95% CI) P value SNP name Allele 
No 
 (N=37) 
Yes 
(N=199) Genotype 
No  
(N=37) 
Yes 
(N=199) 
rs10504151 T 0.97 (33) 0.98 (179) 1.606 (0.173-14.93) 0.677 TT 0.85 (29) 0.79 (144)   
 
C 0.15 (5) 0.21 (39) 1.546 (0.553-4.321) 0.406 TC 0.12 (4) 0.19 (35) 1.302 (0.541-3.136) 0.556 
 
     CC 0.03 (1) 0.02 (4)   
rs7836120 A 0.97 (33) 0.96 (175) 0.784 (0.094-6.527) 0.822 AA 0.71 (24) 0.68 (124)   
 
G 0.29 (10) 0.32 (59) 1.029 (0.454-2.333) 0.945 AG 0.26 (9) 0.28 (51) 1.05 (0.525-20.98) 0.891 
 
     GG 0.03 (1) 0.04 (8)   
rs6473799 T 0.91 (31) 0.96 (175) 2.547 (0.632-10.27) 0.189 TT 0.62 (21) 0.59 (107)   
 
C 0.38 (13) 0.42 (76) 1.191 (0.553-2.565) 0.655 TC 0.29 (10) 0.37 (68) 0.965 (0.512-1.818) 0.911 
 
     CC 0.09 (3) 0.04 (8)   
rs1365098 G 0.85 (29) 0.91 (166) 1.682 (0.562-5.033) 0.352 GG 0.6 (19) 0.43 (80)   
 
T 0.44 (15) 0.57 (103) 1.633 (0.77-3.46) 0.201 GT 0.29 (10) 0.47 (86) 1.172 (0.658-2.09) 0.59 
 
     TT 0.15 (5) 0.09 (17)   
rs7016778 T 1.0 (34) 0.99 (181) <0.0001 0.999 TT 0.73 (25) 0.73 (133)   
 
A 0.27 (9) 0.28 (50) 0.964 (0.414-2.244) 0.932 TA 0.27 (9) 0.26 (48) 1.013 (0.451-2.275) 0.975 
 
     AA 0 (0) 0.01 (2)   
rs7824175 G 1.0 (34) 0.98 (179) <0.0001 0.999 GG 0.73 (25) 0.8 (146)   
 
C 0.27 (9) 0.2 (37) 0.863 (0.356-2.09) 0.744 GC 0.27 (9) 0.18 (33) 0.973 (0.437-2.168) 0.947 
 
     CC 0 (0) 0.02 (4)   
rs16918875 C 1.0 (34) 0.995 (182) <0.0001 1.0 CC 0.88 (30) 0.83(152)   
 
T 0.12 (4) 0.17 (31) 1.547 (0.507-4.882) 0.433 CT 0.12 (4) 0.165 (30) 1.591 (0.525-4.825) 0.412 
 
     TT 0 (0) 0.005 (1)   
rs963549 G 0.97 (33) 0.96 (176) 0.531 (0.058-4.888) 0.576 GG 0.68 (23) 0.65 (119)   
 A 0.32 (11) 0.35 (64) 1.28 (0.571-2.868) 0.549 GA 0.29 (10) 0.31 (57) 1.285 (0.64-2.58) 0.48 
      AA 0.03 (1) 0.04 (7)   
Logistic regression corrected for clinical factors (lower GI tumour) 
Data are given as % (N) 
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Table 7.8 OPRD and Bowel problems on morphine 
 
  Allele carriage (dominant model) Genotype frequency (additive model) 
  Bowel problems on 
morphine  
OR (95% CI) P value 
 Bowel problems on 
morphine  
OR (95% CI) P value SNP name Allele 
No 
 (N=37) 
Yes 
(N=199) Genotype 
No  
(N=37) 
Yes 
(N=199) 
rs1042114 T 1.0 (34) 0.98 (178) <0.0001 0.999 TT 0.79 (27) 0.73 (131)   
 
G 0.21 (7) 0.28 (51) 1.438 (0.581-3.562) 0.432 GT 0.21 (7) 0.25 (47) 1.534 (0.662-3.551) 0.318 
 
     GG 0 (0) 0.02 (4)   
rs533123 A 0.97 (33) 0.96 (175) 0.529 (0.057-4.868) 0.574 AA 0.68 (23) 0.63 (114)   
 
G 0.32 (11) 0.37 (68) 1.262 (0.57-2.795) 0.566 GA 0.29 (10) 0.33 (61) 1.27 (0.64-2.519) 0.494 
 
     GG 0.03 (1) 0.04 (7)   
rs419335 A 0.82 (28) 0.92 (168) 2.577 (0.892-7.448) 0.08 AA 0.41 (14) 0.48 (91)   
 
G 0.59 (20) 0.5 (91) 0.691 (0.324-1.473) 0.339 AG 0.41 (14) 0.42 (77) 0.65 (0.373-1.131) 0.127 
 
     GG 0.18 (6) 0.08 (14)   
rs2236857 C 0.47 (16) 0.43 (78) 0.82 (0.387-1.735) 0.603 CC 0.15 (5) 0.05 (9)   
 
T 0.85 (29)* 0.95 (173)* 3.544 (1.081-11.613)* 0.037 TC 0.32 (11) 0.38 (69) 0.683 (0.383-1.22) 0.198 
 
     TT 0.53 (18) 0.57 (104)   
rs2234918 C 0.65 (22) 0.66 (120) 1.038 (0.474-2.273) 0.926 CC 0.21 (7) 0.18 (32)   
 
T 0.79 (27) 0.82 (150) 1.164 (0.457-2.965) 0.751 CT 0.44 (15) 0.49 (88) 0.971 (0.574-1.642) 0.911 
 
     TT 0.35 (12) 0.34 (62)   
Logistic regression corrected for clinical factors (lower GI tumour) 
Data are given as % (N) 
* Nagelkerke R2 = 0.079 
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7.5 Study 4: Constipation assessment audit 
 
As we previously demonstrated, the management of constipation in cancer patients is 
poor. We proposed that one of the reasons for such poor constipation management 
might be related to inadequate symptom assessment. We carried out a retrospective 
audit on a random sample of the patients who had been included in the original study to 
evaluate 1) the documentation of constipation assessment and 2) the documentation of 
constipation management in nursing and medical notes. We aimed to identify areas in 
which documentation of constipation assessment and management could be improved.  
 
7.5.1 Subjects and methods 
 
This retrospective audit was carried out on a random sample of patients who had 
originally participated in the constipation on morphine study (section 7.2). The audit 
was approved by the Royal Marsden Audit Committee.  
 
We used information from the constipation on morphine study regarding whether or 
not the patient had reported being constipated at the time of recruitment to the study. 
We accessed the medical, nursing and electronic patient records to carry out the audit. 
The audit focused on the clinical episode during which the patient had been recruited 
onto the constipation on morphine study. These clinical episodes varied from 2002 to 
2008. If the patient was recruited to the constipation on morphine study during an 
outpatient clinic, then the episode only lasted 1 day. However, for follow up questions, 
e.g. was the change in laxative reviewed, subsequent outpatient appointment letters 
were reviewed. For inpatients, the clinical episode lasted until discharge from the 
hospital or death of the patient, if that occurred during the same inpatient stay.  
 
The audit standards were derived from the literature: 
o Constipation assessment involves regular reassessment of usual bowel 
pattern, stool consistency, straining and frequency. 
o Constipation is a significant problem in cancer patients and should be 
proactively assessed at every clinical episode.  
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In addition, adherence to the local nursing care standard of using a dedicated “bowel 
care plan” if the patient is known to have constipation, was assessed. An audit 
proforma was designed to assess documentation of constipation assessment and 
management (Appendix G). Data on three key areas were recorded: 1) evidence as to 
whether constipation was identified as a problem or not, 2) documented evidence of 
assessment of constipation and 3) documentation of laxative use. 
 
In order to ensure accuracy of data collection, two data collectors completed the audit 
proforma on 5 patients initially and the results were compared.  
 
We aimed to audit at least 33.3% of the records of patients who had participated in the 
original study.  
 
Where the patient had attended an outpatient clinic, the electronic patient record and/or 
the medical notes were reviewed. In these cases there was no separate nursing 
assessment. 
 
The data were analysed using descriptive statistics. Differences between patients 
known to the specialist palliative care team and those not known were assessed using 
chi-squared test. In most cases subgroup analysis was not feasible due to small 
numbers. In some cases there was missing data from the patient paper records, e.g. the 
nursing documentation from that period was not available. In these cases the missing 
cases were excluded and the total cases of non-missing data were used in the analysis. 
In each case the total numbers of cases available for analysis are presented in brackets. 
 
7.5.2 Results  
 
109 sets of patient records were analysed. Of these two were omitted because the 
patient was in bowel obstruction at the time. Therefore 107 patients’ data were 
included in the audit. 
 
74% (79/107) of episodes occurred in the inpatient oncology unit and 26% (28/107) in 
the outpatient setting.  
  297
There was documentation that the palliative care team were involved in 63% (68/107) 
cases. 
 
Identification of constipation: 
 
A substantial proportion of patients (37%) who stated that they were constipated in the 
Prospective Morphine Study were not identified in the medical records as being 
constipated by the medical or nursing teams (figure 7.3). Nearly 20% of these patients 
had severe (grade 3) constipation.  
 
When constipation was correctly documented as having been identified as a problem, 
in most cases this was documented by the nursing staff or the palliative care team.  
 
 
 
Figure 7.3 Identification of constipation in medical records 
Documentation of constipation as an issue in the medical records was compared to 
whether the patient felt that he/she was constipated or not. The latter information was 
collected as part of the Prospective Morphine Study. 
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Documentation of constipation assessment: 
 
62% (66/107) of patients had some documentation of bowel function within the first 
one – two days of the clinical episode. Of those who did not (41/107), 42% (17/41) had 
mild (grade 1) constipation, 17% (7/41) moderate (grade 2) and 17% (7/41) severe 
(grade 3) constipation.  
 
Of those patients who did have documentation of bowel function within the first couple 
of days, in half of cases there was documentation about bowel frequency. 
Documentation about stool consistency or straining at stool was found in much fewer 
medical records (Figure 7.4). Only 1 patient had documented details about all three 
aspects of the constipation assessment. When the palliative care team were involved, 
stool consistency and straining were documented in a higher (but not statistically 
significant) proportion of cases.  
 
Figure 7.4 Documentation of identification and assessment of constipation. 
Documentation of assessment of the three key constipation assessment questions 
(straining at stool, frequency of evacuation and stool consistency). There was 
documentation of bowel function in the patient notes within the first one-two days of 
the clinical episode in 66 cases. The graph details the proportion of these patients in 
whose records these assessment questions were documented.  
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There was documentation of the patient’s usual bowel pattern in 33% (32/97) of patient 
records. (There was missing data on this question in 10 cases.) 53% (17/32) of these 
were recorded in the medical notes and in 69% (22/32) in the nursing notes.  
 
60 patients were identified as being constipated, 51 of which were inpatient. Of these 
39% (18/46) had evidence that the bowel care plan was being used. (The bowel care 
plan is an inpatient nursing paper document therefore patients who were only seen in 
the outpatient department at the time of the clinical episode were excluded from this 
analysis. There were missing data in five cases).  
 
Documentation of constipation management: 
 
50% (50/100) patients were on no laxatives at the start of the clinical episode. (These 
data were missing in 7 cases).  
 
Of those who were constipated (according to the Prospective Morphine Study data), 
45% (36/80) were on no laxatives at the start of the clinical episode. 58% (21/36) of 
these had either grade 2 or 3 constipation (figure 7.5). (There were data missing on this 
question in five cases.) 
 
Of those who were constipated but on no laxatives at the start of the clinical episode, 
constipation was identified by the clinical team in 58% (21/36) cases. Laxatives were 
initiated in 86% (18/21) of these patients.  
 
22 patients were not subjectively constipated. 70% (14/20) of those who were not 
constipated were on no laxatives (missing data on 2 patients) (figure 7.5).  
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Figure 7.5 Documentation of constipation management 
A: The proportion of patients who were subjectively constipated who were on 
laxatives on admission / at the start of the clinical episode.  
B: The severity of constipation of patients who were subjectively constipated but who 
were on no laxatives at the start of the clinical episode (N=36) 
 
 
Of those 60 patients who had been identified as being constipated, 46 patients in total 
had documented evidence that their laxative regimen was changed (type of laxative 
changed, laxative initiated or dose titrated), missing data in 3 cases. Of these, 40 were 
inpatients. In 90% of these inpatients (36/40) there was documentation that the 
response to the change was reviewed in either the medical notes.  
 
Ninety two patients were known to be alive at the end of the episode. Of these 78% 
(72/92) had stated that they felt they were constipated in the Prospective Morphine 
Study. There was documentation that 51% (47/92) of patients who were still alive at 
the end of the clinical episode had been identified as being constipated in the patient 
notes. 43% (20/47) of these had follow-up plans documented. 
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7.6 Study 5: Constipation assessment tool 
 
I designed a substantial amendment to the protocol of the Randomised Controlled 
Trial of Oral Morphine versus Oral Oxycodone which was approved by the MHRA, 
REC and CCR. The main objective of this amendment was to add the Constipation 
Assessment Tool in order to: 
  
• Begin development of a clinically useful constipation assessment tool. 
• Improve the definition of constipation as a phenotype to be used clinically and 
in trials. 
• Promote improved rational management of this symptom with available 
laxatives according to the Royal Marsden symptom control guidelines 283. 
 
The aims of this study were: 
• Assessment of the patient’s experience of constipation in a cancer. 
• Comparison of subjective constipation assessment measures (e.g. 11 point 
numerical rating scale, categorical adjectival scale) that are often used in 
research and clinical practice  
• Comparison of patient subjective assessment of constipation with objective 
assessment of constipation in a cancer and palliative care population 
• Identify the items to be used in a composite constipation assessment score. 
 
This study was not designed to determine the efficacy of the constipation assessment 
tool as there is no comparison group. Similarly a comparison of constipation scores 
between subjects on morphine versus those on oxycodone was not carried out as this 
will form part of the final study analysis. 
 
The data presented here represent part of the interim analysis for the Randomised 
Controlled Trial of Oral Morphine versus Oral Oxycodone. The full data set will be 
analysed once the study is complete. 
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7.6.1 Subjects and Methods 
 
The study population was comprised of patients recruited to the Randomised 
Controlled Trial of Oral Morphine versus Oral Oxycodone.  
 
Each patient recruited to the study completed the Constipation Assessment Tool 
(Appendix B) at recruitment (Time Point A) and each week for four weeks 
afterwards. They also completed the questionnaire again if they reached another 
particular study time point. If the completed questionnaire suggested that the study 
subject was constipated, the research team liaised with either the clinical palliative 
care team, the oncology team or the community medical teams so that the patient’s 
laxatives could be optimised according to the Royal Marsden symptom control 
guidelines 283. 
 
The study subject was also given a copy of the daily Stool and Laxative diary to fill 
out to aid assessment over the phone. It was anticipated that not all patients would fill 
out this diary. 
 
7.6.2 Constipation Assessment Tool Items 
 
Items for the constipation assessment tool were identified through literature review 
and are detailed in Appendix A. The tool consisted of subjective and objective 
constipation scores. 
 
All questions in the tool involved assessment of bowel function over the preceding 
week. 
 
Subjective bowel assessment: 
 
• The 11 point NRS (0 = no constipation and 10 = worst imaginable). This scale 
was in the original protocol for the Randomised Controlled Trial of Oral 
Morphine versus Oral Oxycodone. It has also been used in other studies 
assessing constipation 252;469. 
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• The four point categorical adjectival scale: “not at all” (grade 0), “a little” 
(grade 1), “quite a bit” (grade 2), and “very much” (grade 3). This assessment 
question was used by our research group in the previous study (Prospective 
Morphine Study) and is similar to that used in the EORTC Quality of Life 
Questionnaire, QLQ-C30 274-276 and Rotterdam Symptom Checklist 277;278. 
• A seven point adjectival scale in which the study subject rated their bowel 
function overall from “severe diarrhoea” to “severe constipation”. A bipolar 
scale has been recommended by Sykes 470 (and personal communication) as 
over-treatment of constipation may cause diarrhoea.  
• A simple binary satisfaction question. 
 
A free-text question about the subjective meaning of constipation was also included. 
 
Objective bowel assessment: 
 
In terms of the objective assessment of constipation, items relating to frequency of 
bowel movements, ease of defecation and stool consistency were included as the key 
questions in constipation assessment, as discussed in chapter 1. Questions relating to 
the subjects usual bowel pattern were also included.  
 
• Stool consistency 
Study subjects were asked the question“Was your stool hard during the past 
week”? They were asked to grade their response on a four point adjectival 
Likert scale: Never (grade 0), rarely (grade 1), occasionally (grade 2), nearly 
always (grade 3). 
 
• Ease of evacuation of stool: 
Study subjects were asked whether they had to strain to open their bowels in 
the past week. They were asked to score this on a four point adjectival Likert 
scale and this scale was graded numerically accordingly: Not at all (grade 0), a 
little (grade 1), quite a bit (grade 2), very much (grade 3). 
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• Frequency in the past week 
Study subjects were asked about their usual frequency (usual number of bowel 
movements per week) and also how many times they had opened their bowels in 
the past week. The difference between the usual and the current frequency of 
bowel movements was calculated. A score was allocated to each patient as 
detailed in table 7.9. 
 
 
Table 7.9 Stool frequency score 
 
Frequency of bowel movements in the 
past week compared to usual 
frequency 
Stool frequency score 
>6 more than usual -3 
4-5 more than usual -2 
2-3 more than usual -1 
Usual bowel frequency per week ± 1 0 
2-3 less than usual 1 
4-5 less than usual 2 
>6 less than usual 3 
 
  
 
• Study subjects were also asked to about their stool consistency using the 
Bristol Stool Chart. The responses were then scored as detailed in table 7.10.  
 
Table 7.10 Scoring using the Bristol Stool Chart 
Bristol Stool Chart Bowel Stool Chart score 
Type 1 3 
Type 2 2 
Type 3 1 
Type 4 0 
Type 5 -1 
Type 6 -2 
Type 7 -3 
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7.6.3 Data analysis 
 
Initially all the data (regardless of time point) were analysed together as one large 
dataset in order to: 
 
• Test the rates of incorrect  / missing responses for each constipation 
assessment question 
• Explore any clustering of the different scales and variables using principal 
components analysis  
• Carry out psychometric analyses: validity (convergent, discriminant and 
concurrent) and internal consistency. This was done in accordance with recent 
US Food and Drug Administration (FDA) guidelines on Patient Reported 
Outcome Measures 471. 
• Decide which assessments should be included in a Constipation Assessment 
Tool and to devise an overall composite constipation assessment score.  
 
The data were then analysed per time point (week 0 and week 1) to analyse overall 
change in constipation scores over time.  
 
7.6.3.1 Assessment of the rates of incorrect response 
 
Correct and incorrect responses were defined as per Jensen et al 472. A correct 
response was defined as a response within the stated scale guidelines. An incorrect 
response was one in which the study subject did not respond according to the scale 
guidelines or when the response was ambiguous e.g. not answered at all, more than 
one box ticked on the scale, the response fell between two marks on the scale or 
extended beyond the boundaries of the scale or presented a range of responses.  
If the study subject presented a range of responses which were within one point from 
each other on the scale, then the higher point was taken. If the subject presented a 
range of responses which were more than one point from each other, the response was 
discounted. The proportion of incorrect and missing responses was calculated for each 
scale. 
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7.6.3.2 Psychometric analyses 
 
The convergent validity, i.e. the extent to which the items in the assessment tool 
correspond with other items relationship was evaluated using Kendall’s tau 
correlation coefficient. (Kendall’s tau was chosen as the dataset was small and the 
results non-parametric).  
 
Principal components analysis (PCA) was used to assess whether there was any 
clustering between the subjective and objective assessment questions of constipation. 
Component scores were calculated using the regression method. All components with 
eigenvalues >1 were retained 319. 
 
Discriminant validity, the ability to distinguish between distinct patient populations 
was assessed by measuring the differences in each item between those who were 
satisfied with their bowel function and those who were not satisfied. 
 
Concurrent validity was measured by assessing correlation between the subjective and 
objective items and the previously validated Bristol Stool Chart.  
 
Internal consistency, the extent to which all items measured a similar construct was 
determined using Cronbach α. The subjective and objective items were assessed as 
subscales separately.  
 
The study was not designed to assess test-retest reliability. Missing data was not 
considered in the analysis at this exploratory stage.  
 
7.6.3.3 Comparison of constipation scores across time 
 
Constipation scores were compared across time i.e. week 0 versus week 1 and week 0 
versus weeks 1-4 using non-parametric paired tests (Wilcoxon signed rank and 
Friedman’s ANOVA).  
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7.6.4 Results 
 
Out of 53 eligible patients, 52 completed the initial assessment, 40 the week 1 
assessment, 33 the week 2 assessment, 18 the week 3 assessment, 19 the week 4 
assessment, 12 an extra assessment at a different study time-point. Together there 
were 174 constipation assessments. Initially these were considered all together in 
order to 1) compare the different constipation scales, 2) test correlations between the 
assessment scales, 3) test the reliability of the scales and 4) assess whether or not 
these scales were answered correctly by the patients.  
 
In the free text question, “What does being constipated mean to you”, 39.4% (41/104) 
of patients included something about altered stool frequency. (There was no response 
to this question in 70 assessments). 
 
 
Figure 7.6“What does being constipated mean to you”. 
 
65% (113/173) felt that they were subjectively constipated, according to the question 
in which they were asked to grade their constipation on a four point adjectival scale. 
(This was not answered in one assessment). Of these, 62% reported opening their 
bowels less frequently than usual, 56% had hard stool and 73% had experienced some 
degree of straining.  
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61.5% (32/52) of patients at time of recruitment (initial assessment) felt that they were 
constipated yet 28% of these (9/32) were on no laxatives.  
 
38.5% (20/52) patients at time of recruitment felt they were not constipated. In total 
33% (17/52) were not constipated and were taking no laxatives. 
 
 
Figure 7.7 Usual bowel frequency 
When asked about their usual bowel frequency, most study subjects (79%) reported 
opening their bowels once a day.  
 
7.6.4.1 Assessment of the rates of incorrect response 
 
The numbers of patients with incorrect or missing responses for each constipation 
assessment question are shown in table 7.11. There were fewer missing / incorrect 
responses for the subjective than for the objective constipation assessment questions. 
The highest rate of incorrect / missing responses was found with the Bristol Stool 
Chart, the second highest with the question about “usual frequency of bowel 
movements”. When compared to the question with the highest correct responses 
(satisfaction with bowel function), these were highly significant.  
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Table 7.11 Proportion of patients who gave correct / incorrect responses to the 
constipation assessment scales 
 
 Number of responses for each assessment scale N (%) 
Scale Total responses 
Correct 
response 
Incorrect 
response  
/ No 
response P value* 
Subjective assessments 
Satisfaction with 
bowel 
function 
173 (99.4) 173 (99.4) 1 (0.6)  
Grade of 
constipation 
173 (99.4) 173 (99.4) 1 (0.6)  
Overall bowel 
function* 
171 (98) 165(95) 9 (5) 0.02 
NRS constipation 168 (96.5) 168 (96.5) 6 (3.5) NS 
Objective assessments 
Stool Frequency 
past week* 
163 (94) 162 (93) 12 (7) 0.003 
Usual Stool 
Frequency* 
161 (92.5) 154 (88.5) 20 (11.5) 0.00001 
Bristol Stool 
Chart score* 
168 (96.5) 150 (86) 24 (14) 7x10-7 
Grade hard stool 171 (98) 171 (98) 3 (2) NS 
Grade need to 
strain 
167 (96) 167 (96) 7 (4) NS 
* Proportion of correct versus incorrect / missing response compared to response rates 
for “satisfaction with bowel function” or “grade of constipation” question.  
NS = not significant when compared to “satisfaction with bowel function” or “grade 
of constipation”. 
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7.6.4.2 Psychometric analyses 
 
Convergent and concurrent validity: Correlation of the subjective and objective 
constipation assessment scores: 
 
Four subjective constipation assessment scores and four objective scores were 
compared using Kendall’s correlation (Table 7.12) 
 
Satisfaction with bowel function during the past week correlated most closely with 
grade and NRS of constipation severity, overall bowel function and frequency of 
bowel movements in the past week. Satisfaction correlated poorly with the score on 
the Bristol Stool Chart, the grade of straining or grade of stool hardness in the past 
week.  
 
The other three subjective constipation assessments i.e. grade and NRS of 
constipation severity and overall bowel function were highly correlated (R=0.789 – 
0.820). All of these correlations were significant suggesting shared variance among 
the assessment scales. These three subjective measures were moderately correlated 
with the grade of straining (R = 0.459 – 0.48), grade of stool hardness (R<0.4) and 
frequency (R=0.497-0.542) 
 
There was moderate correlation between the three objective constipation assessments, 
frequency, straining and stool consistency.  
 
The Bristol Stool Chart was most highly correlated with stool consistency (R = 
0.573). There was only weak correlation between the subjective constipation 
assessment items and the Bristol Stool Chart (-0.153 - 0.358). 
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Table 7.12 Correlations between subjective and objective constipation assessment scores 
 
 Subjective constipation assessments Objective constipation assessments 
 
Satisfied 
with bowel 
function 
Grade of 
constipation 
Overall 
bowel 
function NRS constipation 
Stool 
Frequency 
Grade 
hard stool 
Grade need 
to strain 
Bristol 
Stool 
Chart 
score 
Satisfied with bowel 
function 1.000 -0.548 -0.416 -0.484 -0.481 -0.201 -0.291 -0.153 
Grade of 
constipation  1.000 0.796 0.820 0.526 0.377 0.480 0.249 
Overall bowel 
function   1.000 0.789 0.542 0.358 0.465 0.358 
NRS constipation 
 
   1.000 0.497 0.360 0.459 0.290 
Stool Frequency 
 
    1.000 0.378 0.461 0.421 
Grade hard stool 
 
     1.000 0.545 0.573 
Grade need to strain       1.000 0.419 
Bristol Stool Chart 
score 
       1.000 
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Comparison between objective measures of factors associated with constipation 
and subjective measures of constipation severity: 
 
Principal components analysis was used to assess whether there was any clustering 
between the subjective and objective assessment questions of constipation.  
 
Seven variables were included in this analysis: grade of constipation, NRS score of 
constipation severity, overall bowel function, difference in frequency of bowel 
motions pre week (usual frequency minus current frequency), score on Bristol Stool 
Chart, grade of straining and grade of stool hardness. The sample size was statistically 
adequate (Overall Kaiser-Meyer-Olkin value 0.853, Bartlett’s test of sphericity 
<0.001).  The individual KMO values ranged from 0.771 – 0.945 suggesting sampling 
adequacy.  
 
Two components were identified with eigenvalues of 3.999 and 3.217 respectively 
(Table 7.13 and figure 7.8). After rotation component 1 was comprised primarily of 
the subjective constipation assessment questions i.e. grade and NRS of constipation 
severity and overall bowel function. Frequency of bowel movements per week was 
also included in this component but with a much lower loading than the others (table 
7.13) Component 2 was comprised of the more objective constipation assessment 
questions i.e. the Bristol Stool Chart score, the grade of stool hardness and to a lesser 
degree, the grade of straining.  
 
These components are not independent of each other, as evidenced by the component 
correlation score, R=0.528.  
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Table 7.13 Pattern matrix showing the loading of each variable onto each component 
after rotation 
 
  Component 
  1 2 
Eigenvalue (after rotation) 3.999 3.217 
% variance explained 63.3 15.5 
Grade of constipation 0.978  
Overall bowel function 0.975  
NRS constipation 0.916  
Stool Frequency 0.556  
Bristol Stool Chart score  0.921 
Grade hard stool  0.918 
Grade need to strain  0.557 
Extraction Method: Principal Component Analysis.  
Rotation Method: Oblimin with Kaiser Normalization. 
Factors <0.4 are not shown here. 
 
 
 
 
Figure 7.8 Principal component analysis for constipation assessment tool items 
Component plot in rotated space demonstrating variables loading onto two main 
components.  
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Discriminant valididty (the ability to distinguish between distinct patient 
populations): 
 
There was a significant difference between the proportions of patients scoring grades 
0-3 on the 4-point categorical constipation scale depending on whether they were 
satisfied with their bowel function in the preceding week or not (table 7.14). 
 
  
Table 7.14 Discriminant validity: Grade of constipation 
 
 
Grade of constipation Total 
0 1 2 3  
Not 
satisfied 12.8 (10) 17.9 (14) 39.7 (31) 29.5 (23) 78 
Satisfied 53.2 (50) 38.3 (36) 6.4 (6) 2.1 (2) 94 
Data shown as %(N) 
Chi2 70, p=4x10-15  
 
There was also a significant difference between the scores using the NRS and the 
overall bowel function score (p<0.0001, Man-Whitney U), as shown in figure 7.9. 
Similarly there was a significant difference in the stool frequency score (p<0.0001), 
and the grades of straining and stool hardness (Chi2 26, p=8.1x10-6 and Chi2 14.4, 
p=0.02 respectively), data not shown.  
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Figure 7.9 Discriminant validity 
NRS and overall bowel function scale were compared in patients who were and were 
not satisfied with their bowel function in the preceding week. 
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Internal consistency:  
 
When analysed together, the subjective assessment items had high internal 
consistency, Cronbach α 0.821.  
  
 
Table 7.15 Reliability statistics for subjective constipation assessment items 
 
  
Corrected Item-
Total Correlation 
Cronbach α if Item 
Deleted 
Grade of constipation 0.910 0.744 
Overall bowel function 0.834 0.688 
NRS constipation 0.885 0.888 
Overall α 0.821 
 
 
The objective assessment items had slightly less internal consistency, Cronbach α 
0.759, which is in keeping with the lower correlation coefficients for these items. This 
value for Cronbach α is still an acceptable value for a positive rating.  
   
Table 7.16 Reliability statistics for objective constipation assessment items 
 
  
Corrected Item-Total 
Correlation 
Cronbach's Alpha if 
Item Deleted 
Stool Frequency Score 0.522 0.752 
Grade hard stool 0.601 0.672 
Grade need to strain 0.665 0.589 
Overall α 0.759 
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Comparing subjective severity scores and objective assessment scores across 
time: 
 
There was no significant overall difference between the constipation scores at week 0 
and those at week 1 (figure 7.10) or between weeks 0-4.   
 
 
Figure 7.10 Constipation assessment items week 0-1 
 
 
7.6.4.3 Developing a composite Constipation Assessment Score 
 
Taking into account the statistical tests above, including accuracy of responses, 
subjective scoring of constipation severity using the 4-point adjectival Likert scale 
appears to be equivalent to using the 11-point Likert scale and preferable to using the 
bipolar overall bowel function scale.  
 
The objective assessments of frequency (in the past week compared to usual), stool 
consistency and ease of evacuation are only moderately correlated, suggesting that 
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they represent different entities. Therefore it is proposed that a Constipation 
Assessment Tool should include either one of these subjective measures, along with 
these three objective scores.  
 
An overall Constipation Assessment Score was devised by summing together one of 
the subjective scores (grade or NRS), together with stool frequency score, grade of 
stool consistency and grade of ease of evacuation. This composite score was devised 
based on two previously published scoring systems 196;260. The higher the composite 
score, the worse the constipation. A score of 0 represented normal bowel function i.e. 
the subject does not feel that they are constipated and is opening his bowels with his 
usual frequency, with no straining and normal consistency. A negative score may 
represent diarrhoea or overflow diarrhoea. 
 
When this composite score was used, there was a significant difference between 
subjects who were satisfied with their bowel function in the preceding week and those 
who were not, p<0.0001 (figure 7.11). 
 
 
Figure 7.11 The Composite Constipation Assessment Score  
This score can distinguish between subjects who are satisfied with their bowel 
function in the past week and those who are not, p<0.0001. 
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7.7 Overall Discussion 
 
The main findings from the five studies presented in this chapter are: 
• Constipation is a very common symptom, occurring in 72% in cancer patients 
on oral morphine. 
• Constipation in this study population appears to be poorly managed. 89% of 
patients in this study were on inadequate treatment for constipation on 
morphine. 
• There is marked inter-individual variation in bowel function in cancer patients 
on oral morphine: Some patients do not experience constipation and do not 
need to take laxatives. Some patients do not experience constipation because 
they are being adequately treated with laxatives. The final group are patients 
who experience constipation despite being on high dose combination 
laxatives. Overall there are two broad groups: patients with bowel problems on 
morphine and those without bowel problems on morphine. 
• No clinical or genetic factors were identified as being associated with bowel 
problems on morphine in this patient group except for tumours of the lower 
gastrointestinal tract. 
• The documentation of assessment of constipation in cancer patients on oral 
morphine is poor.  
• Objective and subjective assessment questions about constipation are distinct 
and both should be included in a constipation assessment tool. Objective 
assessment of constipation may be assessed using an 11-point NRS or a 4-
point adjectival Likert scale with equal merit. 
• A Constipation Assessment Tool with a composite Constipation Assessment 
Score is presented comprised of a subjective score (4 point adjectival Likert 
scale), bowel frequency compared to usual frequency, consistency and 
straining. 
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7.7.1 Constipation management 
 
In keeping with other published data 189;190, the data presented in this chapter suggest 
that constipation is a significant problem in cancer patients taking morphine. The 
results from both the Prospective Morphine Study and the Randomised Controlled 
Trial demonstrate that constipation in cancer patients is generally poorly treated. In 
the latter, one third of patients who felt they were constipated at time of recruitment 
were on no laxatives. Most, if not all of these patients were already taking weak 
opioids for cancer pain, therefore would have been known to be at risk of developing 
constipation. In the Prospective Morphine Study, overall ninety percent of the 
constipated study population was on inadequate laxative treatment. These findings 
have also been demonstrated in a recent large multicentre study of cancer patients on 
opioids. In that study 41% and 27% of patients reporting moderate or severe 
constipation respectively, had not been given any laxatives in the preceding 24 hours 
and overall 60% of patients were inadequately treated for constipation 473. 
 
Documentation of constipation management in the Constipation Audit was also poor. 
Despite the fact that 80% of patients were subjectively constipated, only 50% were on 
laxative therapy at the start of the clinical episode. Although the evidence in this area 
is lacking, most guidelines, including local guidelines, recommend that most if not all 
patients who are on opioids should also be on oral laxatives 283;474. The data from this 
study suggest that either these guidelines are not being adhered to or that patients are 
non-compliant with recommended regimens. Where the patient was on no laxatives at 
the start of the clinical episode but who was identified correctly as being constipated, 
laxatives were started in the majority of cases. In most cases there was documentation 
that the response was reviewed. There was a significant proportion of patients 
however who felt that they were constipated according to the morphine study data, 
who were on no laxatives but who were not identified as being constipated by the 
clinical teams. Similarly, documentation of follow up plans for those patients for 
whom constipation had been identified as a problem was poor.  
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There appear to be two main areas in which laxative prescribing in cancer patients on 
oral morphine is inadequate: 
• Some patients who are constipated are on no laxatives at all  
• Most patients who are constipated were taking laxative regimens which are 
clearly not effective as the patient was still experiencing the symptom. 
 
The range of laxatives used to treat constipation in the Prospective Morphine Study 
reflects those commonly used in clinical practice. Previous studies have attempted to 
compare laxatives in terms of laxative units 195;214. This study was not designed to 
compare laxatives in terms of efficacy. This study identified patients who were 
constipated despite taking laxatives and stratified them according to whether or not 
they were taking adequate laxative doses. Although the relationship between symptom 
intensity and symptom treatment has been used in other studies to determine adequacy 
of treatment 284, this is the first time in which the dose of laxative treatment has been 
taken into consideration. Since publication of the paper from this part of this thesis, 
this approach has been adopted to examine adequacy of treatment of other symptoms 
including nausea, depression and poor sleep 473. 
 
There is much discussion in the literature about the use of novel opioid antagonists for 
the management of constipation on opioids. Using the results of this study, one might 
propose that that the small group of patients who have constipation that does not 
appear to be responsive to maximum recommended doses of combination laxatives 
may benefit from the use of such alternative measures. Similarly these agents may be 
efficacious in those patients who simply cannot tolerate laxative therapy. For most 
patients however, optimisation of laxatives and titration of laxative type and laxative 
dose according to patient symptoms would be the most obvious first step. Like all 
other drugs, rational laxative prescribing is essential to limit unnecessary and 
unsuccessful medication burden in the cancer patient population. Education to address 
this simple management strategy needs to be prioritised before newer, expensive and 
more complex treatments are added.  
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7.7.2 Inter-individual variation in constipation on morphine 
 
It is well known that there is considerable inter-individual variation in analgesic 
response to opioids 11;95 A previous study in normal volunteers suggested variability 
in the constipating effects of opioids 212. The data presented in this paper demonstrate 
that there is substantial inter-individual variation in constipation in patients on opioids 
for cancer pain. Some patients appear to be “constipation resisitant” i.e. they have no 
constipation and are taking no laxatives. This group of patients was defined in both 
the Prospective Morphine Study and the Randomised Controlled Trial. Another group 
of patients have no constipation because they are taking adequate laxatives. The final 
group are patients who remain constipated despite high dose combination laxatives.  
 
In order to define a clinically meaningful phenotype which would be useful for 
subsequent studies, these subgroups were further redefined into two broad cohorts: 
those with bowel problems on morphine and those without. This definition was made 
possible with the information collected about laxative use. This approach will be 
applied to the data from the Randomised Controlled Trial once the study is complete. 
 
7.7.2.1 Clinical factors associated with inter-individual variation in constipation 
on morphine 
 
It has been suggested that approximately 25% of constipation in terminal illness is 
attributable to opioids 195. It is difficult to determine what proportion of patients in this 
study are constipated solely because of the opioid and to what extent other 
constipating factors play a role. Constipation in cancer patients is known to be multi-
factorial in nature 475. Other factors which may contribute to constipation in cancer 
patients were explored in terms of this inter-individual variation in constipation on 
opioids.   
 
Increasing age and female gender are thought to be associated with an increased 
prevalence of constipation 476. In our study inter-individual variation in constipation 
on opioid was not age-dependant. Similarly there was no significant difference 
between the cohorts in terms of gender. In this study was no difference between the 
two groups in terms of the daily dose of morphine. These data support previous 
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suggestions that constipation on morphine is not associated with the dose of morphine 
196
. There was no difference in terms of time on morphine either, which is in keeping 
with the widely accepted idea that tolerance to gastrointestinal effects of opioids does 
not usually occur11. 
 
The study subjects had a wide variety of cancer diagnoses but there was no 
association between most cancer diagnosis and inter-individual variation in 
constipation on opioids. This is in keeping with a larger study of 1840 cancer patients 
477
. An increased prevalence of constipation and laxative use however has been 
associated with tumour involvement of the abdominal cavity 214. In the study 
presented in this thesis, a larger proportion of patients without bowel problems had a 
diagnosis of a tumour in the lower intestinal tract. In the multicentre EPOS study of 
1938 cancer patients on opioids, patients with a gastrointestinal tumour had a lower 
risk of being inadequately treated for constipation 473. 
 
In this study performance status and diet were not measured. It has been shown that 
patients with lower performance status may be more predisposed to constipation in 
general 260. Fluid balance is also important in the pathogenesis of constipation in 
cancer patients. Fluid intake was not recorded in these patients however there was no 
difference in biochemical parameters that reflect fluid balance and hydration (blood 
urea and haematocrit). There was also no difference in terms of serum calcium levels.  
 
The data were also analysed in terms of potentially constipating concomitant 
medications. The numbers of patients taking these medications was small but there 
was no association found between the use of these medications and the inter-
individual variation in constipation on opioids.  
 
Therefore this study failed to identify any clinical factor associated with bowel 
problems on morphine with the exception of location of the tumour in the lower 
gastrointestinal tract. This prompted the hypothesis that perhaps genetic factors 
account for the clearly defined inter-individual variability in the constipating effects 
of morphine in cancer patients.  
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7.7.2.2 Inter-individual variation in constipation on morphine and variation in 
candidate genes 
 
A large number of polymorphisms in OPRM, OPRK and OPRD were examined in 
this study. Despite the fact that opioid receptors play a key role in gastrointestinal 
function, only one SNP on OPRD was found to be associated with variability in the 
clinical phenotype. This finding did not remain significant after correcting for 
multiple testing. The effect of opioids on gastrointestinal function may be more 
complex than simply opioid receptor activation. Interactions between the serotonergic, 
adrenergic and opioid systems have been been postulated 208;478. Polymorphisms in 
SLC6A4, ARRB2 and ADRA2A however were not found to be associated with the 
clinical phenotype of constipation in cancer patients taking opioids.  
 
It is likely that there are other genes involved in opioid-induced constipation. These 
may include: 
 
• CLCN2, the gene coding for the chloride channel protein 2. Lubiprostone is a 
prostaglandin which activates this chloride channel to stimulate gut lumen 
secretion. This indirectly counteracts the anti-secretory effects of morphine 479. 
• MDR-1, the gene coding for p-glycoprotein. P-glycoprotein is expressed in the 
luminal membrane of enterocytes and limits gastrointestinal drug absorption. 
Inhibitors of p-glycoprotein (e.g. grapefuit juice and quinidine) have been 
shown to increase gastrointestinal morphine absorption in rats 117;480. 
 
In order to fully explore inter-individual variation in the constipating effects of 
morphine, larger studies (to accommodate the relatively lower proportion of patients 
with no bowel problems on morphine) are required with analysis of multiple genes 
and environmental interactions.  
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7.7.3 Constipation Assessment 
 
The data from the Prospective Morphine Study were used to examine why 
constipation is so poorly managed in this patient population. The results of the 
Constipation Audit highlight a number of concerning short-comings in daily clinical 
practice:  
 
• Although constipation was a symptom for the large majority of patients, there 
was no documentation of constipation being a clinical problem in a significant 
proportion of cases.  
• In those patients who were identified as being constipated, detailed assessment 
was often inadequate, as was documentation of rationale constipation 
management. 
• Local, national and international standards as to the assessment and 
management of constipation were not being adhered to. 
 
The data presented in this audit are consistent with other studies suggesting that the 
documentation of constipation assessment is sub-optimal. A retrospective chart 
review of 122 palliative care inpatients examined the patient charts for details about 
stool frequency, and symptoms associated with constipation. In many cases there was 
no reference at all to these symptoms 249. In two Danish studies, comparison was 
made between the record of symptoms in medical and nursing records and the extent 
of symptoms as reported by patients in self-assessment questionnaires. With the 
exception of pain, both studies demonstrated that many patients experience symptoms 
which are not documented in medical or nursing notes. In terms of constipation, 
significant constipation (scored as “quite a bit” or “very much” on the EORTC 
Quality of Life Questionnaire, QLQ-C30) was recognised and documented by nurses 
in 38% of cases and by doctors in only 50% of cases 481;482.  
 
Underestimation of symptom intensity by healthcare providers has been shown to be 
associated with inadequate symptom control 473. Accurate and detailed symptom 
assessment is essential to facilitate rational symptom management. Rigorous symptom 
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assessment promotes 1) identification of the severity of the problem and 2) review of 
the impact of management plans.  
 
In a study of 200 patients, 5.5% volunteered constipation as a current symptom they 
were experiencing when assessed using open ended questions, however 33.5% were 
identified as being constipated using a symptom checklist 483. This suggests that 
certain symptoms are less likely to be volunteered by patients, perhaps because of 
cultural pressures, patient education or issues with time during the assessment period 
483
. A study carried out in London suggested that patients are less likely to volunteer 
information about constipation as they believe that the doctor would not consider this 
important 484. Many different constipation assessment tools exist however there is no 
such tool which has been designed, validated and is commonly used in cancer and 
palliative care patients. The data from the Constipation Audit suggest that since 
standard documentation of assessment and management of constipation is lacking, 
there is a need for a simple, brief, standardised constipation assessment tool for cancer 
and palliative patients. 
 
When bowel function was assessed, the audit data demonstrate that the assessment 
process was patchy and inconsistent, mainly focused on bowel frequency. The data 
from this audit are consistent with previous data suggesting that objective assessment 
of bowel function is often based on bowel frequency 485. In the Randomised 
Controlled Trial, stool frequency again appeared to be an important factor in an 
individual’s perceptions of what it means to be constipated. Nearly 40% of patients 
mentioned stool frequency in the free text question of what constipation meant to 
them. The subjective assessment items in the Randomised Controlled Trial correlated 
highest with the stool frequency score as compared to the other objective assessment 
scores. Similarly the subjective measures and stool frequency loaded onto the same 
component in PCA. Stool frequency may however be an unreliable marker of 
constipation 486, mainly because most people have an irregular bowel habit. In the 
Randomised Controlled Trial, most subjects stated that they usually opened their 
bowels once a day. 12% of patients however, usually opened their bowels less 
frequently than this. A survey of 1897 people demonstrated that only 40% of men and 
33% of women have a regular daily bowel movement 487. As bowel function varies so 
widely, constipation assessment and management must take into account the patient’s 
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individual usual bowel pattern. In the Constipation Audit, documentation of usual 
bowel pattern was poor.  
 
The necessity to strain at stool is much more reliable constipation assessment than 
frequency with 94% sensitivity 488. In the Randomised Controlled Trial very few 
patients cited straining or stool consistency when they were asked what being 
constipated means to them. This is despite the fact that a high proportion of study 
subjects were experiencing these symptoms on direct questioning. Similarly, in the 
Constipation Audit, details on straining and stool consistency were not often recorded. 
These results differ from two studies, one a survey of 1128 young adults and the other 
a survey of 209 older people, in which most defined constipation as straining and hard 
stools 489;490. 
 
7.7.4 Constipation Assessment Tool 
 
The constipation study in the Randomised Controlled Trial represents an initial 
attempt to define the items which best capture the patient’s experience of constipation 
and to explore which assessment system is most applicable to this patient group. The 
data presented here represent an interim analysis of data in a larger clinical trial. Once 
the clinical trial is complete, full analysis including a longitudinal analysis of 
constipation and laxative use over time will be possible. 
 
The items included in the Constipation Assessment Tool (bowel frequency, straining 
and consistency) were derived from the literature: from previous studies of 
constipation in other patient populations and in palliative care and cancer patients, 
from definitions of constipation and from data supporting the pathogenesis of 
constipation 196;251;255;260;491. In some assessment tools used in other patient 
populations, abdominal symptoms are included as test items e.g. the Constipation 
Assessment Scale (CAS)265, the Constipation Assessment Scale for Pregnancy492, the 
Cleveland Clinic Constipation Scoring System266, the Patient Assessment of 
Constipation Symptoms (PAC-SYM)258, the Bowel Function Diary263. This item was 
not formally included in this constipation assessment tool as abdominal pain / bloating 
is a common symptom in cancer patients in general and was felt to be non-specific 
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and non-discriminatory in this patient group. The PAC-SYM also includes rectal 
symptoms but in this study no patient included rectal symptoms in their definition of 
what constipation meant to them 
 
Subjective versus objective: 
Constipation in patients taking morphine for cancer pain is usually a symptom or a 
secondary effect rather than a primary disorder.  Thus the subjective assessment of the 
symptom of constipation is essential in defining constipation on opioids. Similarly the 
management of symptoms in cancer patients is generally dependant on the subjective 
experience of those symptoms. Therefore the subjective assessment of whether the 
patient felt he/she was constipated was chosen as an adequate outcome measure in the 
observational Prospective Morphine Study.  
 
The constipation assessment question used in the Prospective Morphine Study is 
similar to that used in the validated European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire 452. The subjective assessment of 
constipation alone has some limitations however, as it does not take into account 
whether or not the patient is on treatment (or adequate treatment) for this symptom. 
Other clinical and genetic association studies of analgesic response to morphine have 
included this four point constipation scale as a secondary outcome without taking into 
account laxative use 92;110. In this thesis, a novel method for defining bowel 
dysfunction on morphine is presented, in which clinical data about the patients’ 
subjective assessment of constipation is combined together with data about their 
laxative use.  
 
Although the phenotype definition presented in this study represents a more clinically 
meaningful classification of the constipating effects of morphine than just using the 
subjective assessment alone, future studies incorporating both subjective and 
objective analysis of constipation in these patients will allow even further definition.  
 
The data from the Randomised Controlled Trial support the idea that subjective 
assessment of constipation does not measure the same things as objective assessment, 
as demonstrated from the lower correlation coefficients between subjective and 
objective measures. Also, there is quite marked disparity between the proportion of 
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patients citing altered frequency, straining and stool consistency as factors defining 
constipation for them when compared to the proportions of subjectively constipated 
patients who reported experiencing these symptoms. A previous study of 44 palliative 
care patients compared patient self-assessment of constipation with two diagnostic 
tools, i.e. compared the subjective and objective assessments of constipation. One 
objective diagnostic tool consisted of three items (frequency, ease of passing stool and 
stool consistency)260 and the other two items (frequency and consistency)196. The 
diagnostic objective tools identified 23 and 45% of the study population as being 
constipated (with a sensitivity and specificity of 22% and 76% and 66% and 61% 
respectively493) but only 23% of patients themselves reported themselves as being 
constipated. The authors concluded that the results were probably due to patient’s 
individual perceptions of constipation 254. 
 
Overall there was not any great difference between the three subjective assessment 
items (grade, NRS and overall bowel function) in terms of psychometric analyses. 
There was strong correlation between all three scores and they all demonstrated 
significant discriminant validity. The overall Cronbach α score suggest that they all 
measure a similar construct and they all load onto the same component in PCA. 
Component 1 as derived by PCA represents a derived composite which may be 
considered as the “best possible” subjective constipation assessment. In previous 
studies, assessments which showed the closest association with the composite score, 
as judged by the loading value, could be deemed to be the most valid 472. All three 
subjective constipation measures were significantly associated with the composite 
score (loadings 0.916 – 0.978), suggesting that they are equally valid. The only 
difference between the three subjective constipation assessments is in the rate of 
correct responses, which is a measure by which pain intensity scales have been 
judged472. The highest correct response rate was found with bowel satisfaction and 
grade of constipation. Study participants also scored highly using the NRS. There was 
a significant difference in correct responses when the overall bowel function question 
was used. Therefore one conclusion is that grading constipation severity on a four 
point adjectival Likert scale and scoring constipation severity on a 0-10 NRS are 
equally valid and accurate and either of these could be used in a constipation 
assessment scale. A bipolar scale “overall bowel function” maybe equally useful with 
the caveat that there may be a relatively lower rate of correct responses.  
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In terms of the objective constipation assessment items, the rate of correct responses 
was much less for straining, frequency and consistency compared to the subjective 
items. The highest incorrect response rate was found with the previously validated 
Bristol Stool Chart.  The Bristol Stool Chart score was included as an item as this is 
one of the most commonly used bowel assessments in cancer and palliative care 
patients. The Bristol Stool Chart is thought to provide information on gut transit time 
264
. In our study the Bristol Stool Chart and the question about stool hardness loaded 
highly onto the same PCA. This and the fact that it correlated best with stool hardness 
are not surprising as both these items measure stool consistency. The correlation 
between the Bristol Stool Chart and objective constipation measures was only 
moderate, and with subjective constipation measures was relatively weak. Therefore 
overall it is uncertain whether the Bristol Stool Chart is indeed a useful item in 
assessing constipation in cancer and palliative care patients.  
 
Overall the interim data from the Randomised Controlled Trial suggest that a 
constipation assessment tool for use in cancer and palliative care patients should 
include: 
• A subjective assessment of constipation, either the NRS or four point 
adjectival scale.  
• An objective assessment of constipation including frequency (current as 
compared to usual), straining and consistency. None of the objective items 
correlate very strongly with each other suggesting that they do not measure the 
same construct and therefore that they may be combined in a composite score 
without redundancy. 
 
The main differences between this tool and many other constipation assessment tools 
are: 
• It was designed specifically for cancer and palliative care patients.  Unlike 
other constipation assessment tools, such a tool would be brief and concise and 
may be useful in both the clinical and the research setting.  
• Clinically, since laxatives may be broadly categorised into stool softeners and 
stimulants, information about frequency, straining and consistency could 
facilitate tailored management with currently available laxatives.  
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• Unlike other scores which focus on absolute numbers of bowel movements per 
week, this tool uses the number of bowel movements as compared to the 
patient’s usual frequency. This captures the wide variation in normal 
frequency of bowel movements. 
 
A composite constipation assessment score was developed using methods derived 
from two previous studies of constipation in cancer patients 196;260. The composite 
constipation assessment score demonstrated significant discriminant validity in terms 
of satisfaction with bowel function. Such a score may be a useful outcome measure in 
clinical trials. 
 
7.7.5 Limitations of these studies: 
 
7.7.5.1 Limitations of the Prospective Morphine Study 
 
This study has a number of limitations which may contribute to the negative 
associations between the clinical outcome and either clinical or genetic predictors. 
There are relatively small numbers of study subjects in the “No bowel problems on 
morphine” group. Correcting for multiple testing in such a small group may 
inadvertently result in type 2 errors. The clinical definition of patients with “no bowel 
problems on morphine” i.e. not constipated and not taking any laxatives, appears 
sound however as it is true in both the Prospective Morphine Study and the 
Randomised Controlled Trial. 
 
The data in this study were collected from a single time point which does not reflect 
the dynamic nature of symptoms in cancer patients. Prospective follow-up studies are 
required. Analysis of the final constipation data set of the Randomised Controlled 
Trial will facilitate such longitudinal assessment.  
 
7.7.5.2 Limitations of the Constipation Audit 
 
One of the unique aspects of the data presented as part of the constipation audit is that 
the constipation status of every subject was known through independent 
documentation as part of the previous research study. Therefore retrospective analysis 
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of the clinical records was thought to be an appropriate method to analyse 
documentation of assessment and management of constipation in these patients.  
 
There are two main limitations in analysis of the data from this audit. Firstly, the 
retrospective audit provides information on documentation of constipation assessment 
and management. A lack of documentation does not necessarily mean that the 
assessment did not take place. However, this raises further questions; if assessment 
and management plans are not documented, it is unclear how the clinical situation can 
be managed adequately. Secondly, as part of the audit, the entire clinical episode was 
reviewed, whereas the subjective assessment of constipation as documented in the 
morphine study was a single time point. Thus the subjective assessment of 
constipation documented in the morphine study does not take into account the 
dynamic nature of bowel function.  
 
7.7.5.3 Limitations of the Randomised Controlled Trial 
 
The data presented here do not show any difference in the individual constipation 
assessment items across time. These interim data however do not take into account 
laxative use in order to define bowel function / dysfunction and the numbers of 
patients when each time point is analysed independently are relatively small. 
Therefore it is not possible at this time to prospectively test the clinical phenotype of 
bowel problems on opioids as defined in the Prospective Genetics Study. Similarly the 
numbers are too small to prospectively validate our earlier findings of other clinical 
factors which may impact on constipation. These analyses will be possible once the 
full complete data set is available. Furthermore, this study was not designed to test the 
efficacy of the constipation assessment tool in terms of improving constipation 
management. Once the analysis on the final data set is completed, the items to be 
included in the final constipation assessment tool will be determined. A further study 
including a comparison group will be necessary to test the efficacy of this tool. 
  333
8 Chapter 8: General Discussion and Future work 
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8.1 Summary of thesis 
 
The aim of this thesis was to examine the inter-individual variation in response to 
morphine for cancer pain. The definition of clinical response to morphine was 
explored using data from the Prospective Morphine Study. Clinical confounders 
influencing morphine response were included in the analysis. Assays were set up to 
study the pharmacogenetics of morphine using both a candidate gene and genome-
wide approach. The interaction of clinical and genetic factors was investigated. 
Constipation as a common troublesome side-effect of morphine treatment was 
explored in detail using data from both the Prospective Morphine Study and the 
Randomised Controlled Trial of Oral Morphine versus Oral Oxycodone. A study was 
set up to begin the development of a constipation assessment tool. 
 
The main findings from this thesis were: 
 
• Pain and side-effect scores and also the dose of morphine required by 
individual patients vary widely.  
 
• Analgesia, central side-effects on morphine and morphine dose requirements 
appear to be distinct dimensions of response to morphine. This hypothesis is 
based on a number of findings: 
 
o Principal Components Analysis demonstrated that pain and central 
side-effect scores loaded onto separate components with little 
correlation between them. 
o The clinical factors associated with analgesia, central side-effects on 
morphine and morphine dose requirements are different.  
o These three outcomes are associated with different polymorphisms in 
different genes with little overlap.   
  
• Genetic variation in a number of genes studied (including the opioid receptor 
genes) may contribute to some of the variation in morphine response. The 
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genes studied however only account for a small proportion of response 
variability.  
• Constipation is a common symptom in cancer patients taking morphine. In 
general, assessment and management of constipation appear to be inadequate.  
 
8.2 Challenges highlighted by this thesis 
 
It is disappointing, but perhaps not surprising, that no single definitive gene defining 
opioid response was identified. Many large genetic association studies examining 
highly heritable complex human traits have only been able account for a small 
proportion of variability in that trait. For example, 90% of variability in human height 
is thought to be due to genetic variation 448. Studies involving thousands of 
individuals have identified multiple genetic associations with height but these only 
account for approximately 3-4% of this variance448;494.  
 
The data presented in this thesis highlight a number of challenges which need to be 
addressed if the genetic factors underlying inter-individual variability in morphine 
response are to be elucidated: 
 
• The highly complex (clinical and genetic) nature of pain perception and 
analgesic response. 
• Study size 
• Phenotype definition and replication of results  
• Recruitment to cancer and palliative care studies 
 
8.2.1 Pain perception and response to morphine are complex traits, both clinically 
and genetically 
 
In this thesis, 53 SNPs in 9 candidate genes were studied. Until publication of the 
EPOS data 135, which included 112 SNPs in 25 genes, this was the largest number of 
SNPs and genes examined (and published) in this field. However it is highly likely 
that there are many more genes which may play a role in differential pain perception 
and pain control. Furthermore, like other complex traits, it is likely that pain 
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perception and analgesic response are influenced by multiple gene-gene and also 
gene-environment interactions 172. In order to explore response to morphine as a 
complex trait, in this thesis both the clinical and genetic factors contributing to the 
phenotype were explored. Clinical variables such as tumour diagnosis, concomitant 
medications and age were found to be associated with the various clinical phenotypes. 
These clinical factors were included in multivariate regression analyses with the 
genetic factors to build models of morphine response.  
 
To date the genetic association studies of response to opioids for cancer (and indeed 
non-cancer) pain, have merely scraped the surface in terms of genetic complexities 
which may underpin this phenomenon. Challenges for future research include 
designing studies to explore epistasis, to account for population stratification and to 
identify and analyse genetic variation other then SNPs. Replication of results has 
traditionally been seen as the gold-standard for validation of genetic associations. 
However, previous candidate and genome-wide association studies (GWAs) in other 
areas have been disappointing, mainly because of failure of replication of findings. 
Less than 20% of genetic associations have been robustly replicated without bias 441. 
Likewise, very few single SNP results are replicated even when there is good 
evidence for the real nature of the association.  Potential reasons for these 
discrepancies include population stratification bias, population heterogeneity, 
inadequate statistical power 430;495, differences in phenotype definition and the fact 
that most genetic association analysis modelling uses a linear framework which only 
considers one SNP at a time, this ignoring gene-gene and gene-environment 
interactions 496. 
 
8.2.1.1 Gene-gene and gene-environment interactions 
 
In recent years there has been increased awareness of the concept of epistasis (gene-
gene interaction) in disease pathogenesis and drug response 173;497. There may be a 
number of genetic variants which have a slight or even a negligible effect when 
analysed independently, however in the presence of another genetic or environmental 
variant, may be quite significant. This notion can be demonstrated in the data 
presented in Chapter 5. For example, on univariate analysis, carriers of the SERTP 
short allele (SS) appeared to have higher pain scores than non carriers but this was not 
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statistically significant (p=0.062). This DIP was however included in the multivariate 
regression model as an independent predictor of analgesic response to morphine 
(p=0.02).Conversely, gene-gene interactions may be antagonistic 173. Gene-gene 
interactions are likely to be much more important and informative than single 
independent associations alone, especially in complex traits such as pain and 
analgesia. Association studies which focus on the association of single variants with 
pain and analgesic response may produce ambiguous results and possibly miss 
clinically relevant genetic variants 449.  
 
In this thesis, gene-gene and gene-environment interactions were examined, albeit in a 
relatively superficial manner. Even with the most robust statistical software, the sheer 
volume of data generated through combinations of polymorphisms is overwhelming. 
Examination of all possible two-gene interactions in a study of n genes would require 
n (n-1)/2 interactions 498. Therefore comprehensive testing of all two-SNP interactions 
in my candidate gene study of 53 SNPs would yield 1378 interactions. Such analysis 
in the GWA would result in 9.7 x 1010 reactions! (This calculation is obviously over-
simplistic and does not take LD into account). The possible number of gene-gene 
interactions in a complex trait such as opioid response is however as yet unknown and 
carries the additional requirements for multiple testing corrections 498. It is easy to 
imagine how a comprehensive search for all interactions would increase the volume 
of data generated and the required study sizes exponentially 451. At present it is 
computationally and biologically challenging to explore all possible SNP-SNP 
interactions in a study such as this. As a result, epistasis was not examined in the 
GWA in this thesis or in many other studies, including the large EPOS study. When 
epistasis is ignored, a linear relationship between genetics and the clinical outcome is 
assumed. Such an assumption is likely to be inaccurate when dealing with complex 
traits such as opioid response. More sophisticated data analysis tools are required to 
deal with the interactive complexity of epistasis. 
 
A number of statistical methods for examining gene-gene interactions have been 
proposed including regression, classification and regression trees, neural networking, 
combinatorial partitioning and multifactor dimensionality reduction 173. None of these 
methods are without limitations and indeed data analysis with each may produce 
dissimilar results 499. In this study multivariate linear regression was used to analyse 
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interactions between genetic and clinical data. This method has a number of 
limitations: 
 
• Firstly, as the number of predictor variables entered into the model increases, 
the distribution of data is reduced. This phenomenon is known as the “curse of 
dimensionality” and is particularly problematic when the number of predictor 
variables exceeds greatly the number of observations 500, there are missing 
data or when the loci have low minor allele frequencies 173. To address some 
of these issues and to reduce the number of markers to a more manageable 
size, a two-step approach has been proposed 500. In the first step a subset of the 
most important markers is chosen and in the second step interactions between 
these markers is explored 500. A number of different approaches to this two-
step model have been used.  
 
In this study the subset of best markers was chosen according to the p-value on 
univariate analysis. A threshold of p<0.1 was chosen as it is likely that some 
factors which are only borderline significant on univariate analysis will 
become more influential in the presence of other factors. A more generous 
threshold e.g. p<0.2, could also have been applied 93, but while this may have 
identified more significant factors which have negligible effects when tested 
independently, there would be a greater risk of type 1 error. The predefined 
threshold may be one reason why in some instances the multivariate additive 
and dominant models are dissimilar. Another explanation may be that the 
numbers in the study are relatively small especially when the additive model is 
used.  
 
• This approach may also run the risk of type 2 error. One of the main 
limitations of stepwise regression model is that the main effects are 
determined before analysis for interaction effects between variables i.e. it 
requires that the predictor variables are only included if they fulfill predefined 
criteria, i.e. in this thesis being significant at a level of p<0.1 173;500. 
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• A further limitation of regression modelling to explore epistasis is that if the 
predictor variable is merely a marker for the true susceptibility variable, then 
the result is likely to be diluted, depending on the extent of LD between the 
two markers 501. This however is a factor which must be considered in all 
genetic association studies, regardless of the statistical test used. 
 
Evidence of a statistical interaction does not necessarily imply a biological interaction 
501
, therefore any statistical modelling must be interpreted with caution. One of the 
major differences between physiological and statistical epistasis is that the latter is 
dependent on allele frequencies in the study population 502. In this thesis a number of 
models were presented from the candidate gene analysis. In each of these models, a 
biologically plausible connection can be made between most of the predictor variables 
and the clinical phenotype. However each of the genes was chosen because of prior 
knowledge of an association with morphine response. In the GWA, genes which were 
not previously known to be associated with morphine response were identified. 
Before any conclusions are drawn about the biological or statistical relevance of these 
findings, replication in larger studies using the same clinical phenotypes is required.  
 
It has been recently proposed that new computational and biostatistical approaches 
should be adopted in genetic association studies to include data mining and machine 
learning methods. This would facilitate modelling of the complex interactive networks 
of biomolecules which may / may not be controlled by environmental influences 496. 
Incorporation of existing information about biological pathways into data analysis 
algorithms will enrich subsequent non-linear analyses 496. In light of the negative 
findings of the EPOS study, Klepstad et al have suggested a move away from 
candidate gene association studies 135. However, in order to maximise the potential of 
finding true associations, analysis of epistasis in genetic association studies (even 
genome-wide association studies) should be guided by existing knowledge of 
plausible underlying biological pathways 501;503. In the candidate gene study presented 
in this thesis, combinations of genetic data pertaining to genes which are known to 
play a role in morphine response and pain perception were explored. Identification of 
and focused study of biologically plausible interactions between genes and 
environment might yield significant and useful results 451.   
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8.2.1.2 Population stratification 
 
Although the number of pharmacogenetic studies of opioids in cancer pain has been 
low, the study populations have been quite distinct in terms of ethnicity and 
geographical location. This adds a further layer of complexity to any comparisons 
between studies, especially if the studies represent collaboration between different 
countries. The EPOS data included study subjects from 11 European countries. 
Although 61 patients in total were excluded from analysis so that the study population 
only included Caucasians, even among European counties marked genetic variation 
between different geographical regions differences has been demonstrated 504;505.  
This was demonstrated in the GWA presented in this thesis, figure 6.3. These 
differences may lead to spurious results in genetic association studies if the difference 
in allele frequency between cases and controls is due to population stratification rather 
than to the outcome being measured 430. Such genetic heterogeneity may also be 
another reason why many genetic association studies fail to replicate in independent 
samples 431. Similarly population stratification makes replication in distinct 
geographic populations important before genetic association study findings can be 
applied in a clinical setting. 
 
8.2.1.3 More complex genetic variation 
 
As mentioned in Chapter 1, differences in response to drugs may be brought about by 
genetic variation at a DNA, RNA or protein level. To date all genetic association 
studies of response to opioids in cancer pain have focused on genetic variation in 
terms of SNPs. There have been no published studies examining the role of 
modifications at an RNA or protein level in this study population. The practical 
challenge of obtaining suitable sample tissue (e.g. nervous or brain tissue) has 
precluded much direct research in this area. However, there has been one small but 
very exciting study examining the influence of SNPs on the production of functionally 
significant splice variants 148. Integration of gene expression data with SNP data will 
undoubtedly enhance our understanding of inter-individual variation in response to 
opioids. 
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8.2.2 Study size 
 
One of the major limitations of the studies presented in this thesis is sample size. 
There are a number of factors which need to be taken into account when determining 
the optimum sample size for any genetic association study. These include: 
 
• The frequency of the susceptibility allele and the allelic odds ratio (effect 
size)442. The lower the frequency of the susceptibility allele and the lower the 
allelic odds ratio (i.e. the weaker the strength of association), the larger the 
samples size required.  
• The prevalence of the disease / trait in the general population. Rare traits often 
require larger sample sizes to identify adequate number of cases.  
• The number of SNPs to be tested, to take into account corrections for multiple 
testing. This however, is less influential than the size of the allelic effect 506.  
• Multifactorial diseases / traits are likely to be influenced by multiple 
incomplete penetrant genetic variants. Any risk-factor strongly associated with 
such a disease / trait is likely to be rare, resulting in a small increase in 
prevalence 80. Genetic variability is usually associated with small or modest 
effect sizes (odds ratio) in common, complex, multifactorial diseases / traits 
such as response to opioids. Therefore larger studies tend to be preferable to 
smaller studies 443. 
 
In the GWA presented in this thesis, the proportions of patients in each phenotype 
group are sizable i.e. in the whole study population 80% of patients achieve a good 
analgesic response compared to 20% who do not. This supports previous data which 
suggests that non-response to morphine is not a rare phenomenon, occurring in 
approximately one third of patients11 .  Depending on the clinical phenotype used, in 
the candidate gene study, up to 207 study subjects were included in the analyses. This 
is a relatively large number in terms of the previously published papers in this field. In 
order to minimise the sample size required, in this study, SNPs were only included if 
they had a minor allele frequency of > 10%. If the fact that response to morphine is a 
complex trait is ignored, and an (incorrect) assumption is made that response to 
morphine is determined by a single gene / SNP, then the number of patients in both 
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the GWA and the candidate gene studies were possibly adequate to allow 
identification of possibly true associations in common alleles (allele frequencies 
>10% 80) with more significant effect sizes. The relatively small size of the sample 
population in these studies undoubtedly resulted in reduced power to identify low-risk 
susceptibility alleles with low minor allele frequencies. Such small sample sizes are 
unquestionably too small if multiple testing for joint gene effects in a complex trait 
was to be taken into account.  
 
8.2.2.1 Multiple testing 
 
The use of multiple endpoints and the application of multiple statistical tests in a 
study increase the likelihood of Type 1 error i.e. increases the likelihood that the test 
will reject a true null hypothesis. In genetic association studies therefore, a significant 
proportion of the positive associations will occur due to chance alone. A number of 
methods have been proposed to adjust for multiple analyses. Two commonly used 
methods include the Bonferroni correction and False Discovery Rate. 
 
Bonferroni correction: 
The Bonferroni correction adjusts the significance level (α) according to the number 
of tests performed. The adjusted α is often calculated as 0.05/n, where n = number of 
tests. In a genetic association study where 500,000 SNPs are tested against one 
clinical outcome, then true positive associations may be considered as those with a 
significance level (α) value of 10-7. The Bonferroni correction has traditionally been 
popular as it is relatively simple to calculate. This was used in the only other GWA in 
pain 81 and was also applied in the GWA presented in this thesis. However this 
correction is often considered to be overly conservative as it assumes that each test is 
independent. In genetic association studies this correction does not take linkage 
disequilibrium into account 507. Therefore in fact the Bonferroni correction may 
actually increase the likelihood of Type 2 errors.  
 
False Discovery Rate (FDR): 
The FDR was proposed by Benjamini and Hochberg in 1995 as an alternative method. 
Instead of adjusting according to the number of tests performed, this method controls 
for the expected proportion of falsely rejected null hypotheses 508. Associations that 
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have a p value above the calculated FDR thresholds are considered to be true 
associations. In practice, instead of using the traditional p value, this approach 
presents a q-value associated with each test. This q value is a measure of statistical 
significance in terms of the false discovery rate 509. This approach is commonly used 
in GWAs.  
 
8.2.3 Accurate Phenotype to reduce required study size 
 
One of the main reasons behind replication failure in genetic association studies is 
lack of consensus about phenotype definition.  
 
Much of this thesis has been based on the need for phenotype definition of response to 
morphine. In terms of sample size, accurate phenotyping reduces the numbers of 
study subjects required. One of the earliest GWAs was carried out in 146 individuals 
(96 cases of advanced age-related macular degeneration (AMD) and 50 controls). 
103,611 SNPs were analysed and a polymorphism in the gene coding for complement 
factor H was found to be significantly associated with the phenotype 510. This 
phenotype was later tightened to include only wet AMD and a GWA conducted in 96 
cases and 130 controls yielded very significant results (p = 4.1 x 10-12) which have 
been subsequently replicated 511. In pharmacogenetic studies in other areas, when the 
phenotype can be precisely defined and where possible confounders are minimal, the 
study power is markedly lower. As discussed in chapter 6, a GWA carried out in only 
85 subjects and 95 controls, yielding significant association with statin-induced 
myopathy which again stood up to replication 447. In chapter 1 the role of UGT1A1 in 
irinotecan toxicity was described. One of the landmark studies identifying the genetic 
variant associated with irinotecan-induced neutropenia included only 63 patients, of 
whom six had the clinical outcome of interest (grade 4 neutropenia) 54. Pain and 
response to opioids however is a very complex outcome with many possible 
confounding factors. Therefore it is reasonable to assume that the numbers required in 
pain and opioid studies are significantly higher. 
 
Apart from accurately defining response to morphine as a clinical phenotype, one of 
the ways in which the genetics of pain and opioid response may be elucidated is 
  344
through collaboration with studies involving normal volunteers or non-cancer 
patients. These studies are “purer” in that the confounding factors are limited and the 
painful stimulus / pain relieving drug is usually standardised. The only GWA 
published in pain included only 221 patients. It is probable that, like our studies, this 
number is too small for any definitive conclusions to be drawn. However, unlike our 
study, this GWA was carried out in a defined population (European Americans, aged 
17-35 years), all of whom underwent the same painful stimulus (third molar 
extraction). Therefore in this population the number of confounding factors 
contributing to pain and pain control were less than in our study of cancer patients.  
 
8.2.4 Recruitment to palliative care studies 
 
The practical and ethical challenges of conducting research in palliative care have 
long been debated 512;513. It is widely acknowledged however that research in this area 
is essential in order to establish best practice based on good quality evidence 514;515. 
Research in palliative care has been recognised as a key area of specialty and service 
development 516 and as recently as July 2008 has been highlighted as a priority agenda 
at a governmental level 517.  
 
Two hundred and ninety eight patients were recruited to the Prospective Morphine 
Study. This was a relatively simple study in that it consisted of a single time point and 
no onerous patient follow-up. The Prospective Randomized Controlled Trial of 
Morphine versus Oxycodone for Cancer Pain is a more complicated study, as 
evidenced by the fact that recruitment is still ongoing. Carrying out research in 
palliative care is difficult, for a number of reasons:  
• Potential study subject identification, recruitment and retention are often 
challenging because of patient frailty, high attrition rates and unequal access to 
palliative care services.  
• Inclusion-exclusion criteria which stipulate minimum life-expectancy and 
performance status may discriminate against many palliative care patients 518, 
especially those at the end of life. This is confounded by the fact that for many 
palliative care patients performance status may vary according to treatment 
and disease trajectory.  
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• Inaccurate prognositication is well recognised and may result in patients being 
excluded from studies 519. 
•  Identification of potential study subjects is often carried out through the 
patient’s health care provider. Although health professionals can advise about 
the potential suitability of patients for a particular study, over-enthusiastic 
protection is potentially damaging to palliative care research on two counts. 
Firstly potentially eligible and suitable patients may be denied the choice and 
opportunity to participate in research. Secondly this may introduce a selection 
bias which may influence the results 513.  
 
Built into the study design of the Randomised Controlled Trial was the 
acknowledgement that patients would reach study endpoint early for a number of 
reasons including death or being too unwell to continue. Therefore in this study death 
was not considered to be a serious adverse event. In both studies, in order to minimise 
recall burden and bias, recall period was at most a week. Study questionnaires were 
kept to a minimum while trying to collect as much clinical data as possible.  
 
The importance of research as a discipline in palliative care was recognised when 
research became a mandatory part of specialist registrar training in 2010 520. More and 
more palliative health care professionals are becoming interested and involved in 
research. Supportive and collaborative bodies have been established, including the 
Junior Forum of the European Association of Palliative Care Research Network 
(EAPC-RN) and the Palliative Care Research Society (PCRS), to promote research in 
this field.  
 
8.3 Challenges for current and future research 
 
In order to address some of the issues discussed above, the main challenges facing 
researchers in the area of genetics and response to opioids are: 
 
• Increasing study size. The recent success of the EPOS study in which 2294 
patients were recruited demonstrates the benefits and possibilities of 
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multicentre collaborations 135. Such collaborations are vital especially if 
GWAs are to be carried out.  
 
• Consensus on outcome measures for morphine response / non-response. The 
use of principal components to define morphine response may be useful if 
validated in other studies. There has been an international call for 
standardisation of assessment tools for symptoms in palliative care, a call 
which has been supported by the European Association of Palliative Care 
Research Network. Such standardisation will facilitate comparison between 
research studies.  
 
• Partnership and collaboration with researchers in other settings. The 
importance and benefits of this are two-fold.  
 
Firstly some of the complexities of morphine response in cancer patients may 
be teased out through collaboration with researchers working with normal 
volunteers and chronic non-cancer pain patients and with basic scientists.  
Clinical and genetic association studies which are carried out under 
experimental conditions in otherwise healthy volunteers or in chronic non-
cancer pain patients are less susceptible to the myriad of confounding factors 
which influence inter-individual variation in response to opioids. Therefore 
such studies may provide a “cleaner” platform from which to unpick this 
conundrum.  Studies in healthy volunteers may facilitate the objective 
definition and classification of analgesic response. Studies in non-cancer 
chronic pain patients may assist in our understanding of the phenomenon of 
physiological tolerance and its impact on response to opioids. Collaboration 
with basic science units is important in order to validate the findings of 
genetic-association studies. For example, if a particular gene was found to be 
strongly associated with a particular response to morphine, then a rational next 
step in proving functional significance would be the development and testing 
of a knock-out model.  
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Secondly, evidence supporting ongoing study of inter-individual variation in 
pain and opioid response in cancer patients comes from a number of sources 
including healthy volunteer, familial and twin studies. Studies of monozygotic 
(MZ) and dizygotic (DZ) twins provide a classical approach to teasing apart 
the influence of genetic and environmental (shared or unique) factors on 
disease and traits. Twin studies have identified a number of painful conditions 
which appear to have some element of heritability, including back pain, 
dysmenorrhoea, sciatica, musculoskeletal pain, spinal pain, back pain and 
irritable bowel syndrome 521-523. In the last five years a number of twin studies 
have been carried out which propose 26-60% heritability of response to 
experimental painful stimuli 524;525. These studies prompted the first opioid 
response study in twins, the preliminary data from which were published in 
2010. The enrolment target for this study was one hundred and twenty-five 
pairs of healthy twins (80 MZ and 45 DZ). Each study participant was 
randomised to receive infusions of saline and alfentanil. Experimentally 
induced pain sensitivity to heat and cold pressor pain, opioid analgesia and 
opioid side-effects (including nausea and respiratory depression) were 
assessed 526. The final results of this study are awaited with interest. Informal 
reporting of these data however suggests that over 50% of variability in opioid 
analgesia and 40-60% of variance in opioid side-effects is due to genetic 
factors 527. These findings add convincing weight to the hypothesis that pain 
and analgesic response are, partially at least, genetically mediated traits. 
 
There are a number of heritable pain conditions in chronic non-cancer pain 
patients in which the underlying genetic mechanism has been identified528. 
One example includes the SCN9A gene, which codes for a peripheral sodium 
channel NaV1.7. As mentioned in chapter 1, variation in this gene is associated 
with either a complete inability to sense pain or extreme pain disorders such as 
erythermalgia and paroxysmal extreme pain disorder 60;61. Such rare disorders 
provide a fascinating insight into the mechanisms and pathophysiology of 
certain pain states. These findings have paved the way for further research into 
the association of the genes involved and other pain states, including cancer 
pain and opioid response.  
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o I have been working with researchers in Denmark (Professor Drewes, 
Laboratory for Experimental Pain Research , Aalborg Hospital, Aarhus 
University Hospital, Denmark) and also in London (Professor Qasim 
Aziz,  Wingate Institute of Neurogastroenterology, Barts and the 
London School of Medicine & Dentistry, Queen Mary University of 
London, London, UK), both of whom have carried out pain studies in 
normal volunteers. The Danish studies consisted of subjects 
undergoing a number of different painful stimuli including somatic and 
visceral pain. Analgesic response to opioids including morphine and 
oxycodone was measured 529-533. The London studies involved an 
attempt to define the pain phenotype through a number of modalities 
including personality testing, autonomic responses, functional 
magnetic resonance imaging and genetics 534;535. I have been involved 
in genotyping the subjects of both groups using some of the assays 
already tested in the Prospective Genetics Study.  
 
• Increasing recognition of the fundamental importance of post-DNA variation. 
Dr Ruth Branford, another PhD student in this department, is examining 
opioid receptor expression in white blood cells from patients recruited to the 
RCT. These data will be combined with SNP data and will hopefully expand 
our understanding of inter-individual variation in morphine response.  
 
8.4 Closing Remarks 
 
I have been extremely fortunate to have had the opportunity of participating in 
research which combined clinical trials and laboratory based techniques. The data 
presented in this thesis add to the growing body of knowledge in the field of opioids 
and cancer pain. The clinical implications of such data however are as yet unclear. 
The possiblity for further research in this area is enormous. The incorporation of 
validated symptom assessment tools with a comprehensive investigation of the 
genetic factors underlying inter-individual variation in response to opioids has the 
potential to revolutionize cancer pain management. Prospective prediction of choice 
and dose of opioid would facilitate targeted and expedited pain management and 
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promote rationale drug use for individualized patient care. Pharmacogenomics is a 
rapidly expanding field. The application of such advances in cancer pain is likely to 
be possible in the future, but not just yet.  
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Appendix B  Case Report forms for the clinical trials 
presented in this thesis 
 
 
This appendix contains the following documents: 
 
Prospective Morphine Study Case Report Form 
o Demographics 
o Pain Assessment (modified Brief Pain Inventory) 
o Morphine Toxicity Scores 
o Opioid and breakthrough medication details 
o Criteria for changing to an alternative opioid 
o Concomitant medication details 
o Reason for study withdrawal and details of death 
 
Randomised Controlled Trial Case Report Form 
o Demographics 
o Pain Assessment (including modified Brief Pain Inventory, S-LANSS) 
o Opioid Toxicity Scores 
o Opioid history and concomitant medications 
o Opioid and breakthrough medication details 
o Criteria for switching to an alternative opioid 
o Follow up log 
o Clinical Assessment sheet 
o Reason for reaching study endpoint 
o Titration diary 
o Constipation assessment tool  
Other study documents used included the patient information sheet, the consent form 
and the GP information sheet (not shown here). 
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Prospective Morphine Study Case Report Form 
 
 
A Study to assess the Genetic Determinants of Response to Morphine 
 
Demographics 
 
Name: 
 
Hospital No: 
Diagnosis 
 
DOB: 
Sex 
 
Date: 
Height (cm): 
 
Weight (Kg): 
 
Information on Ethnicity 
Please select one of the following that most clearly resembles your ethnic origin. 
 
White -      
British      1 
Irish      2 
Any other White background   3 
Please specify………………………………………………   
   
Black or Black British  -  
       Carribean      4 
        African      5 
      Any other Black background    6 
Please specify…………………………………………………   
  
Asian or Asian British –  
       Indian      7 
        Pakistani      8 
       Bangladeshi     9 
      Any other Asian background   10 
Please specify………………………………………………… 
 
Mixed -     White and Black Carribean   11 
White and Black African    12 
White and Asian     13 
Any other Mixed background    14  
  Please specify…………………………………………………. 
 
Chinese       15 
 
Jewish -                Sephardic     16 
 Ashkenazi     17 
 
Any other Ethnic Background    18 
  395
Please specify………………………………………………….  
 
Current alcohol consumption. 
 
How many units of alcohol do you take, on average, per week?   
(Please circle one of the following) 
  
- 0 - 7 units? 
 
- 7 - 14 units? 
 
- 14 - 21 units? 
 
- More than 21 units? 
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MODIFIED BRIEF PAIN INVENTORY (Short Form) 
 
 
 
Name:  
____________________________________________________________________ 
 
 
Date:  ___/____/____ 
 
 
Circle as appropriate       Control / Switch    (Patients who are switched need to 
have a pain score repeated 1 week after they are switched- appendix 5 and 6). 
 
Date pain and toxicity scores need to be repeated:  ___/____/____ 
 
1. Throughout our lives, most of us have had pain from time to time (such as 
minor headaches, sprains and toothaches).  Have you h ad pain other than 
these everyday kinds of pain today? 
 
   1. Yes   2. No 
 
 
2. On the diagram, shade in the areas where you feel pain. Put an X on the area 
where you have pain. 
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3. Please rate your pain by circling the one number that best describes your  pain 
at its worst in the last 24 hours. 
0   1 2 3 4 5 6 7 8 9 10 
No pain         Pain as 
bad as           you 
can imagine 
 
4. Please rate your pain by circling the one number that best describes your  pain 
at its least in the last 24 hours. 
0   1 2 3 4 5 6 7 8 9 10 
No pain         Pain as 
bad as           you 
ca imagine 
 
 
5. Please rate your pain by circling the one number that best describes your 
pain on the average. 
0    1 2 3 4 5 6 7 8 9 10 
No pain         Pain as 
bad as           you can 
imagine 
 
 
6. Please rate your pain by circling the one number that tells how much pain 
you have right now. 
0   1 2 3 4 5 6 7 8 9 10 
No pain         Pain as 
bad as           you 
can imagine 
7. In the last 24 hours, how much relief  have pain  treatments or medications 
provided for your pain? Please circle the one percentage that most shows how 
much relief you have received?   
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
No relief         Complete 
relief 
 
 
 
  398
A Study to assess the Genetic Determinants of Response to Morphine 
 
Toxicity Scores 
 
Name:  
____________________________________________________________________ 
 
Date:  ___/____/____ 
 
During the past week: 
 
 
 
Not at All A Little Quite a Bit Very Much 
1) Have you felt nauseous? 
 
 
0 1 2 3 
2) Did you vomit? 
 
 
0 1 2 3 
3) Have you had 
constipation? 
 
0 1 2 3 
4) Have you had 
diarrhoea? 
 
0 1 2 3 
5) Have you been drowsy? 
 
 
0 1 2 3 
6) Have you felt confused, 
disorientated or had 
hallucinations? 
7)  
0 1 2 3 
8) Have you had bad 
dreams? 
0 1 2 3 
 
 
Please record here any other adverse effects you have experienced with the study 
medication, and score appropriately as above: 
 
Symptom 
 
Not at All A Little Quite a Bit Very Much 
8)…………………………… 
 
0 1 2 3 
9)…………………………… 
 
0 1 2 3 
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Opioids and Breakthrough Medication  
 
 
Name:  
____________________________________________________________________ 
 
 
Date:  ___/____/____ 
 
 
Current Regular Opioid  
 
 
Dose and Frequency 
Breakthrough Opioid 
 
 
Dose and Frequency 
No of breakthrough doses per day 
(Average daily requirements over past 3 
days) 
 
 
 
• Time and Date of last dose of opioid  .............................................................................  
 
• Time and Date of study blood sample ............................................................................  
 
• Time and Date of study urine sample  ............................................................................  
 
What date did you start taking opioids  ................................................................................  
(If you cannot remember the date, give an approximation in weeks and days of the length of time you 
have been on this dose). 
 
What date did you start taking this dose of opioid  ..............................................................  
(If you cannot remember the date, give an approximation in weeks and days of the length of time you 
have been on this dose). 
 
 
If you have changed your opioid medication in the last month, please tell us why you 
changed it :   
 
 ...............................................................................................................................................  
 ...............................................................................................................................................  
 
• Do you take anything else for your breakthrough pain?  
 
Describe:  ..............................................................................................................................  
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Criteria for changing to an alternative opioid 
 
 
Name:_______________________________________________________________
___ 
 
 
Date:  ___/____/____ 
 
 
Please give reason for changing to an alternative opioid 
 
 
1) Uncontrolled Pain 
 
 
2) Opioid Toxicity  
(Side effects which are intractable despite appropriate intervention 
and at a level unacceptable to the patient) 
 
- Nausea 
 
 
- Vomiting 
 
 
- Constipation 
 
 
- Drowsiness 
 
 
- Confusion / Hallucinations 
 
 
- Nightmares 
 
 
- Pruritis 
 
 
- Myoclonus 
 
 
- Any other symptom 
 
Describe…………………………………………. 
 
 
 
 
Was patient already on medications to control this symptom?   Y/N 
If so, what (Medication and dose)?:- 
 
 ...............................................................................................................................................  
 ...............................................................................................................................................  
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Concomitant Medication 
 
 
Name:  
____________________________________________________________________ 
 
 
Drug  
Date __/____/____ 
Enter dose and frequency 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
Date and Time last chemo given:  ................................................................................ 
 
Date and Time of last Blood transfusion:  .................................................................. 
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Reasons for withdrawal 
 
Name:  
____________________________________________________________________ 
 
 
On what date did the patient withdraw from the study? .............................................. 
 
What was the reason for withdrawal? 
   
  patient requests to withdraw ?       Y/N 
 
  patient too ill to continue?             Y/N 
 
                       patient unable to complete assessments?   Y/N 
 
  other                      Y/N 
  please specify   ................................................................ 
     ................................................................ 
 
Date of Death    ................................................................ 
 
Certified Cause of Death Ia ................................................................ 
    Ib ................................................................ 
    Ic ................................................................ 
    II ................................................................ 
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Randomised Controlled Trial Case Report Form 
 
Morphine versus Oxycodone for Pain Relief 
 
 
Patient Study Number: RCT_____________ 
 
Name: 
 
Hospital No: 
Diagnosis 
 
DOB: 
Sex 
 
Date: 
Height (cm): 
 
Weight (Kg): 
Postcode:  
 
NHS number: 
 
Information on Ethnicity 
Please select one of the following that most clearly resembles your ethnic origin. 
 
White -      
British      1 
Irish      2 
Any other White background   3 
Please specify………………………………………………   
   
Black or Black British  -  
       Carribean      4 
        African      5 
      Any other Black background    6 
Please specify…………………………………………………   
  
Asian or Asian British –  
       Indian      7 
        Pakistani      8 
       Bangladeshi     9 
      Any other Asian background   10 
Please specify………………………………………………… 
 
Mixed -     White and Black Carribean   11 
White and Black African    12 
White and Asian     13 
Any other Mixed background    14  
  Please specify…………………………………………………. 
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Chinese       15 
 
Jewish -                Sephardic     16 
- Ashkenazi     17 
Any other Ethnic Background    18 
 
Please specify………………………………………………….  
 
 
 
 
 
Current alcohol consumption. 
 
How many units of alcohol do you take, on average, per week?   
(Please circle one of the following) 
  
- 0 - 7 units? 
 
- 7 - 14 units? 
 
- 14 - 21 units? 
 
- More than 21 units? 
 
 
 
 
Is your natural hair colour red?  Yes      /        No 
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MODIFIED BRIEF PAIN INVENTORY (Short Form) 
 
 
 
 
Name:  ___________________    Date:  ___/____/____ 
 
Time points: (please circle) 
 
A:  At time of entry to the study (baseline). 
 
B: When the patient is stabilised on first line opioid (approx one week).  
 
C:  If patients do not respond to the first line opioid and require switching to the 
alternative arm of the study (samples must be taken before receiving their first 
dose of alternative opioid). 
 
D:  If the patient is stabilised on second line opioid (approx one week post-switch). 
 
E:  If patients’ analgesic requirements have increased by 200% of their initial stable 
dose of opioid.  
 
F: If patients do not respond to the second opioid and fit the criteria to exit from the 
study. 
 
 
 
1. Throughout our lives, most of us have had pain from time to time (such as 
minor headaches, sprains and toothaches).  Have you had pain other than these 
everyday kinds of pain today? 
    
1. Yes   2. No 
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2. On the diagram, shade in the areas where you feel pain. Put an X on the area 
where you have pain. 
 
 
 
 
 
 
What type of pain is the participant describing? (please circle) 
 
Somatic  Body surface (usually sharper and may have a burning or 
pricking quality)or deep tissues (ie musculoskeletal) 
 
Somatic (bony) dull ache within bones or tender hot spot  
 
Visceral Pain due to infiltration, compression, extension or stretching of 
the thoracic, abdominal or pelvic viscera (internal organs within 
a cavity).  Visceral pain is usually not well localized and 
described pressure-like/squeezing. 
 
Neuropathic Due to injury to the nervous system, usually burning or 
tingling. 
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3. Please rate your pain by circling the one number that best describes your  
pain at its worst in the last 24 hours. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain         Pain as bad as 
           
 you can imagine 
 
 
4. Please rate your pain by circling the one number that best describes your  
pain at its least in the last 24 hours. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain             Pain as bad as 
              
you can imagine 
 
 
5. Please rate your pain by circling the one number that best describes your 
pain on the average. 
 
0    1 2 3 4 5 6 7 8 9 10 
No pain         Pain as 
bad as            you 
can imagine 
 
 
6. Please rate your pain by circling the one number that tells how much pain 
you have right now. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain         Pain as 
bad as           
 you can imagine 
 
7. In the last 24 hours, how much relief  have pain  treatments or 
medications provided for your pain? Please circle the one percentage that 
most shows how much relief you have received?   
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
No relief         Complete 
relief 
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S-LANSS 
 
1. In the area where you have pain, do you also have ‘pins and needles’, 
tingling or prickling sensations? 
 
a) NO – I don’t  get these sensations (0) 
b) YES – I get these sensations (5) 
 
 
2. Does the painful area change colour (perhaps looks mottled or more red) 
when the pain is particularly bed? 
 
a) NO – The pain does not affect the colour of my skin (0) 
b) YES – I have noticed that the pain does make my skin look different from normal (5) 
 
 
3. Does your pain make the affected skin abnormally sensitive to touch? 
Getting unpleasant sensations or pain when lightly stroking the skin 
might describe this. 
 
a) NO – The pain does not make my skin in that area abnormally sensitive to touch (0) 
b) YES – My skin in that area is particularly sensitive to touch (3) 
 
 
4. Does your pain come on suddenly and in bursts for no apparent reason 
when you are completely still? Words like ‘electric shocks’, jumping and 
bursting might describe this. 
 
a) NO – My pain doesn’t really feel like this (0) 
b) YES – I get these sensations often (2) 
 
 
5. In the area where you have pain, does your skin feel unusually hot like a 
burning pain? 
 
a) NO – I don’t have burning pain (0) 
b) YES – I get burning pain often (1) 
 
 
6. Gently rub the painful area with your index finger and then rub a non-
painful area (for example, an area of skin further away or on the opposite 
side from the painful area). How does this rubbing feel in the painful 
area? 
 
a) The painful area feels no different from the non-painful area (0) 
b) I feel discomfort, like pins and needles, tingling or burning in the painful  
 area that is different from the non-painful area (5) 
 
 
7. Gently press on the painful area with your finger tip then gently press in 
the same way on to a non-painful area (the same non-painful area that 
you chose in the last question). How does this feel in the painful are? 
 
a) The painful area does not feel different from the non-painful area (0) 
b) I feel numbness or tenderness in the painful area that id different from the 
 non-painful area (3) 
 
 
Scoring: a score of 12 or more suggests pain of predominately neuropathic origin 
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TOXICITY SCORES 
 
Name:  __________________                                     Date:  ___/____/____ 
     
 
Current Opioid (please circle)  Morphine / Oxycodone 
 
 
Time point (please circle)  A B C D E F 
 
 
During the past 24 Hours: 
 
 
Symptom  Not  
at all 
  
Worst  
imaginable 
 
Have you felt nauseous due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you vomited due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you been constipated due to the opioid?  
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you had diarrhoea due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you felt drowsy due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
 
10 
 
Have you felt confused, disorientated or 
experienced hallucinations due to the opioid? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
 
 
10 
 
Have you had bad dreams due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you had any other notable symptoms due 
to the opioid? 
……………………………………………. 
 
0 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
 
…………………………………………….. 
 
0 
 
 
1 
 
2 
 
3 
 
 
4 
 
5 
 
6 
 
7 
 
 
8 
 
9 
 
10 
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OPIOID HISTORY AND CONCOMITANT MEDICATION 
 
 
Name:……………………………    Date  ….. / …… / ……. 
 
Current Opioid: (please circle)  Morphine/Oxycodone 
 
Time Point: (please circle)  A B C D E F 
 
 
Opioid History: (Baseline data collection only) 
 
Name of previous step 2 analgesia 
 
Approximate dates of administration 
(start – finish) 
  
  
  
  
 
Concomitant Medications:  
 
Drug Dose and frequency 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
Chemo:  Date and time last given ………………………………………. 
 
Blood transfusion: Date and time last given ……… 
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OPIOID DOSAGE AND BREAKTHROUGH MEDICATION 
 
 
Name:………………………………    Date: ……/……/……..
      
 
Time Point: (please circle) A    B C D E F 
 
 
Current Regular Opioid:  (please circle) 
 
                Morphine  /  Oxycodone 
 
 
Dose and Frequency 
Breakthrough Opioid 
 
 
 
Dose and Frequency 
Number of breakthrough doses per day 
(Average daily requirements over past 3 
days) 
 
 
 
 
• Time and Date of last dose of opioid 
………………………………………………….. 
 
 
 
• Time and Date of study blood sample 
………………………………………………. 
 
 
 
• Time and Date of study urine sample ……………………………………………… 
 
 
• What date did you start taking this dose of opioid 
………………………………… 
(If you cannot remember the date, give an approximation in weeks and days of the length of time you have 
been on this dose). 
 
 
• Do you take anything else for your breakthrough pain?  
 
Please specify……………………………………………………………….. 
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CRITERIA FOR CHANGING TO AN ALTERNATIVE OPIOID 
 
 
Name: ………………………………    Date: ……./……../…….. 
 
Current Opioid: (please circle) Morphine / Oxycodone 
 
Has the participant already switched once? (please circle) Y   /    N  
 
 
 
Please give the primary reason for changing to an alternative opioid 
 
1) Uncontrolled Pain 
 
 
2) Opioid Toxicity  
(Side effects which are intractable despite appropriate intervention 
and at a level unacceptable to the patient) 
 
- Nausea 
 
 
- Vomiting 
 
 
- Constipation 
 
 
- Drowsiness 
 
 
- Hallucinations 
 
 
- Nightmares 
 
 
- Pruritis 
 
 
- Myoclonus 
 
 
- Any other symptom 
 
Describe…………………………………………. 
 
 
 
Was patient already on medications to control this symptom?   Y/N 
If so, what (please specify medication and dose) 
 
…………………………………………………………………………………………
…… 
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SOURCE OF REFERRAL 
 
 
 
 
Name ………………………………………… Date ……./………./……… 
 
 
Referring Team: (please circle) 
 
Medical Oncology 
 
Clinical Oncology 
 
Surgical 
 
Palliative Care 
 
 
 
Geography of Patient: (please circle) 
 
   Outpatient Clinic 
 
   Inpatient 
 
   Ward (please specify)………………………………………… 
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FOLLOW UP PROFORMA 
 
 
Name ……………………………………………   
 
TELEPHONE CALLS 
 
DATE REASON OUTCOME 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
OUTPATIENT CLINICS 
 
CLINIC DATE ROUTINE  
(Y / N) 
TRANSPORT 
BOOKED 
(Y / N) 
OUTCOME 
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CLINICAL ASSESSMENT FORM 
 
 
 
Name……………………………………….. Date ……/………/……… 
 
 
Current Opioid (please circle)   Morphine  /  Oxycodone 
 
 
Initial Stable Dose Of Opioid …………  Present Dose Of Opioid 
………… 
 
 
1. Have there been any significant clinical events in last 4 weeks?  
 
     
 ……………………………………………… 
       
     
 ……………………………………………… 
 
2. Is there any specific evidence of disease progression?  
(blood tests/tumour markers, imaging) 
     
 ……………………………………………… 
    
     
 ……………………………………………… 
  
     
 ……………………………………………… 
 
3. Have there been any changes to concurrent medication? (please specify 
medication) 
 
     
 ……………………………………………… 
 
     
 ……………………………………………… 
 
     
 ……………………………………………… 
 
4. Is there any other relevant information?  
     
 …………………………………………….. 
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STUDY ENDPOINT 
 
Name: ………………………………. 
 
On what date did the patient reach the study endpoint? ....................... 
 
 
Why has the subject reached the study endpoint? 
 
1. Non-response to 2nd line opioid (ie reached Time Point F) 
2. Converted to parenteral opioids 
3. Unable to take oral opioids 
4. Renal impairment (>1.5 upper limit of normal) 
5. Patient requested to withdraw 
6. Patient has died 
 
7. Other 
…………………………………………………………………. 
 
 
Date of Death ................................................................ 
 
Certified Cause of Death
 Ia…………………………………………. 
 Ib…………………………………………. 
 Ic………………………………………… 
 II…………………………………………. 
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OPIOID TITRATION DIARY 
 
 
Name:………………………………    Today’s date:
 ……/……/……..      
CURRENT OPIOID (please circle) Morphine / Oxycodone 
4 hourly dose 
  
mg 
Number of 4 hourly doses taken in last 24hours 
 
 
Breakthrough dose 
 
mg 
Number of breakthrough doses in last 24hours 
 
 
Total dose (mg) of morphine/oxycodone  in last 24hours 
 
mg 
 
SIDE EFFECTS:  In the past 24hours……. 
Symptom  Not  
at all 
  
Worst  
imaginable 
 
Have you felt nauseous? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you vomited due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you been constipated due to the opioid?  
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you had diarrhea due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you felt drowsy due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
 
10 
 
Have you felt confused, disorientated or 
experienced hallucinations due to the opioid? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
 
 
10 
 
Have you had bad dreams due to the opioid? 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Have you had any other notable symptoms? 
 
……………………………………………. 
 
0 
 
1 
 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
PAIN SCORES IN LAST 24 HOURS 
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1. Please rate your pain by circling the one number that best describes your  
pain at its worst in the last 24 hours. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain          Pain as 
bad as           
 you can imagine 
 
2. Please rate your pain by circling the one number that best describes your  
pain at its least in the last 24 hours. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain             Pain as 
bad as             
  you can imagine 
 
3. Please rate your pain by circling the one number that best describes your 
pain on the average. 
 
0    1 2 3 4 5 6 7 8 9 10 
No pain         Pain as 
bad as           
 you can imagine 
 
4. Please rate your pain by circling the one number that tells how much pain 
you have right now. 
 
0   1 2 3 4 5 6 7 8 9 10 
No pain         
 Pain as bad as        
   you can imagine 
 
5. In the last 24 hours, how much relief  have pain  treatments or medications 
provided for your pain? Please circle the one percentage that most shows how 
much relief you have received?   
0% 10% 20% 30% 40% 50% 60% 70% 80% 90%
 100% 
No relief        
 Complete relief 
 
 
 
OTHER PAIN KILLERS TAKEN IN LAST 24 HOURS?  
ie paracetamol, ibuprofen, gabapentin 
 
…………………………………………………………………………………………
……………………………………………………………………………………… 
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Study number: _____________________  Date: ____________________________ 
Constipation on Opioids Assessment 
 
 
Are you satisfied with how your bowel has functioned during the PAST WEEK?      
(Please tick) Yes□     No□  
What does being constipated mean to you? _______________________________________ 
 
During the PAST WEEK how active have you been? (Please tick) 
□  Fully active, able to carry out all activities without restriction 
□ Fully mobile, able to carry out light work. Unable to carry out 
physically strenuous activity 
□ Mobile, capable of self-care, unable to carry out any work. Up and 
about more than 50% of waking hours. 
□ Capable only of limited self-care, confined to bed or chair more than 
50% of waking hours. 
□  Unable to carry out self care. Totally confined to bed or chair 
 
  
In the PAST WEEK have you been constipated? (Please tick) 
 
Not at all □  A little□  Quite a bit □  Very much □ 
 
In the PAST WEEK how has your bowel functioned OVERALL? (Please tick) 
Severe diarrhoea  □ 
Moderate diarrhoea  □ 
Mild diarrhoea   □ 
Normal    □ 
Mild constipation  □ 
Moderate constipation  □  
Severe constipation  □ 
 
In the PAST WEEK please rate how constipated you been?                                                  
0=not at all, 10 = worst imaginable                                                                                                                                   
(Please tick) 
0 □ 1□ 2□ 3□ 4□ 5□ 6□ 7□ 8□ 9□ 10□ 
 
During the past week what has your food intake been like?  
As usual□  Less than usual□  More than usual□ 
During the past week what has your fibre intake been like?  
As usual□  Less than usual□  More than usual□ 
During the past week what has your fluid intake been like? 
As usual□  Less than usual□  More than usual□ 
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Everyone’s usual bowel activity is different.  
During the PAST WEEK has your bowel activity been USUAL FOR YOU, MORE 
CONSTIPATED than usual or LESS CONSTIPATED than usual? (Please tick) 
 
 
 
 
 
 
 
 
 
 
 
 
During the PAST WEEK how many times did you open your bowels?                                     
(Please tick) 
More than once a day□  _______times in the week□   None at all □    
 
Everyone’s usual bowel activity is different. How many times a week do you USUALLY open 
your bowels? ___________________________________________ 
During the PAST WEEK did you open your bowels MORE or LESS FREQUENTLY 
than usual? (Please tick) 
 
 
 
 
 
 
 
 
 
During the PAST WEEK what  
 
During the PAST WEEK what has your STOOL CONSISTENCY been like in general?               
(See Bristol stool chart. Please tick) 
 
Type  1□ 2□ 3□ 4□ 5□ 6□ 7□ 
 
During the PAST WEEK have your stool been HARD (Please tick) 
 
Never □  Rarely□  Occasionally □ Nearly always □ 
 
 
During the PAST WEEK did you have to STRAIN to open your bowels? (Please tick) 
 
Not at all □  A little□  Quite a bit □  Very much □ 
A little bit more constipated □   
 
Quite a bit more constipated □ 
 
A lot more constipated    □ 
A little less constipated       □ 
 
Quite a bit less constipated   □ 
 
A lot less constipated   □ 
A little bit less frequently  □ 
 
Quite a bit less frequently  □ 
 
A lot less frequently    □ 
 
A little bit more frequently □ 
 
Quite a bit more frequently □ 
 
A lot more frequently  □ 
Usual for you □ 
Usual for you □ 
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Laxatives taken during the past week: 
  422
 
Laxative Name 
 
Laxative dose and 
how often taken a 
day? 
How many days 
did you take this 
medication? 
Any side-
effects with 
this 
medication? 
  
 
   
  
 
   
  
 
   
  
 
   
  
 
   
  
 
   
 
Other current medications: 
Medication Name Dose and frequency 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
 
Planned change to laxative regimen:  
 
 
  423
 
The Royal Marsden NHS Foundation Trust 
RCT 2586 
Adverse / Serious Adverse Event Log 
Patient Initials and Study Number: 
Date entered study: Date completed: 
AE 
No 
Adverse event 
(Diagnosis or syndrome if known 
or signs / symptoms) 
Start date 
DD/MM/YY 
Stop date 
DD/MM/YY 
Ongoing 
Tick if ‘yes’ 
Once stop date 
known enter 
date in stop 
date field and 
draw a line 
through 
ongoing box. 
Initial / date 
Severity 
1=mild 
2=moderate 
3 =Severe 
Expectedness 
1 = expected 
2 = not expected 
Relationship to 
study drug 
1= probably 
2= possibly 
3=unrelated 
Action 
taken with 
study drug 
1=None 
2=dose 
reduced 
temporarily 
3=study med 
interrupted  
Outcome 
1=recovered 
2= stabilized 
3=recovered 
with sequelae 
4= not yet 
recovered 
5=fatal 
6=unknown 
Serious Adverse 
Event 
If serious complete 
SAE form as per 
SOP 
Yes / No 
CI/Delegated 
individual 
review 
Please initial and 
date 
     
 
 
       
 
            
 SAE Definition: 
Hospitalisation / prolongation of hospitalisation 
Death 
Life-threatening event 
Resulting in persistent / significant incapacity 
Resulting in congenital abnormality 
 
AE Definition: 
Any untoward medical occurrence in a subject to whom a medicinal product has 
been administered, including occurrences which are not necessarily caused by or 
related to that product. 
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Appendix C  OPRM, OPRD and OPRK 
 
This appendix contains details of the primer sequences for OPRM, OPRD and OPRK. Negative findings from the candidate gene association 
study are also presented here. 
 
Primer sequences 
 
Primer sequence for OPRD 
Gene /                   
rs number 
Location Absolute 
position 
(bp) 
AA 
change 
Nucleotide 5’ – 3’ specific primer sequence Product 
length 
Vol (uL)2 Control 
primer 
rs 1042114 Exon 1 29011562 Cys-Phe G GCCTACCCTAGCGCCTG 693 10 210/211 
    T CGCCTACCCTAGCGCCTT  10  
    Consensus AAGCTCACACCAACAGATGAGC  10  
rs 533123 Intron 1 29013742  G GTTGGCTGACTGAGCACAG 819 10 210/211 
    A TGGTTGGCTGACTGAGCACAA  10  
    Consensus TCTGCTCTCTGAGGACTCTAA  10  
rs 419335 Intron 1 29024431  A TCCCTGCCTCTCTCTCACTTT 702 10 210/211 
    G CCTGCCTCTCTCTCACTTC  10  
    Consensus AGGCACCCTGCCTAGAGAT  10  
rs 2236857 Intron 1 29034196  T TCCAACACTCAGACAGCATGT 267 10 63/64 
    C TCCAACACTCAGACAGCATGC  10  
    Consensus ACACTCAACAAGAAGCAGGAC  10  
rs 2234918 Exon 3 29062184 Gly-Gly C TTGAGGCTGCTATTGGCGTAG 766 10 63/64 
    T TTGAGGCTGCTATTGGCGTAA  10  
    Consensus TGTTGTCTGTCTTAGCAGTCC  10  
These primers were designed by Dr Sophy Gretton  
OPRD reference sequence NT_004610.18 
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Primer sequence for OPRM 
Gene /                   
rs number 
Location Absolute 
position 
(bp) 
AA 
change 
Nucleotide 5’ – 3’ specific primer sequence Product 
length 
Vol (uL)2 Control primer 
rs6912029* Exon 1 154402201 Gln-His G GGAGAATGTCAGATGCTCAG 520 10 210/211 
    T AGGAGAATGTCAGATGCTCAT  10  
    Consensus CATTGAGCCTTGGGAGTTAG  10  
rs1799971*  Exon 1  154402490 Asn-Asp A TTGTCCCACTTAGATGGCA 670 10 210/211 
    G TGTCCCACTTAGATGGCG  10  
    Consensus GTTGCCAAGGTCCATCTC  10  
rs589046* Intron 1 154434831 - C ACAGACTGATGGTTAGCAACC 310  4 63/64 
    T CACAGACTGATGGTTAGCAACT  4  
    Consensus CTGCCTACCTTGCTATGCC  2  
rs563649  Intron 1 154449660 - C GATCATGCAGGTCTATAACCAAC 647 5 210/211 
    T GATCATGCAGGTCTATAACCAAT  5  
    Consensus  GCTTCTGATTTACACGGTGCC  4  
rs9479757* Intron 2 154453037 - G CATATCAGGCTGTGAACCC 530 10 210/211 
    A AACATATCAGGCTGTGAACCT  10  
    Consensus AATAGCCAAGCTGATACTGG  10  
rs2075572* Intron 2 154453697 - G CTCTGGTCAAGGCTAAAAATG 750 20 210/211 
    C CTCTGGTCAAGGCTAAAAATC  20  
    Consensus CAATTTGCTTCCCCTCTTC  20  
rs533586 Intron 3 154455367 - C TGTGAGGACAGATGGCTCC 209 5 63/64 
    T ACTGTGAGGACAGATGGCTCT  5  
    Consensus  ATGACGGATGTATCTGGGCC  5  
*These primers were designed by Dr Joy Ross  
     OPRM reference sequence NT_025741.14  
 
  
  426
Prmer sequence for OPRK 
Gene /                   
rs number 
Location Absolute 
position 
(bp) 
AA 
change 
Nucleotide 5’ – 3’ specific primer sequence Product 
length 
Vol (uL)2 Control 
primer 
rs 10504151 Intron 2 54320793  T CCTGACAGTTATGGCCACACA 746 10 210/211 
    C CTGACAGTTATGGCCACACG  10  
    Consensus AGCTTCTTGGAGGAGTAATCC  10  
rs 7836120  Intron 2 54320092  A GAGTATAAGGGAGGATCTGCA 679 10 210/211 
    G GAGTATAAGGGAGGATCTGCG  10  
    Consensus TTAGAAGGACCAAGCTCTAG  10  
rs 6473799  Intron 2 54315676  T ACTCATCTCTGACCATGCTCAT 673 10 210/211 
    C CTCATCTCTGACCATGCTCAC  10  
    Consensus AGTAAAGGAACTCAGGCTTTC  10  
rs 1365098 Intron 2 54315236  G CATTGTTTTGTCCATTGAGGGG 659 10 210/211 
    T CATTGTTTTGTCCATTGAGGG T  10  
    Consensus TTCCTGCTGAGGAGTCACAG  10  
rs 7016778  Intron 2 54312658  T CATTCCCCAAGCTTTGTCTCAA 279 10 63/64 
    A CATTCCCCAAGCTTTGTCTCAT  10  
    Consensus TAGAAGGGCAGTAGTTTCGG  10  
rs 7824175 Intron 3 54306727  G CAGTTCACATTCTGGATGGAG 278 10 63/64 
    C CAGTTCACATTCTGGATGGAC  10  
    Consensus GTAGAAGAGTTTCCTTGGAGG  10  
rs 16918875 Exon 4 54304707 Val-Val C AGTCCAGCAGACGACGAAG 244 10 63/64 
    T GAGTCCAGCAGACGACGAAA  10  
    Consensus ATTGAGTGCTCCTTGCAGTTC  10  
rs 963549 3UTR 54304377  G TCATTGAACTCCTCTCTTCCC 261 10 63/64 
    A GATCATTGAACTCCTCTCTTCCT  10  
    Consensus ACTTCTGCATCGCCTTAGGC  10  
These primers were designed by Dr Sophy Gretton  
OPRK reference sequence NT_008183.18 
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Analgesic response 
 
Effects of OPRM on analgesic response to morphine (Additive model) 
    
Univariate linear regression 
Log10Component1 (pain scores) as dependent variable 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β 
P 
value 
rs6912029 GG 91.8 (178) 0.45 (0.01)     
 GT 8.2 (16) 0.45 (0.04) -0.004 0.038 -0.008 0.911 
 TT 0 -     
rs1799971  AA 74.7 (145) 0.45 (0.01)     
 AG 21.1 (41) 0.43 (0.02) <0.001 0.02 0.002 0.981 
 GG 4.1 (8) 0.49 (0.06)     
rs589046 CC 50.3 (95) 0.45 (0.02)     
 CT 43.4 (82) 0.46 (0.01) -0.017 0.017 -0.073 0.319 
 TT 6.3 (12) 0.35 (0.04)     
rs563649  CC 80.4 (152) 0.45 (0.01)     
 CT 17.5 (33) 0.45 (0.03) 0.005 0.023 0.015 0.842 
 TT 2.1 (4) 0.44 (0.09)     
rs9479757 AA 1.0 (2) 0.23 (0.01)     
 AG 21.1 (41) 0.44 (0.02) -0.034 0.023 -0.105 0.148 
 GG 77.8 (151) 0.45 (0.01)     
rs2075572 CC 35.2 (68) 0.45 (0.02)     
 CG 46.6 (90) 0.44 (0.02) 0.003 0.015 0.013 0.861 
 GG 35.2 (68) 0.46 (0.02)     
rs533586 TT 48.7 (92) 0.45 (0.02)     
 
CT 40.7 (77) 0.45 (0.02) 0.005 0.016 0.025 0.734 
 
CC 10.6 (20) 0.44 (0.03)     
* mean (SEM) of log10Component1 scores  
No statistically significant associations found 
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Effects of OPRD on analgesic response to morphine (Dominant model) 
  
Carrying allele Not carrying allele Univariate linear regression 
Log10Component1 (pain scores) as dependent variable 
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P 
value 
rs1042114 T 98.4 (186) 0.45 (0.01) 1.6 (3) 0.4 (0.03) 0.043 0.084 0.038 0.607 
 G 26.5 (50)  0.45 (0.02) 73.5 (139) 0.45 (0.01) 0.001 0.024 0.002 0.98 
rs533123 A 95.2 (180)  0.45 (0.01) 4.8 (9) 0.44 (0.03) 0.009 0.049 0.014 0.851 
 G 34.9 (66)  0.44 (0.02) 65.1 (123) 0.45 (0.01) -0.006 0.022 -0.02 0.79 
rs419335 A 89.4 (169)  0.44 (0.01) 10.6 (20) 0.47 (0.04) -0.023 0.034 -0.05 0.499 
 G 55 (104)  0.44 (0.02) 45 (85) 0.46 (0.01) -0.017 0.021 -0.807 0.42 
rs2236857 C 45 (85)  0.44 (0.02) 55 (104) 0.45 (0.01) -0.013 0.021 -0.046 0.533 
 T 92.6 (175)  0.45 (0.01) 7.4 (14) 0.43 (0.05) 0.014 0.04 0.025 0.731 
rs2234918 C 65.6 (124)  0.45 (0.01) 34.4 (65) 0.44 (0.02) 0.018 0.022 0.058 0.434 
 T 81.5 (154)  0.45 (0.01) 18.5 (35) 0.44 (0.02) 0.011 0.027 0.029 0.693 
* mean (SEM) of log10Component1 scores 
No statistically significant associations found 
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Effects of OPRD on analgesic response to morphine (Additive model) 
    
Univariate linear regression 
Log10Component1 (pain scores) as dependent variable 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β 
P 
value 
rs1042114 TT 73.5 (139) 0.45 (0.01)     
 GT 24.9 (47) 0.45 (0.02) 0.002 0.022 0.008 0.912 
 GG 1.6 (3) 0.4 (0.03)     
rs533123 AA 65.1 (123) 0.45 (0.01)     
 GA 30.2 (57) 0.44 (0.02) 0.005 0.018 0.021 0.773 
 GG 4.8 (9) 0.44 (0.03)     
rs419335 AA 45 (85) 0.46 (0.01)     
 AG 44.4 (84) 0.43 (0.02) 0.005 0.016 0.021 0.773 
 GG 10.6 (20) 0.47 (0.04)     
rs2236857 CC 7.4 (14) 0.43 (0.05)     
 TC 37.6 (71) 0.44 (0.02) 0.011 0.017 0.047 0.527 
 TT 55 (104) 0.45 (0.01)     
rs2234918 CC 18.5 (35) 0.44 (0.02)     
 CT 47.1 (89) 0.46 (0.01) -0.005 0.015 -0.308 0.758 
 
TT 34.4 (65) 0.44 (0.02)     
* mean (SEM) of log10Component1 scores  
No statistically significant associations found 
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Central Side-effects  
 
Effects of OPRD on central side-effects of morphine (Dominant model) 
  
Carrying allele Not carrying allele Univariate linear regression 
Log10Component2 (central side-effect scores) as 
dependent variable 
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P 
value 
rs1042114 T 98.4 (186) 0.39 (0.01) 1.6 (3) 0.42 (0.03) -0.023 0.089 -0.019 0.8 
 G 26.5 (50)  0.39 (0.02) 73.5 (139) 0.4 (0.01) -0.009 0.025 -0.027 0.716 
rs533123 A 95.2 (180)  0.39 (0.01) 4.8 (9) 0.41 (0.05) -0.015 0.052 -0.021 0.773 
 G 34.9 (66)  0.38 (0.02) 65.1 (123) 0.4 (0.01) -0.022 0.023 -0.07 0.341 
rs419335 A 89.4 (169)  0.39 (0.01) 10.6 (20) 0.43 (0.03) -0.035 0.036 -0.071 0.337 
 G 55 (104)  0.41 (0.02) 45 (85) 0.38 (0.02) 0.035 0.022 0.116 0.115 
rs2236857 C 45 (85)  0.41 (0.02) 55 (104) 0.38 (0.01) 0.03 0.022 0.098 0.182 
 T 92.6 (175)  0.39 (0.01) 7.4 (14) 0.46 (0.03) -0.067 0.042 -0.116 0.114 
rs2234918 C 65.6 (124)  0.39 (0.01) 34.4 (65) 0.4 (0.02) -0.006 0.024 -0.02 0.788 
 T 81.5 (154)  0.4 (0.01) 18.5 (35) 0.38 (0.03) 0.022 0.029 0.055 0.454 
* mean (SEM) of log10Component2 scores 
No statistically significant associations found 
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Effects of OPRD on central side-effects of morphine 
Genotype (Additive model) 
    
Univariate linear regression 
Log10Component2 (central side-effect scores) as dependent 
variable 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β 
P 
value 
rs1042114 TT 73.5 (139) 0.4 (0.01)     
 GT 24.9 (47) 0.39 (0.02) 0.0065 0.023 0.02 0.79 
 GG 1.6 (3) 0.42 (0.03)     
rs533123 AA 65.1 (123) 0.4  (0.01)     
 GA 30.2 (57) 0.38 (0.02) 0.013 0.019 0.05 0.499 
 GG 4.8 (9) 0.41 (0.05)     
rs419335 AA 45 (85) 0.38 (0.02)     
 AG 44.4 (84) 0.41 (0.02) -0.027 0.017 -0.12 0.103 
 GG 10.6 (20) 0.43 (0.03)     
rs2236857 CC 7.4 (14) 0.46 (0.03)     
 TC 37.6 (71) 0.4 (0.02) -0.03 0.018 -0.126 0.087 
 TT 55 (104) 0.38 (0.01)     
rs2234918 CC 18.5 (35) 0.38 (0.03)     
 
CT 47.1 (89) 0.4 (0.02) 0.009 0.016 0.044 0.554 
 
TT 34.4 (65) 0.4 (0.02)     
* mean (SEM) of log10Component2 scores  
No statistically significant associations found 
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Daily morphine dose 
 
Effects of OPRD on daily morphine dose (mg) 
Genotype (Additive model) 
    
Univariate linear regression 
log10 Daily morphine dose (mg) as dependent variable 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β 
P 
value 
rs1042114 TT 71.4 (95) 1.98 (0.04)     
 GT 26.3 (35) 2.02 (0.05) -0.035 0.06 -0.58 0.563 
 GG 2.3 (3) 2.04 (0.16)     
rs533123 AA 61.7 (82) 2.0 (0.04)     
 GA 33.1 (44) 1.95 (0.05) 0.009 0.051 0.015 0.861 
 GG 5.3 (7) 2.1 (0.08)     
rs419335 AA 45.9 (61) 1.97 (0.04)     
 AG 44.4 (59) 1.97 (0.05) -0.073 0.046 -0.137 0.115 
 GG 9.8 (13) 2.2 (0.1)     
rs2236857 CC 6.0 (8) 2.24 (0.15)     
 TC 36.8 (49) 1.98 (0.05) -0.062 0.05 -0.109 0.211 
 TT 57.1 (76) 1.98 (0.04)     
rs2234918 CC 18.8 (25) 2.0 (0.07)     
 
CT 48.1 (64) 2.03 (0.05) -0.038 0.043 -0.077 0.377 
 
TT 33.1 (44) 1.94 (0.05)     
* mean (SEM) of Log10 Daily morphine dose(mg) 
No statistically significant associations found 
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Effects of OPRK on daily morphine dose (mg) 
Genotype (Additive model) 
    
Univariate linear regression 
log10 Daily morphine dose (mg) as dependent variable 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β 
P 
value 
rs10504151 TT 78.4 (105) 2.0 (0.03)     
 TC 20.1 (27) 2.02 (0.08) 0.049 0.066 0.064 0.464 
 CC 1.5 (2) 1.54 (0.24)     
rs7836120 AA 69.4 (93) 2.0 (0.03)     
 AG 26.9 (36) 2.03 (0.07) 0.056 0.055 0.088 0.313 
 GG 3.7 (5) 1.5 (0.13)     
rs6473799 TT 61.9 (83) 2.04 (0.04)     
 TC 32.8 (44) 1.91 (0.06) -0.12 0.061 -0.169 0.052 
 CC 5.2 (7) 2.0 (0.12)     
rs1365098 GG 47.8 (64) 2.0 (0.04)     
 GT 42.5 (57) 1.97 (0.05) 0.069 0.046 0.131 0.131 
 TT 9.7 (13) 1.89 (0.11)     
rs7016778 TT 74.6 (100) 2.0 (0.03)     
 TA 24.6 (33) 1.98 (0.07) 0.058 0.066 0.076 0.384 
 AA 0.7 (1) -     
rs7824175 GG 81.3 (109) 2.0 (0.03)     
 GC 17.9 (24) 1.95 (0.07) 0.004 0.073 0.005 0.955 
 CC 0.7 (1) -     
rs16918875 CC 83.6 (112) 2.0 (0.03)     
 CT 16.4 (22) 1.97 (0.1) 0.03 0.081 0.032 0.712 
 TT 0 -     
rs963549 GG 67.2 (90) 2.0 (0.03)     
 GA 30.6 (41) 1.98 (0.06) 0.013 0.058 0.02 0.822 
 AA 2.2 (3) 2.05 (0.25)     
* mean (SEM) of Log10 Daily morphine dose(mg) 
No statistically significant associations found 
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Appendix D  ADORA1 / ADRA2A / TRPV1 / ALOX12 / ARRB2 / SLC6A4 
 
This appendix contains details of the primer sequences for ADORA1, ADRA2A, TRPV1, ALOX12, ARRB2 and SLC6A4. Negative findings 
from the candidate gene association study are also presented here. 
 
Primer sequences 
 
 
Primer sequence for ALOX12 
rs number Location Absolute Position (bp) 
AA 
change Primer Type 5'-3' primer 
Vol 
(uL)2 
Control 
primer 
rs6502999 Promoter 6833363 - A TTG CTG CTT CAC CTT GCA CTT 5 210/211 
    G TTG CTG CTT CAC CTT GCA CTC 5  
    CONSENSUS CTT GGT GTG CTT CTC ACA GTA 5  
rs1126667 Exon 6 6843484 Gln-Arg G GTT CTT TCT CCA GTT GAG CCC 10 63/64 
    A AGT TCT TTC TCC AGT TGA GCC T 10  
    CONSENSUS ATA TAC CTG AAC CCC TGG GGT 10  
rs434473 Exon 8 6845658 Asn-Ser A TCC CAG ATT CAG CCT CCC AA 10 63/64 
    G TCC CAG ATT CAG CCT CCC AG 10  
    CONSENSUS ACA GTC TCC TCT TCA CTC ACA 10  
These primers were designed by Dr Sophy Gretton 
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Primer sequence for ADRA2A 
rs number Location Absolute Position (bp) 
AA 
change Primer Type 5'-3' primer 
Vol 
(uL)2 
Control 
primer 
rs638019 promoter 112821819 - G GAA AAC ACC TGG CTT AAT TTT CCG 10 63/64 
    A GAA AAC ACC TGG CTT AAT TTT CCA 10  
    CONSENSUS CCT TGG GAA TCC CAT CGT TAT 10  
rs11195418 promoter 112825149 - A TGT ATC ACT GGT GCG GGC TA 10 210/211 
    G TAT CAC TGG TGC GGG CTG 10  
    CONSENSUS TTG AGG ACC GAA AGC TAG ACT 10  
rs1800544 promoter 112826493 - C AGT TGG CCA TGC AGC TC 5 210/211 
    G AGT TGG CCA TGC AGC TCGC 5  
    CONSENSUS AGT CTA GCT TTC GGT CCT CAA 5  
rs11195419 3UTR 112829358 - C ATC CCC AGT TGT TGG TTT GGC 15 63/64 
    A ATC CCC AGT TGT TGG TTT GG 15  
    CONSENSUS GAG AGA GAG TTG GGA ATG GAAA 15  
rs3750625 3UTR 112829591 - C AAG AAA AAT GCT AAG GGC AGC C 10 63/64 
    A AAG AAA AAT GCT AAG GGC AGC A 10  
    CONSENSUS GAA ATC TCA AAG CAG GTC CGT 10  
rs602618 Downstream 112833075 - A TTG ACA CAA AGC AGG CAC AGT 5 63/64 
    C TTG ACA CAA AGC AGG CAC AGG 5  
    CONSENSUS TAG AGC CAG AAG CAT CCT CAT 5  
These primers were designed by Dr Sophy Gretton 
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Primer sequence for SLC6A4 
rs number 
Location Absolute 
Position 
(bp) 
AA change 
Primer Type S/AS 5'-3' primer Product length 
Vol 
(uL)2 
Control 
primer 
rs7214991 PROMOTOR 3300457 -  A S ACA ACT TCA GCC CAT TTC CCT A 486  5 63/64 
     G S ACA ACT TCA GCC CAT TTC CCT G  5  
    CONSENSUS AS TAC CGA CCG GCT TGG TGA T  5  
rs 25528 
INTRON 
BOUNDARY 1 3278162 -  T S TGA TGC TGG GGT GGT TGG TT 332  
5 63/64 
     G S ATG CTG GGG TGG TTG GTG  5  
    CONSENSUS AS ATA AAC AGT CCA TCC CTG GC  5  
rs 6354 5UTR  3278082 -  T AS CGA CCT TGC TTG CCC TCT A 501  5 210/211 
     G AS  GAC CTT GCT TGC CCT CTC  5  
    CONSENSUS S ACT CGC TTC CCT TTG AGC CA  5  
rs 140700 INTRON 6 3271585 -  C S AAG ACC TTG AGA AAG GAG GGC 257  5 63/64 
     T S AAG ACC TTG AGA AAG GAG GGT  5  
    CONSENSUS AS AAG ATT CCT TCA ACC CAC TGG  5  
rs 4583306 INTRON 9 32668911 -  A S GTA ACA GAT CCA AGA CCC AGA  565  5 210/211 
     G S GTA ACA GAT CCA AGA CCC AGG  4  
    CONSENSUS AS AGT GGG TTT GCT TCC TGT GAT  4  
SERTP*302 PROMOTOR 3292128 - FORWARD S GAG GGA CTG AGC TGG ACA ACC AC 484/528  5 63/64 
    REVERSE  AS GGC GTT GCC GCT CTG AAT GC   5  
SERTP*303 PROMOTOR 3292079 - FORWARD S GGA G GAA CTG ACC CCT GAA AAC TG 484/528  5 63/64 
    REVERSE  AS GCC GCT CTG AAT GCC AGC AC  5  
        
  
Reference primer sequence NW_926750 
*This denotes the reference paper from which the primer is taken 
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Primer sequence for ADORA1 
rs number Location Absolute Position (bp) 
AA 
change Primer Type 5'-3' primer 
Vol 
(uL)2 
Control 
primer 
rs2364571 Promoter 201327167 - C ACA CGG AGG GAA AGT AGA AGA C 5 63/64 
    G ACA CGG AGG GAA AGT AGA AGA G 5  
    CONSENSUS AGT GAG GTT AAA CCT GGG AGC 5  
rs9660662 Intron 2 201335343 - T GTG AAC TCC ATA GCT GTG TGA 5 63/64 
    C GTG AAC TCC ATA GCT GTG TGG 5  
    CONSENSUS TAG CTC TGC CAT TAA CCC GTA 5  
rs11590405 Intron 2 201346887 - T GTA TAA GGC TTA CCT CTC TGG GT 5 63/64 
    C AT AAG GCT TAC CTC TCT GGG C 5  
    CONSENSUS ATC TAG CAT GGG CCA GTA AGA 5  
rs903361 Intron 2 201357897 - A GTC CCA GAT CTG CTC TGT AGT 5 63/64 
    G TCC CAG ATC TGC TCT GTA GC 5  
    CONSENSUS CAC AGC GTC TTG GAT GAT CTT 5  
rs10920568 Exon 5 201364898 Ala-Ala T GGC CCT GCT GGC AAT TGC T 5 63/64 
    G TGC CCT GCT GGC AAT TGC G 5  
    CONSENSUS AGT TCA CAG TAC AGT CCT CCA 5  
rs10800901 Intron 5 201377927 - G GCA CAT AGT AGG CAC TCC G 5 63/64 
    A TGG CAC ATA GTA GGC ACT CCA 5  
    CONSENSUS CTT CCC AAC CTG GCT TAC TCA 5  
rs3766560 Intron 5 201385017 - C CCT TCT TCT CCT TAT CCC CAC 5 210/211 
    T CCT TCT TCT CCT TAT CCC CAT 10  
    CONSENSUS CAC ATC TTG GTT GGC CTC ATT 5  
rs10920576 Intron 5 201395802 - C TGC TCC AAG CTT CCA TCC C 5 63/64 
    T CTG CTC CAA GCT TCC ATC CT 5  
    CONSENSUS TCA ACC AGC GGG TAT AAT GCA 5  
These primers were designed by Dr Sophy Gretton 
  
  438
 
Primer sequence for TRPV1 
rs number Location Absolute Position (bp) 
AA 
change Primer Type 5'-3' primer 
Vol 
(uL)2 
Control 
primer 
rs877610 Exon 15 3422240 - G TTG CCT GAG CGG AAG GCC 5 63/64 
    A TTG CCT GAG CGG AAG GCT 5  
    CONSENSUS GAT CTT GGC TGA CTG CAA CC 5  
rs2277679 Intron 12 3427524 - C TGG GAA GGG GCT GGT TTA C 5 63/64 
    G TGG GAA GGG GCT GGT TTA G 5  
    CONSENSUS GGG ATG CGT CTT GAG AAC GT 5  
rs222745 Intron 9 3435620 - C CCC TGC CTC AGG CTG TAC 5 63/64 
    T CCC TGC CTC AGG CTG TAT 5  
    CONSENSUS GGT TTC ACC ATG TTG GTC AG 5  
rs161393 Intron 8 3436263 - A GGG AGG GAG TTA TTA GAC ACA A 5 63/64 
    G GGA GGG AGT TAT TAG ACA CAG 5  
    CONSENSUS CAT GTC GTG GCG ATT CTA GG 5  
rs222747 Exon 7 3439949 Met-Ile C TGC AGT TTG GCC CCC AGC 5 63/64 
    G TGC AGT TTG GCC CCC AGG 5  
    CONSENSUS AGG TTT GGG CAG AGA CAG AG 5  
rs3744683 Promoter 3460211 - A GGC ATG GGG CAG TTC TCT T 5 210/211 
    G GCA TGG GGC AGT TCT CTC 5  
    CONSENSUS ATA GCA GTC CCT GAG CCC A 5  
These primers were designed by Dr Sophy Gretton 
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Primer sequence for ARRB2 
rs number 
Location Absolute 
Position 
(bp) 
AA 
change Primer Type 5'-3' primer 
Vol 
(uL)2 
Control 
primer 
rs1973555 Promoter 4552636 C:T C CTGCATAATTGAGGGTGACAAG 5 63/64 
    T CTGCATAATTGAGGGTGACAAA 5  
    CONSENSUS CTTGAGGCTGGGAAATGGAG 5  
rs3786047 Intron 1 4561847 G:A G GCCAAGTTAGCAGTCTCCTTC 10 63/64 
    A GCCAAGTTAGCAGTCTCCTTT 10  
    CONSENSUS GAGGGTATCAGGAATAGGGAAT 10  
rs4522461 Intron 9 4568522 C:T C GAGGCTCCCCGTATCATTC 2 63/64 
    T CGAGGCTCCCCGTATCATTA 2  
    CONSENSUS ACACACTGATGATGGGAACAG 2  
rs1045280 Exon 11 4569387 T:C T CCATAACCCCACTGCTCAGT 4 63/64 
    C CATAACCCCACTGCTCAGC 4  
    CONSENSUS CCTTCATACTTGTCACTAAACC 4  
These primers were designed by Dr Joy Ross 
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ADORA1 
 
Effects of ADORA1 on analgesic response to morphine 
Allele carriage (Dominant model) 
  
Carrying allele Not carrying allele Univariate linear regression 
Log10Component1 (pain scores) as dependent variable 
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P value 
rs 2364571  C 89.5 (170) 0.45 (0.011) 10.5 (20) 0.4 (0.026) 0.054 0.034 0.116 0.115 
 
G 53.2 (101) 0.47 (0.015) 46.8 (89) 0.43 (0.015) -0.031 0.021 -0.108 0.141 
rs 9660662  T 88.4 (168) 0.46 (0.011) 11.6 (22) 0.39 (0.025) 0.063 0.032 0.141 0.053 
 
C 55.8 (106) 0.44 (0.015) 44.2 (84) 0.46 (0.015) -0.021 0.021 -0.073 0.321 
rs11590405  T 88.4 (168) 0.46 (0.011) 11.6 (22) 0.39 (0.025) 0.063 0.032 0.141 0.053 
 
C 55.3 (105) 0.44 (0.015) 44.7 (85) 0.46 (0.015) -0.02 0.021 -0.069 0.345 
rs903361  A 89.5 (171) 0.45 (0.011) 10.5 (20) 0.39 (0.025) 0.062 0.034 0.133 0.069 
 
G 56 (107) 0.43 (0.015) 44 (84) 0.47 (0.015) -0.037 0.021 -0.126 0.084 
rs10920568  T 90 (171) 0.45 (0.011) 10 (19) 0.39 (0.026) 0.06 0.035 0.126 0.086 
 
G 53.7 (102) 0.44 (0.015) 46.3 (88) 0.46 (0.015) -0.025 0.021 -0.088 0.232 
rs10800901  G 90 (171) 0.45 (0.011) 0.45 (0.026) 10 (19) <0.01 0.035 <0.01 0.997 
 
A 57.4 (109) 0.44 (0.013) 42.6 (81) 0.46 (0.017) -0.027 0.021 -0.092 0.21 
rs3766560  C 95.7 (180) 0.45 (0.011) 4.3 (8) 0.39 (0.051) 0.064 0.052 0.091 0.218 
 
T 27.7 (52) 0.43 (0.017) 72.3 (136) 0.45 (0.013) -0.021 0.024 -0.067 0.366 
rs10920576  C 98.4 (187) 0.45 (0.011) 1.6 (3) 0.44 (0.098) 0.01 0.084 0.009 0.901 
 
T 25.3 (48) 0.43 (0.018) 74.7 (142) 0.45 (0.013) -0.026 0.024 -0.079 0.284 
* mean (SEM) of log10Component1 scores 
 
  
  441
Effects of ADORA1 on analgesic effects morphine 
Genotype (Additive model) 
    
Univariate linear regression 
Log10Component1 (pain scores) as dependent variable 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β P value 
rs 2364571  CC 46.8 (89) 0.47 (0.015)     
 
CG 42.6 (81) 0.44 (0.017) 0.029 0.016 0.134 0.067 
 
GG 10.5 (20) 0.4 (0.026)     
rs 9660662  TT 44.2 (84) 0.46 (0.015)     
 
TC 44.2 (84) 0.45 (0.017) 0.026 0.016 0.121 0.098 
 
CC 11.6 (22) 0.39 (0.025)     
rs 11590405  TT 44.7 (85) 0.46 (0.015)     
 
TC 43.7 (83) 0.45 (0.017) 0.025 0.015 0.118 0.106 
 
CC 11.6 (22) 0.39 (0.025)     
rs 903361  AA 44 (84) 0.47 (0.015)     
 AG 45.5 (87) 0.44 (0.017) -0.034 0.016 -0.157 0.031 
 GG 10.5 (20) 0.39 (0.025)     
rs 10920568  TT 46.3 (88) 0.46 (0.015)     
 
TG 43.7 (83) 0.45 (0.017) 0.027 0.016 0.124 0.09 
 
GG 10 (19) 0.39 (0.026)     
rs 10800901  GG 42.6 (81) 0.46 (0.017)     
 
GA 47.4 (90) 0.43 (0.015) -0.015 0.016 -0.07 0.339 
 
AA 10 (19) 0.45 (0.026)     
rs 3766560  CC 72.3 (136) 0.45 (0.013)     
 
CT 23.4 (44) 0.44 (0.018) 0.023 0.019 0.088 0.234 
 
TT 4.3 (8) 0.39 (0.051)     
rs 10920576  CC 74.7 (142) 0.45 (0.013)     
 
CT 23.7 (45) 0.43 (0.019) 0.022 0.022 0.074 0.313 
 
TT 1.6 (3) 0.44 (0.098)     
* mean (SEM) of log10Component1 scores  
 
  
  442
Effects of ADORA1 on central side-effects on morphine 
Allele carriage (Dominant model) 
  
Carrying allele Not carrying allele Univariate linear regression 
Log10Component2 (central side-effect scores) as dependent 
variable 
SNP name 
 Allele 
% (N) Mean* 
(SEM) 
% (N) Mean* 
(SEM) 
B Std Error B β            P value 
rs 2364571  C 89.5 (170) 0.4 (0.012) 10.5 (20) 0.39 (0.035) 0.003 0.036 0.006 0.933 
 
G 53.2 (101) 0.4 (0.017) 46.8 (89) 0.39 (0.015) -0.007 0.022 -0.304 0.762 
rs 9660662  T 88.4 (168) 0.4 (0.012) 11.6 (22) 0.38 (0.032) 0.012 0.035 0.025 0.733 
 
C 55.8 (106) 0.39 (0.015) 44.2 (84) 0.4 (0.017) -0.004 0.023 -0.014 0.845 
rs 11590405  T 88.4 (168) 0.4 (0.012) 11.6 (22) 0.38 (0.032) 0.012 0.035 0.025 0.733 
 
C 55.3 (105) 0.39 (0.015) 44.7 (85) 0.4 (0.017) -0.003 0.023 -0.011 0.878 
rs 903361  A 89.5 (171) 0.4 (0.012) 10.5 (20) 0.36 (0.029) 0.035 0.036 0.071 0.334 
 
G 56 (107) 0.39 (0.015) 44 (84) 0.4 (0.017) -0.001 0.022 -0.005 0.949 
rs 10920568  T 90 (171) 0.4 (0.012) 10 (19) 0.36 (0.031) 0.033 0.037 0.065 0.376 
 
G 53.7 (102) 0.39 (0.015) 46.3 (88) 0.4 (0.017) -0.002 0.022 -0.006 0.938 
rs 10800901  G 90 (171) 0.39 (0.012) 0.45 (0.026) 0.42 (0.033) -0.025 0.037 -0.049 0.509 
 
A 57.4 (109) 0.38 (0.014) 42.6 (81) 0.41 (0.018) -0.025 0.023 -0.082 0.262 
rs 3766560  C 95.7 (180) 0.4 (0.012) 4.3 (8) 0.34 (0.046) 0.055 0.055 0.074 0.318 
 
T 27.7 (52) 0.38 (0.02) 72.3 (136) 0.4 (0.013) -0.02 0.025 -0.058 0.433 
rs 10920576  C 98.4 (187) 0.4 (0.011) 1.6 (3) 0.4 (0.101) -0.01 0.089 -0.008 0.908 
 
T 25.3 (48) 0.37 (0.021) 74.7 (142) 0.4 (0.013) -0.026 0.026 -0.073 0.318 
* mean (SEM) of log10Component2 scores 
No statistically significant associations found 
 
  
  443
Effects of ADORA1 on central side-effects on morphine 
Genotype (Additive model) 
    
Univariate linear regression 
Log10Component2 (central side-effect scores) as dependent variable 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β P value 
rs 2364571  CC 46.8 (89) 0.4 (0.017)     
 
CG 42.6 (81) 0.39 (0.017) 0.004 0.017 0.02 0.791 
 
GG 10.5 (20) 0.39 (0.035)     
rs 9660662  TT 44.2 (84) 0.4 (0.017)     
 
TC 44.2 (84) 0.39 (0.017) 0.005 0.017 0.023 0.759 
 
CC 11.6 (22) 0.38 (0.032)     
rs 11590405  TT 44.7 (85) 0.4 (0.017)     
 
TC 43.7 (83) 0.39 (0.017) 0.005 0.017 0.02 0.783 
 
CC 11.6 (22) 0.38 (0.032)     
rs 903361  AA 44 (84) 0.4 (0.017)     
 
AG 45.5 (87) 0.4 (0.017) -0.008 0.017 -0.037 0.618 
 
GG 10.5 (20) 0.36 (0.029)     
rs 10920568  TT 46.3 (88) 0.4 (0.017)     
 
TG 43.7 (83) 0.4 (0.017) 0.008 0.017 0.034 0.643 
 
GG 10 (19) 0.36 (0.031)     
rs 10800901  GG 42.6 (81) 0.41 (0.018)     
 
GA 47.4 (90) 0.38 (0.016) -0.009 0.017 -0.04 0.586 
 
AA 10 (19) 0.42 (0.033)     
rs 3766560  CC 72.3 (136) 0.4 (0.013)     
 
CT 23.4 (44) 0.39 (0.022) 0.02 0.02 0.074 0.315 
 
TT 4.3 (8) 0.34 (0.046)     
rs 10920576  CC 74.7 (142) 0.4 (0.013)     
 
CT 23.7 (45) 0.37 (0.021) 0.021 0.023 0.065 0.38 
 
TT 1.6 (3) 0.4 (0.101)     
* mean (SEM) of log10Component2 scores  
No statistically significant associations found 
 
  
  444
ADRA2A 
 
Effects of ADRA2A on analgesic response to morphine 
Allele carriage (Dominant model) 
  
Carrying allele Not carrying allele Univariate linear regression 
Log10Component1 (pain scores) as dependent variable 
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P value 
rs638019  G 94.7 (179) 0.45 (0.011) 5.3 (10) 0.46 (0.049) 0.003 0.047 0.005 0.946 
 A 40.2 (76) 0.45 (0.018) 59.8 (175) 0.45 (0.013) -0.003 0.022 -0.011 0.881 
rs11195418  A 100 (188) 0.45 (0.011) 0 - - - - - 
 G 8.5 (16) 0.44 (0.048) 91.5 (172) 0.45 (0.011) -0.018 0.038 -0.035 0.64 
rs1800544  C 94.7 (177) 0.45 (0.017) 5.3 (10) 0.45 (0.014) 0.004 0.047 0.007 0.925 
 G 46 (86) 0.45 (0.011)  54 (101) 0.46 (0.049)  -0.002 0.021 -0.007 0.922 
rs11195419  C 98.4 (182) 0.45 (0.011) 1.6 (3) 0.52 (0.026) -0.07 0.084 -0.062 0.405 
 A 17.3 (32) 0.47 (0.027) 82.7 (153) 0.44 (0.012) 0.03 0.028 0.081 0.279 
rs3750625  C 99.5 (187) 0.45 (0.011) 0.5 (1) - -0.022 0.145 -0.011 0.878 
 A 9 (17) 0.46 (0.042) 91 (171) 0.45 (0.011) 0.011 0.037 0.022 0.77 
rs602618  A 94.2 (178) 0.45 (0.011) 5.8 (11) 0.45 (0.046) 0.014 0.045 0.024 0.75 
 C 45.5 (86) 0.45 (0.017) 54.4 (103) 0.45 (0.014) -0.001 0.021 -0.003 0.964 
* mean (SEM) of log10Component1 scores 
 
 
 
 
 
 
 
 
 
 
 
  445
 
 
Effects of ADRA2A on analgesic effects morphine 
Genotype (Additive model) 
    
Univariate linear regression 
Log10Component1 (pain scores) as dependent variable 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β P value 
rs638019  GG 59.8 (113) 0.45 (0.013)     
 GA 31.9 (66) 0.45 (0.02) -0.003 0.018 -0.011 0.882 
 AA 4.8 (10) 0.46 (0.049)     
rs11195418  AA 91.5 (172) 0.45 (0.011)     
 AG 8.5 (16) 0.44 (0.048) -0.018 0.038 -0.035 0.64 
 GG 0 -     
rs1800544  CC 54 (101) 0.45 (0.014)     
 CG 40.6 (76) 0.44 (0.018) -0.002 0.018 -0.009 0.907 
 GG 5.3 (10) 0.46 (0.049)     
rs11195419  CC 82.3 (153) 0.44 (0.012)     
 CA 16.1 (30) 0.47 (0.03) -0.026 0.024 -0.079 0.287 
 AA 1.6 (3) 0.52 (0.026)     
rs3750625 CC 91 (171) 0.45 (0.011)     
 CA 8.5 (16) 0.46 (0.045) -0.01 0.034 -0.023 0.76 
 
AA 0.5 (1) -     
rs602618  AA 54.5 (103) 0.45 (0.014)     
 
AC 39.7 (75) 0.45 (0.018) -0.003 0.017 -0.012 0.872 
 
CC 5.8 (11) 0.45 (0.046)     
* mean (SEM) of log10Component1 scores  
 
  
  446
Effects of ADRA2A on central side-effects on morphine 
Allele carriage (Dominant model) 
  
Carrying allele Not carrying allele Univariate linear regression 
Log10Component2 (central side-effect scores) as dependent 
variable 
SNP name 
 Allele 
% (N) Mean* 
(SEM) 
% (N) Mean* 
(SEM) 
B Std Error B β            P value 
rs638019  G 94.7 (179) 0.39 (0.012) 5.3 (10) 0.41 (0.038) -0.022 0.05 -0.032 0.661 
 A 40.2 (76) 0.41 (0.018) 59.8 (175) 0.38 (0.015) 0.028 0.023 0.09 0.223 
rs11195418  A 100 (188) 0.39 (0.011) 0 - - - - - 
 G 8.5 (16) 0.47 (0.039) 91.5 (172) 0.39 (0.012) 0.063 0.04 0.117 0.113 
rs1800544 p C 94.7 (177) 0.41 (0.038) 5.3 (10) 0.39 (0.012) -0.024 0.05 -0.035 0.633 
 G 46 (86) 0.41 (0.017) 54 (101) 0.38 (0.016) 0.025 0.023 0.081 0.277 
rs11195419  C 98.4 (182) 0.39 (0.011) 1.6 (3) 0.44 (0.131) -0.053 0.089 -0.044 0.552 
 A 17.3 (32) 0.43 (0.026) 82.7 (153) 0.38 (0.013) 0.035 0.03 0.088 0.239 
rs3750625  C 99.5 (187) 0.39 (0.011) 0.5 (1) - -0.089 0.153 -0.043 0.562 
 A 9 (17) 0.39 (0.032) 91 (171) 0.39 (0.012) -0.011 0.039 -0.02 0.785 
rs602618  A 94.2 (178) 0.39 (0.012) 5.8 (11) 0.43 (0.043) -0.048 0.047 -0.075 0.311 
 C 45.5 (86) 0.41 (0.017) 54.4 (103) 0.38 (0.016) 0.029 0.022 0.096 0.194 
* mean (SEM) of log10Component2 scores 
No statistically significant associations found 
 
  
  447
Effects of ADRA2A on central side-effects on morphine 
Genotype (Additive model) 
    
Univariate linear regression 
Log10Component2 (central side-effect scores) as dependent variable 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β P value 
rs638019  GG 59.8 (113) 0.38 (0.015)     
 GA 31.9 (66) 0.41 (0.02) 0.022 0.019 0.086 0.242 
 AA 4.8 (10) 0.41 (0.038)     
rs11195418  AA 91.5 (172) 0.39 (0.012)     
 AG 8.5 (16) 0.47 (0.039) 0.063 0.04 0.117 0.113 
 GG 0 -     
rs1800544  CC 54 (101) 0.38 (0.016)     
 CG 40.6 (76) 0.41 (0.018) 0.021 0.019 0.081 0.277 
 GG 5.3 (10) 0.41 (0.038)     
rs11195419 CC 82.3 (153) 0.38 (0.013)     
 CA 16.1 (30) 0.43 (0.027) -0.034 0.026 -0.096 0.195 
 AA 1.6 (3) 0.44 (0.131)     
rs3750625  CC 91 (171) 0.39 (0.012)     
 CA 8.5 (16) 0.39 (0.033) 0.004 0.036 0.009 0.908 
 
AA 0.5 (1) -     
rs602618  AA 54.5 (103) 0.38 (0.016)     
 
AC 39.7 (75) 0.4 (0.018) 0.027 0.018 0.108 0.143 
 
CC 5.8 (11) 0.43 (0.043)     
* mean (SEM) of log10Component2 scores  
No statistically significant associations found 
 
  
  448
Effects of ADRA2A on morphine dose 
Allele carriage (Dominant model) 
  
Carrying allele Not carrying allele Univariate linear regression 
log10 Daily morphine dose (mg) as dependent variable 
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P value 
rs638019  G 94.7 (126)  2.002 (0.032) 5.3 (7) 1.917 (0.138) 0.098 0.135 0.063 0.471 
 A 39.1 (52) 1.95 (0.044) 60.9 (81) 2.028 (0.043) -0.078 0.062 -0.11 0.209 
rs11195418  A 100 (132) 1.998 (0.031) 0 - - - - - 
 G 8.3 (11) 1.8 (0.119) 91.7 (121) 2.013 (0.032) -0.227 0.109 -0.18 0.039 
rs1800544  C 94.7 (124) 2.002 (0.032) 5.3 (7) 1.916 (0.138) 0.093 0.137 0.059 0.5 
 G 45.8 (60) 1.965 (0.041) 54.2 (71) 2.025 (0.045) -0.067 0.062 -0.096 0.276 
rs11195419  C 98.5 (128) 1.991 (0.31) 1.5 (2) 2.433 (0.111) -0.445 0.249 -0.156 0.076 
 A 15.4 (20) 1.918 (0.079) 84.6 (110) 2.012 (0.034) -0.109 0.086 -0.112 0.203 
rs3750625 C 99.2 (131) 1.995 (0.031) 0.8 (1) - -0.329 0.352 -0.082 0.351 
 A 9.1 (12) 2.021 (0.095) 90.9 (120) 1.99 (0.033) 0.05 0.106 0.041 0.642 
rs602618 A 94.7 (126) 2.002 (0.032) 5.3 (7) 1.916 (0.138) 0.014 0.045 0.024 0.75 
 C 45.1 (60) 1.965 (0.041) 54.9 (73) 2.025 (0.045) -0.001 0.021 -0.003 0.964 
* mean (SEM) of log10 Daily morphine dose (mg)  
 
  
  449
Effects of ADRA2A on morphine dose 
Genotype (Additive model) 
    
Univariate linear regression 
log10 Daily morphine dose (mg)as dependent variable 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β P value 
rs638019  GG 60.9 (81) 2.028 (0.042)     
 GA 33.8 (45) 1.955 (0.047) -0.066 0.051 -0.114 0.192 
 AA 5.3 (7) 1.916 (0.138) 
    
rs11195418  AA 91.7 (121) 2.013 (0.032)     
 AG 8.3 (11) 1.8 (0.119) -0.227 0.109 -0.18 0.039 
 GG 0 -     
rs1800544  CC 54.2 (71) 2.025 (0.045)     
 CG 40.5 (53) 1.971 (0.043) -0.06 0.051 -0.102 0.245 
 GG 5.3 (7) 1.916 (0.138)     
rs11195419  CC 84 (110) 2.012 (0.034)     
 CA 14.5 (19) 1.857 (0.074) 0.048 0.074 0.057 0.516 
 AA 1.5 (2) 2.433 (0.111)     
rs3750625  CC 90.9 (120) 1.99 (0.033)     
 CA 8.3 (11) 2.057 (0.101) -0.063 0.095 -0.058 0.506 
 
AA 0.8 (1) -     
rs602618  AA 54.9 (73) 2.025 (0.045)     
 
AC 39.8 (53) 1.971 (0.043) -0.05 0.051 -0.085 0.328 
 
CC 5.3 (7) 1.916 (0.138)     
* mean (SEM) of log10 Daily morphine dose (mg)  
 
  450
TRPV1  
 
Effects of TPRV1 on analgesic response to morphine 
Allele carriage (Dominant model) 
  Carrying allele Not carrying allele     
SNP name 
 Allele 
% (N) Mean* 
(SEM) 
% (N) Mean* 
(SEM) 
B Std Error B β            P value 
rs877610  G 99.5 (186) 0.45 (0.011) 0.5 (1) - 0.038 0.145 0.019 0.795 
 
A 11.2 (21) 0.4 (0.027) 88.8 (166) 0.45 (0.012) -0.041 0.033 -0.091 0.218 
 
         
rs2277679  C 86.8 (165) 0.45 (0.012) 13.2 (25) 0.41 (0.025) 0.027 0.031 0.065 0.377 
 
G 51.1 (97) 0.44 (0.015) 48.9 (93) 0.45 (0.015) -0.012 0.021 -0.041 0.581 
 
         
rs222745  C 188 (100) 0.45 (0.011) 0 - - - - - 
 
T 15.4 (29) 0.44 (0.02) 84.6 (159) 0.39 (0.011) -0.005 0.03 -0.013 0.857 
 
         
rs161393  A 91.5 (173) 0.44 (0.011) 8.5 (16) 0.47 (0.038) -0.017 0.039 -0.032 0.665 
 
G 53.4 (101) 0.43 (0.015) 46.6 (88) 0.46 (0.015) -0.029 0.021 -0.1 0.173 
 
         
rs222747  C 94.2 (179) 0.45 (0.011) 5.8 (11) 0.45 (0.054) 0.005 0.047 0.008 0.911 
 
G 46.8 (89) 0.44 (0.017) 53.2 (101) 0.45 (0.013) -0.023 0.021 -0.079 0.284 
 
         
rs3744683  A 186 (100) 0.45 (0.011) 0 - - - - - 
 G 3.8 (7) 0.48 (0.04) 96.2 (178) 0.44 (0.011) 0.036 0.056 0.048 0.520 
* mean (SEM) of log10Component1 scores 
No statistically significant associations found 
 
  
  451
Effects of TPRV1 on analgesic response to morphine 
Genotype (Additive model) 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β 
P 
value 
rs877610  GG 88.8 (166) 0.45 (0.012)     
 
GA 10.7 (20) 0.4 (0.028) 0.038 0.031 0.089 0.228 
 
AA 0.5 (1) -     
rs2277679  CC 48.9 (93) 0.45 (0.015)     
 
CG 37.9 (72) 0.45 (0.018) 0.012 0.015 0.06 0.412 
 
GG 13.2 (25) 0.41 (0.025)     
rs222745  CC 84.6 (159) 0.45 (0.012)     
 
CT 15.4 (29) 0.44 (0.02) -0.005 0.03 -0.013 0.857 
 
TT 0 -     
rs161393  AA 46.6 (88) 0.46 (0.015)     
 
AG 45 (85) 0.43 (0.016) 0.015 0.017 0.065 0.374 
 
GG 8.5 (16) 0.47 (0.038)     
rs222747  CC 53.2 (101) 0.45 (0.013)     
 
CG 41.1 (78) 0.43 (0.019) -0.017 0.018 -0.069 0.349 
 
GG 5.8 (11) 0.45 (0.054)     
rs3744683  AA 95.7 (178) 0.44 (0.011)     
 AG 4.3 (8) 0.48 (0.04) - - - - 
 GG 0 -     
* mean (SEM) of log10Component1 scores  
No statistically significant associations found 
 
  
  452
Effects of TPRV1 on central side-effects on morphine 
Allele carriage (Dominant model) 
  Carrying allele Not carrying allele     
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P 
value 
rs877610  G 99.5 (186) 0.39 (0.11) 0.5 (1) - 0.043 0.154 0.02 0.782 
 
A 11.2 (21) 0.4 (0.029) 88.8 (166) 0.39 (0.012) 0.012 0.036 0.025 0.737 
 
         
rs2277679  C 86.8 (165) 0.39 (0.013) 13.2 (25) 0.38 (0.024) -0.009 0.033 -0.02 0.791 
 
G 51.1 (97) 0.38 (0.015) 48.9 (93) 0.41 (0.017) -0.024 0.022 -0.077 0.293 
 
         
rs222745  C 188 (100) 0.39 (0.011) 0 - - - - - 
 
T 15.4 (29) 0.43 (0.025) 84.6 (159) 0.39 (0.013) 0.028 0.031 0.066 0.369 
 
         
rs161393  A 91.5 (173) 0.4 (0.012) 8.5 (16) 0.33 (0.034) 0.065 0.041 0.117 0.112 
 
G 53.4 (101) 0.39 (0.016) 46.6 (88) 0.39 (0.017) <0.001 0.002 <0.001 0.996 
 
         
rs222747  C 94.2 (179) 0.4 (0.012) 5.8 (11) 0.31 (0.049) 0.051 0.05 0.075 0.307 
 
G 46.8 (89) 0.38 (0.017) 53.2 (101) 0.4 (0.015) -0.019 0.022 -0.062 0.395 
 
         
rs3744683  A 186 (100) 0.39 (0.011) 0 - - - - - 
 G 3.8 (7) 0.42 (0.068) 96.2 (178) 0.39 (0.012) 0.029 0.059 0.037 0.624 
* mean (SEM) of log10Component1 scores,  
No statistically significant associations found 
 
  
  453
Effects of TPRV1 on central side-effects morphine 
Genotype (Additive model) 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β P value 
rs877610  GG 88.8 (166) 0.39 (0.012)     
 
GA 10.7 (20) 0.4 (0.031) -0.008 0.033 -0.019 0.8 
 
AA 0.5 (1) 0     
rs2277679  CC 48.9 (93) 0.41 (0.017)     
 
CG 37.9 (72) 0.38 (0.018) 0.01 .0.16 0.045 0.537 
 
GG 13.2 (25) 0.38 (0.024)     
rs222745  CC 84.6 (159) 0.39 (0.013)     
 
CT 15.4 (29) 0.43 (0.025) 0.028 0.031 0.066 0.369 
 
TT 0 0     
rs161393 AA 46.6 (88) 0.39 (0.017)     
 
AG 45 (85) 0.41 (0.017) 0.012 0.018 0.051 0.493 
 
GG 8.5 (16) 0.33 (0.034)     
rs222747  CC 53.2 (101) 0.4 (0.015)     
 
CG 41.1 (78) 0.39 (0.018) -0.021 0.019 -0.081 0.273 
 
GG 5.8 (11) 0.31 (0.049)     
rs3744683  AA 95.7 (178) 0.39 (0.012)     
 AG 4.3 (8) 0.42 (0.068) -0.021 0.055 -0.029 0.7 
 GG 0 -     
* mean (SEM) of log10Component1 scores  
No statistically significant associations found 
 
  454
ALOX12 
 
Effect of  ALOX12 on analgesic response 
Allele carriage (Dominant model) 
  Carrying allele Not carrying allele     
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P 
value 
rs6502999 A 83.8 (160) 0.45 (0.012) 16.2 (31) 0.44 (0.025) 0.015 0.028 0.038 0.602 
 G 59.2 (113) 0.46 (0.014) 40.8 (78) 0.45 (0.015) 0.032 0.021 0.108 0.141 
rs1126667 G 83.2 (159) 0.45 (0.012) 16.8 (32) 0.46 (0.025) -0.015 0.028 -0.04 0.584 
 A 60.7 (116) 0.46 (0.014) 39.3 (75) 0.43 (0.016) 0.036 0.021 0.123 0.092 
rs434473 A 82.2 (157) 0.44 (0.012) 17.8 (34) 0.46 (0.026) -0.017 0.027 -0.045 0.536 
 G 60.7 (116) 0.46 (0.014) 39.3 (75) 0.44 (0.012) 0.036 0.021 0.123 0.092 
* mean (SEM) of log10Component1 scores 
No statistically significant associations found 
 
Effect of  ALOX12 on analgesic response 
Genotype (additive) model 
SNP name 
 
Genotype % (N) Mean*  (SEM) B Std. Error B β P value 
rs6502999 AA 40.8 (78) 0.43 (0.015)     
 AG 42.9 (82) 0.47 (0.017) 0.011 0.015 0.054 0.461 
 GG 16.2 (31) 0.44 (0.025)     
rs1126667 GG 39.3 (75) 0.43 (0.016)     
 AG 44 (84) 0.46 (0.016) 0.021 0.015 0.105 0.15 
 AA 16.8 (32) 0.46 (0.025)     
rs434473 AA 39.3 (75) 0.43 (0.016)     
 AG 42.9 (82) 0.46 (0.016) -0.021 0.014 -0.107 0.144 
 GG 17.8 (34) 0.46 (0.026)     
* mean (SEM) of log10Component1 scores 
No statistically significant associations found 
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Effect of ALOX12 on central side-effects  
Allele carriage (Dominant model) 
  Carrying allele Not carrying allele     
SNP name 
 Allele 
% (N) Mean* 
(SEM) 
% (N) Mean* 
(SEM) 
B Std Error B β            P value 
rs6502999 A 83.8 (160) 0.39 (0.012) 16.2 (31) 0.4 (0.025) -0.004 0.03 -0.01 0.895 
 G 59.2 (113) 0.4 (0.014) 40.8 (78) 0.38 (0.018) 0.02 0.023 0.072 0.328 
rs1126667 G 83.2 (159) 0.39 (0.012) 16.8 (32) 0.4 (0.025) -0.011 0.03 -0.027 0.714 
 A 60.7 (116) 0.41 (0.014) 39.3 (75) 0.37 (0.019) 0.031 0.023 0.1 0.172 
rs434473 A 82.2 (157) 0.39 (0.013) 17.8 (34) 0.4 (0.024) -0.002 0.029 -0.006 0.939 
 G 60.7 (116) 0.41 (0.014) 39.3 (75) 0.37 (0.019) 0.031 0.023 0.1 0.172 
* mean (SEM) of log10Component1 scores 
No statistically significant associations found 
 
Effect of ALOX12 on central side-effects  
Genotype (Additive model) 
SNP name 
 
Genotype % (N) Mean*  (SEM) B Std. Error B β P 
value 
rs6502999 AA 40.8 (78) 0.38 (0.018)     
 AG 42.9 (82) 0.4 (0.017) 0.012 0.016 0.054 0.46 
 GG 16.2 (31) 0.4 (0.025)     
rs1126667 GG 39.3 (75) 0.37 (0.019)     
 AG 44 (84) 0.41 (0.017) 0.018 0.016 0.082 0.261 
 AA 16.8 (32) 0.4 (0.025)     
rs434473 AA 39.3 (75) 0.37 (0.019)     
 AG 42.9 (82) 0.41 (0.017) -0.015 0.015 -0.07 0.339 
 GG 17.8 (34) 0.4 (0.024)     
* mean (SEM) of log10Component1 scores 
No statistically significant associations found 
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Effect of ALOX12 on daily morphine dose (mg) 
Allele carriage (Dominant model) 
  Carrying allele Not carrying allele     
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P 
value 
rs6502999 A 82.1 (110) 1.997 (0.33) 17.9 (24) 1.988 (0.076) 0.009 0.079 0.01 0.908 
 G 56.7 (76) 1.997 (0.42) 43.3 (58) 1.995 (0.043) 0.002 0.061 0.002 0.98 
rs1126667 G 82.1 (110) 2.002 (0.03) 17.9 (24) 1.965 (0.068) 0.037 0.079 0.041 0.637 
 A 58.2 (78) 2.005 (0.4) 41.8 (56) 1.983 (0.046) 0.021 0.061 0.03 0.733 
rs434473 A 81.3 (109) 1.995 (0.03) 18.7 (25) 1.998 (0.073) -0.002 0.077 -0.003 0.975 
 G 58.2 (78) 2.005 (0.04) 41.8 (56) 1.984 (0.046) 0.021 0.061 0.03 0.733 
* mean (SEM) of log10Component1 scores 
No statistically significant associations found 
 
Effect of ALOX12 on daily morphine dose (mg) 
Genotype (Additive model) 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β 
P 
value 
rs6502999 AA 43.3 (58) 1.995 (0.43)     
 AG 38.8 (52) 2.000 (0.05) -0.002 0.041 -0.004 0.966 
 GG 17.9 (24) 1.988 (0.76)     
rs1126667 GG 41.8 (56) 1.984 (0.05)     
 AG 40.3 (54) 2.021 (0.05) -0.001 0.041 -0.001 0.987 
 AA 17.9 (24) 1.965 (0.07)     
rs434473 AA 41.8 (56) 1.984 (0.05)     
 AG 39.6 (53) 2.008 (0.05) -0.01 0.041 -0.021 0.808 
 GG 18.7 (25) 1.998 (0.07)     
* mean (SEM) of log10Component1 scores 
No statistically significant associations found 
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SLC6A4 
 
 
Effects of SLC6A4 on central side-effects on morphine 
Allele carriage (Dominant model) 
  Carrying allele Not carrying allele     
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P 
value 
rs 7214991 A 90 (171) 0.39 (0.012) 10 (19) 0.43 (0.039) -0.036 0.037 -0.072 0.331 
 
G 59.8 (113) 0.4 (0.016) 40.2 (76) 0.39 (0.016) 0.016 0.023 0.051 0.487 
rs 22528 T 94.6 (174) 0.39 (0.012) 5.4 (10) 0.42 (0.028) -0.02 0.05 -0.03 0.685 
 
G 36.2 (67) 0.41 (0.0190 63.8 (118) 0.39 (0.015) 0.024 0.024 0.074 0.318 
rs 6354 T 93.7 (177) 0.4 (0.012) 6.3 (12) 0.4 (0.032) -0.01 0.046 -0.016 0.826 
 
G 34.2 (65) 0.42 (0.019) 65.8 (125) 0.38 (0.014) 0.035 0.023 0.11 0.134 
rs 140700 C 97.9 (183) 0.4 (0.012) 2.1 (4) 0.41 (0.068) 0.006 0.077 0.006 0.934 
 
T 18.2 (34) 0.42 (0.027) 81.8 (153) 0.39 (0.013) 0.028 0.029 0.072 0.329 
rs 4583306 A 78.9 (150) 0.4 (0.013) 21.1 (40) 0.38 (0.023) 0.026 0.028 0.07 0.338 
 
G 71.1 (135) 0.4 (0.014) 28.9 (55) 0.39 (0.022) 0.003 0.025 0.008 0.917 
SERTP S 69 (126) 0.38 (0.014) 31 (56) 0.4 (0.02) -0.015 0.024 -0.047 0.529 
 
L 82 (149) 0.39 (0.013) 18 (33) 0.39 (0.024) -0.004 0.029 -0.01 0.889 
* mean (SEM) of log10Component1 scores,  
No statistically significant associations found 
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Effects of SLC6A4 on central side-effects morphine 
Genotype (Additive model) 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β P value 
rs 7214991 AA 40.2 (76) 0.39 (0.016)     
 
AG 49.7 (94) 0.39 (0.0170 0.017 0.017 0.072 0.332 
 
GG 10.1 (19) 0.43 (0.039)     
rs 22528 TT 63.9 (117) 0.39 (0.015)     
 
TG 30.6 (56) 0.41 (0.022) -0.021 0.019 -0.083 0.27 
 
GG 5.5 (10) 0.42 (0.028)     
rs 6354 TT 66.1 (125) 0.38 (0.014)     
 
TG 27.5 (52) 0.42 (0.022) -0.023 0.018 -0.093 0.209 
 
GG 6.3 (12) 0.4 (0.032)     
rs 140700 CC 81.8 (153) 0.39 (0.013)     
 
CT 16 (30) 0.42 (0.029) 0.02 0.025 0.06 0.421 
 
TT 2.1 (4) 0.41 (0.068)     
rs 4583306 AA 28.9 (55) 0.39 (0.022)     
 
AG 50 (95) 0.4 (0.017) -0.008 0.016 -0.486 0.628 
 
GG 21.1 (40) 0.38 (0.023)     
SertP SS 17.8 (33) 0.4 (0.0230     
 LS 51.4 (95) 0.39 (0.017) 0.006 0.016 0.026 0.731 
 LL 30.8 (57) 0.41 (0.021)     
* mean (SEM) of log10Component1 scores  
No statistically significant associations found 
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Effects of SLC6A4 on morphine dose  
Allele carriage (Dominant model) 
  Carrying allele Not carrying allele     
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P 
value 
rs 7214991 A 88.8 (119) 2 (0.03) 11.2 (15) 20.6 (0.12) -0.068 0.097 -0.061 0.482 
 
G 62.4 (83) 2.01 (0.04) 37.6 (50) 1.98 (0.05) 0.026 0.064 0.035 0.687 
rs 22528 T 94.6 (122) 2 (0.03) 5.4 (7) 2.07 (0.05) -0.069 0.139 -0.044 0.619 
 
G 36.6 (48) 1.99 (0.05) 63.4 (83) 2 (0.04) -0.015 0.065 -0.02 0.82 
rs 6354 T 93.2 (124) 2 (0.03) 6.8 (9) 1.99 (0.1) 0.013 0.123 0.01 0.913 
 
G 34.3 (46) 1.99 (0.05) 65.7 (88) 2.01 (0.04) -0.027 0.064 -0.036 0.68 
rs 140700 C 99.2 (131) 2 (0.03) 0.8 (1) - 0.049 0.358 0.012 0.891 
 
T 16.7 (22) 1.98 (0.07) 83.3 (110) 2.01 (0.03) -0.022 0.083 -0.023 0.796 
rs 4583306 A 80.6 (108) 2.01 (0.03) 19.4 (26) 1.96 (0.09) 0.055 0.077 0.062 0.475 
 
G 70.9 (95) 2.01 (0.04) 29.1 (39) 1.99 (0.05) 0.014 0.067 0.018 0.836 
SERTP S 67 (88) 2 (0.038) 33 (43) 2.01 (0.05) -0.006 0.067 -0.008 0.924 
 
L 82 (108) 1.99 (0.03) 18 (23) 2.1 (0.08) -0.07 0.082 -0.075 0.394 
* mean (SEM) of log10Component1 scores 
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Effects of SLC6A4 on morphine dose  
Genotype (Additive model) 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β P value 
rs 7214991 AA 3706 (50) 1.98 (0.05)     
 
AG 51.1 (68) 2 (0.04) 0.031 0.048 0.057 0.511 
 
GG 11.3 (15) 2.06 (0.12)     
rs 22528 TT 63.6 (82) 2.01 (0.04)     
 
TG 31 (40) 1.98 (0.05) -0.002 0.053 -0.004 0.968 
 
GG 5.4 (7) 2.07 (0.05)     
rs 6354 TT 66.2 (88) 2.01 (0.04)     
 
TG 27.1 (36) 1.98 (0.06) 0.02 0.05 0.034 0.695 
 
GG 6.8 (9) 1.99 (0.1)     
rs 140700 CC 83.3 (110) 2.01 (0.03)     
 
CT 15.9 (21) 1.99 (0.07) -0.021 0.078 -0.024 0.786 
 
TT 0.8 (1) -     
rs 4583306 AA 29.1 (39) 1.99 (0.05)     
 
AG 51.5 (69) 2.02 (0.04) -0.012 0.044 -0.024 0.786 
 
GG 19.4 (26) 1.96 (0.09)     
SertP SS 17.6 (23) 2.06 (0.08)     
 LS 49.6 (65) 1.98 (0.04) -0.018 0.045 -0.035 0.688 
 LL 32.8 (43) 2.01 (0.05)     
* mean (SEM) of log10Component1 scores  
No statistically significant associations found 
 
  461
ARRB2 
 
 
Effects of ARRB2 on analgesic response to morphine 
Allele carriage (Dominant model) 
  Carrying allele Not carrying allele     
SNP name 
 Allele 
% (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β            P 
value 
rs1973555 C 92.1 (176) 0.45 (0.011) 7.9 (15) 0.46 (0.042) 0.005 0.041 0.009 0.905 
 T 52.9 (101) 0.45 (0.015) 47.1 (90) 0.46 (0.016) -0.013 0.021 -0.043 0.557 
          
rs3786047 G 87.8 (166) 0.45 (0.012) 12.2 (23) 0.47 (0.026) -0.013 0.033 -0.029 0.698 
 A 57.9 (110) 0.45 (0.015) 42.1 (80) 0.46 (0.016) -0.013 0.022 -0.044 0.547 
          
rs4522461 C 95.8 (182) 0.45 (0.011) 4.2 (8) 0.53 (0.05) -0.045 0.056 -0.058 0.43 
 T 41.6 (79) 0.44 (0.018) 58.4 (111) 0.46 (0.014) -0.022 0.022 -0.075 0.304 
          
rs1045280 T 89.2 (165) 0.45 (0.012) 10.8 (20) 0.45 (0.026) 0.002 0.036 0.005 0.95 
 
C 54.6 (101) 0.44 (0.015) 45.4 (84) 0.46 (0.015) -0.024 0.022 -0.083 0.265 
* mean (SEM) of log10Component1 scores 
No statistically significant associations found 
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Effects of ARRB2 on analgesic response to morphine  
Genotype (Additive model) 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β 
P 
value 
rs1973555 CC 47.1 (90) 0.46 (0.016)     
 CT 45 (86) 0.44 (0.016) 0.009 0.017 0.038 0.603 
 TT 7.9 (15) 0.46 (0.042)     
rs3786047 GG 42.3 (80) 0.46 (0.016)     
 GA 45.5 (86) 0.44 (0.018) 0.003 0.016 0.013 0.856 
 AA 12.2 (23) 0.47 (0.026)     
rs4522461 CC 58.4 (111) 0.46 (0.014) 
    
 CT 37.4 (71) 0.43 (0.018) 0.012 0.019 0.046 0.532 
 TT 4.2 (8) 0.53 (0.05)     
rs1045280 TT 45.4 (84) 0.46 (0.015)     
 
TC 43.8 (81) 0.44 (0.018) 0.014 0.016 0.065 0.385 
 
CC 10.8 (20) 0.45 (0.026)     
* mean (SEM) of log10Component1 scores  
No statistically significant associations found 
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Effects of ARRB2 on variability in morphine dose required to achieve adequate analgesia 
Allele carriage (Dominant model) 
  Carrying allele Not carrying allele     
SNP name Allele % (N) Mean* (SEM) % (N) Mean* (SEM) B Std Error B β 
P 
value 
rs1973555 C 93.2 (123) 1.99 (0.032)  6.8 (9) 1.96 (0.149) 0.064 0.121 0.046 0.599 
 T 55.3 (73) 1.98 (0.042) 44.7 (59) 2.01 (0.047) -0.022 0.061 -0.031 0.721 
          
rs3786047 G 87.8 (115) 1.99 (0.033) 12.2 (16) 2.01 (0.094) 0.006 0.094 0.006 0.949 
 A 61.4 (81) 1.99 (0.039) 38.6 (51) 1.99 (0.053) -0.003 0.063 -0.004 0.963 
          
rs4522461 C 97.7 (128) 1.99 (0.031) 2.3 (3) 2.21 (0.308) -0.046 0.205 -0.02 0.821 
 T 43.5 (57) 1.98 (0.05) 56.5 (74) 2.0 (0.041) -0.016 0.062 -0.022 0.801 
          
rs1045280 T 88.2 (112) 1.98 (0.033) 11.8 (15) 2.06 (0.094) -0.073 0.097 -0.067 0.451 
 
C 58.3 (74) 1.97 (0.04) 41.7 (53) 2.02 (0.05) -0.05 0.063 -0.071 0.426 
* mean (SEM) of log10Daily morphine dose 
No statistically significant associations found 
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Effects of ARRB2 on variability in morphine dose required to achieve adequate analgesia  
Genotype (Additive model) 
SNP name Genotype % (N) Mean*  (SEM) B Std. Error B β 
P 
value 
rs1973555 CC 44.7 (59) 2.01 (0.047)     
 CT 48.5 (64) 1.98 (0.044) 0.025 0.05 0.045 0.611 
 TT 6.8 (9) 1.96 (0.149)     
rs3786047 GG 38.9 (51) 1.99 (0.053)     
 GA 48.9 (64) 1.98 (0.043) 0.002 0.046 0.005 0.958 
 AA 12.2 (16) 2.01 (0.094)     
rs4522461 CC 56.5 (74) 2.0 (0.041) 
    
 CT 41.2 (54) 1.97 (0.05) 0.009 0.057 0.015 0.867 
 TT 2.3 (3) 2.21 (0.31)     
rs1045280 TT 41.7 (53) 2.02 (0.05)     
 
TC 46.5 (59) 1.95 (0.044) 0.01 0.047 0.02 0.824 
 
CC 11.8 (15) 2.06 (0.094)     
* mean (SEM) of log10Daily morphine dose 
No statistically significant associations found 
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Appendix E  GWA primers 
 
This appendix contains details of the primer sequences for PRKD3, NTRK3 and ZDHHC14, used in the validation study in the GWA. 
 
SSP-PCR primers designed for PRKD3 (chr2:37,331,152-37,397,726 2p22.2) 
Rs / “Affy” id Position 
(absolute 
bp) 
Locus Primer Type S/AS 5'-3' primer  Product 
size 
rs 1124574 37,352,793 Intron 11 SPECIFIC  AS GCC TTC TCT TTG AAC CAG TCT 
TAT 
357 
   SPECIFIC  AS CCT TCT CTT TGA ACC AGT CTT 
AC 
 
   CONSENSUS S TAT CCT GTA GCC CAG GTG GT  
       
rs 6730503 37,381,982 Intron 1 SPECIFIC  S CCT TTG TTC TTT GTT CTC CTG G 443 
   SPECIFIC  S CCT TTG TTC TTT GTT CTC CTG A  
   CONSENSUS AS CAA ATT GCT CTT TAT GGC GGT 
C 
 
       
rs 1158219 37400324 Promoter  SPECIFIC  S TGA GAA CAC ATC AGC ATC CGA 286 
   SPECIFIC  S TGA GAA CAC ATC AGC ATC CGT  
   CONSENSUS AS CAG ATA GTT TGT ACC CCG TAG  
Reference sequences used for primer design: NW_001838769 
CHIP Bioinformatics PRKD3 accessed 20/11/08 
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SSP-PCR primers designed for ZDHHC14 (chr6:157,722,545-158,014,965 6q25.3) 
rs 
Position 
(absolute 
bp) 
Locus Primer Type S/AS 5'-3' primer Product 
size 
rs17165436 157907605 Intron 2 SPECIFIC AS CTG CTC TTT CAG GGT AGG TCT 406 
   SPECIFIC AS TGC TCT TTC AGG GTA GGT CC  
   CONSENSUS S GCA TGG AGG CAC ATG CTT G  
       
rs4463281 157900894 Intron 2 SPECIFIC S GGC CTA TTT CAA CTT CTT TCA CAT 305 
   SPECIFIC S GGC CTA TTT CAA CTT CTT TCA CAG  
   CONSENSUS AS AGC CAC CCT GCC ATC TTG AA  
       
rs17165429 157900789 Intron 2 SPECIFIC S TCT CTC TCT GTA AAT CCA GAC A 330 
   SPECIFIC S CTC TCT CTG TAA ATC CAG ACG  
   CONSENSUS AS TTG CCT CTT TCC GTG GGC AT  
Reference sequences used for primer design: NW_001838991 
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SSP-PCR primers designed for NTRK3 (chr15:86,220,992-86,600,665 15q25.3) 
rs Position 
(absolute 
bp) 
Locus Primer Type S/AS 5'-3' primer Product  size 
rs17755717 86,425,100 Intron 12 SPECIFICG AS CTG AGG CCA TTC GAT CAG AG 384 
   
SPECIFIC A AS CTG AGG CCA TTC GAT CAG AA 
 
   
CONSENSUS S GAG TCT CAC TTT GTC ACC CA 
 
       
rs1559822 86,564,157 Intron 2 SPECIFIC A AS GGT CAC ACA GCT CTC ACT GA 529 
   
SPECIFIC G AS   GT CAC ACA GCT CTC ACT GG 
 
   
CONSENSUS S AGT GGC AGA GCC TAG ATT TGA 
 
       
rs8026216 86,585,243 Intron 2 SPECIFIC T S CAGT AAA GAC CTG TGG ACT GT 278 
   
SPECIFIC G S AGT AAA GAC CTG TGG ACT GG 
 
   
CONSENSUS AS GGA CCT GCC ATG TCA CTG T 
 
       
rs1075891 86,585,302 Intron 2 SPECIFIC A S TAC GTG CTC TTC CCA GGC A 247 
   
SPECIFIC G S TAC GTG CTC TTC CCA GGC G 
 
   
CONSENSUS AS AAT GGA CGG AAT CTG CCG TG 
 
       
rs4887382 86,555,933 Intron 2 SPECIFICG S CTT TTC ACC TTA GCT GCC AG 515 
   
SPECIFIC A S CCT TTT CAC CTT AGC TGC CAA 
 
   
CONSENSUS AS CTA TTG AGC AGT CAC ACT CCC 
 
       
rs1863482 86,560,748 Intron 2 SPECIFIC T S CTA ATT TGG GGT CGT GCA GAA T 324 
   
SPECIFIC C S TAA TTT GGG GTC GTG CAG AAC 
 
   
CONSENSUS AS GAG CGA GTT GTT ATG TTG TAG C 
 
Reference sequences used for primer design: NM_002530 Chip Bioinformatics, accessed 21/11/08  
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Appendix F   Constipation on morphine: Genetic association study 
 
Negative findings from the genetic association study of constipation on morphine are presented here. 
 
ARRB2 and Bowel problems on morphine  
Logistic regression corrected for clinical factors (lower GI tumour) 
% (N) 
 Genotype frequency (additive model) Allele carriage (dominant model) 
SNP Genotype No bowel 
problems 
on 
morphine 
N=34 
Bowel 
problems 
on 
morphine 
N=183 OR (95% CI) P value 
Allele No bowel 
problems 
on 
morphine 
N=37 
Bowel 
problems 
on 
morphine 
N=199 OR (95% CI) 
P 
value 
rs1973555 CC 0.5 (17) 0.44 (21)   C 0.94 (32) 0.9 (165) 0.653 (0.143-2.975) 0.581 
 CT 0.44 (15) 0.45 (83) 0.789 (0.431-1.444) 0.442 T 0.5 (17) 0.56 (102) 1.294 (0.611-2.739) 0.501 
 TT 0.06(2) 0.1 (19)        
rs3786047 GG 0.47 (16) 0.41 (74)   G 0.91 (31) 0.84 (153) 0.616 (0.174-2.184) 0.453 
 GA 0.44 (15) 0.43 (79) 1.32 (0.75-2.325) 0.336 A 0.53 (18) 0.6 (109) 1.386 (0.652-2.945) 0.396 
 AA 0.9 (3) 0.16 (29)        
rs4522461 CC 0.65 (22) 0.57 (105)   C 1.0 (34) 0.96 (175) <0.0001 0.999 
 CT 0.35 (12) 0.39 (70) 0.664 (0.323-1.365) 0.265 T 0.35 (12) 0.43 (78) 1.407 (0.644-3.076)  
 TT 0 (0) 0.04 (8)        
rs1045280 TT 0.5 (17) 0.42 (74)   T 0.88 (30) 0.84 (148) 0.763 (0.246-2.37) 0.64 
 
TC 0.38 (13) 0.42 (74) 1.304 (0.75-2.266) 0.347 C 0.5 (17) 0.59 (103) 1.475 (0.692-3.143)  
 
CC 0.12 (4) 0.16 (29)        
No statistically significant differences seen 
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SLC6A4 and Bowel problems on morphine 
Logistic regression corrected for clinical factors (lower GI tumour) 
  Allele carriage (dominant model) Genotype frequency (additive model) 
  Bowel problems on 
morphine  
OR (95% CI) P value 
 Bowel problems on 
morphine  
OR (95% CI) P value SNP name Allele 
No 
 (N=37) 
Yes 
(N=199) Genotype 
No  
(N=37) 
Yes 
(N=199) 
rs 7214991 A 91 (31) 90 (163) 0.81 (0.221-2.978) 0.752 AA 38 (13) 40 (72)   
 
G 62 (21) 60 (109) 1.014 (0.47-2.189) 0.47 AG 53 (18) 50 (90) 0.947 (0.526-1.705) 0.855 
 
     GG 9 (3) 10 (19)   
rs 22528 G 44 (14) 37 (67) 0.77 (0.353-1.670) 0.511 GG 3 (1) 6 (10)   
 
T 97 (31) 94 (169) 0.516 (0.061-4.369) 0.544 GT 41 (13) 31 (56) 0.902 (0.477-1.707) 0.752 
 
     TT 56 (18) 63 (112)   
rs6354 G 41 (14) 36 (65) 0.825 (0.385-1.768) 0.62 GG 3 (1) 7 (12) 0.969 (0.524-1.792) 0.92 
 
T 97 (33) 93 (170) 0.424 (0.052-3.461) 0.423 GT 38 (13) 29 (52)   
 
     TT 59 (20) 65 (118)   
Rs 140700 C 100 (34) 98 (177) <0.0001 0.999 CC 77 (26) 83 (150)   
 
T 24 (8) 17 (31) 0.744 (0.299-1.848) 0.524 CT 23 (8) 15 (27) 1.144 (0.509-2.57) 0.744 
 
     TT 0 (0) 2 (4)   
rs 4583306 A 77 (26) 81 (149) 1.325 (0.542-3.24) 0.537 AA 32 (11) 31 (57)   
 
G 68 (23) 69 (126) 1 (0.449-2.23) 1 AG 44 (15) 50 (92) 1.098 (0.648-1.858) 0.729 
 
    
 
GG 24 (8) 19 (34)   
SertP      SS 24 (8) 17 (31)   
 
     LS 41 (14) 54 (96) 0.965 (561-1.661) 0.561 
 
     LL 35 (12) 29 (52)   
Data are given as % (N) 
No significant associations found 
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ADRA2A and Bowel problems on morphine  
Logistic regression corrected for clinical factors (lower GI tumour) 
 Genotype frequency (additive model) Allele carriage (dominant model) 
SNP Genotype No bowel 
problems 
on 
morphine 
N=37 
Bowel 
problems 
on 
morphine 
N=199 OR (95% CI) 
P 
value 
Allele No bowel 
problems 
on 
morphine 
N=37 
Bowel 
problems 
on 
morphine 
N=199 OR (95% CI) 
P 
value 
rs638019  GG 57.6 (19) 60.1 (110)   G 100 (33) 94 (172) <0.001 0.999 
 GA 42.4 (14) 33.9 (62) 0.904 (0.477-1.713) 0.756 A 42.4 (14) 39.9 (73) 0.901 (0.425-1.909) 0.785 
 AA 0 6 (11)        
rs11195418  AA 88.2 (30) 92.3 (167)   A 100 (34) 100 (181) - - 
 AG 11.8 (4) 7.7 (14) 1.59 (0.49-5.162) 0.44 G 11.8 (4) 7.7 (14) 0.629 (0.194-2.04) 0.44 
 GG 0 0        
rs1800544  CC 50 (17) 55 (99)   C 100 (34) 93.3 (168) <0.001 0.999 
 CG 50 (17) 38.3 (69) 0.955 (0.517-1.763) 0.882 G 50 (17) 45 (81) 0.818 (0.393-1.704) 0.592 
 GG 0 6.7 (12)        
rs11195419  CC 76.5 (26) 84.4 (152)   C 97.1 (33) 98.3 (176) 1.778 (0.179-17.617) 0.623 
 CA 20.6 (7) 13.9 (25) 0.652 (0.309-1.375) 0.261 A 23.5 (8) 15.1 (27) 0.577 (0.237-1.408) 0.227 
 AA 2.9 (1) 1.7 (3)        
rs3750625  CC 82.4 (196) 92.8 (168)   C 100 (34) 99.4 (180) <0.001 1 
 CA 17.6 (6) 6.6 (12) 0.435 0.164 – 1.156) 0.095 A 17.6 (6) 7.2 (13) 0.361 (0.127-1.029) 0.057 
 
AA 0 0.6 (1)        
rs602618  AA 52.9 (18) 55.5 (101)   A 100 (34) 92.9 (169) <0.001 0.999 
 
AC 47.1 (16) 37.4 (68) 0.881 (0.476-1.63) 0.687 C 47.1 (16) 44.5 (81) 0.902 (0.433-1.88) 0.784 
 
CC 0 7.1 (13)        
% (N) No statistically significant differences seen 
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Appendix G  Proforma for Constipation Audit 
 
Constipation audit number_____________________________ 
Patient initials________________________________________ 
 
Constipated?  Yes  No  
 
Outpatient   Inpatient  (dates of inpatient admission___________ to  _________) 
 
 
1. Is there documentation of the patient’s bowel function in the medical notes/EPR 
within the first 1-2 days of the current clinical episode 
                                    Yes   No                                       
       
2. If the answer to question 1 is yes is there documentation of the following in the 
medical notes/EPR 
            Straining          Yes   No  
            Frequency        Yes   No  
           Consistency       Yes  No  
 
3. Was there documentation of the patient’s usual bowel function at any stage in the 
clinical episode in the: 
           Medical notes/EPR      Yes   No  
 
           Nursing notes       Yes   No  
 
4. Who identified constipation as a problem? 
           Medical Oncologists       Yes  No  
           Surgeons                         Yes  No  
           Palliative Care Team      Yes  No  
           Nursing Staff                  Yes  No  
           Other                               Yes  No Specify----------------  
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5. If constipation was identified by medical/ nursing staff was the constipation core 
care plan being used? 
                                                Yes   No  
6a. Was the patient on laxatives on admission / at the start of this clinical episode? 
Yes   No  
6b. Was there evidence that laxatives had been changed (changed, initiated or titrated) 
on the medication chart if constipation was identified?       
                                              Yes   No  
7. Was there evidence of changes in laxative therapy based on the patient’s  
    symptoms?         
                       Medical notes/EPR                      Yes   No  
                       Nursing notes                         Yes   No  
Describe______________________________________________________________
_____________________________________________________________________ 
8. If laxatives were changed/initiated was there evidence that the response was  
reviewed? 
                        Medical notes/EPR                       Yes  No  
                        Nursing notes                                Yes  No  
 
9a. Did the patient die in hospital this admission?   Yes   No  
9 b. If not was there evidence either from the medical/nursing notes or on EPR that a 
follow up plan was in place for the management of constipation following this clinical 
episode (details in discharge letter etc) 
                                               Yes   No                                                                                                                              
   
 
